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The heterotrimeric G-proteins are critically important intracellular signalling 
molecules that regulate fundamental processes in cellular homeostasis. A 
unique bacterial toxin, Pasteurella multocida toxin (PMT) modifies 3 of the 4 
families of G-proteins (Gq, Gi, and G12) by deamidation which leads to a 
plethora of downstream signalling. PMT induces drastic morphological 
changes such as loss of adherence to the matrix, foci and stress fibre 
formation in Swiss 3T3 and Vero cells. PMT is mitogenic for many cell types 
but not all, and the work reported in this thesis aims to compare two cell 
lines that respond differently to PMT.  
 
Swiss 3T3 and Vero cells were treated with different concentrations of PMT 
to determine the effects on cell proliferation, cytoskeletal reorganisation and 
cell death. PMT induced prominent cytoskeletal changes, mitogenic and 
anti-cell death responses in Swiss 3T3 cells while delayed cytoskeletal 
changes with no evidence of mitogenicity and cell death were observed in 
Vero cells. PMT modified G-proteins at different times in Swiss 3T3 and 
Vero cells. The PMT-induced anti-cell death response in Swiss 3T3 cells 
was dose-dependent while the delayed cytoskeletal response in Vero cells 
was linked to the late PMT-mediated G12 activation. The amino acid 
sequence of Gα12 differed in the two cell types – the G12 subunit in Vero 
cells is missing N-terminal cysteine residue, which may have contributed to 
the differences. Gq/11 signalling is active and sustained in Swiss 3T3 cells, 
but not in Vero cells. G may have inhibited adenylyl cyclase activity so it is 
unknown whether Gi signalling is active and sustained over the 3-day period 
as the forskolin-stimulated cAMP level decreased in both serum-starved 
untreated and PMT-treated cell lines. In summary, I have identified changes 
in both the primary effect of PMT on the two cell types and also on 
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1  INTRODUCTION 
 
1.1  Signal Transduction 
 
Cells use a large array of defined signalling pathways to regulate their 
activities. The cell membrane separates the soluble, organised and 
proteinaceous intracellular content of the cell from its extracellular 
environment. It permits passage of some extracellular non-charged and 
small polar molecules while other molecules are transported via vesicles, 
carrier or channel proteins (Cooper, 2000). Information from non-permeant 
molecules is transferred across its lipid bilayer via a specialised signal 
transduction system.  
 
One of the hallmarks of multicellular organisms is their cells’ ability to 
communicate with each other using signalling molecules. These cells, 
therefore, are constantly bombarded by extracellular signals generated 
locally or remotely. Coupling of extracellular molecules to specific membrane 
receptors may lead to activation of signalling pathways. Signals are then 
conveyed across the cell membrane by a variety of transducers and 
amplifiers thereby producing a cascade of events that lead to specific 
biochemical responses. These intracellular signalling molecules are 
controlled by regulatory molecules via enhancement of their activities, 
modulation of their active or inactive states in the form of covalent 




   





complexity of such signalling system resulting in cellular altered gene 
expression, phenotype and biological function involves many key signalling 
players. 
 
  1.2  Cell Surface Receptors: Physical Conduits For  
        Extracellular Message Transfer 
 
In the late 1800s, the concept of the receptor was presented by German 
immunologist, Paul Ehrlich through his early work on blood cells and 
chemotherapy for infectious diseases, and British physiologist, John Langley 
who postulated that some molecules act and behave in cells as ‘receptive 
molecules’ (Klinge and Rao, 2008; Maehle, 2009; Lefkowitz, 2013). For 
decades, pharmacologists and endocrinologists further supported and 
developed the concept of receptors as membrane-associated molecules that 
specifically recognise and bind extracellular molecules. The initial direct 
evidence of the receptor-ligand binding concept came from the availability of 
highly purified peptide hormones and the ability to radio-label them without 
losing their biological activity (Lefkowitz et al., 1974; Williams et al., 1976; 
Hoffman and Lefkowitz, 1981; Klinge and Rao, 2008).  
 
The advancement in receptor research has established cell surface 
receptors as the major gateways for the conversion of extracellular message 
to intracellular message. All cells maintain a diversity of receptors located on 




   





transmission of extracellular signals across the cell membrane. The major 
classes of membrane receptors are divided into two: the enzymatically active 
tyrosine and serine/threonine kinases, and the non-enzymatically active G-
protein coupled receptors (GPCRs), also known as seven transmembrane 
(7TM) receptors or heptahelical receptors (Little et al., 2012). GPCRs 
constitute the largest panoply of specialised integral membrane receptors for 
therapeutic drugs (Little et al., 2012).  
 
    1.2.1  The Promiscuous G-protein Coupled Receptors  
 
G-protein coupled receptors are the most diverse and ubiquitously 
expressed transmembrane domain proteins in all cell types of mammalian 
organisms (Lodish et al., 2000; Lefkowitz, 2004). All GPCRs share similar 
topology with the N-terminal extracellular domain responsible for binding the 
extracellular signal molecules; the seven transmembrane spanning helices 
which contain the hydrophobic region embedded in the lipid bilayer and 
serve to anchor the receptor to the membrane; and the intracellular C-
terminal domain, responsible for relaying the extracellular signals to the 
cytoplasm (Uings and Farrow, 2000). Following activation of GPCR by a 
ligand, attentuation and cessation of GPCR-mediated signalling is regulated 
by a class of serine/threonine kinases known as G-protein coupled receptor 
kinases (GRKs). Phosphorylation of GPCR by GRK prepares the receptor 
for -arrestin binding (Lefkowitz and Shenoy, 2005). Recruitment of -




   





endocytosis, inhibits further G-protein mediated signalling, and diverts the 
existing signalling to non-G-protein signalling such as -arrestin signalling 
(Luttrell and Lefkowitz, 2002).   
 
There are about 950 predicted human GPCR members responsible for 
converting extracellular signals from chemical or physical stimuli such as 
neurotransmitters, hormones and sensory stimuli to intracellular signals 
(Maudsley et al., 2005). Most of these GPCRs are orphans as their 
physiological roles are still unknown (Deupi and Kobilka, 2007). Based on 
sequence identity of all predicted 7TMs, these GPCRs can be grouped into 
five families namely, rhodopsin, secretin, adhesion, glutamate, and 
frizzled/taste (Fredrikson et al., 2003).   
 
GPCRs virtually control many essential biological functions including 
development, hormone secretion from endocrine and exocrine glands, 
neurotransmission, inflammatory responses, and cardiac functions 
(Reynolds et al., 1991). Many potent mitogens stimulate cell proliferation via 
GPCRs. Constitutively active mutant GPCRs can be oncogenic. Recent 
cancer sequencing studies in some of the most prevalent human 
malignancies revealed a high proportion of GPCR mutations (~5-30%) 
(O’Neill, 2012). Due to the importance of their role in intracellular signalling, 
they are common targets of over 30% of all approved pharmaceutical drugs 





   





Fig 1.2  The G-protein Coupled 
Receptor. A schematic diagram of 
GPCR showing the 7 TM domains 
(TM1 - TM7) embedded in cell 
membrane, extracellular loops (EL1 – 
EL3), and intracellular loops (ICL1 – 
ICL3). Image adapted from Neumann 
et al. (2014). 
 
Our understanding of the complexity of GPCR signalling mechanisms has 
increased since their discovery through major advances in GPCR research 
and pharmacology. Initially, it was thought that activation of GPCRs only 
stimulated the canonical linear signalling pathways involving signal 
amplification and propagation via these three secondary messengers: 
phospholipase C (PLC), adenylyl cyclase (AC), and phosphoinositide-3- 
kinase (PI3K) (Little et al., 2012) but different studies have provided 
mechanistic insights into the novel features of GPCR signalling leading to 
the generation of pleiotropic biochemical responses. Evidence suggest that 
different agonists could bind to the same receptor type coupled to different 
effector pathways and produce multiple biochemical responses (Kenakin, 
1995a; Kenakin, 1995b; Leff et al., 1997; Little et al., 2012). These 
generated GPCR-mediated responses led to the understanding of the 
growing promiscuity of these versatile cell surface receptors, which depend 
on the strength of the extracellular signals, and the molecules involved in 




   





In the 1990s, a two-model conformation equilibrium state of GPCRs:  the 
active (R*) and the inactive (R), was proposed to explain the efficacy of 
ligands (Lefkowitz et al., 1993; Leff, 1995). The efficacy of ligands reflects 
their ability to alter the intrinsic properties of the receptor. Agonists have high 
affinity to GPCRs in their active state and can stabilise the GPCRs’ R* state 
or when bound to an inactive GPCR, can allosterically shift the receptor’s R 
state in to R* state, while partial agonists can bind to both states but are less 
effective in shifting equilibrium of the receptor from the R to R* state. Inverse 
agonists, on the other hand, favour and stabilise GPCRs’ R state while 
antagonists have no effect in shifting equilibrium in either direction but can 
inhibit the function of the previously mentioned agonists when bound to the 
receptor (Kenakin, 1995a; Deupi and Kobilka, 2007; Park et al., 2008, Park 
et al., 2012). However, the proposed two-model conformational state of 
receptors did not fit other evidence involving complex GPCR-mediated 
signalling. An extended ternary complex model which explains GPCR 
activation by cooperative interactions between receptor, G protein, and 
agonist was proposed (De Lean et al., 1980). Lefkowitz et al. (1993) 
reported that agonists have higher affinity to constitutively active mutant 
receptors than their counterpart wild-type receptors by which they assumed 
that the ‘mutation increases all parameters of trimolecular interaction 
between the ligand, GPCR, and G-proteins (the key mediators of 
extracellular information transfer to intracellular signaling). More studies 
indicated that receptors undergo different active conformational substates 




   





to selective binding of specific G-protein subtypes (Spengler et al., 1993; 
Park et al., 2012). One example came from a study of type-1 pituitary 
adenylylcyclase-activating polypeptide (PACAP) receptor and two different 
agonists: PACAP-27 and -38 (Spengler et al., 1993). Spengler et al. (1993) 
showed that both PACAP-27 and -38 stimulate adenylyl cyclase via the 
GPCR-Gs complex while only PACAP-38 stimulates PLC with high potency 
via the GPCR-Gq/11 complex.  
 
Two decades ago, scientists discovered that cognate GPCR-agonist 
activation could also result in the transactivation of enzymatically active 
receptors (Daub et al., 1996; Little et al., 2012). One example is the 
transactivation of Epidermal Growth Factor Receptor (EGFR), a Tyrosine 
Kinase Receptor (TKR), via GPCR using agonists such as thrombin, 
lysophosphatidic acid (LPA), and endothelin-1 in Rat-1 fibroblasts (Daub et 
al., 1996; Pyne and Pyne, 2011). Different studies revealed that occurrence 
of kinase receptor transactivation may be ligand dependent or independent, 
as in the case of EGFR activation via selective phosphorylation of its 
tyrosine residues by GPCR-activated Src kinase (Slomiany and Slomainy, 
2005; Little et al., 2012).  
 
Alderton et al. (2001) reported that two GPCRs tethered to platelet-derived 
growth factor  (PDGF) receptors lead to a significant increase in p42/44 
MAPK activation. Activation of multiple signalling pathways could also 




   





intracellular molecules, i.e. activation of bradykinin receptors caused a 
decrease in the level of 3'-5'-cyclic adenosine monophosphate, (cyclic AMP 
or cAMP) through a pathway involving phospholipase C in cultured rat 
mesangial cells (Bascands et al., 1993; Kenakin, 1995b).  
 
Receptor density may also affect the type of G-proteins that the receptors 
interact with and activate. According to Eason et al. (1992), overexpression 
of 2-adrenergic receptor in Chinese hamster ovary (CHO) cells resulted in 
coupling and activation of not just Gi, but also Gs, not an 2-adrenergic 
receptors’ target. In some cases, GPCRs activate multiple G-protein 
families, independent of receptor density, as in the case of the opioid 
agonist, D-Ala2,D-Leu5-enkephalin (DADLE) binding to -opioid receptors 
which results in the activation of multiple G-protein types in NG108-15 cells 
(Prather et al., 1994). Various studies also suggested that most receptors 
coupled to G12/13 are also coupled to Gq (Riobo and Manning, 2005; 
Hermans, 2003; Zhang et al., 2006).  
 
Lastly, there is evidence suggesting that ‘active’ GPCRs can activate 
signalling pathways in the absence of agonists, and that active GPCRs, and 
their cognate G-proteins may already be pre-coupled (Kenakin, 1995a; 
Nakashima et al., 2013). GPCRs can also activate signalling pathways 
independently of G-proteins, as in the case of G protein-independent β-




   





Shenoy et al., 2006; Zheng et al., 2010). It is also well established that G-
protein activation via GPCRs leads to activation of signalling pathways 
regulated by two functional subunits that comprise the heterotrimeric G-
proteins: the G and the  subunits. This will be discussed in more detail in 
sections 1.3 and 1.6 of this chapter. 
 
  1.3  Transducers of GPCR Signalling 
 
GPCRs have no catalytic domain, and therefore require specialised 
information-transducing proteins found in the inner leaflet of the cells. 
GPCR-mediated signals are transduced by a specific class of molecules 













Fig 1.2.2  The heterotrimeric G-protein activation-deactivation cycle and early 






   





    1.3.1 Classes of G-proteins and the Ras-like GTPases 
 
GTPases (or GTP-binding proteins) are important regulators of major cellular 
processes. They are divided into two large classes according to their 
sequence and structure similarity: the TRAFAC class (translation factor) and 
SIMIBI class (signal recognition particle, MinD, and BioD) (Verstraeten et al., 
2011). Signal recognition-associated GTPases, the MinD-like GTPases, and 
proteins with kinase or phosphate transferase activity belong to the SIMIBI 
class while the TRAFAC class includes the elongation factor GTPases, 
related motor ATPases, SEPTIN GTPases, and the Ras-like superfamily of 
GTPases (Nelson, 2008).  The latter includes two well-known families of 
GTPases: the monomeric G-proteins and heterotrimeric G-proteins. The 
heterotrimeric G-proteins play a major role in reception and numerous signal 
transduction involved in proliferation, motility, differentiation, transformation 
and cell death (Yanamadala et al., 2009). This will be discussed in great 
detail in section 1.3.2. 
 
The monomeric G-proteins consist of five families: 1) Ras which regulates 
gene expression involved in cell differentiation and proliferation, 2) Rho 
which is responsible for the regulation of cytoskeletal reorganisation, and 
gene expression via actin and actin-binding proteins, 3) Rab and 4) Sar1/Arf 
which each regulate vesicle trafficking, and 5) Ran which is responsible for 
nucleocytoplasmic transport and microtubule organization (Takai et al., 




   





characterised small G-proteins, which are involved in cytoskeletal 
reorganisation and adhesion, are the Rho, Rac, and cdc42 subfamilies from 
the Rho family (Wojciak-Stothard and  Ridley, 2003; Holmes et al., 2012). 
The members of the Rho subfamily (RhoA, B, C) have very similar 
sequences and are all involved in contractility, stress fibre formation, and 
focal adhesion (Burridge and Wennerberg, 2004). RhoA and RhoC are 
involved in cell proliferation while RhoB negatively regulates this effect (Du 
et al., 1999; Chen et al., 2000).  RhoA is also involved in many physiological 
and biochemical changes such as cell rounding, and serum response factor 
(SRF)-dependent gene expression (Mizuno and Itoh, 2009). Rac, on the 
other hand, is specifically responsible for the formation of lamellipoedia and 
membrane ruffling while cdc42 helps form filopodia (Nobes and Hall, 1995). 
Rac1 also has a role in stress fibre and focal adhesion complex formation. 
Genetic deletion of Rac1 in MEF abrogated stress fibre and focal contact 
formation (Guo et al., 2006). Both G-protein types are substrates of many 
bacterial toxins, which either inhibit their functions or render them in their 
locked activated state. 
 
    1.3.2  The Heterotrimeric G-proteins: The Molecular Switch 
             for GPCR Signalling 
   
The discovery of the GTP-binding proteins started from the observation that 
glucagon-induced adenylyl cyclase activity in hepatocytes specifically 




   






binding protein (G-protein or heterotrimeric G-protein) was adopted (Rodbell 
et al., 1971).  
 
The guanine nucleotide binding proteins (G-proteins) are made up of three 
polypeptides: ,  and  subunits. In humans, there are twenty one , five  
and twelve  subunits (Yanamadala et al., 2009). Human heterotrimeric G-
proteins, based on subsequent cloning by homology, are derived from 35 
genes of which 16 genes encode  subunits, 5 for  subunits, and 14 for  
subunits (Milligan and Kostenis, 2006). These G-proteins, unlike the G-
protein coupled receptors (GPCRs), are loosely attached to the cytoplasmic 
leaflet of the plasma membrane through covalently attached lipids on the G 
subunit and G subunit. G is tightly attached to the G subunit.  G-proteins 
are closely associated to the C-terminal intracellular domain of GPCRs 
(McCudden et al., 2005). 
 
    
 
Fig 1.3.2. The heterotrimeric G-
protein structure. The subunits are 
indicated as , , and  with the 
amino acid terminus indicated as N 
and the carboxyl terminus as C 








   





G-proteins act as molecular switches (Kleuss et al., 1994). In the inactive 
state, the guanosine diphosphate (GDP)-bound G subunit is bound to the 
 complex. In the classical GPCR-G-protein signalling paradigm, upon 
agonist-dependent receptor activation, the GPCR functions as a guanine 
nucleotide exchange factor (GEF) triggering release of GDP and promoting 
binding of GTP in the guanine nucleotide-binding cleft of the linked G 
subunit (Sprang, 1997b; McCudden et al., 2005; Maudsley et al., 2005). 
Nucleotide release is negatively regulated by guanine nucleotide 
dissociation inhibitors (GDIs). The binding of GTP to the G subunit leads to 
a conformational change in the GTPase domain of the switch II region of the 
G subunit which reduces its affinity to the receptor, and the  heterodimer 
resulting in their dissociation (Neer, 1995; Hamm, 2001; McCudden et al., 
2005; Kleuss et al., 1994). However, some evidence suggests that the GTP-
mediated conformational change does not always lead to subunit 
dissociation and that tethered heterotrimers are still functional (Levitzki and 
Klein 2002; Klein et al., 2000). 
 
Both the G and  subunits have a set of effector partners and 
independently trigger specific signalling pathways (Diel et al., 2006; Smrcka, 
2008; Dupre et al., 2009). The activity of both signalling molecules 
terminates upon hydrolysis of the GTP in the G subunit thereby reverting 
the G-protein into its GDP-bound inactive state, reinstating its heterotrimeric 




   





      1.3.2.1  The G Subunit 
 
The G subunit is the largest of the three subunits with molecular masses 
ranging from 33 to 55 kDa (Malbon, 2005). The G subunits can be divided 
into four major groups based on their sequence similarity: G(s, olf), G(i-1, i-2, i-
3, o, t-rod, t-cone, gust, z), G(q, 11, 14, 15/16), and G(12, 13) (McCudden et al., 2005; 
Moreira, 2014). Sixteen of them are direct gene products while others are 
alternatively spliced isoforms (Kaziro et al., 1991; Simon et al., 1991; 
Sandhya and Vemuri, 1997). Sequence identity amongst the G subunits is 
~45-80% (Simon et al., 1991). The G subunit consists of two domains: the 
GTP-binding domain, and the helical domain; the two held together by two 
highly conserved linker regions (Heydorn et al., 2004). The GTP-binding 
domain comprises about ~200 amino acid residues made up of six-stranded 
 sheets surrounded by  helices. It provides the binding surfaces for the  
complex, receptors and effectors, and has three flexible loops: switch 
regions I, II, and III, while the function of the helical domain is still unclear 
(Mizuno and Itoh, 2009).   
 
The G subunits are synthesised on free ribosomes in the cytoplasm and 
require the chaperone protein known as resistance to inhibitors of 
cholinesterase 8 (Ric-8) for proper folding and the initial association of the 
heterotrimeric G-protein to the plasma membrane (Gabay et al., 2011; Chan 




   





complex: 1) the N-terminal  helix of the G subunit interacts with blade 1 on 
the side of the G propeller (discussed in more detail in section 1.3.2.2), 2) 
the G switch II region interacts with the top of the G propeller (Smrcka, 
2008). Several studies indicate that association of the  complex with the 
G subunit makes the heterotrimer stable and a better substrate for G 
subunit palmitoylation, a lipid modification essential for plasma membrane 
localisation and anchorage, than the G subunit alone (Fishburn et al., 1999; 
Bhattacharyya and Wedegaertner, 2000).  
 
The activated G subunits interact with their immediate effectors to amplify 
extracellular signals via production of secondary signals. Signal modulators 
such as GPCR kinases, and regulators of G-protein signalling (RGS) 
proteins enhance the performance of G-proteins as molecular switches of 
signal transduction. The GTP hydrolysis of many G-proteins can be slow and 
requires the intervention of G-protein activating proteins (GAPs) to facilitate 
the intrinsic GTPase activity (Sprang, 1997b). Some findings suggest that 
apart from the regulatory G-protein signalling molecules; target effectors can 
also enhance and influence the duration of the GTPase activity of the G 








   





      1.3.2.2  The  Heterodimer 
 
The tightly complexed  subunits function as a monomer. The G subunit 
has two distinct regions: the N-terminus is made up of a 25-amino acid  
helix and a loop (residues 26-45) that connects the helix to the WD-repeats, 
a 40 amino acid motif, which comprises the C-terminus (Dupre et al., 2009). 
The WD-repeats contain seven distinct anti-parallel  strands arranged like 
blades on a propeller-like structure (see Fig 1.3.2.2). The regions of G that 
bind G are found in blade 5 and the adjacent small  helix. Observations on 
the structure of the  subunit showed that there is no significant difference 
in the overall structure whether it is linked or unlinked to the G subunit or 
any effector proteins except in the case of  linked to phosducin, which 
shows movement in blades 6 and 7 forming a cavity between these two 
blades (Smrcka, 2008). It is unknown whether this movement has 
significance in G-protein function.  
 
The G1-4 subunits share ~80% amino acid sequence identity while G5 is 
structurally distinct from other G5 subunits with only ~51-53% sequence 
identity and has an additional 13 amino acid residues (Schwindinger and 
Robishaw, 2001). The G5 subunits, which appears to be an outlier of all G 
polypeptides, can form a stable complex with RGS7, an RGS protein. The 
function of the G/RGS7 complex, its physiological role and regulation 




   





folding by a chaperone protein called chaperonin containing tailless-complex 
polypeptide 1 (CCT), which also prevents aggregation of unfolded G 
subunits, and a co-chaperon protein called phosducin-like protein (PhPL1) 
(Kubota et al., 2006; Marrari et al., 2007).  
The G subunit, on the other hand, is more structurally diverse than the G 
subunits with 27-76% sequence homology (Dupre et al., 2009). G1, G11, 
and G13 subunits share 62-73% homology (Schwindinger and Robishaw, 
2001). The ~70 amino acid G subunit, however, consists of two helices, and 
is folded by a chaperon protein called dopamine receptor interacting protein 
78 (DRiP78), an ER resident protein (Dupre et al., 2007). In cultured cells, 
the G and G subunits interact to form the  heterodimer within 2.5 
minutes after synthesis (Rehm and Ploegh, 1997; Marrari et al., 2007). It is 
not clear whether the G and G subunits assemble in the ER, but according 
to reports, G can compete with DRiP78 in binding G and DRiP78 interacts 
with phosducin-like protein (PhLP) suggesting a role for both proteins in G 
and G subunit assembly (Dupre et al., 2007; Marrari et al., 2007). Although 
G can bind to lipid-modified or unmodified G, it preferentially binds to 
unmodified G (Higgins and Casey, 1996). Most G and G subunits can 
irreversibly form a complex (Marrari et al., 2007). Some exceptions have 
also been reported; for example the G1 subunit can pair with all G 
subunits, while G2 can form a functional dimer with G2 but not G1, which is 




   





Dupre et al., 2009). In comparison to other GPCRs, the rhodopsin receptor 





Fig 1.3.2.2  The  structure. The subunits are 
indicated as Gβ and G with the amino acid 
terminus indicated as N and carboxyl terminus 
as C. Image adapted from Bohm et al. (1997). 





Initially, the  heterodimer was thought to be a negative regulator of G 
signalling and was responsible for slowing the rate of GDP release in the G 
subunits (Dupre et al., 2009). In 1987, purified  dimers from bovine brain 
were shown to activate a cardiac potassium channel (Logothetis et al., 
1987). Devoid of a catalytic site, the active lifetime of β complex signalling 
depends on the rate of GTP hydrolysis in the G subunits (Neer, 1995).  
The G and G subunits are both essential for the regulation of their 
effectors. A fully functional C-terminal extremity of the G2 subunit is required 
for the activation of Kir3 channels (Peng et al., 2003), while a point mutation 
(S67K, T128F, S98T) in the G1 subunit alters the regulation of the Kir3 





   





et al., 2002). Recombinant G1-32 has been shown to stimulate PI3K, while 
G52 could not. Reports also show that the combinations G52 and G12 
could activate PLC1 and PLC2 while only G12 could activate PLC3 
(Khan et al., 2013).  
 
Other studies showed that the  heterodimer interacts with GPCRs, and 
receptors on the ER, and modulates some downstream effectors that are 
also regulated by G subunits (Robishaw and Berlot, 2004; Dupre et al., 
2009). It has been suggested that the region where the G subunit defines 
its specificity to form a complex with the G subunit is localised to 14 amino 
acid residues near the middle of the molecule (Spring and Neer, 1994). 
Different combinations of these subunits suggest that there is a selectivity, 
with generation of a wide range of signals transmitted via different G-protein 
combinations.  
 
  1.4 Specificity Determinant of G-proteins 
 
Despite being fewer in number and less diverse than the GPCRs, G-protein 
signalling leads to diverse biological responses. Different contact sites in the 
 subunits are thought to contribute to coupling specificity to GPCRs and 
their target effectors (Baltoumas et al., 2013). A chimeric G subunit 
consisting of the N-terminus of Gq fused to the C-terminus of the GTPase 




   





cyclase, a Gs effector (Orth et al., 2013). In a similar study with a different 
result, chimeric G subunits consisting of Gq with a Gi C-terminus via Gi-
coupled receptor resulted in the stimulation of phospholipase C, a Gq 
effector (Conklin et al., 1993).  
 
Diversity in the heterotrimeric G-proteins due to the potential combination of 
different subunits (also discussed in section 1.3.2.2) has been a major 
challenge to understanding their function in cell regulation. GPCRs such as 
somatastin and muscarinic cholinergic receptors use different G-protein 
combinations in controlling a calcium channel in pituitary cells (Kleuss et al., 
1993), while adrenergic and prostaglandin receptors use different G-protein 
combinations to stimulate adenylyl cyclase activity (Wang et al., 1997b). 
Schwindinger et al. (2003) demonstrated the first conclusive evidence for a 
receptor recognising a specific heterotrimeric G-protein combination in an 
organism using a gene-targeting approach. According to them, the 7 subunit 
is required for the D1 dopamine receptor to stimulate adenylyl cyclase 
activity in striatum. Reports on the different combinations of G-protein 
subunits provide strong evidence for functional selectivity and generation of 








   





  1.5 Modifications of  and  subunits  
 
The activity of G-protein subunits is regulated by a number of covalent 
modifications, such as phosphorylation, dephosphorylation, palmitoylation, 
depalmitoylation, myristoylation, prenylation and carboxymethylation (Chen 
and Manning, 2001). These modifications are involved in plasma membrane 
localisation, anchorage of G-protein subunits and protein-protein interaction. 
G subunits are considered non-functional without undergoing essential 
covalent modifications linked to their function. Most G subunits except t 
and gust are palmitoylated by palmitoyl acyltransferase on a cysteine(s) 
within the first 20 amino acids in the N-terminal region with the exception of 
Gs which can also be palmitoylated at N-terminal Gly
2 residue (Sprang, 
1997a; Chen and Manning, 2001;  Vogler et al., 2008). Membrane 
association of most Gi subunits follow a two-membrane trapping model: 
irreversible myristoylation and reversible palmitoylation (Chen and Manning 
2001). The polypeptides o, i, z, and t (belonging to the Gi family) are 
additionally N-myristoylated by N-myristoyltransferase (NMT) on Gly2 which 
requires specifically Ser6 or Thr6 as well and a removal of a methionine 
residue prior to lipidation (Sprang, 1997a). The covalent attachment of a 
myristate moiety in Gi is critical for docking of the subunit to the plasma 
membrane and a pre-requisite process prior to palmitoylation, although over-
expression of  subunits appears to replace myristate group function as a 




   





1990; Mumby et al., 1994; Hallak et al., 1994; Galbiati et al., 1994; Chen and 
Manning 2001). It is believed that the geranylgeranyl group in the  
complex is a functional equivalent of the myristate moiety, as a membrane-
targeting signal (Morales et al., 1998; Chen and Manning, 2001). The 
reversible palmitoylation of the G subunits appears to be an important 
process in recycling the subunits between the membrane and cytosolic 
compartments, but other studies have shown that depalmitoylation of G 
subunits by thioesterase did not lead to translocation of G subunits from 
the plasma membrane to the cytosol (Wedegaertner and Bourne, 1994; 
Mumby et al., 1994; Huang et al., 1999; Chen and Manning, 2001).  
 
Some studies also show that myristoylation and palmitoylation of G 
subunits have significant roles in signal transduction. Gallego et al. (1992) 
reported that myristoylation of constitutively active mutant Gi2, also known 
as gip2 oncoproteins, is essential in cell transformation. Myristoylated 
mutant Gi-2 negatively regulated adenylyl cyclase activity and stimulated 
activation of p42 mitogen-activated protein kinase (MAPK) while the non-
myristoylated active mutant Gi-2 was unable to do so. A similar study 
showed that a constitutively active mutant G12 devoid of palmitoylation in 
NIH3T3 cells was incapable of causing cell transformation (Jones and 
Gutkind, 1998). Bhattacharyya and Wedegaertner (2000) reported that G13 
required palmitoylation for its plasma membrane localisation in transfected 




   





the Rho-dependent serum response factor-mediated transcription, p115-
RhoGEF translocation, and actin stress fibre formation. 
 
Palmitoylation also negatively regulates the intrinsic GTPase activity of G 
subunits via RGS, while depalmitoylation promotes interaction between G 
subunits and RGS (Tu et al., 1997; Chen and Manning, 2001). Palmitoylated 
Gz decreased the maximal rate of GTP hydrolysis and had reduced affinity 
to Gz GTPase-accelerating protein (GAP) while palmitoylation of Gz and 
Gi inhibited their response to G-interacting protein (GAIP), and RGS4 
respectively (Tu et al., 1997).  
 
The G subunits undergo several post-translational modifications, including 
the irreversible isoprenylation of a cysteine residue in a CAAX motif at the 
carboxyl terminal of the protein (Schafer and Rine, 1992). Isoprenylation 
involves covalent attachment of either a farnesyl or a geranylgeranyl moiety 
to the G subunit. If the X in the CAAX motif is a leucine, then a 
geranylgeranyl group via a thioester bond is covalently attached to the 
preceding cysteine, but in some G subunits such as G1, G9, G11, the X is 
a serine or methionine which permits attachment of a farnesyl group 
(Balcueva et al., 2000; Ong et al, 1995; Wedegaertner et al., 1995; Vogler et 
al., 2008). Isoprenylation of this cysteine in G is followed by removal of 
three amino acids at the C-terminus and reversible carboxymethylation 




   





modification augments hydrophobicity of the subunit especially in the case of 
farnesylated G, thereby enhancing its membrane anchorage properties 
(Vogler et al., 2008). These modifications are essential for membrane 
anchorage of the  complex. 
 
G-proteins also undergo reversible phosphorylation at tyrosine, serine, or 
threonine residues, which may affect the specificity of their interactions with 
other proteins and their function in a positive or negative fashion (Sandhya 
and Vemuri, 1997; Sprang, 1997). In yeast, phosphorylation of G in the free 
 dimer is essential for mediating signal amplification, communication 
between receptor and the chemotropic complex which are all important for 
chemotrophic growth (DeFlorio et al., 2013).  
 
Kozasa and Gilman (1996) reported that PKC equally phosphorylated G12 
and Gz on a serine residue in their GDP- or GTP-bound forms. Such 
modification reduced the affinity of both functional G and  subunits and 
did not alter the guanine nucleotide binding properties and function of the 
subunits. Other studies indicated that PKC preferentially phosphorylates a 
monomeric form of Gz, as the  heterodimer negatively regulates such 
process by blocking the N-terminus of the G polypeptide, which is the 
apparent site for phosphorylation (Fields and Casey, 1995; Wang et al., 
1999a). Phosphorylation of G inhibits binding of the  complex and various 




   





prolonging the activity of G-proteins (Fields and Casey, 1995; Glick et al., 
1998; Wang et al., 1998).  
 
In an early in vitro experiment, Krupinski et al. (1988) showed that Gi and 
Go were phosphorylated on tyrosine residue by the insulin receptor. The 
GDP-bound G subunits were the preferred substrates for phosphorylation 
as guanosine 5'-[-[35S]thiotriphosphate (GTPS) prevented the G subunit 
from being phosphorylated. The presence of these phosphorylated G 
subunit also resulted in an enhanced insulin-stimulated receptor 
autophosphorylation and incorporation of insulin receptors to phospholipid 
vesicles. However, they did not report any functional consequences of such 
phosphorylation events and speculated that phosphorylation may help in 
keeping a G subunit in its inactive GDP-bound state and thus, serves as an 
‘off switch’ for signalling pathways, or in facilitating G activation, or 
stimulate the activity of the effector proteins. In a study involving a different 
kinase protein, Hausdorff et al. (1992) reported that pp60c-src preferentially 
phosphorylates a tyrosine residue of inactive GDP-bound Gs and 
transducin, which resulted in a modestly increased rate of GTPS binding 
and GTP hydrolysis, and that coupling of  subunits inhibited such 
processes. Although they did not specifically identified the tyrosine residue 
site for phosphorylation, initial speculation pointed to near the amino terminal 
region due to the anti-phosphorylation properties of the  complex. 




   





terminus and the investigators proposed two conserved residues as possible 
phosphorylation sites: Tyr170 and Tyr312.  
 
Phosphorylation may also result in positive or negative regulation of signal 
transduction. Phosphorylation of G13 at Thr
203 by protein kinase A (PKA) 
led to stabilised coupling of receptor and G subunit, destabilised coupling 
of G and  subunits, and inhibition of Rho activation (Manganello et al., 
2003). Stimulation of tyrosine phosphorylation of Gi2 by PDGF receptors 
coupled to GPCRs in human embryonic kidney (HEK) 293 cells led to an 
increase in p42/p44 MAPK activation (Alderton et al., 2001) while epidermal 
growth factor (EGF)-induced tyrosine phosphorylation of Gs decreased 
bradykinin-induced activation of cAMP signalling pathway in A431 cells 
(Liebmann et al., 1996). 
 
Another question that needs addressing is whether phosphorylation is 
required for activation of G-proteins or not. Umemori et al. (1997) reported 
that activation of Gq/11 essentially requires phosphorylation of G subunits at 
tyrosine356 residue. Baldwin et al. (2003), on the other hand, reported that 
Pasteurella multocida toxin (PMT), and non-toxic mutant PMTC1165A 
stimulated phosphorylation of Gq at tyrosine
349 but such phosphorylation 
event did not in itself lead to Gq activation as only the wild-type (WT) PMT 
was able to activate Gq. However, they showed that both active and mutant 




   





activate PLC (Baldwin et al., 2003; Lax et al., 2004). It is not clear whether 
activation depends on the tyrosine site, cell type (although both experiments 
were carried out mostly in fibroblasts: Swiss 3T3, mouse embryonic 
fibroblast (MEF), Gq/11 -/- double deficient fibroblasts, with the exception of 
CHO cells which, however, generated similar results), the origin of G 
subunit, or the type of agonists used. It appears that in most cases, 
phosphorylation of G blocks association of G, may upregulate or 
downregulate downstream biochemical signals, and enhances effector 
protein activities. 
 
Several bacterial toxins specifically attack certain G subunits, as the main 
substrates of their catalytic activity. Pertussis toxin (PT), an AB enterotoxin 
produced by the bacterium Bordetella pertussis, modifies all members of the 
Gi family, except Gz, by a process called ADP-ribosylation. The addition of 
an ADP-ribose moiety to the cysteine residue located at the C-terminus of 
G subunits inhibits the polypeptides from interacting with the receptors and 
abolishes their GTPase activity (Locht, 1999; Carbonetti, 2010; Locht et al., 
2011).  Cholera toxin (CT), produced by the bacterium Vibrio cholerae, and 
E. coli heat-labile enterotoxin toxin (LT) each catalyse ADP-ribosylation of 
Gs to promote GDP release, GTP binding, and inhibition of GTP hydrolysis 
thereby locking the G-proteins in their constitutive active state (Lee et al., 
2001; Moss and Vaughan, 1991; Lemichez and Barbieri, 2013). Pasteurella 




   





heterotrimeric G-proteins and catalyses deamidation of their glutamine 
residue to convert it into glutamic acid rendering the G-proteins in their 
constant active state. Bacterial toxins and toxin-catalysed modifications will 
be discussed in more detail in section 1.8 of this chapter. 
  
  1.6  The Heterotrimeric G-proteins: 4 Distinct Classes  
 
The heterotrimeric G-proteins are classified according to the specific class of 
the  subunit, having amino acid homology of 50% or more, namely Gq, 
G12, Gs, and Gi (Simon et al., 1991; Goldsmith and Dhanasekaran, 
2007).  
 
Each G-protein has been linked to a specific (canonical) signalling pathway.  
However, there is now an increasing evidence of non-canonical functions of 
G-proteins independent of GPCRs. In this chapter, signalling pathways via 




   





                                  
 Gi-2 H.sapiens P04899-3
 Gi-2 H.sapiens P04899-5
 Gi-2 H.sapiens P04899-2
 Gi-2 H.sapiens P04899-1
 Gi-2 H.sapiens P04899-4
 Gi-2 H.sapiens P04899-6
 Gi-2 M.musculus P08752
 Gi-3 H.sapiens P08754
 Gi-3 M.musculus Q9DC51
 Gi-1 H.sapiens P63096-1
 Gi-1 H.sapiens P63096-2
 Gi-1 M.musculus B2RSH2
 Gt-3 H.sapiens A8MTJ3
 Gt-3 M.musculus Q3V3I2
 Gt-1 H.sapiens P11488
 Gt-1 M.musculus P20612
 Gt-2 H.sapiens P19087
 Gt-2 M.musculus P50149
 Go H.sapiens P09471-1
 Go M.musculus P18872-1
 Go H.sapiens P09471-2
 Go M.musculus P18872-2
 Gz H.sapiens P19086
 Gz M.musculus O70443
 G15 H.sapiens P30679
 G15 M.musculus P30678
 G14 H.sapiens O95837
 G14 M.musculus P30677
 Gq M.musculus P21279
 Gq H.sapiens P50148
 G11 M.musculus P21278
 G11 H.sapiens P29992
 G13 H.sapiens Q14344-1
 G13 H.sapiens Q14344-2
 G13 M.musculus P27601
 G12 M.musculus P27600
 G12 H.sapiens Q03113-1
 G12 H.sapiens Q03113-2
 G12 H.sapiens Q03113-3
 Golf M.musculus Q8CGK7
 Golf H.sapiens P38405-3
 Golf H.sapiens P38405-1
 Golf H.sapiens P38405-2
 Gs M.musculus P63094-2
 Gs M.musculus P63094-1
 Gs M.musculus P63094-3
 Gs H.sapiens Q5JWF2-1
 Gs H.sapiens Q5JWF2-2
 Gs H.sapiens P63092-1
 Gs H.sapiens P63092-2
 Gs H.sapiens P63092-3
 Gs H.sapiens Q5JWF2-3
 Gs M.musculus Q6R0H7-3
 Gs M.musculus Q6R0H7-2
 Gs M.musculus Q6R0H7-1
 Gs M.musculus Q6R0H7-4
Fig 1.6  The Phylogenetic 
Tree of G Subtypes in 
Homo sapiens, and Mus 
musculus with their Uniprot 
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    1.6.1 The Gq Family 
 
The Gq family has five members: Gq, G11, G14, and G15 (mouse orthologue) 
G16 (human orthologue) with overall 57% amino acid sequence identity 
(Hubbard and Hepler, 2006; Mizuno and Itoh, 2009). Gq and G11 are the 
most ubiquitously expressed members of this family with 88.5% amino acid 
sequence identity (Astesano et al., 1999), whereas the expression of G14 is 
more restricted and normally seen in specialised cells. G15/16, on the other 
hand, is limited to a subset of haematopoietic cells (Amatruda et al., 1991; 




Fig 1.6.1  The Phylogenetic Tree of Gq Family Members Protein Sequences of H. 
sapiens, and M. musculus with their Protein Identifier. The scale bar indicates the 
average number of amino acid substitutions per site. A supplement figure (Fig A1) 
of the aligned amino acid sequence of the above proteins can be found in the 
appendix section. 
 
Activation of these G-proteins stimulates activation of their canonical 
downstream targets: different beta isoforms of phospholipase C (PLC) 
 Gq H.sapiens P50148
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 G11 H.sapiens P29992
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(PLCβ1-4). PLC1 and PLCβ3 are ubiquitously expressed in most cell types 
while PLC2 is restricted to haematopoietic cells, and PLC4 is largely 
expressed in retina (Mizuno and Itoh, 2009; Kozasa et al., 1993). Gq, G11, 
and G14 activate PLC1-4 in vitro with PLC2 being poorly activated while 
G15/16 activates PLC1-3 in vitro, which in the case of PLC2, could be cell 
type specific as both G15/16 and PLC2 expression are restricted to 
haematopoietic cells and thus, could be functionally linked. PLC activation 
leads to hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2), and 
generation of second messengers: inositol-1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG). The free IP3 binds to IP3-specific receptors, which lead 
to intracellular Ca2+ mobilisation while the membrane bound DAG activates 
PKC. These events lead to a profound biochemical and physiological 
alteration of the cells and are involved in mitogenesis, muscle contraction, 
chemotaxis, opioid sensitivity, survival and others (Lyon and Tesmer, 2013). 
PLC, apart from being a target effector of the Gq/11, also serves as GAP by 
increasing the intrinsic GTPase activity of the G subunit (Paulssen et al., 
1996; Chidiac and Ross, 1999). Gq-mediated intracellular Ca
2+ mobilisation 
resulted in downregulation of -catenin signalling by promoting nuclear 
export and calpain-mediated degradation of -catenin (Li and Iyengar, 
2002). Gq-PLC activates the extracellular-signal-regulated kinase (ERK)-
proliferative pathway via a novel pathway involving proline-rich tyrosine 




   





Recently, the p63RhoGEF, Trio, and Duet were identified as target effectors 
of Gq, which activates RhoA (Rojas et al., 2007, Williams et al., 2007). A 
crystal structure of the Gq-p63RhoGEF-RhoA complex confirms 
involvement of Gq in RhoA signalling (Lutz et al., 2007). p63RhoGEF binds 
to Gq to increase GTP exchange on RhoA, RhoB, and RhoC. In another 
study, activation of Gq/11 was shown to inhibit osteoblast differentiation via 
the RhoA-p63RhoGEF activation (Siegert et al., 2013). 
 
Various reports show the involvement of Gq/11 in promoting apoptosis or cell 
survival in different cell types. In HeLa cells, Ueda et al. (2001 and 2004) 
reported that Gq/11 induced apoptosis via proteolytic activation of Rho-
associated kinase I (ROCK-I) by caspase, activation of RhoA and reduced 
phosphorylation of Akt by insulin-stimulated tyrosine phosphatase. A similar 
observation in HEK293 cells was reported but according to investigators, 
RhoA activation did not involve stimulation of PKC and calcium signalling, 
and inhibition of Akt phosphorylation did not involve PLC activation (Ueda et 
al., 2001; Chikumi et al, 2002). In another study using HEK293 cells, 
constitutively active G11, G14, and G16 supressed basal and EGF-induced 
Akt phosphorylation and such inhibitory effect in pro-survival signalling was 
PLC-independent and dependent on mobilisation of intracellular calcium (Wu 
et al., 2006). In CHO and COS-7 cells, Gq-mediated apoptosis is PKC 
dependent while G11-mediated apoptosis is independent of PLC (Althoefer et 




   





In contrast, constitutively active mutant G11 did not induce apoptosis and 
promoted Akt phosphorylation in NIH3T3 cells (Ueda et al., 2001). Two 
papers reported contradicting observations on the effect of Gq on Akt 
activation in COS-7 cells. Murga et al. (1998) reported Gq-mediated 
activation of Akt while Bommakanti et al. (2000) reported Gq-mediated 
inhibition of Akt stimulation. Thus, it appears that Gq/11-mediated apoptosis is 
cell-specific and in the case of similar cell type e.g. COS-7, variability among 
different COS-7 cell lines or the origin of the cell line.  
 
Ric-8A, a cytosolic resident protein, possesses a GEF activity to Gq, Gi-1, Go 
and G12 but not Gs. Ric-8A appears to enhance Gq-mediated ERK activation 
in intact cells (Nishimura et al., 2006). Ric-8B, another homologue of Ric-8, 
associates with Gq, Gs but not Gi, and G12 (Tall et al., 2003). Ric-8B 
and Golf are both predominantly expressed in mature olfactory sensory 
neurons and appear to be functional partners in G-protein-mediated odorant 
signal transduction. To understand the biochemical role of Ric-8B and 
regulation of Golf, Von Dannecker et al. (2005) showed that Ric-8B 
potentiated the Golf-dependent cAMP level in HEK293 cells.  
 
The scaffolding protein, Caveolin-1 and the lipid raft resident proteins, 
flotillins interact with Gq and appear to serve as scaffolding proteins of Gq 
signalling (Oh and Schnitzer, 2001; Sugawara et al., 2007). Caveolin-1 




   





siRNA knockdown of caveolin-1 impaired GPCR signalling which suggests 
that caveolin-1 may have a role in receptor coupling (Gonzalez et al., 2004; 
Bhatnagar et al., 2004). A knockdown of flotillins-2, on the other hand, 
attenuated the UTP (a P2Y GPCR agonist)-induced p38 MAPK activation via 
Src kinases in lipid rafts (Sugawara et al., 2007; Nagao et al., 1998). Src 
kinase inhibitors can disrupt p38 MAPK activation by UTP and lipid rafts 
(Sugawara et al., 2007). Gq-GPCR-mediated p38 MAPK activation has been 
previously reported to be dependent on Src kinases.  
 
    1.6.2  The G12 Family 
                                                                                                                      
The G12 family consists of two ubiquitously expressed 43 kDa proteins: G12 
and G13 with over 67% identity in amino acid sequences (Strathmann and 
Simon, 1991). The GPCR-mediated activation of G12/13 has a slow rate of 
nucleotide exchange and GTP hydrolysis (Suzuki et al., 2009). Both 
members activate the small GTPases Rho that leads to the downstream 
activation of c-Jun N-terminal kinase (JNK) and PLD amongst other effects 
(Juneja et al., 2011). 
 
The downstream effectors of G12/13 are Rho, Rac, and Cdc42, which belong 
to the Rho GTPases family from the Ras superfamily of small GTP-binding 
proteins. These small G-proteins are regulated by two groups of proteins: 
GEF which catalyses the exchange of GDP to GTP, and GAP which 




   





via RhoGEFs is the best described of the signalling pathways regulated by 
G12/13. These G-proteins interact with RhoGEFs, which contain the N-
terminal homology RGS (known as RH-RGS or rgRGS) domain, such as 
PDZ-RhoGEF/GTRAP48, leukaemia-associated RhoGEF (LARG) and 
lymphoid blast crisis-like-2 (Lsc), also known as p115-RhoGEF (Hart et al., 
1996; Kozasa et al, 1998; Fukuhara et al., 2001). Apart from acting as 
effector proteins, these RhoGEFs also function as RGS, i.e. LARG and 
p115-RhoGEF were shown to enhance the GTPase activity of G12/13 in vitro 
by acting as GAPs (Kozasa et al., 1998; Suzuki et al., 2003).  
 
 
Fig 1.6.2  The Phylogenetic Tree of G12 Family Members Protein Sequences 
of H. sapiens, and M. musculus with their Protein Identifier. The scale bar 
indicates the average number of amino acid substitutions per site. A supplement 
figure (Fig A2) of the aligned amino acid sequence of the above proteins can be 
found in the appendix section. 
 
Wu et al. (2006) reported that constitutively active G12/13 inhibits the pro-
survival Akt signalling via activated RhoA in HEK293 cells while a dominant 
negative mutant RhoA blocked that effect. Similar to the effect of G11/14/16, 
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the constitutively active G12/13 also attenuated basal and EGF-induced Akt 
phosphorylation (Wu et al., 2006). 
 
As mentioned in section 1.6.1, G12 (also Gq, Gi1, Go) binds to Ric-8A, which 
contributes in the enhancement of ERK activation (Nishimura et al., 2006).  
G12/13 also binds to Bruton’s tyrosine kinase (Btk), a non-receptor tyrosine 
kinase belonging to the Tec family, which is involved in B-cell maturation, 
differentiation and signalling. However, the functional importance of such 
interaction remains unclear (Jiang et al., 1998). Btk contains a pleckstrin 
homology (PH) domain and binds to phosphatidylinositol (3,4,5)-triphosphate 
(PIP3) which then phosphorylates PLC leading to hydrolysis of PIP2 and 
generation of two second messengers: IP3 and DAG (Mohamed, 2009).  
 
Activated G12 also directly interacts with E-cadherin, a cell-cell adhesion 
molecule, leading to the release of the pro-mitogenic factor -catenin, a key 
component of the canonical Wnt pathway (Meigs et al., 2001). G12/13 is also 
involved in platelet shape change via regulation of Rho-Rho kinase-
dependent phosphorylation of myosin light chain (MLC) which also includes 
tyrosine phosphorylation of pp72syk and stimulation of pp60c-src.   
 
    1.6.3  The Gi Family 
 
The Gi family is the most diverse of all G-protein classes. It has six 




   





and Gz. Gi-1, Gi-2, and Gi-3 share 85-95% amino acid sequence identity 
(Plummer at al., 2012). The Gi: rod transducin Gt-r, cone transducin Gt-c, and 
gusducin Gg are involved in the signal transduction related to vision and 
taste.  
 
With the exception of Gz, the pertussis toxin targets the G subunits of this 
family by ADP-ribosylation which results to the paralysis of their normal 
signalling function in receptor coupling and their own activation (Casey et al., 
1990; Fong et al., 1988). Gi and Gz regulate Gs activity by inhibiting the 
activity of adenylyl cyclase and the production of cAMP. However, prolonged 
activation of Gi/o-coupled receptors-Gi/o may also result in sensitisation or 
superactivation of AC thereby enhancing AC activity (Brust et al., 2015).  
 
The sensory Gg activates PLC resulting in an increase in intracellular 
Ca2+. Activation of the cyclic cGMP-dependent phosphodiesterase (PDE) 8 
by Gt-r and Gt-c causes a decrease in intracellular cGMP and 
hyperpolarisation of photocells via cGMP-gated ion channels (Meoli, 2010). 
Reduction in Gi-2 led to differentiation of F9 cells into a primitive endoderm 
(Dhanasekaran et al., 1998). Similar to Gq and G12 (as discussed in sections 
1.6.1 and 1.6.2), Gi1 and Go also bind to Ric-8A, which contribute in the 




   






Fig 1.6.3  The Phylogenetic Tree of Gi/o Family Members Protein Sequences 
of H. sapiens, and M. musculus with their Protein Identifier. The scale bar 
indicates the average number of amino acid substitutions per site. A supplement 
figure (Fig A3) of the aligned amino acid sequence of the above proteins can be 
found in the appendix section. 
 
    1.6.4  The Gs family 
 
The Gs family has two members: the ubiquitous Gs and the olfactory Golf 
with over 88% identity in amino acid sequences (Jones and Reed, 1989). 
Cholera toxin targets this family of G-proteins by constitutively activating the 
G subunits by ADP-ribosylation (Cassel and Pfeuffer, 1978; Gill and Meren, 
1978). 
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Fig 1.6.4  The Phylogenetic Tree of Gs Family Members Protein Sequences of 
H. sapiens, and M. musculus with their Protein Identifier. The scale bar 
indicates the average number of amino acid substitutions per site. A supplement 
figure (Fig A4) of the aligned amino acid sequence of the above proteins can be 
found in the appendix section. 
 
The Gs/olf family is known to activate adenylyl cyclase, which leads to an 
increase in intracellular cAMP and activation of Protein Kinase A (PKA). 
cAMP-mediated signalling pathways activated by growth hormone releasing 
hormone (GHRH) and thyroid stimulating hormone (TSH) via Gs-GPCR 
results in cell proliferation (Dhanasekaran et al., 1998). Phosphorylation of 
PKA, on the other hand, attenuates 2-adrenoceptor-Gs uncoupling and 
promotes 2-adrenoceptor-Gi coupling, which results in the activation of 
MAPK pathway (Hill and Baker, 2003). However, other data showed that 
 Gs H.sapiens P63092-2
 Gs H.sapiens P63092-3
 Gs H.sapiens P63092-1
 Gs H.sapiens Q5JWF2-2
 Gs H.sapiens Q5JWF2-1
 Gs M.musculus Q6R0H7-4
 Gs M.musculus Q6R0H7-1
 Gs M.musculus P63094-3
 Gs M.musculus P63094-1
 Gs M.musculus P63094-2
 Golf H.sapiens P38405-1
 Golf H.sapiens P38405-2
 Golf H.sapiens P38405-3
 Golf M.musculus Q8CGK7
 Gs M.musculus Q6R0H7-3
 Gs M.musculus Q6R0H7-2




   





MAPK activation is independent of Gi but instead works via Gs/PKA-
dependent activation of Rap1, a small G-protein and the serine/threonine 
kinase B-Raf (Schmitt and Stork, 2000; Friedman et al., 2002). According to 
Lefkowitz et al. (2002), such conflicting data were all derive from the use of 
different HEK293 cell lines, which may display differences in the role of Gs/Gi 
switching. 
 
Beas et al. (2012) reported that inactive Gs-G226A (GA) binds to GIV (also 
known as Girdin, a signal transducing protein), which then negatively 
regulates the EGF-induced proliferative signalling via early endosome 
antigen 1 (EEA1) endosomes (Beas et al., 2012). Gs and GIV promote 
maturation of EEA1 endosomes by facilitating dissociation of EEA1 in 
endosomal membranes. Depletion of Gs and/or GIV resulted in increased 
level of EEA1 in membranes, prolonged residence of activated EGFR and 
EGF in EEA1 endosomes, activation of ERK1/2, increased EGFR 
autophosphorylation, src homology 2 (SH2) adaptor recruitment and cell 
proliferation. 
 
Gs can also activate L-type voltage gated calcium channels in skeletal 
muscle cells, and cardiac myocytes via the cAMP/PKA pathway. Gs can also 
inhibit cardiac sodium channels via coupling of -adrenergic receptors and 
sodium channels and lead to enhanced membrane depolarisation (Wickman 




   





Kamp and Hell, 2000). Constitutive activation of Gs also plays a role in the 
regulation of osteoblast function, which results in increased trabecular bone 
formation (Hsiao et al., 2010). 
 
Ric-8B, a homologue of Ric-8, associates with Gq, Gs but not Gi and 
G12 (Tall et al., 2003). Ric-8B and Golf are both predominantly expressed in 
mature olfactory sensory neurons and appear to be functional partners in G-
protein-mediated odorant signal transduction (Von Dannecker et al., 2005).  
 
    1.6.5  The G Signalling 
 
The  heterodimer is a membrane associated signalling partner of the G 
subunit. The β heterodimers are known to regulate PLC, AC isoforms, 
phosphoinositide 3-kinase (PI3K), G protein-coupled receptor kinase 2 
(GRK2), and G protein-inwardly-rectifying K+ channels (GIRKs), also known 
as Kir3 channels (Lin and Smrcka, 2011). G also binds to a protein 
involved in regulating the visual signalling system called phosducin. 
 
The GIRK or Kir3 channel is the first discovered direct effector protein of G 
(Khan et al., 2013). Binding of G to GIRK strengthens the interaction of 
PIP2 and the channel, and also alters the conformation of the conductance 
pore of the channel, which increases its activity (Jin et al., 2002; Mirshahi et 




   





GRK2, which then phosphorylates and desensitises the activated agonist-
GPCR complex (Pitcher et al., 1996; Daaka et al., 1997). G also has an 
odd biochemical function in a non-canonical system involving the protein 
GRK2. Zha et al. (2015) reported that G2 binds to DDB1 of the DDB1-
CUL4A-ROC1 ubiquitin ligase independently of G, which then targets GRK2 
for ubiquitylation and degradation by the 26S proteasome thereby keeping a 
steady-state level of the protein.  
 
The ubiquitin-proteasome pathway is a complex regulatory system 
responsible for intracellular protein degradation (Lecker et al, 2006). Proteins 
bound for degradation are tagged with ubiquitin, which are then recognised 
by 26S proteosome. The covalent attachment of mono or poly-ubiquitins in 
the lysine residues of proteins is carried out by E1 (Ub-activating), E2 (Ub-
conjugating) and E3 (Ub-ligating) enzymes. The main internal lysine sites for 
ubiquitin tagging are lysine 48 and lysine 63, yielding K48- and K63-linked 
polyubiquitin chains (Sun, 2008). The K48 linkages having a closed 
conformation serve as a signal for target protein degradation by the 26S 
proteasome, while the K63 linkages with an extended linear conformation 
serve as non-proteasome addressing dock sites for a variety of functions 
such as DNA repair, endosomal trafficking, signal transduction, transcription, 
and multivesicular body sorting for lysosomal decay (Marx et al., 2010). 
Protein ubiquitylation can be reversed by deubiquitinating enzymes (DUBS), 




   





Specific amino acid residues (E574-K583) and a PH homology domain were 
identitfied as binding regions on PLC2 (Sankaran et al., 1998). It was 
proposed that such interactions may contribute to the reorientation of PLC 
for efficient binding of effector proteins (Drin and Scarlata, 2007; Drin et al., 
2006). G also regulates voltage dependent Ca2+ channels, which facilitate 
calcium ion flux across the plasma membrane. Binding of G to these 
channels inhibits the activity of the channel, a phenomenon known as 
voltage-dependent inhibition (Khan et al., 2013). In macrophages, the 
activated Gi- and Gq-coupled GPCRs require  subunits for the 
synergistic increase in intracellular Ca2+ via PLC3 and with a minor 
contribution from PLC2, while PLC4 antagonises such synergy (Brothers 
et al., 2011).  
 
Certain isoforms of AC are canonical cascade effectors of G, which may 
either promote production or reduction of cAMP. All AC isoforms have two 
catalytic domains: C1 and C2. G interacts with two motifs in AC: the QEHA 
motif found in C2 which is less important and the PFAHL motif (only found in 
AC2, AC4 and AC7) in the C1 domain, which proves to be an important 
binding site for G. G released from Gs-coupled receptors but not Gi-
couple receptors inhibits AC1, AC5 and AC6 (Nielsen et al., 1996); such 
inhibition depends on particular combinations of G and G (Bayewitch et 
al., 1998a and b). G is also involved in heterologous sensitisation of AC2 




   





opioid receptor inhibits AC2 in COS-7 cells (Conley and Watts, 2013; 
Schallmach et al., 2006).  
 
The G-activated PI3K phosphorylates phosphotidylinositols. PIP3, a 
primary product is a downstream cascade effector of the survival signalling 
pathway, and also an activator of protein kinase B (PKB). G activates and 
binds to multiple sites of two class I PI3Ks namely PI3K and PI3K (Khan et 
al., 2013) which contain P110 catalytic subunit and P101 regulatory subunit 
responsible for increased specificity to PIP2 (Stephens et al., 1997; Maier et 
al., 1999). Although G heterodimer stimulates the PI3K/Akt survival 
signalling, the inhibitory effects of Gq on this pathway is greater than G 
as G signalling pathways typically require 10-100 folds concentration of 
G than the G (Lee et al., 1993).  
 
G is also involved in the activation of MAPKs by three different 
mechanisms (Khan et al., 2013). The first one is through PI3K. Touhara et 
al. (1995) reported that G is involved in Gi-GPCR-mediated activation of 
MAPK and p21ras. They reported that G mediates early phosphorylation of 
p52, an Shc protein, which is an early event prior to p21ras activation. 
Inhibition of G-mediated PI3K activation abolished p52 phosphorylation. 
The second mechanism is via recruitment of different proteins that serve as 
scaffolds for MAPK activation. G can recruit kinase suppressor of Ras-1 




   





GPCRs, which then result in the recruitment and binding of -arrestins. The 
latter protein may serve as an adaptor protein for Src (Luttrell et al., 1999). 
The last mechanism is via transactivation of RTKs, which is the major 
activator of the classic MAPK signalling pathways (Della Rocca et al., 1999).  
 
  1.7  G-protein Signalling in Diseases and Development 
 
G-proteins are known to regulate many different cell functions, which involve 
a complex networking of various signalling pathways.  
 
The role of G-proteins in the regulation of cell growth and differentiation 
became apparent when several hormones were shown to promote cell 
proliferation and differentiation via the cAMP-dependent pathway, 
suggesting that Gs or Gi might be involved (Radhika and Dhanasekaran, 
2001). This observation was followed by studies involving a number of 
endocrine tumours which showed mutations in Gs and Gi. 
 
A number of pituitary and thyroid tumours show constitutively active Gs. 
Point mutation in either arginine 201 (R201) or glutamine 227 (Q227) in Gs 
was found in pituitary GH secreting tumours and thyroid hyperfunctioning 
adenomas. Mutated and constitutively active Gs later became known as the 





   





The involvement of Gi in cell transformation is the result of mutations in 
R179 or Q205 which lead to its constitutive activation. These Gi2 mutant 
forms are referred to as gip2 oncogenes. Although the mechanism linking 
this oncogene in cell growth is not clear, its negative effect on the levels of 
cAMP leads to constitutive activation of the Ras-independent MERK-ERK 
signalling, and transactivation of T-cell factors (TCFs) in the nucleus may be 
responsible.  
 
Investigation of Gq bearing the mutation in GqQ209L confirms its role in 
the transformation of different cell lines in tumour formation. Expression of 
GqQ209L in NIH3T3 cells leads to transformation and foci formation, albeit 
cytotoxicity was more prominent than its transforming effect (De Vivo and 
Iyengar, 1994; Kalinec et al., 1992). Based on the findings from the NIH3T3 
studies, it has been proposed that low levels of expression of the mutant 
Gq leads to transformation of fibroblasts, while a high concentration leads to 
cell death. The mechanisms by which transformation occurs involve a 
number of Gq interacting partners and downstream effectors. Microinjection 
of PLC resulted in mitogenic transformation of NIH3T3 cells (Smith et al., 
1989). Expression of different PLC-coupled GPCRs such as m1, m2, m5 
muscarinic-, 1b adrenergic- or 5HTlc-receptors also caused oncogenic 
transformation of NIH3T3 cells suggesting that transformation occurs via the 
PLC pathway. Activation of PLC generates two products, DAG and IP3 via 




   





ERK through Raf. Depending on the cell type, the ERK-mediated mitogenic 
effect involves two pathways; one is PKC-dependent but Ras-independent; 
the other involves a Pyk2 and Ras via IP3. IP3 leads to Ca
2+ flux which then 
stimulates Pyk2 activity to activate Shc through tyrosine phosphorylation. 
This results in the formation of Shc-GRB2-SOS complexes which then 
stimulate Ras leading to the activation of ERK. Both pathways lead to the 
activation of TCFs or TRE-specific transcription factors. A recent report 
about a highly conserved GEF, Trio, showed its essential role in the 
activation of JNK and p38 via Rho- and Rac-regulated signalling pathways 
from Gq (Vaque et al., 2013).                                     
                   
G12 was first identified as the transforming oncogene in some soft-tissue 
osteosarcomas and was classified as part of the gep family of oncogenes 
(Chan et al., 1993; Radhika and Dhanasekaran, 2001). However, the 
transforming ability of G12 is dependent on the presence of serum, as 
serum starvation caused a loss of its potent mitogenic effect (Chan et al., 
1993). On the other hand, expression of the GTPase-deficient G12Q229L 
led to transformation even in a serum-starved environment or in the absence 
of agonists. As expected, the transforming effects of G12Q229L and 
G13Q226L did not involve generation of cAMP, Ca
2+ or IP3 but resulted in 
Ras-, Rac- and CDC42-mediated activation of JNK without an apoptotic 
effect. Other growth-promoting signals include Ras/Rac-dependent transient 




   





complex formation. Ras-dependent ERK and Ras/Rac-dependent JNK 
activities are essential for G1 to S phase cell cycle progression in NIH3T3 
cells. The synergistic cooperation of G12, Raf1, and Rac1 are also 
important in the G12-mediated transformation of NIH3T3 cells. G12 is 
involved in the phosphorylation and activation of tyrosine kinases such as 
FAK and Tec/Bmx kinases. G12 activation of other signalling pathways 
involves activation of small GTPases such as Ras, Rac, CDC42 and Rho. 
These signalling pathways are a result of Ras/Rho dependent stimulation via 
PC-PLC or PLD, and Rac, Rho-dependent activation of phosphotidylinositide 
4-kinase (PI4K), and phosphotidylinositide 4-phosphate and 5-kinase 
(PIP5K). In other cell types, PKC-dependent signalling pathways can also be 
activated by G12. G12QL has been shown to activate SRF via the Rho-
dependent signalling pathway while G13QL activates the transcription of 
egr-1 which is considered to be a primary response for cell proliferation and 
differentiation (Prasad et al., 1994). Both members can also activate 
transcription of the pro-oncogene cyclooxygenase-2 (COX-2) (Radhika and 
Dhanasekaran, 2001).  
 
Various studies showed that G12 and G13 can also activate small GTPases 
by stimulating specific GEFs, competing with GDIs, or inhibiting specific 
GAPs. There have been suggestions that G12 can activate Ras and Rac via 
Shc and Tiam-1, an exchange factor for Rac through a PKC-dependent 




   





may play a role in cell proliferation and oncogenic transformation but this still 
needs to be defined (Jiang et al., 1998). 
 
Reports show that G12/13 plays an important role in organism development. 
Mice deficient in G13 died during at the early embryonic stage due to a 
malfunction in angiogenesis while deficiency in G12 with fully functional G13 
appeared to be normal (Offermanns et al., 1997).  G12-deficient mice with 
only one intact G13 allele, on the other hand, also lead to death in utero. The 
role of G12/13 in cell proliferation appears to be mediated by the small 
GTPases Rac, Ras, and Rho. These molecules and cdc42 play an important 
role in cell cycle progression from G1 to S phase. Rac appears to be 
essential for cell cycle progression from G2 to M phase. Rho also has a role 
in the regulation of cytoskeletal rearrangements, which is associated with 
cell division and proliferation. It also activates specific SRFs by an unknown 
mechanism, which may contribute to a mitogenic effect in some cell types 
(Hill et al., 1995).  
 
Free G has been shown to enhance -catenin/TCF signalling (Jernigan et 
al., 2010). The  complex, together with Dsh activates GSK3 which then 
phosphorylates LRP6. The phosphorylated LRP6 inhibits the degradation of 
-catenin leading to its stability. The -catenin then translocates to the 





   





An abnormally high level of GRK2, a G effector protein, has been linked to 
many human diseases such as heart attack/failure, portal hypertension, 
insulin resistance, and Alzheimer’s disease (Zha, et al. 2015). Previously, 
the regulation of the steady-state level of GRK2 via the G2-E3 ligase 
complex-dependent ubiquitylation and degradation was mentioned in section 
1.6.5 of this chapter. 
 
  1.8  Bacterial Toxins and Modification of GTP-binding   
         Proteins 
 
Bacterial toxins are powerful tools for understanding the molecular 
mechanisms behind cellular signal transduction exploited by pathogens. 
Such toxins helped in the discovery and characterisation of G-proteins in 
mammalian cells, which up to present remain essential in the studies of 
many G-proteins (Milligan and Kostenis, 2006; Denis et al., 2012).  
 
Some strains of bacteria produce toxins as a mechanism to increase their 
chance of survival. Many of these toxins modify cellular signalling pathways 
by acting on their host proteins. Bacterial toxins can be classified as 
endotoxins or exotoxins. Endotoxins are cell-associated toxins and integral 
part of the cell wall of the gram-negative bacteria i.e. lipopolysaccharide, 
which is released upon lysis or death while exotoxins are proteins 
synthesised and released by bacteria during their exponential growth or 




   





Bacterial exotoxins are grouped according to their structure and functions: 
the A-B toxins, superantigens (SAgs which also include the superantigen-
like toxins (SSL)) and the pore forming toxins. SAgs do not enter the cell but 
binds to cell surface molecules (e.g. SAgs bind to major histocompatibility 
complex II and T-cell receptor while SSL binds to sialyllactosamine, C5 or 
IgA) and activate the immune system (Henkel et al., 2010). SAgs such as 
Streptococcal pyrogenic exotoxin (Spe), Toxic shock syndrome toxin 
(TSST), and Staphylococcal enterotoxin are responsible for toxic shock-like 
syndrome and scarlet fever, toxic shock syndrome, and food poisoning 
respectively.  
 
The pore-forming toxins (PFTs) make up 25 - 30% of cytotoxic bacterial 
proteins produced by many pathogenic bacteria such as Staphylococcus 
aureus, Streptococcus pneumoniae, Escherichia coli, and Mycobacterium 
tuberculosis (Woodford and Livermore, 2009; Los et al., 2013). The main 
function of this bacterial protein is to perforate the membranes (plasma or 
intracellular organelle membranes) of the host cells (Iacovache et al., 2010).  
These toxins are produced to kill other bacterial species, escape the immune 
system by killing the immune cells, enter the host system and escape a 
phagosome. PFTs are divided into two groups: -PFTs and -PFTs based 
on the structure of their spanning elements: -helix or -sheets (Henkel et 
al., 2010; Del Peraro and Van Der Goot, 2016). These toxins bind to specific 




   





which leads to oligomerisation, an essential process for pore formation. 
Colicin produced by E. coli, haemolysin E by Salmonella enterica, 
Shigella flexneri and some strains of E. Coli, and cry toxins from 
Bacillus thuringiensis are examples of -PFT while V. cholerae cytolysin 
(VCC) from V. cholerae, and necrotic enteritis toxin B (NetB) from C. 
perfringens are examples of  -PFT. 
 
Almost all A-B toxins have two domains. The A domain harbours a catalytic 
activity while the B domain is responsible for cellular receptor binding and 
translocation of the toxin inside the cell (Henkel et al., 2010). Many of these 
bacterial toxins target GTP-binding proteins, which lead to deregulation of 
their specific signalling pathways via different covalent modification: 
deamidation (Schmidt et al., 1997; Schmidt et al., 1998; Flatau et al., 1997; 
Orth et al., 2009), ADP-ribosylation (Sehr, et al., 1998, Aktories et al., 1987), 
glucosylation (Just et al., 1995; Sehr, et al., 1998), adenylylation (Worby et 
al., 2009), transglutamination (Schmidt et al., 1998; Schmidt et al., 1999), 
and proteolysis (Shau et al., 2003).  
 
The cytotoxic necrotizing factor types 1 and 2 (CNF1/2) from necrotizing E. 
coli are responsible for gastrointestinal diseases, urinary tract infections and 
septicemia in humans and animals (Kadhum et al., 2008). Both share 99% 
amino acid sequence similarity and target Rho proteins (Oswald et al., 1994; 




   





The N-terminal of CNF1 and CNF2 contains the cellular binding domain 
which has 24% and 27% amino acid sequence identity respectively to PMT, 
while the C-terminus contains the catalytic domain which has amino acid 
sequence similarity with the Bordetella dermonecrotic toxin (Lemichez et al., 
1997; Busch et al., 2001) (PMT will be discussed in more detail in section 
1.8.1). CNF toxins activate Rho via deamidation of glutamine 63 (Gln63) of 
Rho or glutamine 61 (Gln61) of Rac or Cdc42 resulting in the inhibition of 
GTP hydrolysis and their constitutive activation (Flatau et al., 1997; Lerm et 
al., 1999; Schmidt et al., 1997). Phenotypic effects dependent on the 
inherent deamidation activity of the toxins include multinucleation, actin 
stress fibre formation, apoptosis, appearance of lamellipodia and filopodia in 
different cell lines (Mills et al., 2000). 
 
Dermonecrotic toxin (DNT) is produced by bacteria from the genus 
Bordetella. It possesses a transglutaminase activity that catalyses 
deamidation of Gln63 of RhoA and Gln61 of Rac and Cdc42 thereby keeping 
them in their constitutive active state (Fukui and Horiguchi, 2004; 
Matsuzawa et al., 2004). DNT causes splenoatrophy in mice (Fukui and 
Horiguchi, 2004), and moderate turbinate atrophy and lobular pneumonia in 
pigs (Brockmeier et al., 2002).  At a cellular level, DNT causes 
reorganisation of actin cytoskeleton, focal adhesion and stress fibres, DNA 
synthesis, inhibition of osteoblast differentiation, and multinucleation (Fukui 





   





Clostridia, Bacilli, and Staphylococci produce the toxin exoenzyme C3 (Just 
et al., 1992; Wilde et al., 2001; Wilde et al., 2003). Devoid of binding and 
translocation domains, its apparent mode of entry is via vimentin-dependent 
endocytosis (Rohrbeck et al., 2014). It is an ADP-ribosylating transferase 
which catalyses the hydrolysis of nicotinamide adenine dinucleotide (NAD) 
to ADP-ribose and nicotinamide, and transfers the ADP-ribose moiety to 
asparagine-41 of Rho isoforms A, B, C thereby inactivating their Rho 
GTPase activity (Aktories et al., 1987; Sekine et al., 1989; Wilde et al., 
2000). ADP-ribosylated Rho results in reduced level of RhoA-GTP, inhibition 
of cell cycle progression, and protection of serum-starved HT22 cells from 
programmed cell death (Rohrbeck et al., 2012).  
 
Heat-labile (LT) toxin from enterotoxigenic E. coli causes diarrhoea by 
inducing water and electrolyte loss from the intestines of humans and 
animals (Nataro and Kaper, 1998). LT is a heterohexameric A-B toxin with 
similar structure and function to cholera toxin (CT) (Spangler, 1992). Cholera 
toxin (CT) is the main virulence factor of Vibrio cholera that causes extreme 
diarrhoea, cramps, and vomiting which may result in death. The A domains 
of LT and CT possesses an ADP-ribosylation activity that modifies the Gs 
subunits thereby locking them in their constitutive active state.  Activation of 
Gs then leads to AC activation, increased cAMP level, and PKA activation 
(Johnson et al., 2009). The activated PKA phosphorylates the R domain of 




   





efflux of ions and water in the infected enterocytes causing the diarrhoeal 
disease. Apart from its role in causing diarrhoea, LT promotes adhesion of 
ETEC to intestinal epithelial cells through its ADP-ribosylation activity 
(Johnson et al., 2009) and LT-induced p38 MAPK activity (Wang et al., 
2012). It has also been implied that vesicle-bound LT can bind to cellular 
GM1 and bacterial LPS at the same time, which appear to contribute to the 
pro-adherence phenotype (Horstman and Kuehn, 2002). 
 
Pertussis toxin (PT) from the bacterium Bordetella pertussis is linked to the 
pathogenesis of whooping cough or pertussis (also discussed in section 
1.5). PT catalyses ADP-ribosylation of Gi, thereby locking the subunit in 
their GDP-bound inactive state and thus, inhibit it from interacting with the 
receptor, unable to inhibit AC activity leading to increased cAMP levels 
(Locht, 1999; Carbonetti, 2010; Locht et al., 2011). 
 
The bacterium Clostridium difficile causes nosocomial diarrhea in mammals. 
The toxigenic strains of C. difficile encode two toxins: A (308 kDa) and B 
(269 kDa), which are essential virulence factors in the pathogenesis of the 
disease (Kuehne et al., 2010). The central part of the C-terminus of the toxin 
harbours a cysteine protease activity responsible for cleaving and releasing 
the N-terminus, which contains the glucosyltransferase domain, into the 
cytosol (Hofmann et al., 1997; Pfeifer et al., 2003; Egerer et al., 2007; 
Reineke et al., 2007). This domain catalyses monoglucosylation of the Rho 




   





Gerhard, 2004). Such modification inhibits Rho GTPase functions, which 
leads to physiological changes in the cell such as cell rounding, actin 
cytoskeletal reorganisation, and apoptosis (Just et al., 1995).  
 
    1.8.1  Pasteurella multocida Toxin (PMT) 
 
Pasteurella multocida, a gram negative coccobacillus, is a pathogenic 
bacterium that causes a wide variety of diseases in mammals and birds 
(Weber et al., 1984; Lloret et al., 2013). They are normally found in oral flora 
of various animals such as cats and dogs. They can cause respiratory tract 
infection, and are found in infected wounds. They have also been linked to 
conditions such as spinal empyema and meningo encephalomyelitis (Lloret 
et al., 2013). Some strains of the organism with a lysogenic bacteriophage 
produce a protein toxin [Pasteurella multocida toxin (PMT)] (Pullinger et al., 
2004). PMT, a 146kDa dermonecrotic toxin is the virulence factor of P. 
multocida associated with atrophic rhinitis in swine, characterised by twisting 
and shortening of the snout, and atrophy of the nasal turbinate bones. At 
less than 1μgkg-1 body weight, PMT is lethal. Experimental injection of PMT 
leads to liver and kidney damage, proliferation of bladder and ureter 
epithelial cells (Hoskins et al., 1997; Lax and Chanter, 1990). 
 
PMT is an intracellularly acting toxin which activates multiple signalling 
pathways downstream of the heterotrimeric G-proteins. PMT activates three 




   





a strong mitogenic response in many cell types (Orth and Aktories, 2009; 
Rozengurt et al., 1990).  
 
      1.8.1.1 Structure and Catalytic Domain of PMT 
 
The N-terminus of PMT harbours the membrane receptor binding and 
translocation domains responsible for its entry and delivery of the catalytic 
domain of the C-terminal in to the cytosol (Baldwin et al., 2004; Pullinger et 
al., 2001). PMT binds to membrane phospholipids such as 
sphingophospholipid sphingomyelin or phosphatidylcholine with other lipid 
components (Brothers et al., 2011) and is then trafficked to a low-pH 
compartment where it is proteolytically activated between pH 5 – 5.5 
(Baldwin et al., 2004; Smyth et al., 1995). 
 
 
Fig 1.6.1.1. Ribbon diagram of C-
PMT. The secondary structure of 
PMT shows a Trojan-horse like 
shape which composed of three 
domains designated as C1 (blue), C2 
(green) and C3 (magenta) 
(Kitakodoro et al., 2007). The helices 
and β-strands are drawn as coils and 




The C-terminus contains the active domain (Pullinger et al., 2001; Orth and 




   





has 3 regions, C1, C2 and C3. The C1 subdomain (residues 575-719), which 
is essential for cytoxicity contains a lipid membrane localisation motif 
(Kitadokoro et al., 2007). The C2 subdomain (residues 720-1104) has 2 
subdomains,  and . Its function is still unknown but according to homology 
searches with DALI, it is similar to folypolyglutamate synthetase and 
cdc14bs phosphatase, which can interact with the phosphate groups of their 
substrates and co-substrates. It has been suggested that this domain may 
have a role in the stabilisation of the entire structure of C-PMT (Kitadokoro et 
al., 2007). Lastly, the C3 subdomain (residues 1105-1285) contains the 
latent cysteine-protease-like catalytic triad, Cys1165-His1205-Asp1220 
(Kitakodoro et al., 2007; Pullinger and Lax, 2007; Ward et al., 1998) which 
functions as a glutamine-specific protein deamidase (Orth and Aktories, 
2010). 
 
      1.8.1.2 Covalent Modification of the G subunits by PMT 
 
PMT changes the conserved glutamine amino acid in the switch II region of 
the  subunit into glutamic acid, which inhibits hydrolysis of bound GTP into 
GDP, thereby locking the G-protein in its constitutive active state. This 
glutamine is responsible for positioning the attacking water molecule during 








   














Fig 1.8.1.2-A  Deamidation of G subunit catalysed by PMT.  PMT converts the 
conserved residue, glutamine in glutamic acid thereby inhibiting GTP hydrolysis. –B  
G subunit in action. Hydrolysis of GTP with water molecule in placed (blue dot) 
Image adapted from Orth and Aktories (2010).  
 
Orth et al. (2009 and 2013) and Babb et al. (2012) confirmed that PMT 
covalently modifies members of the Gi family (Gi-1, Gi-2 and Gi-3), Gq 
family (Gq and G11) and G12 family (G12, G13) but not Gs. Babb et al. 
(2012) also reported that prolong treatment of Swiss 3T3 cells with PMT led 











   













Fig 1.8.1.2-B A schematic representation of PMT-induced activation of 
different G subunits and their immediate downstream effector proteins. The 
active G dimer, although indirectly activated by PMT, also shows their regulated 
downstream effector proteins. 
 
      1.8.1.3 PMT, the Antagonist of Cellular Homeostasis 
 
Various studies showed that PMT caused morphological havoc in different 
cell types via deregulation of some of the major signalling pathways.  
 
PMT is a potent mitogen in confluent, quiescent fibroblastic cells causing 
pleiotropic effects such as increased levels of inositol phosphates, activation 
of PKC, intracellular Ca2+ mobilisation, activation of small GTPases, 
stimulation of -catenin signalling, and depression of cyclic AMP (Orth et al, 
2008; Aminova and Wilson, 2007; Lax and Grigoriadis, 2001; Wilson et al., 
















   





1992; Staddon et al., 1990). Enhanced DNA synthesis, anchorage-
independent growth, development of foci, cytoskeletal rearrangements with 
prominent stress fibres and later on decreased adherence were observed in 
cultured fibroblasts (Higgins et al, 1992; Rozengurt et al, 1990; Wilson et al, 
2000). According to Rozengurt et al. (1990), PMT stimulated-DNA synthesis 
was comparable to the mitogenic effect induced by 10% serum. However, in 
other cell lines such as Vero (kidney epithelial cells derived from African 
Green Monkey), PMT caused a cytotoxic or cytopathic effect, cytoskeletal 
rearrangements without prominent stress fibres and no apparent cellular 
growth or proliferation (Pennings and Storm, 1984; Sunder and Kumar, 
2000; Wilson et al., 2000). 
 
Numerous studies showed that PMT activates MAPK signalling pathways via 
Gq/11 which lead to cell proliferation. In HEK293 cells, PMT activates the 
ERK1/2 pathway via Gq-dependent transactivation of the EGFR (Seo et al., 
2000). In cardiomyocytes however, stimulation of the ERK/MAPK pathway 
via Gq occurs in an EGFR-independent manner (Sabri et al., 2002). PMT 
activates PLCβ via the Gq/11 α-subunits which then leads to the production of 
IP3 and DAG via PIP2 cleavage. The release of these secondary 
messengers stimulates Ca2+ mobilisation, activates PKC-dependent 
phosphorylation and calcineurin-dependent Nuclear factor of activated T 
cells. The released Ca2+ binds and activates calmodulin (CaM) and other 
effector proteins. Notch1 has also been linked to PMT-induced activation of 




   





unclear but activation of the Ca2+/calmodulin-dependent serine/threonine 
phosphatase calcineurin downstream of Gq blocks adipocyte differentiation 
(Wilson and Ho, 2011).  
 
PMT also induced the expression of serine/threonine kinase Pim-1 via 
phosphorylation of Akt which effectively disrupts the activity of suppressor of 
cytokine signalling 1 (SOCS-1). The phosphorylated SOCS-1 enhances the 
JAK-STAT (Janus kinase, signal transducer and activator of transcription) 
activity (Hildebrand et al., 2010). These actions lead to stimulation of survival 
pathways and inhibition of apoptotic pathways. Activation of STAT1, 3, and 5 
alters gene expression, e.g. upregulation of cancer-associated 
cyclooxygenase (COX)-2 expression (Orth et al., 2007). Activation of Gq and 
G12/13 also leads to the activation of c-jun, a critical step for transformation 
via the MAPK pathway (Marinissen et al., 2003).  
 
The mammalian target of rapamycin complex 1 (mTORC1) protein activated 
via the Gq/11/PLC/PKC pathway has been shown to be partially involved in 
the mitogenic response induced by PMT (Oubrahim et al., 2013). PMT 
induces upregulation of the connective tissue growth factor (CTGF) which 
then leads to the phosphorylation of ribosomal S6 kinase (S6K1) at Thr389 
residue by mTOR (Koch et al., 1991). S6K1 then phosphorylates its 
substrate, ribosomal S6 protein (rpS6) at Serine residues. All of these 
actions lead to protein and ATP synthesis which are involved in cell growth, 




   





Cytoskeletal signalling is an early event mediating cell growth and 
differentiation. PMT via Gq and G12/13 families activates RhoA via RhoGEFs 
leading to proliferation and cytoskeletal rearrangements (Orth et al., 2005). 
The formation of actin stress fibre and focal adhesion assembly in Swiss 3T3 
cells are the result of activation of focal adhesion kinase and Src proto-
oncogene, phosphorylation of p125FAK and adaptor protein paxillin via Rho 
(Lacerda et al., 1996).  
 
PMT affects bone formation by inhibiting osteoblast differentiation via the 
Rho/ROK pathway (Harmey et al., 2004). PMT acts on osteoblast precursors 
to promote proliferation of the primary osteogenic cells via activation of the 
Ras-dependent Erk/MAPK pathway. This activation inhibits expression of 
growth factors such as bone morphogenetic protein (BMP) 2 and 4 and 
expression of osteoblast differentiation markers such as Cbfa1, as well as 
osteocalcin and alkaline phosphatase. PMT also inhibits osteoblast 
differentiation by transactivation of MAPK via activation of Gq/11, p63RhoGEF 
and RhoA (Siegert et al., 2013).  
 
Wilson et al. (2000) analysed the effects of PMT on the expression of cell 
cycle markers such as MAPKs, cyclins D and E, p21, PCNA, c-Myc, and Rb 
proteins. They reported that in Swiss 3T3 cells, recombinant PMT (rPMT) 
stimulated phosphorylation of Rb/p130 and upregulated the expression of 
cyclins D and E which are required for cell cycle progression in particular 




   





D1 and 2 were detected on the first day. Cyclins D3 and E were almost not 
detectable.  
 
PMT induces an anti-apoptotic effect in HEK293 cells. PMT was able to 
block stauroporine-induced apoptosis (Preuss et al., 2010). Staurosporine is 
a protein kinase inhibitor and a pro-apoptotic chemical, which works via 




















   





  1.9  Aims 
 
PMT inhibits the intrinsic GTPase activity of some members of Gi, Gq and 
G12 families. In many cell types (e.g. Swiss 3T3 cells), stimulation of 
signalling by PMT leads to a mitogenic response and cytoskeletal 
rearrangements while in others (e.g. Vero cells), PMT induces a cytotoxic 
phenotype with no evidence of mitogenicity (Wilson et al., 2000). The 
primary aim of this research is to investigate the cause of this notable 
difference as a tool to understand how G-protein activation leads to different 
responses in different cell types and the downstream interactions of these 
signalling molecules in controlling cellular function. Swiss 3T3 cells are 
mouse-derived fibroblast cells that are a standard model for cell proliferation 
assay while Vero cells are kidney epithelial cells derived from African Green 
Monkey. The specific aims are outlined below to help understand the 
primary aim. 
 
• To quantify G-protein content and compare at the subtype level  
 
• To determine which G-protein subtypes are modified by PMT 
 
• To obtain preliminary evidence of downstream signalling events 
 
• To investigate whether PMT causes differential loss of specific  




   





2  MATERIALS AND METHODS 
 
  2.1  General Solutions 
 
The water used in all stock solutions was autoclaved at 123 °C for 28 min in 
Prioclave bench top autoclave. All recipes listed are for solutions made up to 
a volume of 1 L. 
 
10x TBS-T  200mM Tris(hydroxymethyl)aminomethane    
  (Sigma-Aldrich 252859), 1.5M NaCl (Sigma-  
  Aldrich S3014), 1% (v/v) Tween-20 (Sigma- 
  Aldrich P2287), distilled water  
 
10x Running Buffer (~pH 8.3)   30.3g Tris(hydroxymethyl)aminomethane,     
144 g glycine (Santa Cruz   
  Technology SC-29096C), 10g sodium   
  dodecyl  sulfate (SDS) (Sigma-Aldrich  
  L3771), distilled water (if properly weighed,   
  pH is approximately 8.3) 
 
10x Transfer Buffer (~pH 8.3)  30.3g Tris(hydroxymethyl)aminomethane, 
144 g glycine, distilled water (if    





   





10x TBE 108g Tris(hydroxymethyl)aminomethane,  
  55g Boric Acid (Sigma-Aldrich  
 B6768), 40ml of 0.5M           
 Ethylenediaminetetraacetic acid (EDTA)  
 (Sigma-Aldrich E9884) (pH 8.0), distilled  
 water 
 
1x TAE 20ml of 50x Tris-acetate-EDTA (TAE)   
 (Thermo-Scientific B-49), distilled water 
 
  2.2   Reagents 
 
NCS and Foetal Bovine Serum (FBS) were obtained from Invitrogen Ltd. 
(Paisley, UK). DMEM, Dulbecco’s Phosphate Buffer Saline (DPBS), 
Trypsin/EDTA solution 0.05%, 10,000 unit/ml:10 mg/ml PS, 200 mM L-
glutamine solution were purchased from Sigma-Aldrich Co. Ltd. (Dorset, 
UK). Cell culture dishes were purchased from Helena Biosciences Ltd. 
(Sunderland, UK). Cell culture flasks were purchased from Triple Red Ltd. 
(Buckinghamshire, UK). Pipette tips were purchased from Greiner Bio-One 
Ltd. (Stonehouse, UK).  
 
Phalloidin Tetramethylrhodamine B isothiocyanate (TRITC) and Hoescht 
33258 were purchased from Sigma-Aldrich. Western stripping buffer and 




   





Biotechnology (Wembley, UK) and GE Healthcare Ltd. (Buckinghamshire, 
UK) respectively.  
 
  2.3   Cell Culture 
 
Swiss 3T3 cells were a kind gift of Dr. Rob Brookes from the School of 
Biomedical Sciences of King’s College London. Vero cells were obtained 
from Dr Gill Pullinger of Pirbright Institute (UK). Swiss 3T3 cells were grown 
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 1% 200 
mM L-glutamine, 1% penicillin streptomycin (PS), and 10% newborn calf 
serum (NCS), in 10% CO2 at 37°C. Vero cells were grown in DMEM 
supplemented with 1% 200 mM L-glutamine, 1% PS, and 10% NCS in 5% 
CO2 at 37°C. 
 
    2.3.1   Preparation of Cell Culture Stock 
 
Ampoules of Swiss 3T3 and Vero cells stock culture (2-4 X 106 
cells/ampoule) containing 10% dimethyl sulfoxide (DMSO) and 90% DMEM-
NCS medium were frozen slowly at -70°C in a Nalgene Cryo 1°C freezing 
container and later stored in liquid nitrogen.  
 
  2.4   Antibodies 
 
The anti-Gq (SC-393), anti-G11 (SC-394), anti-G12 (SC-409), anti-G13 




   





5573) were purchased from Santa Cruz Biotechnology (Wembley, UK)  and 
the anti-Gi-1 was purchased from Merck Chemicals Ltd - Calbiochem 
(Nottingham, UK). The anti-Gi-1 for immunoprecipitation was purchased 
from Abcam (Cambridge, UK). The anti-Na+/K+ ATPase α-1 was purchased 
from Merck Millipore (Hertfordshire, UK). The anti-RhoA (Part No. 240302), 
anti-Rac1 (Part No. 240106), and anti-Cdc42 (Part No. 240201) used in the 
pull-down assay were part of the RhoA/Rac1/Cdc42 Activation Assay 
Combo Kit from Cell Biolabs (Cambridge, UK). The anti-rabbit and anti-rat 
IgG, HRP-linked were purchased from Santa Cruz Biotechnology while the 
anti-mouse IgG, HRP-linked was purchased from Cell Signaling Technology 
Inc.  
 
The anti-QE-producing Hybridoma cells were a kind gift of Dr. Yasuhiko 
Horiguchi from the Research Institute for Microbial Diseases, Osaka 
University, Japan. The anti-QE antibody, which recognises only the 
deamidated form of G polypeptides, from the Hybridoma cells was 
prepared by Arshiya Banu, a PhD student of this institute. 
 
The anti-PMT monoclonal antibody was a kind gift of Dr. Gill Pullinger from 







   





  2.5   Bacterial Toxin  
 
The recombinant Pasteurella multocida toxin (rPMT) and mutant toxin 
rPMTC1165S had been previously prepared by Dr. Rebecca Babbs of this 
institute, according to published protocols (Ward et al., 1998). PMTC1165S is 
the mutant form of PMT where the 8th cysteine (C1165) is replaced with 
alanine in the catalytic core, abrogating its catalytic activity on the G 
subunits (Ward et al., 1998). The recombinant toxins were kept at –20ºC 
freezer. 
 
Fig 2.5  The purified recombinant PMT and 
PMTC1165S. The stock solution of rPMT and 
rPMTC1165S (3 µg) were resolved by SDS-PAGE 
and protein bands were visualised using CCBB 
stain (see section 2.13).  
 
  2.6   Cell Proliferation Assay Using Haemocytometer 
 
    2.6.1   Confluent Swiss 3T3 and Vero Cells 
 
Swiss 3T3 and Vero cells were plated in 24-well plates at 2 x 104 cells and 4 
x 104 cells per well respectively and cultured in media (DMEM containing 1% 
PS, and 1% L-glutamine) supplemented with 10% FBS and 10% NCS for 5 
days until cells were confluent and quiescent. Swiss 3T3 and Vero cells 
were incubated at 37C in 10% and 5% CO2 respectively. Cells were 












   





previous cell culture medium, and serum-starved using media only for 40-48 
h. Subsequently, cells were washed three times with DPBS and treated with 
200 ng/ml of recombinant PMT (rPMT) or PMT-C1165S (rPMT-C1165A) in media 
with 1% FBS for Swiss 3T3, and media with 1% NCS for Vero cells. Cells 
were washed twice with DPBS, trypsinised, neutralised with media with 10% 
FBS or NCS and counted at different time points: 0, 24, 48, 72, 96, 120, 144, 
168, 192 h using a haemocytometer. Morphological changes were captured 
using a phase-contrast microscope (see section 2.8). 
 
    2.6.2  Subconfluent Swiss 3T3 and Vero Cells 
 
For the 3- and 10-day proliferation assays, Swiss 3T3 and Vero cells were 
cultured in 24-well plates at 2 x 104 cells and 4 x 104 cells per well 
respectively in media with 10% NCS for 3-4 days until cells were ~50 - 60% 
confluent. Cells were washed with DPBS, serum-starved and subsequently 
washed with DPBS (as described in section 2.6.1) prior to treatment with or 
without 15 ng/ml of rPMT or PMT-C1165S in media with or without 10% NCS. 
For the 10-day treatment, Swiss 3T3 and Vero cells were either left 
untreated or treated with 15 ng/ml of rPMT maintained in media with or 
without 1% NCS. Cells were washed twice with DPBS, trypsinised, 
neutralised with media supplemented with 10% NCS, and counted at 
different time points: 0, 24, 48, 72, 96, 120, 144, 168, 192 h for the 10-day 





   





  2.7  Phalloidin Staining of Actin Filaments  
 
Swiss 3T3 and Vero cells were cultured on 22 x 22 mm Corning coverslips 
(Thermo-Scientific, UK) in 6-well plates at 4 x 104 cells and 8 x 104 cells per 
well respectively in media with 10% NCS for 4 days until cells were confluent 
and quiescent. Cells were washed with DPBS, serum-starved and 
subsequently, washed with DPBS (as described in section 2.6.1) prior to 
treatment with or without 200 ng/ml of rPMT in media with 1% NCS. 
 
Cells were fixed at different time points with 4% paraformaldehyde (Santa 
Cruz Biotechnology) and left overnight at 4ºC. Cell membranes were 
permeabilised with 0.1% Triton X-100 in DPBS for 15 min at 4ºC, then non-
specific sites were blocked with a blocking buffer (1% BSA in DPBS). Fixed 
cells were stained with Phalloidin TRITC and left for 1 h at 37ºC. Cells were 
washed three times with wash buffer (DPBS with 0.5% Tween-20) at 5 min 
intervals. Stained cells were washed three times with a wash buffer and 
fixed with Mowoil 4-88 (Sigma-Aldrich) anti-fade mounting medium (4.8% 
(w/v) Mowoil 4-88, 12% (w/v) glycerol, 24% (v/v) 0.2M Tris-HCl buffer 
(pH8.5), 64.8% (v/v) distilled water, sodium azide (NaN3) on a microscope 
slide (Thermo-Scientific). Cells were visualised using a fluorescence 







   





  2.8  Microscopy/Photography 
 
Phase-contrast and fluorescence imaging were done using an Olympus IX5I 
Fluorescence microscope and captured by CellSens version 1.12 software. 
Image J (National Institutes of Health, Maryland, USA) was used to merge 
fluorescent images. A two-photon excitation fluorescence Nikon Eclipse Ti 
microscope was also used in fluorescence imaging (used in section 3.2.2.2 
of chapter 3). 
 
  2.9  Cytotoxicity Assay 
 
    2.9.1  LDH Assay 
 
The Cytotox® 96 Non-Radioactive Cytotoxicity Assay Kit (Promega, UK) 
was used to assess the cytotoxicity of rPMT in Swiss 3T3 and Vero cells. 
Swiss 3T3 and Vero cells were cultured in 96-well plates at 8 x 104 cells and 
1.6 x 105 cells per well respectively in media with 10% NCS for 2 days until 
cells were confluent and quiescent. Cells were washed with DPBS, serum-
starved and subsequently washed with DPBS (as described in section 
2.6.1). Cells were either left untreated or treated with 0.01, 0.1, 1, or 10 
ng/ml rPMT or rPMTC1165S in media without or with 10% NCS.  
 
A standard curve was generated using lactate dehydrogenase from porcine 
heart (Sigma-Aldrich) to determine the concentration of LDH in the samples. 




   





Cytotoxicity Assay Kit. Supernatant (50 µl) from each well was transferred to 
a new 96-well plate including supernatant from wells without cells. Cytotox® 
96 reagent (12 ml of assay buffer, 1 bottle of Cytotox® substrate mix) (50 µl) 
was added to each well. Samples were incubated at 37C for 30 min. 
Cytotox® stop reaction solution (50 µl) was added to each well. Plates 
containing the standard curve and samples were immediately read using 
Microplate Reader Labtech LT-4000 (Labtech, Vienna, Austria) at 495 nm 
and data were acquired using Labtech Manta software. 
 
  2.10  Calcium Assay 
 
The Fluo-4 NW Calcium Assay Kit was used to determine Gq activity by 
measuring the calcium influx in the cytosol from the Ca2+ stores.  
 
Swiss 3T3 and Vero cells were cultured in 96-well plates at 8 x 104 cells and 
1.6 x 105 cells per well respectively in media with 10% NCS until cells were 
confluent. Cells were washed with DPBS, serum-starved and subsequently 
washed with DPBS (as described in section 2.6.1) prior to treatment with or 
without 15 ng/ml of rPMT in media only. 
 
After 24, 48, or 72 h, growth medium was removed from the plates and 100 
µl of the dye-loading solution (10 ml of assay buffer and 100 µl of probenecid 
stock solution [1 vial of probenecid and 1 ml of assay buffer]) was added to 




   





room temperature. Fluorescence was measured in Flouraskan Ascent/FL 
(Thermo Scientific) with wavelengths: Excitation 485; Emission 510 nm.  
 
  2.11  Activation of Rho GTPases 
 
The RhoA/Rac1/Cdc42 Activation Assay Combo Kit (Cell Biolabs, 
Cambridge, UK), which includes Rhotekin RBD and PAK PBD agarose 
beads, antibodies  for RhoA, Rac1, and Cdc42, was used to determine the 
activity of Rho GTPase family members. Swiss 3T3 and Vero cells were 
cultured in 150 mm plates at 8 x 104 cells and 1.6 x 105 cells per well 
respectively in media with 10% NCS until cells were subconfluent 
(approximately 80 - 90% confluent as per manufacturer’s protocol). Cells 
were washed with DPBS, serum-starved and subsequently washed with 
DPBS (as described in section 2.6.1) prior to treatment with or without 15 
ng/ml of rPMT in media only. 
 
After 24, 48, or 72 h, culture media were removed and washed twice with 
ice-cold PBS. Ice-cold 1x Assay Lysis buffer (1.5 ml) was added to the cells 
and incubated for 15 min on ice. Cells were detached using a cell scraper 
and lysates were transferred to a 2 ml microtube and kept on ice. Lysates 
were centrifuged at 14,000 x g for 4C for 10 min. The protein concentration 
of the samples was determined using the BCA assay. The supernatant (1 
ml) with a protein content of >0.5 mg was aliquoted to a new centrifuge tube 




   





Assay Lysis Buffer). Rhotekin RBD (for RhoA) or PAK PBD beads (for Rac1 
or Cdc42) (40 μl) was added to each tube and incubated at 4C for 1 h with 
gentle agitation. The beads were pelleted at 14,000 x g for 10 s. The 
supernatant was aspirated and the pellet was washed three times with 0.5 
ml Assay Lysis Buffer with centrifugation after each wash. The bead pellet 
was resuspended with 2x SDS-PAGE sample buffer and heated at 95°C for 
5 min. Proteins were separated by conventional SDS-PAGE, transferred to 
PVDF membrane and subjected to Western blotting analysis. 
 
  2.12  Suppression of cyclic AMP (cAMP) 
 
The cAMP Glo® Assay (Promega) was used to determine the activity of Gi 
via suppression of the cAMP level. A standard curve was generated using a 
cAMP standard (Promega) to determine the concentration of cAMP in the 
samples. Swiss 3T3 and Vero cells were cultured in 96-well plates at 8 x 104 
cells and 1.6 x 105 cells per well respectively in media with 10% NCS for 3 
days until cells were confluent and quiescent. Cells were washed with 
DPBS, serum-starved and subsequently washed with DPBS (as described in 
section 2.6.1) prior to treatment with or without 15 ng/ml of rPMT in media 
only. 
 
Samples were processed at different time points: 0, 24, 48, or 72 h. 
Forskolin (Sigma-Aldrich) or DPBS (20 μl) was added to each well of the 




   





cAMP-GloTM Lysis Buffer (20μl) was added to each well. Plates were 
incubated with gentle shaking at room temperature for 15 min. cAMP-GloTM 
Detection Solution (2.5μl of Protein Kinase A per 1.0ml of cAMP-GloTM 
Reaction Buffer) (40μl) was added to each well with 30-60 s shaking before 
incubation at room temperature for 20 min. Kinase Glo Reagent (80μl) was 
added to each well with 30-60 s shaking before incubation at room 
temperature for 10 min. Luminescence was measured in Flouraskan 
Ascent/FL (Thermo Scientific). 
 
  2.13  Molecular and Cell Biology 
 
    2.13.1  Preparation of membrane and cytoplasmic fractions  
               from Swiss 3T3 cells and extraction of G-proteins  
               from membrane fractions 
 
Quiescent cultures of Swiss 3T3 and Vero cells were grown in 150 mm 
dishes and rinsed twice with ice cold DPBS and scraped into 2 ml of DPBS 
containing proteinase inhibitors (CompleteTM, Roche Diagnostics). Cells from 
20 dishes were transferred to 12 ml falcon tubes and pelleted by 
centrifugation (200g, 10 min, 4°C), DPBS was aspirated and the cell pellet 
was frozen at –70°C until required. The frozen cell pellets were thawed on 
ice and suspended in 5 ml of membrane buffer (10 mM Tris-HCl, 10 mM 
MgCl2, 0.1 mM EDTA, pH 7.4, containing
 proteinase inhibitors). The cells 




   





homogenate was centrifuged at 800g for 10 min to remove intact cells and 
nuclei. The resulting supernatant was centrifuged at 50,000g using a 
Beckman CoulterTM Avanti-J-20 XPI Expanded-Performance Centrifuge unit 
(Kendro Laboratory Products Ltd.) for 30 min at 4°C. The membrane pellet 
was resuspended in membrane buffer to a protein concentration of 1 mg/ml 
and centrifuged at 50,000g for 30 min to remove contaminating cytosolic 
proteins. The membrane pellet was resuspended in 1ml of membrane buffer 
and protein concentration was determined using the BCA assay. The 
membrane proteins (1.5 mg/ml) from Swiss 3T3 cells or (2.5 mg/ml) Vero 
cells were mixed with 2x sample buffer and boiled at 95°C for 5 min. 
Proteins were separated by conventional SDS-PAGE, transferred to PVDF 
membrane and subjected to Western blotting analysis. 
 
    2.13.2  Sodium-Dodecyl-Sulphate Polyacrylamide Gel  
   Electrophoresis (SDS-PAGE)  
 
SDS-PAGE was based on the method provided by Laemmli (1970) and 
BioRad (Hempstead, UK) SDS-PAGE Laemmli Buffer System. Resolving 
gels were prepared using 10 – 14 % acrylamide/bis (30 %, 37.5:1), and 4 % 
stacking gel acrylamide/bis (30 %, 37.5:1). Samples were denatured by the 
addition of an equivalent volume of 2x SDS PAGE buffer (240mM Tris/HCL, 
pH 6.8, 8 % (w/v) SDS, 40 % (v/v) glycerol, 7 % (v/v) 2-mercapthoethanol, 




   





mini-Protean system (Bio-Rad) using SDS-electrophoresis at 200V for ~45 
min or until the dye had reached the end of the gel.  
 
    2.13.3  Colloidal Coomassie Blue Staining 
 
Colloidal Coomassie Blue Staining (CCBB) staining was used to visualise 
the protein bands on the gels. Following electrophoresis, gels were rinsed 
three times for 5 min in a large volume of ultra-pure water and stained with 
Coomassie Brilliant Blue R-250 solution (50 % methanol, 10 % acetic acid, 
and 0.05 % Brilliant Blue R-250) for 1 h, and destained with Coomasie 
destain solution (40 % methanol, 50 % distilled water, and 10 % acetic acid) 
for 1 - 2 h.  
 
    2.13.4  Protein Transfer and Western Blotting 
 
Proteins separated by SDS PAGE were transferred to PVDF membranes by 
a method adapted from Towbin et al. (1979). A gel ‘sandwich’ (fibre pad 
(BioRad), thick filter paper membrane (BioRad), SDS gel, nitrocellulose or 
methanol-pre-wetted PVDF membrane (BioRad), thick filter paper 
membrane and fibre pad) in a gel cassette holder was assembled and 
placed in a Mini TransBlot cell (Bio-Rad) filled with pre-chilled transfer buffer 
(25 mM Tris base, 192 mM glycine, 10 % methanol). Transfer was 





   





Following protein transfer the membrane was soaked briefly in methanol and 
allowed to air dry to fix the proteins before being rewetted in methanol and 
washed three times in distilled water. Membranes could then be stained with 
Ponceau S (0.1 % (w/v) Ponceau S in 5 % (v/v) acetic acid) if visualisation of 
transferred proteins was required. Membranes were incubated in blocking 
buffer (5 % non-fat dried milk and Tris buffered saline (TBS, 137 mM Sodium 
Chloride, 20 mM Tris, 0.1 % Tween-20 at pH 7.6) solution for 1h at room 
temperature on an orbital shaker. The blocking buffer was removed and 
membrane was washed three times for 10 min each with wash buffer (0.1 % 
Tween 20 in TBS). The membrane was probed with primary antibody 
(1:1000) in 5 % non-fat dried milk and 0.1 % Tween-20 in TBS overnight at 
4ºC on an orbital shaker. Following the primary antibody incubation period 
the membrane was washed three times for 10 min each with wash buffer, 
followed by incubation with horseradish peroxidase-coupled secondary 
antibody at a dilution of 1:10000 for 1 h at room temperature. The membrane 
was washed three times for 10 min each with wash buffer. Membrane was 
incubated with ECL™ chemiluminescent substrate (GE HealthCare) and 
signals were detected using the BioRad ChemiDocTM MP Imaging System 









   





    2.13.5  Determination of Protein Concentration Using  
 Bicinchoninic Acid (BCA) Assay 
 
The Pierce™ BCA protein assay kit was purchased from Life Technologies 
(Paisley, UK). The Bovine Serum Albumin (BSA) used as the protein 
standard to generate the standard curve was purchased from Sigma-Aldrich. 
BSA standard (25 µl) (BSA in DPBS or lysis buffer) with concentrations: 0, 
62.5, 125, 250, 375, 500, 750, and 1000 µg/ml and samples (25 µl) with 
unknown protein concentration were transferred in triplicates to a 96-well 
plate. 200µl of BCA working reagent (50:1 Reagents A and B) was added to 
each well. The 96-well plate was then incubated at 37°C for 30 min and 
cooled to room temperature for 5 min prior to OD measurement (540 nm). 
The linear regression equation from the standard curve was used to 
determine the unknown protein concentration of each sample. 
 
    2.13.6  Detection of Unmodified and Deamidated G  
                subunits by Immunoprecipitation 
 
Unmodified and deamidated endogenous G-proteins alpha subunits of Swiss 
3T3 and Vero cells were resolved by immunoprecipitation. Quiescent 
cultures of Swiss 3T3 and Vero cells were grown in 150 mm dishes, serum 
starved, left untreated or treated with rPMT (as per section 2.7.2), collected 
and processed (as per section 2.13.1). Frozen pelleted samples kept in -




   





NaCl, 5 mM EDTA, 50 mM NaF, 1 mM Na3VO4, 1 % CHAP, 0.02 % NaN3) 
supplemented with 1x protease inhibitor cocktail solution and kept on ice for 
30 min, vortexing at 10-min intervals and subjecting to brief sonication. 
Samples were centrifuged at 17,000 x g for 10 min at 4ºC. Clear lysates 
were transferred to clean microtubes. Protein concentration was determined 
by the BCA assay. Proteins from Swiss 3T3 (500 µg) or Vero cells (700 µg) 
was aliquoted in each tube and stored at -70ºC until required. 
 
Samples ready for immunoprecipitation, 1 μg of antibody specific to G 
subunit was added to each tube and left to conjugate overnight at 4ºC on an 
orbital shaker. Magnetic Dynabeads® (Life Technologies Ltd) (50 μl) were 
added to each tube and left to cross-link for 10-15 min at room temperature 
on an orbital shaker. The cross-linked Dynabeads® (antibody-antigen) were 
washed three times with 100 μl wash buffer (0.1%Tween-20 in DPBS). 4x 
sample buffer (1 part) and nuclease free water (3 parts) were added to the 
cross-linked Dynabeads® and boiled at 95ºC for 5 min. Proteins were 
separated by conventional SDS-PAGE, transferred to PVDF membrane and 
subjected to Western blotting analysis.  
 
    2.13.7  RNA Extraction from Swiss 3T3 and Vero Cells 
 
RNA molecules from Swiss 3T3 and Vero cells were extracted using the 





   





Buffer RLT Plus (600 µl) (containing 0.1 % of β-mercaptoethanol) was added 
to each microcentrifuge tube containing ~1 x 107 Swiss 3T3 or Vero cells. 
Tubes were then vortexed for 10s to homogenise. The homogenised lysate 
was transferred to the gDNA eliminator spin column placed in a 2ml 
collection tube and centrifuge for 30 s at ≥8000 x g. The column was 
discarded and 1 volume of 70 % ethanol was mixed with the flow-through. 
Part (700 μl) of this mixture was transferred to a RNeasy spin column placed 
in a 2ml collection tube which was then centrifuged for 15 s at ≥8000 x g. 
The flow-through was discarded and 700 μl of Buffer RW1 was added to the 
RNeasy spin column in a 2 ml collection tube and centrifuged for 15 s at 
≥8000 x g. Flow-through was discarded and 500 µl of Buffer RPE (containing 
80 % (v/v) of 94 - 100 % ethanol) was added to the RNeasy spin column and 
centrifuged for 15 s at ≥8000 x g. The last step was repeated and 
centrifuged for 2 min instead of 5 s. To elute the RNA molecules from the 
RNeasy spin column which was placed in a new 1.5 collection tube, 30 µl of 
nuclease free water (BioRad) was added to it and centrifuged for 60 s at 
≥8000 x g. RNA elution was repeated using the same RNA eluate. 
 
    2.13.8  Integrity and Purity of the Extracted Cellular RNA 
 
One of the most common methods to assess integrity of total RNA samples 
is by visualising 28s and 18s ribosomal RNAs (rRNAs) on a denaturing 
agarose gel stained with gel red or ethium bromide (EtBr)  (Fleige and Pfaffl, 




   





therefore would not migrate according to their size. Samples with intact total 
RNAs will have a clear ~2:1 ratio intensity of 28s and 18s rRNA bands. 
 
Extracted RNAs in samples were electrophoresed on 1 % (w/v) agarose gel, 
which were composed of molecular grade agarose (Sigma-Aldrich) dissolved 
in 1x TAE (Thermo-Scientific) containing 1 % household bleach (Clorox®, 
CA, USA), by heating the solution in a microwave oven. RNA samples were 
mixed with approximately 1/6 volume of loading dye (Thermo-Scientific) prior 
to loading. A commercially prepared 100bp DNA ladder (New England 
Biolabs, UK) was used to determine that electrophoresis was successful. 
Electrophoresis was carried out in horizontal electrophoresis unit in trays at 
approximately 6V/cm of gel (constant voltage) for ~1 - 1.5 h. Gels were then 
stained using GelRed (Biotum, UK) for 30 min then visualised on UV 
transilluminator (AlphaImager; λ= 302) to allow the UV detection of the 
stained DNA bands.  
 
    2.13.9  Generation of cDNA from extracted RNA by PCR 
 
For the generation of cDNA template from mRNA, Precision nanoScript™ 2 
Reverse Transcription kit (Primerdesign, UK) containing dNTPs, reaction 
buffer, enzymes, DTT, oligodT primer, nuclease-free water. For a 10μl 
reaction (designated as tube A), 2ng-2μg of mRNA template, 1 μl of primer, 
nuclease-free water were mixed and heated to 65°C to denature any double 




   





transferred to ice. In another tube (designated as tube B), 2 μl of buffer, 
dNTPs, 2 μl of 100 mM DTT, 1 μl of enzymes, and 4 μl of nuclease-free 
water were mixed. Tube A and B were mixed to make a 20 μl reaction and 
briefly vortexed followed by a pulse spin and incubation at 55C for 20 min. 
cDNA was stored at -20C until use. 
 
High-Capacity cDNA Reverse Transcription Kit (Life Technologies) was also 
used to generate cDNA. The 2x RT master mix was prepared on ice by 
mixing 2 μl of 10x RT buffer, 0.8 μl of 25x dNTP mix (100 mM), 2 μl of 10x 
RT random primers, 1 μl of Multiscribe™ reverse transcriptase, 1 μl of 
RNAse inhibitor, and 3.2 μl of nuclease-free water. cDNA reverse 
transcription reaction was then prepared by mixing 10 μl of RT master mix 
and 10 μl of RNA sample and was briefly centrifuge to eliminate any air 
bubbles. Individual tubes containing the mix were placed in a thermal cycler 
with different temperatures. Samples were then stored at -70°C until 
required. 
 
    2.13.10   Amplification of cDNA by Real-Time Polymerase  
                 Chain Reaction (RT-PCR) 
 
Primers for sequencing the complete CDS (coding sequence) of G-proteins 
in Vero cells were designed using primer3 software (http://primer3plus.com/) 
and the National Center for Biotechnology Information (NCBI) primer blast 




   





mRNA of Homo sapiens, and the predicted mRNA of Chlorocebus sabaeus 
of Gq, G11, G12, G13, Gi-1, Gi-2 and Gi-3. A comparative analysis of 
the gene sequences of the G-proteins alpha subunits from primates such as 
Chlorocebus aethiops, Chlorocebus cynosuros, Chlorocebus pygerythrus, 
Chlorocebus sabaeus, and Chlorocebus tantalus using Exonorate was also 
consulted (by our senior bioinformatics office, Phil Cunningham).    
 
For the amplification of cDNA, GoTaq® Hot Start Colourless Master Mix 
(Promega, UK), a premixed ready-to-use solution containing Taq 
Polymerase, dNTPs, MgCl2 and reaction buffers for real-time Polymerase 
Chain Reaction (rt-PCR) was used. For a 25 μl reaction volume, the PCR 
mixture consisted of 1x GoTaq® Hot Start Colourless Master Mix, 1 μM each 
of the forward and reverse primers, 1 μM each of the forward and reverse 
primers, <250 ng of the DNA template, and nuclease free water. The 
reaction was carried out in a PCR machine programmed to carry out 40 












   
















































































   
    2.13.11  DNA Agarose Gel Electrophoresis 
 
PCR (cDNA) products were electrophoresed on 1 – 2 % (w/v) agarose gels, 
which were composed of molecular grade agarose (Sigma-Aldrich) dissolved 
in 0.5x TBE (Tris-Borate EDTA) buffer or 1x TAE (Tris-acetate-EDTA) buffer 
(Thermo-Scientific), by heating the solution in a microwave oven. DNA 
samples were mixed with approximately 1/6 volume of loading dye (Thermo-
Scientific) prior to loading. A commercially prepared 100 bp DNA ladder 
(New England Biolabs, UK) or 1 kb DNA ladder (New England Biolabs, UK) 
were used as molecular markers. Electrophoresis was carried out in 
horizontal electrophoresis unit in trays at approximately 3-6V/cm of gel 
(constant voltage) for 1 - 2 h. Gels were then stained using Gel Red (Biotum, 
UK) for 30 min then visualised on a UV transilluminator (AlphaImager; λ= 




   





    2.13.12  DNA Extraction and Sequencing 
 
For samples with more than one band on the gel, each band was cut using a 
scalpel, weighed and placed in an eppendorf tube. DNA fragments were 
extracted using the QIAquick Gel Extraction Kit (QIAGEN). Buffer GQ (6 
volumes) was mixed with 1 volume of 2 % agarose gel containing the DNA 
fragments (100 mg ~ 100 μl). Samples were then incubated at 50C for 10 
min, vortexing the tube every 2 - 3 min. One volume of isopropanol was 
added to the sample mix. Sample mix was then transferred to a QIAquick 
spin column in a 2 ml collection tube and centrifuge for 1 min at 17,900 x g. 
The flow-through was discarded and 500 µl of Buffer GQ was added to the 
QIAquick spin column and centrifuge for 1 min at 17,900 x g. The flow-
through was discarded and the QIAquick spin column containing the DNA 
was washed with 750 µl Buffer PE mixed with ethanol. QIAquick spin column 
was centrifuged twice for 1 min at 17,900 x g before placing it into a clean 
1.5 ml microcentrifuge tube. The DNA from the QIAquick spin column was 
eluted by incubating with 30 µl nuclease-free water for 4 min prior to 
centrifugation for 1 min at 17,900 x g. Samples were then sent to Eurofins 









   





    2.13.13   Quantification of mRNA Level by RT-qPCR (Real- 
                 Time Quantitative Polymerase Chain Reaction) 
 
For the quantification of mRNA level, Precision™ 2X qPCR SYBRgreen 
Mastermix (Primer Design, Southampton, UK), a premixed ready-to-use 
solution containing 2x reaction buffer, 0.025 U/µl Taq Polymerase, 5 mM 
MgCl2, dNTP Mix (200 µM each dNTP) was used. For a 10 l real-time PCR 
volume, the PCR mixture consisted of 5 l of Precision™ 2X qPCR 
Mastermix, 25 ng of cDNA template, 6 pmols of primer mix (forward and 
reverse), and nuclease free water. The reaction was carried out in a 
Corbett Rotor-Gene 6000 qPCR machine programmed to carry out 40 cycles 
at different temperatures. The primers for the qPCR for Swiss 3T3 cells were 















   





Table 2.13.13  The RT-qPCR Primer Sequences for G subunits of  
Swiss 3T3 Cells 
   
2.14  Statistical Analysis 
 
All values in the graphs are expressed as mean ± SD. The statistical 
significance of differences between rPMT-, rPMTC1165S-treated, and 
untreated cells in two cell lines was evaluated by Two-way ANOVA while the 
statistical significance of differences between rPMT-treated and untreated 
cells in each cell was evaluated by an F-test two sample variances. P < 0.05 
was considered statistically significant. All experiments were performed in 


















































































   





3  THE EFFECTS OF PMT ON SWISS 3T3 AND  
VERO CELLS: CELL PROLIFERATION, 
CYTOSKELETAL REORGANISATION, CELL 
DEATH 
 
PMT is a potent intracellular-acting mitogen to various cell lines (Rozengurt 
et al., 1990; Higgins et al., 1992; Lacerda et al., 1996; Mullan and Lax, 1996; 
Ward et al., 1998; Wilson et al., 2000) but not to others such as Vero cells 
(Wilson et al., 2000). The action of PMT includes constitutive activation of 
Gq/11, G11/13, and Gi-1-3 leading to numerous sequelae as detailed in chapter 1.  
 
  3.1  The Growth Kinetics of Swiss 3T3 and Vero Cells 
 
Swiss 3T3 cells are contact inhibited mouse-derived fibroblasts from Mus 
musculus while Vero cells are kidney epithelial cells derived from African 
Green Monkey. To compare the effect of PMT on the growth kinetics of 
Swiss 3T3 and Vero cells, confluent Swiss 3T3 and Vero cells were 
subjected to serum deprivation for 2 days to quiesce them before treatment 
with a final concentration of 200 ng/ml of rPMT or rPMTC1165S, or left 
untreated and maintained in media with 1 % serum (see section 2.6.1) 
throughout the 7-day period as opposed to Wilson et al. (2000) experimental 




   














   









Fig 3.1.1  Effects of rPMT on the growth kinetics of confluent Swiss 3T3 (A) and Vero (B) cells.  Shown above are time courses of cell 
number for confluent (A) Swiss 3T3 (P = 0.00003) B) Vero (P = 0.16) cells that were either left untreated or treated with 200 ng/ml of rPMT- or 
rPMTC1165S-treated and maintained in media supplemented with 1% serum. Red (Untreated), Blue (rPMT-treated), and Purple (rPMTC1165S-
treated). Each value is the mean and ± SEM (n = 3).  






   





rPMT-treated confluent Swiss 3T3 cells in the presence of 1 % serum 
proliferated and reached a maximum of a 2.3-fold increase in cell number at 
96 h post rPMT exposure with an exponential increase of ~0.5 – 0.7 fold in 
cell number from 1 – 4 days compared to the untreated and rPMTC1165S-
treated cells which had approximately similar cell number with a ~0.5 fold 
decrease in cell number from 2 days (Fig 3.1.1 A). The confluent Vero cells, 
on the other hand, had a ~1.5-fold increase in cell number over the 4 days 
but there was no significant change in cell numbers between untreated, 
rPMT-, and rPMTC1165S-treated cells (Fig 3.1.1 B).  Cell debris in both rPMT-
treated cell lines was observed during counting, but this observation was 
more prominent in Vero cells as they appeared to be very fragile especially 
during trypsination and pipetting of cells to break up the clumps.  
 
Wilson et al. (2000) treated subconfluent Swiss 3T3 and Vero cells with a 
final concentration of 200 ng/ml of rPMT in media with 15% NCS and 10% 
FBS respectively and showed a similar mitogenic effect in rPMT-treated 
confluent Swiss 3T3 maintained in media with 1% serum, but not in Vero 
cells. A very high concentration of rPMT (200 ng/ml) appeared to be 
detrimental to the morphological stability of confluent Swiss 3T3 and Vero 
cells. Also, Rozengurt et al. (1990) reported that rPMT (at a concentration of 
1.25 ng/ml) and 10% FBS each stimulated DNA synthesis in a strikingly 





   





To determine if subconfluent Swiss 3T3 or Vero cells would behave 
differently when exposed to PMT at a lower concentration, Swiss 3T3 and 
Vero cells were cultured until they reached 50% confluence before 
subjecting them to serum starvation for 40 h (see section 2.6.2). The 
subconfluent quiescent cells were then treated with 15 ng/ml of rPMT or left 
untreated in media with 1% NCS.  Cell numbers were counted in triplicate 
using a haemocytometer at the following time points: 0, 2, 4, 6, 8, and 10 
days.  
 
The rPMT-treated Swiss 3T3 cells underwent proliferation, reaching a ~0.8-
fold increase by day 4 which is also the onset of the plateau growth phase 
compared to its untreated counterpart (Fig 3.1.2 B). The untreated and 
rPMT-treated Vero cells, on the other hand, each demonstrated a ~0.8-fold 
increase in cell numbers (Fig 3.1.2 B). Many untreated and rPMT-treated 
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Fig 3.1.2  Effects of rPMT on the growth kinetics of subconfluent Swiss 3T3 (A) and Vero (B) cells. Shown above are time courses of 
cell number of (A) Swiss 3T3 (P = 0.006) and (B) Vero (P = 0.58) cells that were either untreated or treated with 15 ng/ml of rPMT-treated 









   











Fig 3.1.3 Effects of rPMT on the growth kinetics of serum-starved subconfluent Swiss 3T3 (A) and Vero (B) cells. Shown above are 
time courses of cell number for subconfluent Swiss 3T3 and Vero cells that were either left untreated or treated with 15 ng/ml of rPMT or 
rPMTC1165S maintained in media with (+) or without (-) 10% serum. rPMT- or rPMTC1165S-treated and untreated A) Swiss 3T3 cells (P = 0.005); 
B) Vero cells (P = 0.005) maintained with or without serum. rPMT- or rPMTC1165S-treated and untreated A) Swiss 3T3 cells (P = 0.04); B) Vero 
cells (P = 0.76) maintained without serum. Brown (Untreated -), Red (Untreated +), Light Blue (rPMT-treated -), Blue (rPMT-treated +), Light 
Green (rPMTC1165S-treated -), Purple (rPMTC1165S-treated +). Each value is the mean and ± SEM (n = 3). 





   





To date, the growth kinetics of rPMT-treated Swiss 3T3 and Vero cells in the 
absence and presence of serum have not been comparatively examined. In 
order to understand the full mitogenic effects of rPMT in the absence of 
serum in Swiss 3T3 and Vero cells and compare it to the growth kinetics of 
untreated cells maintained in 10% serum over a 3-day period, cells were 
cultured until they reached 50 - 60% confluence before subjecting them to 
serum starvation for 40 h then either left untreated or treated with 15 ng/ml 
of rPMT or rPMTC1165S in media with or without 10% NCS.  
 
The untreated, rPMTC1165S- and rPMT-treated subconfluent Swiss 3T3 cells 
maintained in media with 10% serum had an approximately ~2.1-fold 
increase in cell number by day 3 compared to the untreated and rPMTC1165S-
treated Swiss 3T3 cells maintained in media without serum (Fig 3.1.3 A). 
rPMT-treated Swiss 3T3 cells maintained without serum, on the other hand, 
underwent marked proliferation and had the same increase in cell number as 
those maintained in media with 10% serum with or without rPMT-treatment.  
 
The increase in cell number of the untreated, rPMTC1165S- and rPMT-treated 
subconfluent Vero cells maintained in media with 10% NCS, on the other 
hand, was ~2.2-fold while those maintained without serum, either untreated, 






   





  3.2  Morphological Changes in Swiss 3T3 and Vero  
         Cells 
  
    3.2.1  Effects of PMT on Confluent Swiss 3T3 and Vero  
             Cells  
 
Growth arrest in cells can be the result of contact inhibition, loss of nutrients 
and/or growth factors, senescence or when cells are in their ‘terminal stage’ 
(Modiano et al., 1999; Nelson and Daniel, 2002; Blagosklonny, 2011). With 
nutrients and in the absence of serum, I have confirmed that PMT acts as a 
growth factor promoting proliferation in Swiss 3T3 cells but not in Vero cells 
(Fig 3.1.3). Various reports showed that PMT induces morphological 
changes such as actin stress fibre formation, and cell rounding in Swiss 3T3 
cells (Lacerda et al., 1996; Dudet et al., 1996; Wilson et al., 2000). Wilson et 
al. (2000) showed a difference in actin stress fibres formation in Swiss 3T3 
and Vero cells at 2 h post rPMT-treatment.  
 
Continuous remodelling of the cytoskeleton is essential to cell adhesion, 
embryonic development, tissue regeneration, and immune responses 
(Hotulainen and Lappalainen, 2006). Deregulation of cytoskeleton dynamics 
is associated with pathological disorders such as cancer (Pollard and 
Cooper, 2009). Stress fibres, a type of cytoskeletal remodelling arising from 
polarisation of actin and assembly of focal adhesions, are responsible for 
adhesion, motility, and morphogenesis. Animal cells contain at least three 




   





dorsal (DSF) (Naumanen et al., 2008; Pellegrin and Mellor, 2007; Hotulainen 
and Lappalainen, 2006). VSFs, positioned at the base of the cell, are actin 
bundles usually associated with focal adhesions at both their ends while 
DSFs are also associated with one of its ends to focal adhesions. TA stress 
fibres, on the other hand, are curved actomyosin filaments unattached to 
focal adhesions (Naumanen et al., 2008; Pellegrin and Mellor, 2007).  
 
To re-examine the morphological changes in rPMT-treated Swiss 3T3 and 
Vero cells, Swiss 3T3 and Vero cells were cultured for 3 days by which time 
cells were confluent. Cells were quiesced by serum deprivation for 40 h 
before treatment with a final concentration of 200 ng/ml of rPMT, or left 















   





Fig 3.2.1.1  The effect of rPMT on serum-starved confluent (A-B) Swiss 3T3 
and (C-D) Vero cells. Shown above are representative phase contrast micrographs 
of untreated (A) Swiss 3T3 and (C) Vero cells, and rPMT-treated (200 ng/ml) (B) 
Swiss 3T3 and (D) Vero cells maintained in media with 1% serum for 6 days.  
 
Swiss 3T3 and Vero cells appeared rounded 24 h post rPMT exposure. 
rPMT-treated confluent Swiss 3T3 cells eventually formed a dense 
monolayer and developed dense cell clusters while Vero cells developed 
more pronounced foci (Fig 3.2.1.1). In agreement with Wilson et al. (2000), 
both rPMT-treated cell lines lost adherence to the matrix, with Vero cells 
detaching in sheets (Fig 3.2.1.1-B-D). In addition to these findings, both cell 
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apparent in the rPMT-treated Vero cells. Both confluent cell types also 
showed a fibroblastic phenotype compared to those that were left untreated. 
 
To check whether different PMT concentrations would give different effects 
compared to the high concentration of rPMT (~200 ng/ml) used in previous 
assays, serum-starved semi-confluent Swiss 3T3 and Vero cells were either 
left untreated or treated with different concentrations of rPMT: 0.01, 0.1, 1, or 




   






















Fig 3.2.1.2 The Effect of rPMT on serum-starved semi-confluent (A-E) Swiss 3T3, and (F-J) Vero cells. Shown above are representative 
phase contrast micrographs of (A) untreated; and (B-E) rPMT-treated with a final concentration of (B) 0.01, (C) 0.1, (D) 1, (E) 10 ng/ml Swiss 
3T3, and (F) untreated (G-J) rPMT-treated Vero cells with a final concentration of (G) 0.01, (H) 0.1, (I) 1, (J) 10 ng/ml maintained in media 
without serum for 3 days.  
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rPMT-treated Swiss 3T3 and Vero cells at concentrations of 1 and 10 ng/ml 
each appeared more rounded than the untreated cells or those with PMT at 
lower concentrations (Fig 3.2.1.2).  Swiss 3T3 cells appeared more 
fibroblastic in character than Vero cells (Fig 3.2.1.2). Swiss 3T3 cells treated 
with 1 and 10 ng/ml of rPMT appeared to form cell clusters at day 3. 
 
Wilson et al. (2000) reported a decrease adherence and formation of foci or 
dense cell clusters in Swiss 3T3 and Vero cells even after changing the 
media with 1% serum everyday. In the previous experiment (Fig 3.1.1) 
where rPMT-treated confluent Swiss 3T3 and Vero cells kept in the same 
media with 1% serum throughout a 7-day time course, significant decrease 
in adherence and formation of foci or dense cell clusters were observed at 
later stage. To check the longer term effects of PMT and whether changing 
of media with minimal amount of serum could attenuate the drastic 
morphological changes brought by PMT, Swiss 3T3 and Vero cells were 
subjected to a 40-hour serum deprivation prior to treatment with 15 ng/ml of 
rPMT in media without serum. Media containing rPMT were removed after 3 
days; cells were gently washed twice with DPBS and replaced with media 
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Fig 3.2.1.3 The long term effect of rPMT on confluent Swiss 3T3 and Vero cells. Shown are representative phase contrast micrographs of 
rPMT-treated (A-C) Swiss 3T3 and (D-F) Vero cells. Swiss 3T3 and Vero cells were treated with 15 ng/ml of rPMT for (A, D) 1, (B, E), 2, and 





   





A minimal loss of adherence and detachment of both cell lines were rarely 
observed during the gentle changing of media. As with earlier observations, 
Swiss 3T3 and Vero cells developed dense cell clusters or foci but this 
development was gradual and more prominent in Vero cells (Fig 3.2.1.3). 
Looking at the development of foci in Vero cells from weeks 1 - 3, it appears 
that the cells underwent proliferation.  
 
    3.2.2  Effects of PMT on Cytoskeletal Organisation 
 
Stress fibres are composed of bundles of actin filament and myosin IIa held 
together by actin crosslinking proteins, which ensure structural and 
mechanical integrity by generating tension forces on focal adhesions that are 
anchored to the extracellular matrix surrounding the cells (Naumanen et al., 
2007). They are involved in adhesion, motility and morphogenesis.  
 
It has been well documented that PMT promotes cytoskeletal rearrangement 
in Swiss 3T3 cells via Rho activation (Lacerda et al., 1996, Wilson et al., 
2000). According to Wilson et al. (2000), Vero cells treated with 200 ng/ml of 
rPMT did not show prominent stress fibres as observed in rPMT-treated 
Swiss 3T3 cells, but these workers reported cytoskeletal disruption in rPMT-






   





To determine the effects of PMT in the cytoskeleton of Swiss 3T3 and Vero 
cells in greater detail, confluent quiescent cells were subjected to a 40-hour 
serum starvation prior to treatment of 200 ng/ml (Figs 3.2.2.1 and 3.2.2.2) of 
rPMT maintained in media with 1% NCS. Cells were then fixed with 4% 
paraformaldehyde in DPBS and stained with Phalloidin-TRITC.  
 
The majority of rPMT-treated Swiss 3T3 cells produced a robust stress fibre 
response from day 1, compared to Vero cells (Fig 3.2.2.1). Long and thick 
stress fibres are scarcely present in rPMT-treated Vero cells on day 1 (Fig 
3.2.2.1-E) but became more heavily visible on day 2 (Fig 3.2.2.1-F). This 
effect was also observed in Swiss 3T3 and Vero cells treated with low 

















   





























   Day 0        Untreated    Day 1      rPMT-treated    Day 2     rPMT-treated 
   
     
Fig 3.2.2.1 The effect of rPMT in actin cytoskeletal organisation of (A-C) Swiss 3T3 and (D-F) Vero cells. Shown above are 
representative TRITC-conjugated-phalloidin-stained fluorescence micrographs of confluent Swiss 3T3 and Vero cells either untreated or 
treated with 200 ng/ml of rPMT as described in section 2.7. (A-C) Swiss 3T3 cells, (D-F) Vero cells; (A) Untreated Swiss 3T3 and (D) Vero 
cells; (B-C) Swiss 3T3 and (E-F) Vero cells treated with rPMT for 1 and 2 days.  
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Fig 3.2.2.2 The effect of rPMT in actin cytoskeletal organisation of (A-I) Swiss 
3T3 and (J-R) Vero cells. Shown above are representative TRITC-conjugated-
phalloidin-stained fluorescence micrographs of confluent Swiss 3T3 and Vero cells 
treated with 200 ng/ml of rPMT. (A-I) Swiss 3T3 cells; (J-R) Vero cells; (A-E) 
Untreated Swiss 3T3 and (J-N) untreated Vero cells; (F-I) rPMT-treated Swiss 3T3 
and (M-R) rPMT-treated Vero cells. 
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Actin stress fibre formation accompanies the stretch-induced cell orientation 
of rPMT-treated Swiss 3T3 and Vero cells. Consistent with the previous 
highly magnified TRITC-conjugated-phalloidin-stained fluorescence 
micrographs (Fig 3.2.2.2), this PMT effect can already be seen in Swiss 3T3 
on day 1 (Fig 3.2.2.2-F) unlike the elongated feature in Vero cells, which 
became more apparent from day 2 (Fig 3.2.2.2-P).  
 
    3.2.3  The Cytotoxic Effects of PMT in Swiss 3T3 and  
     Vero Cells 
 
Preuss et al. (2010) reported that PMT treatment in HEK293 cells inhibited 
staurosporine-mediated apoptosis via PI3K-dependent Akt phosphorylation, 
and Pim-1 expression. On the other hand, PMT has been reported to cause 
apoptosis (Pennings and Storm, 1986) in Vero cells, and in cardiomyocytes 
via inhibition of Akt phosphorylation (Sabri et al., 2002). Wilson et al. (2000) 
reported that the detached Vero cells appear to be viable by tryphan blue 
exclusion assay and that such phenomena were consistent with the results 
obtained by Pennings and Storm (1986), but no data were shown.  Pennings 
and Storm (1986) used diluted supernatant from a Pasteurella multocida 
culture containing PMT in media without serum. They reported that the 
cytopathic effect in Vero cells could be detected after 48 h. Sunder and 
Kumar (2000) observed a cytopathic effect (CPE) of PMT on Vero cells after 
7 days. They reported that a minimum cytopathic dose of 5.8 g of crude 




   





To determine and confirm whether confluent quiescent Swiss 3T3 and Vero 
cells would behave differently to different concentrations of rPMT, and also if 
PMT would prevent or promote cell death in the two representative cell lines, 
confluent quiescent cells were subjected to 40-h serum deprivation before 
treating them with 0.01, 0.1, 1, or 10 ng/ml rPMT or rPMTC1165S.  
 
Cell death can be measured using the lactodehydrogenase (LDH) released 
in cell culture (Burd and Usategui-Gomez, 1973). LDH assay measures 
cytoplasmic LDH or the membrane integrity of cells. LDH is a stable 
cytoplasmic enzyme released upon cell lysis which converts tetrazolium salt 
(INT) into formazan product in LDH assay. A spectrophotometer was used to 
measure the colorimetric product (see section 2.9).  
 
Similar to the report of Preuss et al. (2010) about the anti-apoptotic effect of 
PMT in HEK293 cells, rPMT also protected Swiss 3T3 cells from cell death, 
which was detected after 2 days post rPMT treatment (Fig 3.2.3-A). In this 
experiment, concentrations of 1 and 10 ng/ml of rPMT in media without 
serum showed a ~1 – 1.5 fold protection from cell death in Swiss 3T3 cells 
compared to untreated and rPMTC1165S-treated ones (Fig 3.2.3-A). Swiss 
3T3 cells treated with 0.1 ng/ml of rPMT in media without serum, on the 
other hand, showed minimal protection (approximately ~0.5 - 0.9 fold) from 
cell death compared to the untreated and rPMTC1165S-treated Swiss 3T3 
cells. Swiss 3T3 cells either untreated, rPMT- or rPMTC1165S-treated 




   





death. After 4 days treatment, the protective effect of rPMT was completely 
abolished (Fig 3.2.3-C). 
 
rPMT treatment of Vero cells, on the other hand, did not show any effect or 
protection against cell death. Cell death appeared to be linked to the 
absence of serum regardless of the presence of rPMT after 2 and 4 days 



















   









Fig 3.2.3 The cytotoxic effect of rPMT on (A and C) Swiss 3T3 and (B and D) 
Vero cells. Confluent (A and C) Swiss 3T3 and (B and D) Vero cells were either left 
untreated or treated with different concentrations (0.01, 0.1, 1 and 10 ng/ml) of 
rPMT or rPMTC1165S maintained with or without serum for 2 (A, P = 0.0000006 and 
B, P = 0.000002) and 4 (C, P = 0.000000005 and D, P = 0.0000001) days. (A and 
C) Swiss 3T3 and (B and D) Vero cells were either left untreated or treated with 
different concentrations (0.01, 0.1, 1 and 10 ng/ml) of rPMT or rPMTC1165S 
maintained without serum for 2 (A, P = 0.02 and B, P = 0.36) and 4 (C, P = 0.46 
and D, P = 0.49) days. Samples were processed using LDH assay (section 2.9.1). 
No serum [-], with 10 % serum [+], Brown (Untreated -), Red (Untreated +), Light 
Blue (rPMT-treated -), Blue (rPMT-treated +), Light Green (rPMTC1165S-treated -), 
Purple (rPMTC1165S-treated +). Each value is the mean and ± SEM (n = 3). 
 
 
















   





3.3  DISCUSSION  
 
    3.3.1  Growth Kinetics of Swiss 3T3 and Vero Cells 
 
PMT is a potent mitogen in vivo (Hoskins et al, 1997) and to most cultured 
cells (Rozengurt et al., 1990; Higgins, et al., 1992; Mullan and Lax, 1996; 
Dudet et al., 1996; Wilson et al., 2000, Lax and Grigoriadis, 2001; Lax et al., 
2004).  
 
To re-examine whether PMT is a mitogen to Swiss 3T3 and not to Vero 
cells, each cell line was either left untreated or treated with a final 
concentration of 200 ng/ml of rPMT or rPMTC1165S in media with 1 % serum 
over a 7-day period, the same rPMT concentration used by Wilson et al. 
(2000). The rPMT-treated confluent Swiss 3T3 cells (Fig 3.1.1A) underwent 
marked proliferation by day 4 which was also the onset of the plateau growth 
phase, compared to the untreated or rPMTC1165S-treated Swiss 3T3 cells. 
The untreated, rPMT- or rPMTC1165S-treated confluent Vero cells (Fig 
3.1.1B), on the other hand, maintained in media with 1 % serum showed no 
significant difference in cell density.  
 
Wilson et al. (2000) reported a ~2-3-fold increase in cell density of rPMT-
treated Swiss 3T3 cells over the 7-day period, but without any evidence of a 
plateau growth phase. Their experimental condition involved changing of the 




   





condition set in this research, keeping the same media with 1 % serum and 
toxin throughout the 7-day period. I attempted to repeat exactly the 
conditions set out in the paper by Wilson et al. (2000), namely changing the 
medium everyday, but found that this gave variable results due to loss of 
cells (data not shown). This occurred even with gentle washing of the cell 
sheet and aspiration of media. It is well known that Vero cells tend to lift 
even with gentle treatment (Dr David Moyes, personal communication).  
 
rPMT-treated Swiss 3T3 and Vero cells each lost adherence after a few 
days and this observation was also reported by Wilson et al. (2000). In order 
to prevent loss of cells, the untreated, rPMTC1165S- and rPMT-treated Swiss 
3T3 and Vero cells were kept in the same medium with or without serum 
over the specified time period for each growth kinetics proliferation assay. 
This might have led to nutrients being depleted, which would inhibit cell 
proliferation. However, the loss of cells during washing and replacement of 
media with fresh nutrients and 1 % serum may be the cause of continuous 
gradual increase in cell numbers of Swiss 3T3 as seen by Wilson and et al. 
(2000).  
 
Wilson et al. (2000) examined if a final concentration of 200 ng/ml of PMT in 
media with full serum (10 % FBS for Vero, and 15 % calf serum (CS) for 
Swiss 3T3) would influence the rate of proliferation of subconfluent Swiss 
3T3 and Vero cells. They reported approximately 45% increase in cell 




   





untreated, heat-inactivated rPMT-treated cells which was also the onset of 
the ‘plateau growth phase’. The untreated, heat-inactivated rPMT- and 
rPMT-treated Vero cells, on the other hand, showed similar exponential 
increase in cell numbers, reaching their maximum cell numbers by day 4 
which also appeared to be the onset of the ‘plateau growth phase’.  
 
Most studies with PMT have used much lower concentration of toxin. In the 
original paper on the subject, Rozengurt et al. (1990) showed that the 
maximum stimulation of DNA synthesis in Swiss 3T3 cells, over a 40-hour 
period, was achieved at around 1.2 ng/ml. Subsequent papers have used 
higher concentrations for longer term experiments, but seldom as high as 
200 ng/ml. Work reported later in this thesis shows that PMT activity can be 
detected several days after toxin removal (chapter 5).  
 
To determine whether a lower concentration of PMT would also influence the 
relative cell growth kinetics of the two cell types cultured subconfluently (Fig 
3.2.2), cells were either left untreated or treated with a final concentration of 
15 ng/ml of rPMT in media with 1 % serum and kept in the same media over 
a 10-day period. Each cell type reached its maximum cell number by day 4, 
which is also the onset of the ‘plateau growth phase’ of Swiss 3T3 (Fig 
3.1.2C). The rPMT-treated subconfluent Swiss 3T3 cells had a significant 
increase in cell number compared to the untreated Swiss 3T3 cells (Fig 
3.1.2C). No significant change in cell number between untreated and rPMT-




   





displayed a cell number increase which ceased by day 4. As before, cell 
debris was more apparent in Vero cells than in Swiss 3T3 cells. The 
termination of cell proliferation by day 4 in both cell lines could be due to the 
loss of nutrients and/or serum in the media compared to the data published 
by Wilson et al. (2000) where they changed the media with 1% serum 
everyday so that growth was still detectable in confluent rPMT-treated Swiss 
3T3 cells throughout the 7-day period but not in confluent Vero cells. The 
rPMT-dependent growth of Swiss 3T3 appears to require continuous 
supplement of nutrients required to keep the cell proliferating. The 
continuous cell number increment in their confluent rPMT-treated Swiss 3T3 
cells may be due to the lost cells being replaced with a fresh supply of media 
supplemented with nutrients and minimal growth factors in the serum. In 
their subconfluent proliferation experiments, it was unclear whether Wilson 
et al. (2000) changed the media with or without full serum but they 
mentioned that they cultured the cells in media with 10% FBS for Vero cells, 
and 15% CS for Swiss 3T3 cells. Both subconfluent cell types showed the 
plateau growth phase after day 4, which is consistent with the results in this 
thesis.  
 
Rozengurt et al. (1990), on the other hand, found that the onset of plateau 
growth phase in subconfluent Swiss 3T3 cells maintained in media with 10% 
FBS occurred after 6 days post treatment with 10 ng/ml of rPMT while 
subconfluent MEF treated with 10 ng/ml of rPMT maintained in media with 




   





The different experimental conditions used in three independent proliferation 
assays led to proliferation in subconfluent rPMT-treated Swiss 3T3 cells. 
However, a delay in the onset of the growth phase in Rozengurt et al. (1990) 
may be due to a high concentration of serum and low concentration of rPMT 
and/or the origin of batch of Swiss 3T3 cells used. Wilson et al. (2000) used 
a high concentration of serum and rPMT and showed a similar onset of the 
plateau growth phase and general growth pattern to the results in this thesis 
which used different experimental conditions: a low concentration of both 
serum and rPMT. It appears that the high concentration of serum (in the 
case of the Rozengurt et al. (1990) experiment) may play a role in the 
integrity of cells by providing anti-apoptotic protection thereby prolonging the 
cells viability and the effect of rPMT. However, the effect of the high 
concentration of serum used by Wilson et al. (2000) may interact with 
cellular effects induced by a high concentration of rPMT, which led to 
constitutive activation of the majority of the G-protein molecules in Swiss 
3T3 cells resulting in the earlier onset of plateau growth phase compared to 
that noted by Rozengurt et al. (1990).  The use of a lower concentration of 
serum in my experiments may have affected the viability of cells and the 
effect of rPMT. The loss of cells during gentle washing and trypsinisation 
prior to counting of cells may also affect the relative cell number of rPMT-
treated Swiss 3T3 cells after 4 - 6 days.  
 
In this research, the growth kinetics of subconfluent Swiss 3T3 and Vero 




   





have been scrutinised (Fig 3.1.3E). rPMT-treated subconfluent Swiss 3T3 
cells underwent proliferation in the absence of serum with the same cell 
number increment per day as the Swiss 3T3 cells maintained in 10% serum 
with or without 15 ng/ml of rPMT-treatment. The untreated or rPMTC1165S-
treated Swiss 3T3 cells maintained in media with 10% serum, and rPMT-
treated Swiss 3T3 cells maintained in media without serum had over ~2-fold 
increase compared to the untreated and rPMTC1165S-treated Swiss 3T3 cells 
maintained in media without serum. The untreated, rPMT- and rPMTC1165S-
treated Vero cells maintained in media with 10% serum, on the other hand, 
proliferated reaching ~2–3-fold increase in cell numbers compared to the 
untreated, rPMT- and rPMTC1165S-treated Vero cells maintained in media 
without serum. The above data confirms that the mitogenic effect of either 
the serum or rPMT masks the proliferative effect of the other in Swiss 3T3 
cells during the 3-day treatment. PMT in media without serum, on the other 
hand, shows the same proliferative effect as the 10% serum in Swiss 3T3 
cells. I have therefore confirmed that PMT is mitogenic to Swiss 3T3 cells 
but not to Vero cells. Rozengurt et al. (1990) reported that DNA synthesis 
elicited by rPMT at a concentration of 1.25 ng/ml had similar effect to that 
induced by 10% FBS in the absence of other factors, and that lower 
concentration (~0.16 - 0.32 ng/ml) resulted only in half-maximal stimulation 







   





    3.3.2  The Morphological Changes in Swiss 3T3 and Vero 
              Cells 
 
I have confirmed that treatment with 200 ng/ml of rPMT results in the 
development of dense clusters and/or foci, loss of adherence and 
detachment in both Swiss 3T3 and Vero cells (Fig 3.2.1-A) (Wilson et al, 
2000). Although both cell lines showed detachment of cells, Vero cells rolled 
up, which suggests weakened cell-cell adhesion. The loss of adherence in 
rPMT-treated Vero cells was observed after 6 - 10 days growth, where the 
decrease in cell number was due to poor adherence of Vero cells to the well 
(Figs 3.1.1, 3.1.2 and 3.2.1.1). Wilson et al. (2000) reported that detached 
Vero cells remained viable by trypan blue exclusion assay. Detached Vero 
cells were difficult to count due to their size, and most appeared to be cell 
debris. The end results of the morphological effects induced by PMT 
treatment in Swiss 3T3 or Vero cells were the same regardless of whether 
cells were treated with high or low PMT concentration, but the progression of 
these effects was concentration-dependent. It appears that the concentration 
of PMT and the rate of cellular response are directly proportional to each 
other, meaning the higher the concentration of PMT, the faster the 
appearance of these effects. Changing of the media, however, containing 
1% NCS twice a week for the course of 3 weeks appeared to lead to both 
rPMT-treated cells being more adherent (Fig 3.2.1.3) than the cells left in the 
same media (Fig 3.2.1.1), but both rPMT-treated cell types still remained 




   





development of foci. This phenomenon was made possible due to the 
presence of 1 % NCS which appeared to help the integrity of cell-cell 
adhesion and possibly cell growth (Fig 3.2.1.3).  
 
The previous observation stating that rPMT-treated Vero cells did not form 
prominent stress fibres as rPMT-treated Swiss 3T3 after 2 h post rPMT 
treatment (Wilson et al., 2000) suggested different mechanisms of stress 
fibre formation in each cell line. Stress fibre formation and actomyosin 
contractility is regulated by activated Rho-associated kinases via RhoA 
GTPases activation (Ridley and Hall, 1992; Pellegrin and Mellor, 2007). 
Rho-associated kinases promote stress fibre assembly via inhibition of actin 
filaments depolymerisation. According to Hotulainen and Lappalainen 
(2006), association and dissociation of actin filament cross-linking may be 
important in the formation and contractility of stress fibres. The role of actin 
filaments in many cellular processes such as migration and cellular   
development is to produce force, which can be achieved via coordinated 
polymerisation of actin filaments against the cell membrane, and formation 
of contractile structure (Tojkander et al., 2012). The orientation of proteins, in 
particular actin filaments and myosin II, which makes up the structure of 
actin filament networks appear to define the polarity of actin filaments and 
the cell’s contractile properties (Pellegrin and Mellor, 2006). 
 
There are many key players involved in the development of stress fibres. 




   





light chain (MLC), and also CPI-17, ZIPK and S19P which are involved in the 
activation of kinases and/or inhibition of phosphatases responsible for 
increased myosin phosphorylation leading to stress fibre assembly and 
contractility (Leung et al., 1996; Pellegrin and Mellor, 2006). Mammalia Dia1 
(mDia1), a Rho GTPases effector protein, is also essential for the formation 
of stress fibres (Watanabe et al., 1997; Pellegrin and Mellor, 2006), 
formation of DSFs in vivo (Hotulainen and Lappalainen, 2006), and 
production of actin filaments via nucleation and polymerization (Narumiya et 
al., 2009). Stress fibre assembly can be blocked by overexpression of small 
GTPases RhoE, which inhibits ROCK (Riento et al., 2003), and Gem and 
Rad (Ward et al., 2002). 
 
There are three types of stress fibres namely, DSF, TA, and VSF (Pellegrin 
and Mellor, 2007; Naunamen et al., 2007). DSFs are short actin bundles 
attached to focal adhesions at their distal end while TAs are curved 
actomyosin bundles that extend to both ends without association to focal 
adhesions and often terminate to DSFs. VSF are made of actin filament 
bundles associated with focal adhesions and considered the major 
contractile machinery of the cell (Tojkander et al., 2012). Hotulainen and 
Lappalainen (2006) showed that DSFs and TAs in motile cells (U2OS cells) 
underwent continuous formation and assembly.  Contraction promotes 
elongation and association of these stress fibres with each other, which 
often lead to their conversion in to VSFs. They proposed that elongation of 




   





However, it is still unclear how each stress fibre type contracts specifically 
those with uniform polarity (i.e. DSFs) and unattached to the membrane (i.e. 
TAs) which raise questions about their contractile nature (Pellegrin and 
Mellor, 2007). DSFs do not contain myosin II, therefore do not have the 
ability to contract (Tojkander et al., 2011). TAs, on the other hand, have 
periodic -actin-myosin contractile pattern and when attached to DSFs could 
convey contractile force (Tojkander et al., 2012). In U2OS cells, VSFs can 
be assembled in 27 minutes through reorganisation of the DSFs and TAs 
(Hotulainen and Lappalainen, 2006). Although stress fibres assembly in non-
motile cells (i.e. Swiss 3T3 and Vero cells) remains unclear, according to 
Deguchi and Sato (2009), based on the similarity of structures of VSFs in 
motile cells such as U2OS, the mechanisms of its assembly appear to be the 
same.  
 
The rPMT-treated Vero cells had less stress fibres than rPMT-treated Swiss 
3T3 cells (Fig 3.2.2.1). Stress fibre formation in rPMT-treated Vero cells 
appeared to be generated at a very slow pace compared to rPMT-treated 
Swiss 3T3 cells. The majority of these stress fibres appeared to be short, 
and were found close to the cell membrane, which indicates that they may 
be DSFs. DSFs do not contain myosin II, therefore, do not have the ability to 
contract. Contraction is essential in the elongation and association of stress 
fibres to generate VSFs. This may be the case why stress fibres in Vero 
cells were not as prominent as the ones in Swiss 3T3 cells, even though 




   





as reported by Wilson et al. (2000). I have shown that both low (15 ng/ml) 
and high concentrations (200 ng/ml) of rPMT resulted in a slower 
development of stress fibres in Vero cells compared to Swiss 3T3 cells, 
which showed prominent cytoskeletal reorganisation by day 1 post rPMT 
treatment. The development of fibroblastic feature or the stretch-induced 
orientation of both rPMT-treated cell lines appears to be associated with the 
presence of advanced formed (i.e. VSFs) or all types of stress fibres.  
 
Contractility, which is essential in stress fibre assembly, is regulated by 
phosphorylated MLC (Somlyo and Somlyo, 2000), which promotes assembly 
of myosin II filaments and increases the myosin motor domain ATPase 
activity (Vincente-Manzanares et al., 2009). The two important pathways that 
regulate this event are Gq-, Ca
2+/calmodulin-dependent and G12/13-, Rho-
dependent (Katoh et al., 2001a and 2001b; Klages et al., 1999; Walsh et al., 
2011; Tojkander et al., 2012), which each lead to phosphorylation of MLC. 
The Ca2+/calmodulin-dependent pathway leads to a rapid response whereas 
the Rho-dependent pathway results in a more sustained response 
(Tojkander et al., 2012). 
 
It is possible that the slow stress fibre response of Vero cells to PMT is due 
to discrimination in activating proteins involved in either pathway, or there 
may be a delay in the activation of one of the pathways. It is impossible to 
speculate that only one of the two pathways was activated by PMT as more 




   





cells from day 2. Such a delay in activation of the one of the two pathways 
involved in stress fibre formation in rPMT-treated Vero cells could also 
indicate specialised mechanisms in which PMT activates G-proteins, which 
will be discussed in great detail in chapter 5. 
 
    3.3.3  The Cytotoxic Effects of PMT in Swiss 3T3 and  
             Vero Cells 
 
According to the reports of Pennings and Storm (1986), and Sunder and 
Kumar (2000), PMT is cytotoxic to Vero cells while Preuss et al. (2010) 
showed the anti-apoptotic effect of PMT in HEK293 cells via PI3K-
dependent Akt phosphorylation, and Pim-1 expression. According to 
Pennings and Storm (1986), the cytotoxicity of PMT can be detected from 48 
h. Wilson et al. (2000), on the other hand, reported that they did not find any 
evidence of cell death under their experimental condition and that the 
detached cells remained viable by trypan blue dye exclusion assay. I have 
shown here that two days post treatment, Swiss 3T3 cells with 1 or 10 ng/ml 
of rPMT showed a marked decrease in cell death while those 0.1 ng/ml 
rPMT showed minimal protection against cell death (Fig 3.2.3-A). However, 
after 4 days, the protective effect of PMT in Swiss 3T3 cells was completely 
abolished (Fig 3.2.3-C). I have shown that PMT exhibited protective behavior 
in Swiss 3T3 cells up to 48 h only, compared to the longer time noted by 





   





In contrast to reports of Pennings and Storm (1986), and Sunder and Kumar 
(2000), there was no significant decrease or increase in the number of dead 
cells in rPMT-treated Vero cells maintained in media without serum 
compared to those untreated and treated with rPMTC1165S maintained in 
media without serum (Fig 3.2.3-B and -D). Untreated, rPMTC1165S- and 
rPMT-treated Vero cells maintained in media with 10% serum showed a 
decrease in the number of dead cells compared to those untreated, 
rPMTC1165S- and rPMT-treated Vero cells maintained in media without serum. 
 
This research confirms that rPMT is not cytotoxic to either cell line and 
exhibits a protective effect against cell death in Swiss 3T3 cells up to 48 h 
only but not to Vero cells. Cytotoxicity appears to be linked to the absence of 
serum or loss of serum/nutrients in both cell lines as observed 4 days post 
rPMT treatment (Fig 3.2.3-C-D).  
 
Wilson et al. (2000) reported that rPMT-treated Swiss 3T3 and Vero cells 
became insensitive to further treatment with rPMT 2 – 3 days after initial 
treatment, and that most of them were found in the G0/G1 phase of the cell 
cycle after 3 – 4 days. The loss of an anti-apoptotic effect of rPMT detected 
after 4 days post treatment appears to coincide with the loss of proliferative 
effect of rPMT in Swiss 3T3 cells.  Assuming that Akt and Pim-1 are also 
involved in the anti-apoptotic effect of PMT in Swiss 3T3 cells similar to that 
shown for HEK293 cells, it is possible that these proteins are involved in 




   





stimulate cell survival, growth and transformation via phosphorylation of 
different apoptotic proteins and stimulation of mTOR signalling in 
haemopoetic cells (Hammerman et al., 2005). In Swiss 3T3 cells, the PMT-
mediated activation of mTORC1 has a partial role in cell growth, migration 
and proliferation (Oubrahim et al., 2013). However, this mTOR signalling is 
Gq/11/PLC/PKC-dependent. It is unknown if the mTOR pathway via Akt is 
also activated in Swiss 3T3 cells. In HEK293 cells, Akt and Pim-1 were 
activated by PMT via G/PI3K which played a role in cell survival and 


















   





4  THE PRESENCE AND ABUNDANCE OF  
      G-PROTEINS IN SWISS 3T3 AND VERO  
          CELLS 
 
The G-protein coupled receptors (GPCRs) and several types of the 
heterotrimeric G-proteins are ubiquitously expressed in all cell types of 
mammalian organisms (Offermanns, 2001). The heterotrimeric G-proteins 
are important internal mediators of the extracellular signals that bind to 
GPCRs, which lead to the generation of a specific biochemical response. 
 
  4.1  The Presence of G-proteins 
 
Babb et al. (2012) reported the presence of all G-proteins in Swiss 3T3 cells 
while reports from Kamitani et al. (2011), Babb et al. (2012), and Orth et al. 
(2013) confirmed that PMT activates Gi1-3, Gq/11, and G12/13 but not Gs.  
 
In spite of the reported differential response of Vero cells to PMT compared 
to other cell lines, the presence of different G-protein subtypes in Vero cells 
has not been investigated. Prior to starting this research, our group predicted 
that the presence and differences in G-protein abundance might have 





   





To determine whether all the G-protein  subtypes that PMT modifies are 
present in untreated Swiss 3T3 and Vero cells, membrane proteins were 
extracted and the G subunits in the samples were analysed using SDS-
PAGE and Western Blotting using antibodies specific to G subtypes. These 
antibodies are listed as interacting to both human and mouse G-proteins, 
and from the information available about green monkey G-proteins (see 
section 4.3) were predicted to interact with both cell types. 
 
This result indicated that all G subtypes that PMT modifies are present in 
both Swiss 3T3 and Vero cells (Fig 4.1.1). This result also confirms the 
report of Babb et al. (2012) that there appears to be less Gi-1 in Swiss 3T3 
cells compared to the other G subtypes. It is impossible to measure and 
compare the amount of all G subtypes in both cell lines as different 
antibodies were used; however, it appears that there is a difference in the 
amount of each G subtype between two cell lines. Prior to SDS-PAGE, 
Vero cell lysate contained ~0.7 fold more proteins than Swiss 3T3 cell lysate. 
It appears that there are more G subunits in Swiss 3T3 cells with the 
exception of Gi-1 than Vero cells. Although the  complex is not directly 
activated by PMT, it participates in PMT-linked signalling, so it was of 
interest to also look for the presence of the  subunit of G-protein (Fig 4.1.1). 
Due to the thickness of the band, the G subunit in both cell lines appears to 
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Fig 4.1.1  The presence of different G subtypes in Swiss 3T3 and Vero cells. 
All G subtypes that are modified by PMT are present in both Swiss 3T3 and Vero 
cells. The G subunit is also shown here. Cell lysates were immunoblotted with 
antibodies against Gq, G11, G12, G13, Gi-1, Gi-2, Gi-3, G and Na
+/K+ ATPase 
-1 subunit. Legend: S = Swiss 3T3 and V = Vero cells. 
 
The molecular weight of different G subtypes is shown in appendix, Table 
A3 (obtained from the Uniprot and National Center for Biotechnology 
Information (NCBI) database). Swiss 3T3 cells appear to have two isoforms 
of G12, which according to Uniprot and NCBI database have a molecular 




   





UniProt/Swiss-Prot). The G12 of Vero cells appeared to have a molecular 
weight of 36 kDa which compared closely to the predicted G12 of C. 
sabaeus, which has a molecular weight of 36 kDa (protein predicted, 
Uniprot/TrEMBL) (see table A3 in appendix section). The aligned amino acid 
sequences show that the G12 subunit of C. sabaeus is 20% shorter than the 
42 kDa G12 isoform in mouse (Fig 4.1.2). Humans (H. sapiens), on the 
other hand, have three G12 isoforms: 1 unspliced form (44 kDa) and 2 
spliced variants (34 kDa and 38 kDa) (NCBI and UniProt). The extra bands 
seen with Gq and G11 antibodies are likely to be a result of cross reaction, 
as there are no isoforms in the protein or nucleotide databases (Fig 4.1.1).  
 
 
Fig 4.1.2  The Aligned Complete Amino Acid Sequences of G12 subunits of H. 
sapiens, C. sabaeus, and M. musculus. The start codon of each G12 was 
highlighted with an arrow which also shows the difference in the length of the 
protein. Each G subtype of species bears the protein identifier. The amino acid 
sequences of G12 of M. musculus obtained from Uniprot is designated with an 
asterisk (*).  
10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
GNA12 M. musculus P27600 MSGVVRTLSR CLLPAEAG-A RERRAG-AAR DAEREARRRS RDIDALLARE RRAVRRLVKI LLLGAGESGK STFLKQMRII HGREFDQKAL LEFRDTIFDN
GNA12 M. musculus Q2NKI3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------MRII HGREFDQKAL LEFRDTIFDN
GNA12 C. sabaeus A0A0D9RYG1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------MRII HGREFDQKAL LEFRDTIFDN
GNA12 H. sapiens Q03113 MSGVVRTLSR CLLPAEAGGA RERRAGSGAR DAEREARRRS RDIDALLARE RRAVRRLVKI LLLGAGESGK STFLKQMRII HGREFDQKAL LEFRDTIFDN
GNA12 H. sapiens Q03113-2 ---------- ---------- ---------- ---------- --------MK RRMFPRPCLA RMPGSRGSGS TP-------- DG----NRKC CRFEHLLIAH
GNA12 H. sapiens Q03113-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------MRII HGREFDQKAL LEFRDTIFDN
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
GNA12 M. musculus P27600 -ILKGSRVLV DARDKLGIPW QHSENEKHGM FLMAFENKAG LPVEPATFQL YVPALSALWR DSGIREAFSR RSEFQLGESV KYFLDNLDRI GQLNYFPSKQ
GNA12 M. musculus Q2NKI3 -ILKGSRVLV DARDKLGIPW QHSENEKHGM FLMAFENKAG LPVEPATFQL YVPALSALWR DSGIREAFSR RSEFQLGESV KYFLDNLDRI GQLNYFPSKQ
GNA12 C. sabaeus A0A0D9RYG1 -ILKGSRVLV DARDKLGIPW QYSENEKHGM FLMAFENKAG LPVEPATFQL YVPALSALWR DSGIREAFSR RSEFQLGESV KYFLDNLDRI GQLNYFPSKQ
GNA12 H. sapiens Q03113 -ILKGSRVLV DARDKLGIPW QYSENEKHGM FLMAFENKAG LPVEPATFQL YVPALSALWR DSGIREAFSR RSEFQLGESV KYFLDNLDRI GQLNYFPSKQ
GNA12 H. sapiens Q03113-2 PGSRGSRVLV DARDKLGIPW QYSENEKHGM FLMAFENKAG LPVEPATFQL YVPALSALWR DSGIREAFSR RSEFQLGESV KYFLDNLDRI GQLNYFPSKQ
GNA12 H. sapiens Q03113-3 -ILKGSRVLV DARDKLGIPW QYSENEKHGM FLMAFENKAG LPVEPATFQL YVPALSALWR DSGIREAFSR RSEFQL---- ---------- ---NYFPSKQ
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
GNA12 M. musculus P27600 DILLARKATK GIVEHDFVIK KIPFKMVDVG GQRSQRQKWF QCFDGITSIL FMVSSSEYDQ VLMEDRRTNR LVESMNIFET IVNNKLFFNV SIILFLNKMD
GNA12 M. musculus Q2NKI3 DILLARKATK GIVEHDFVIK KIPFKMVDVG GQRSQRQKWF QCFDGITSIL FMVSSSEYDQ VLMEDRRTNR LVESMNIFET IVNNKLFFNV SIILFLNKMD
GNA12 C. sabaeus A0A0D9RYG1 DILLARKATK GIVEHDFVIK KIPFKMVDVG GQRSQRQKWF QCFDGITSIL FMVSSSEYDQ VLMEDRRTNR LVESMNIFET IVNNKLFFNV SIILFLNKMD
GNA12 H. sapiens Q03113 DILLARKATK GIVEHDFVIK KIPFKMVDVG GQRSQRQKWF QCFDGITSIL FMVSSSEYDQ VLMEDRRTNR LVESMNIFET IVNNKLFFNV SIILFLNKMD
GNA12 H. sapiens Q03113-2 DILLARKATK GIVEHDFVIK KIPFKMVDVG GQRSQRQKWF QCFDGITSIL FMVSSSEYDQ VLMEDRRTNR LVESMNIFET IVNNKLFFNV SIILFLNKMD
GNA12 H. sapiens Q03113-3 DILLARKATK GIVEHDFVIK KIPFKMVDVG GQRSQRQKWF QCFDGITSIL FMVSSSEYDQ VLMEDRRTNR LVESMNIFET IVNNKLFFNV SIILFLNKMD
310 320 330 340 350 360 370 380
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ..
GNA12 M. musculus P27600 LLVEKVKSVS IKKHFPDFKG DPHRLEDVQR YLVQCFDRKR RNRSKPLFHH FTTAIDTENI RFVFHAVKDT ILQENLKDIM LQ
GNA12 M. musculus Q2NKI3 LLVEKVKSVS IKKHFPDFKG DPHRLEDVQR YLVQCFDRKR RNRSKPLFHH FTTAIDTENI RFVFHAVKDT ILQENLKDIM LQ
GNA12 C. sabaeus A0A0D9RYG1 LLVEKVKTVS IKKHFPDFRG DPHRLEDVQR YLVQCFDRKR RNRSKPLFHH FTTAIDTENV RFVFHAVKDT ILQENLKDIM LQ
GNA12 H. sapiens Q03113 LLVEKVKTVS IKKHFPDFRG DPHRLEDVQR YLVQCFDRKR RNRSKPLFHH FTTAIDTENV RFVFHAVKDT ILQENLKDIM LQ
GNA12 H. sapiens Q03113-2 LLVEKVKTVS IKKHFPDFRG DPHRLEDVQR YLVQCFDRKR RNRSKPLFHH FTTAIDTENV RFVFHAVKDT ILQENLKDIM LQ




   





  4.2  The Abundance of G-proteins 
 
Little is known about the differences in G subtypes in different cells. 
Krumins and Gilman (2006) catalogued the presence and abundance of 
different G-proteins in HeLa cells.  
 
Fig 4.1.1 shows that the amounts of G-protein  subtypes that PMT modifies 
differ between the two cell lines. However, it is not possible to measure the 
amounts of G-proteins present using different antibodies. I, therefore, 
decided to attempt to quantify the expression levels of these G subunits. 
Real-time qPCR (RT-qPCR) would confirm the mRNA level of the G 
subtypes in Swiss 3T3 and Vero cells. 
 
  4.3  Sequencing of the Collaborative Consensus  
         Coding Sequences (CCDS) of Different G  
          subunits in Vero Cells 
 
The CCDS of each G-protein  subtype is represented by the complete 
mRNA sequences, composed of exons, that translate into protein while the 
reference mRNA (or RNA) sequence includes untranslated regions 
(Mignone et al., 2002; Pruitt et al, 2009).  
 
Vero cells are kidney epithelial cells derived from African Green Monkey, 




   





within the genus Chlorocebus (Haus et al., 2013). Researchers are still 
disputing about this taxonomy and consider Chlorocebus aethiops as one 
species with 4 monotypic and 2 polytypic species with subspecies. 
According to Groves (2001), the 4 monotypic species are C. aethiops (Grivet 
Monkey, also known as African Green Monkey and Savannah Monkey) 
(Kingdon, 1997; Kingdon and Butynski, 2008), C. sabaeus (Green Monkey, 
also known as Sabaeus Monkey or Callithrix Monkey) (Groves, 2005), C 
djamdjamensis (Bale Monkey or Blue Mountain Vervet), and C. cynosauros 
(Malbrouck Monkey). According to Yamasura and Kawakita (1963), Vero 
cells were derived from the African Green Monkey (C. aethiops) but 
according to genome analysis, Vero cell lineage came from a female C. 
sabaeus (Osada et al., 2014). 
 
As there was confusion regarding where Vero cells derived from, the 
importance of the sequences to determine the amount of different G-protein 
 subtypes in Vero cells, I did a nucleotide comparative analysis of G-protein 
 subtypes in C. aethiops and C. sabaeus. Also, since the CCDS of all G-
protein G-protein  subtypes of Homo sapiens (human) and Mus musculus 
(mouse – origin of Swiss 3T3 cells) are available in the NCBI database they 
were used to search for refseq RNA, CCDS or any nucleotide sequences of 
each G-protein  subtype in C. aethiops. The NCBI blast tool, however, did 
not resolve any refseq RNA, CCDS or nucleotide sequences with high 




   





sapiens or M. musculus. After multiple blast runs, it was concluded that the 
nucleotide sequences of C. aethiops in the NCBI database were incomplete 
and had not been annotated. King’s senior bioinformatics officer, Phil 
Cunningham was also consulted, and did independent multiple comparative 
analyses, and came to a similar conclusion (data not shown).  
 
Due to limited sequence information available for C. aethiops, and also in 
order to carry out comparative nucleotide analysis of G-protein  subtypes to 
C. sabaeus, I have attempted to sequence the different G-protein  subtypes 
in Vero cells. In order to design a primer for each of the G subunits of C. 
aethiops, comparative nucleotide and amino acid sequence analyses were 
carried out. The sequences from the NCBI database were used since the 
database contains all the RefSeq RNA, CCDS and the corresponding 
protein sequences of each G subtype of the different species. The CCDS 
of each of G subtype of H. sapiens was compared to M. musculus and the 
predicted refseq RNA from C. sabaeus stored in the NCBI database (Table 
4.3-A).  
 
The nucleotide sequences of Chlorocebus sabaeus appeared to have been 
annotated, albeit mostly were predicted sequences. The CCDS (taken from 
the predicted refseq RNA) of different G subunits of C. sabaeus generated 
a very high degree of identity, 98 - 99% to H. sapiens. The CCDS of H. 




   





identity. The CCDS of different G subtypes between M. musculus and C. 
sabaeus, on the other hand, were only 84 – 94% identical. It appears that 
the predicted CCDS of G12 of C. sabaeus is different to its mouse and 
human counterparts, covering only 93 – 94 % of the full CCDS coverage 
query, which may indicate a difference in the size of G12 in C. sabaeus 
compared to these other species. The coverage query is the percent of the 
query length (i.e. the CCDS) that was included in the comparative blast runs 
(see appendix Figs A5 and A6). 
 
 Next, the CCDS of all G subunits in the three species were obtained from 
the NCBI database and aligned by ClustalW in the Bioedit Sequence 
Alignment Editor (Hall, 1999) and the MEGA6.0 (Tamura et al., 2013) 
programs. A phylogenetic tree was constructed using MEGA6.0 program to 
show common homology and identity in nucleotide sequences (i.e. CCDS) 












   





 Table 4.3-A  A Comparative Analysis of CCDS of Different G subunits of H. 
 sapiens, M. musculus and C. sabaeus 
 
   *  The percentage of CCDS covering the CCDS of two species
+ and ++
. 
  **  The percentage of sequence identity in the coverage query between two species
+ and ++
.  
       The identifier/accession number of CCDS of each G subunit are in Fig 4.3-A.   
 
      
The phylogenetic tree summarises the common homology and identity in 
nucleotide sequences of G subtypes between three species (Fig 4.3-A). It 
shows that Gq and G11, G12 and G13, Gi-1,2,3 are grouped together 
according to their homology and sequence identity, with Gi-1 and Gi-3 
sharing higher identity than Gi-2. All the G subtypes of H. sapiens have a 
higher identity to the nucleotide sequences of C. sabaeus than M. musculus, 
as might be expected. All the aligned nucleotide and amino acid sequences 
























Gq 100 95 100 99 100 94 
G11 100 90 100 98 100 89 
G12 100 92 93 98 94 91 
G13 100 91 100 98 100 90 
Gi-1 100 89 100 99 100 89 
Gi-2 100 92 100 99 100 92 




   







Fig 4.3-A  The Phylogenetic Tree of Different CCDS of G Subtypes in H. 
sapiens, M. musculus, and C. sabaeus with their Identifier obtained from the 
NCBI Database. The scale bar indicates the average number of nucleotide 
substitutions per site. 
 
A comparative analysis of the amino acid sequences of different G subunits 
of H. sapiens, and M. musculus and C. sabaeus, was also carried out (Table 
4.3-B). All protein sequences were obtained from the NCBI database and 
aligned by ClustalW in the Bioedit Sequence Alignment Editor (Hall, 1999) 
and the MEGA6.0 (Tamura et al., 2013) programs. A phylogenetic tree was 
constructed using MEGA6.0 program to show common homology and 
 Gi-1 H.sapiens CCDS5595.1
 Gi-1 C.sabaeus XM007982374.1
 Gi-1 M.musculus CCDS39018.1
 Gi-3 M.musculus CCDS17751.1
 Gi-3 H.sapiens CCDS802.1
 Gi-3 C.sabaeus XM007977682.1
 Gi-2 M.musculus CCDS23502.1
 Gi-2 H.sapiens CCDS2813.1
 Gi-2 C.sabaeus XM007984297.1
 Gq H.sapiens CCDS6658.1
 Gq C.sabaeus XM007969549.1
 Gq M.musculus CCDS29684.1
 G11 M.musculus CCDS24061.1
 G11 H.sapiens CCDS12103.1
 G11 C.sabaeus XM007994753.1
 G12 H.sapiens CCDS5335.1
 G12 C.sabaeus XM008018831.1
 G12 M.musculus CCDS19825.1
 G13 M.musculus CCDS25577.1
 G13 H.sapiens CCDS11661.1




   





identity in amino acid sequences between G subtypes in different species 
(Fig 4.3-B). 
    
 Table 4.3-B  A Comparative Analysis of Amino Acid Sequences of Different 
G subunits of H. sapiens, M. Musculus and C. sabaeus 
  
  *  The percentage of CCDS covering the CCDS of two species
+ and ++
. 
 ** The percentage of sequence identity in the coverage query between two species
+ and ++
.  




The G-proteins, Gq/11, G13, and Gi-1,2,3 show 97 – 100% amino acid 
sequence identity with 100% coverage query in H. sapiens, M. musculus, 
and C. sabaeus. G12, on the other hand, has 99 – 100% identity and 
covering only 80% of the whole sequence query, which indicates a 
difference in the size of G12 (both CCDS and protein sequences) of C. 
sabaeus compared to G12 of H. sapiens and M. musculus. 
 
The amino acid sequences of Gi-1 in the three species appear to be 
identical (see also Fig A5 in the appendix section). The amino acid 























Gq 100 99 100 100 100 100 
G11 100 98 100 98 100 97 
G12 100 98 80 100 80 99 
G13 100 97 100 100 100 97 
Gi-1 100 100 100 100 100 100 
Gi-2 100 98 100 100 100 98 




   





NCBI database and aligned by ClustalW in Bioedit Sequence Alignment 
Editor and MEGA6.0 programs.  
 
A phylogenetic tree was constructed using the MEGA6.0 program to show 
common homology and identity in amino acid sequences between G 
subtypes in different species (Fig 4.3-B). The phylogenetic tree summarises 
the common homology and identity in amino acid sequences of G subtypes 
amongst the three species (Fig 4.3-B). Similar to the nucleotide sequences, 
it shows that Gq and G11, G12 and G13, Gi-1,2,3 are grouped together 
according to the homology and identity of their amino acid sequences. The 
amino acid sequence of Gi-1 is conserved across the three species. 
Similarly, all G subtypes of H. sapiens have a higher identity with the amino 




   







Fig 4.3-B  The Phylogenetic Tree of Different G Subtypes Protein Sequences 
of H. sapiens, M. musculus, and C. sabeus with their Protein Sequence 
Identifier based on each CCDS obtained from the NCBI Database. The scale 
represents the average number of amino acid substitutions per site. 
 
The nucleotide and protein sequences of G12 of Swiss 3T3 cells from 
Uniprot which were not available in the NCBI database were also obtained to 
determine their similarity with G12 from Vero cells (see Fig A5 in the 
appendix section). This particular CCDS gave a 100% coverage query to 
G12 of Vero cells.  
 Gi-2 H.sapiens NP002061.1
 Gi-2 C.sabaeus XP007982488.1
 Gi-2 M.musculus NP032164.2
 Gi-3 M.musculus NP034436.1
 Gi-3 H.sapiens NP006487.1
 Gi-3 C.sabaeus XP007975873.1
 Gi-1 C.sabaeus XP007980565.1
 Gi-1 H.sapiens NP002060.4
 Gi-1 M.musculus NP034435.1
 Gq H.sapiens NP002063.2
 Gq C.sabaeus XP007967740.1
 Gq M.musculus NP032165.3
 G11 M.musculus NP034431.1
 G11 H.sapiens NP002058.2
 G11 C.sabaeus XP007992944.1
 G12 H.sapiens NP031379.2
 G12 C.sabaeus XP008017022.1
 G12 M.musculus NP034432.1
 G13 M.musculus NP034433.3
 G13 H.sapiens NP006563.2




   





Since the nucleotide sequences of C. aethiops in the NCBI database were 
incomplete and had not been annotated, in order to measure the expression 
levels of all G subunits, it is essential to sequence the CCDS of all G 
subunits of Vero cells. PCR will amplify the cDNA prior to sequencing and 
genotyping. The generated sequences will be used for primer design for RT-
qPCR.  
 
  4.4  Designing of Primers 
 
The Primer3 program was used to design the primers based on the mRNA 
sequences of each G subunit of C. sabaeus and H. sapiens in order to 
sequence the CCDS of each of the G subunit of Vero cells. The primers for 
the RT-qPCR for Swiss 3T3 cells were obtained from Origene Technologies. 
The untranslated regions of the mRNA were included in order to get the full 
CCDS.  
 
In order to quantify the mRNA levels of each G-protein  subtype, a Real-
Time PCR requires forward and reverse primers with high degree of 
specificity for each G-protein  subtype. The NCBI primer design tool was 
used to design the RT-qPCR primers for the G subunits of Vero cells after 
sequencing and genotyping. The generated primers for sequencing (Table 
4.4-A) and RT-qPCR (Table 4.4-B) were run on NCBI primer blast tool to 




   





other than the target product. The primers were synthesised by Eurofins 
MWG Operon (https://ecom.mwgdna.com).    
 
The two main sets of primers for G12 were G12 (A) or G12 (AA) (for 
forward and reverse), and G12 (B) or G12 (BB) (Table 4.4-A). They were 
also used interchangeably which also generated 2 more sets, e.g. forward 
primer of set A was paired with the reverse primer of set B which was 
denoted as G12 (AB), and vice versa (G12 (BA)). The latter 2 sets of 
primers were also run on the NCBI primer tool to confirm their specificity to 
the target cDNA template, determine the product size, and avoid 
amplification of other products. 
 


















































































   





Table 4.4-B  The RT-qPCR Primer Sequences for G subunits of  












































































  4.5  Extraction of mRNA  
 
 Construction of a cDNA library that can be translated to mRNA requires 
cellular RNA of high quality. Extraction of the RNA pool from Swiss 3T3 and 
Vero cells was carried out using the RNeasy Plus Mini Kit (QIAGEN). The 
RNA content and quality were determined using a NanoDrop 1000 
Spectrophotometer (Thermo Scientific) (Table 4.5). The RNA samples from 
Swiss 3T3 and Vero cells both had A260/280 ratio of >2.0 which is 








   

















Another common method to assess integrity of total RNA samples is by 
visualising 28s and 18s ribosomal RNAs (rRNAs) on a denaturing agarose 
gel stained with gel red or ethium bromide (EtBr)  (Fleige and Pfaffl, 2006; 
Wieczorek et al., 2012). RNAs are usually not visible on denaturing agarose 
gel as their secondary structure alters their migration properties and 
therefore would not migrate according to their size.  
 
The extracted RNAs was electrophoresed on a 1% denaturing agarose gel 
dissolved in 1x TAE, which contains 1% household bleach (Clorox) (Aranda 
et al., 2012) and later on stained with gel red. A DNA ladder was used only 
to show that the gel and samples were run properly. Intact total RNA in the 
samples should give a sharp intensity of the 28s and 16s rRNA bands when 
run on agarose gel. A clear 2:1 ratio of 28s and 16s rRNA is an indicative of 
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were visualised on UV transilluminator (AlphaImager; λ= 302) to allow the 
UV detection of the stained RNA bands.  
 
Fig 4.5  The 28s and 16s rRNA in Swiss 3T3 and Vero cells. 5l of each RNA 
sample mixed with 1l dye and DNA marker were run on 1% agarose gel in TAE 
with 1% household bleach, and visualised as described in the text. Legend: S = 
Swiss 3T3 and V = Vero cells. 
 
The RNA samples from Swiss 3T3 and Vero cells produced visible clear 28s 
and 16s rRNA bands with light smearing but did not give a clear 2:1 ratio 
(Fig 4.5). However, these samples were used for the construction of cDNA 
library of different G subunits of Vero cells. The 2:1 ratio of 28s and 16s 
rRNA was not achieved, however, Fleige and Pfaffl (2006) reported that 28s 
rRNA rapidly disappears under UV light. According to Imbeaud et al. (2005), 





   





  4.6  Generation of cDNA template  
 
In order to generate cDNA templates for qPCR, a reverse transcription 
polymerase chain reaction was carried out using the mRNA from the 
extracted RNA samples, and the Precision nanoScript™ 2 Reverse 
Transcription Kit (PrimerDesign) or High-Capacity cDNA Reverse 
Transcription Kit (Life Technologies) (see section 2.13.9 in chapter 2). After 
reverse transcription, the cDNA content and quality were determined using a 
NanoDrop 1000 Spectrophotometer (Table 4.6). The cDNA samples from 
Swiss 3T3 and Vero cells both had A260/280 ratio of almost 1.8 which is 
considered good quality. 
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4.7  Amplification of CCDS of Different G Subunits  
         by  Real-Time Polymerase Chain Reaction (RT- 
         PCR) 
 
In order to design the forward and reverse primers for each of the G 
subunit in Vero cells for RT-qPCR, it was essential to sequence the CCDS of 
each G subunit. The CCDS of different G subunits in Vero cells were 
amplified using GoTaq® Hot Start Colourless Master Mix (Promega, UK), 
cDNA templates, and Primer3-generated forward and reverse primers (Table 
4.4-A). The amplified CCDS of each G subunit were electrophoresed in 1 - 
2% denaturing agarose gel in either 1x TBE or TAE. The prospective bands 
(cDNA) with molecular size from 974 – 1463 (denoted by the red box) in the 















   





Fig 4.7  The Amplified cDNA of Different G Subunits of Vero cells Using the 
Primers for Sequencing. The generated cDNA of different G subunits (left, 
denoted by the red box) on agarorse gel. The expected and calculated molecular 
weights of G subunits according to their NCBI sequences their relative migration 
distance (Rf) (right). Lanes 1: Gq, 2: G11, 3: G13, 4: Gi-1, 5: Gi-2, 6: Gi-3, 7: 
G12 (AA), 8: G12 (BB), 9: G12 (AB), 10: G12 (BA), 11: GADPH, 12: H2O, 13: 
Master Mix (MM), 14: MM+H2O+Template,  15: MM+H2O+Primer 
 
  4.8  Sequencing of G subtypes 
 
The DNA bands in the denaturing agarose gel were extracted using 
QIAquick Gel Extraction Kit (QIAGEN). The extracted DNA was mixed with 
either the forward or reverse primer and the pre-mixed samples were 
sequenced by Eurofins. These sequences were aligned and compared to 
CCDS of H. sapiens, C. sabaeus, and M. musculus using ClustalW in the 





   





After successful sequencing of some of the G subunits of Vero cells, these 
sequences were aligned and compared to the CCDS of H. sapiens, C. 
sabaeus, and M. musculus by ClustalW in Bioedit Sequence Alignment and 
MEGA6.0 programs (Table 4.8-A, and Fig A7 in the appendix section). The 
whole sequence of each G subunit was used to design the primers for RT-
qPCR. The NCBI primer design tool was used to design the RT-qPCR 
primers for G subunits of Vero cells (Table 4.8-B). The generated primers 
were run on the NCBI primer blast tool to check for identical sequences in 
closely related genes and thus to avoid amplification of other products 
(Table 4.4-B). 
 
Table 4.8-A  A Comparative Analysis of the Nucleotide Sequences of Different   
G subunits of H. sapiens, C. sabaeus, M. musculus and the Sample 
       




  ** The % of nucleotide sequence identity in the query coverage between sequence of the  




































Gq 82 92 82 97 82 96 
G11 --- --- --- --- --- --- 
G12 69 86 69 88 68 81 
G13 --- --- --- --- --- --- 
Gi-1 88 84 92 95 92 94 
Gi-2 --- --- --- --- --- --- 




   









  4.9  The Quantification of mRNA Levels of Different  
         G Subtypes 
  
It was predicted that the presence and differences in G-protein abundance 
may have functional differences in both cell types and therefore, it was the 
aim of this research to quantify the mRNA level of each G subunit.  
 
Prior to quantification of mRNA level of all G subunits of Swiss 3T3 cells, 
using the generated cDNA templates all primers were tested by amplifying 
the target products by RT-PCR. Amplicons were electrophoresed in 2% 
agarose gel and visualised on UV transilluminator (AlphaImager; λ= 302) to 
allow the UV detection of the stained DNA bands.   
 
The amplicons of each G subunit appeared to be the correct size with the 
exception of Gi-1, which was not detected (Fig 4.9). The cDNA templates 














































   





each G subunit using RT-qPCR technique. A 10-l real-time PCR reaction 
was prepared using 5 l Precision 2X qPCR SYBRgreen Mastermix, 25 ng 
of cDNA template, 6 pMol of primer mix, and nuclease-free water. 
 
Fig 4.9  The Amplified cDNA (Amplicons) of Different G Subunits of Swiss 
3T3 Cells Using the RT-qPCR Primers (left) on Agarose Gel. The expected and 
calculated molecular weights of G subunits according to their NCBI sequences 
their relative migration distance (Rf). Lanes 1: Gi-1, 2: Gi-2, 3: Gi-3, 4: Gq, 5: 
G11, 6: G12, 7: G13, 8: H2O, 9: Master Mix (MM), 10: MM+H2O+Template, 11: 
MM+H2O+ Primers 
 
After many alterations in the amount of cDNA templates, primers, and 
temperature (data not shown), no result was generated. In addition, the 
difficulties in obtaining accurate sequence for Vero cell G-proteins made this 
whole approach very difficult and it was decided to discontinue this line of 







   





  4.10  Discussion 
 
I have confirmed that the G subunits that PMT modifies are present in both 
Swiss 3T3 and Vero cells. However, the relative amount of each G subunit 
differs between two cell lines (Fig 4.1.1). While it is not possible to compare 
relative amounts of different G-proteins using different antibodies, it is 
possible to compare between two cell lines. In particular, the amount of Gi-1 
in Swiss 3T3 cells was less than in Vero cells, confirming the observation 
made by Babb et al. (2012). Gi-1 is known to bind to microtubules and 
activates the tubulin GTPase activity which results in microtubule dynamic 
instability (Roychowdhury et al., 1999; Parekh et al., 2006). Although this 
subunit has been implicated to have a role in cytokinesis or the completion 
of mitosis, Swiss 3T3 cells has less Gi-1 than Vero cells. Gi-1 may have 
other roles such as depression of cAMP level.  
 
In general, it appears that there are more G-proteins in Swiss 3T3 than in 
Vero cells considering that prior to SDS-PAGE, Vero cell lysate contained 
~0.7 fold more proteins than Swiss 3T3 cell lysate. The differences in the 
amount of G subtypes might have a role in the differential responsiveness 
of Swiss 3T3 and Vero cells to PMT. As different antibodies each with 
different avidities can not be used to quantify different proteins, it was hoped 
to determine the amount of each G subunit in both cell lines by quantifying 




   





validated the Western Blot results regarding the amounts of the different G 
subunits. The absence of reliable sequence information for C. aethiops 
(Yamasura and Kawakita, 1963), or C. sabaeus (Osada et al., 2014), from 
which Vero cells were derived, made this task extremely difficult and time-
consuming and it was eventually decided not to pursue it further.  
 
Relative protein abundance can not be assessed directly by measuring 
mRNA levels. Others have had variable success in correlating these two 
properties (Gry et al., 2009; Pascal et al., 2008; Schedel et al., 2004; 
Greenbaum et al, 2003). Discrepancies in the correlation of mRNA level and 
protein expression may be due to protein turnover, complicated post-
transcriptional mechanisms involved in gene expression and other factors 
(Greenbaum et al, 2003).  Different cell types within the same animal, 
although containing the same DNA sequence may have variable protein 
composition which may affect different cellular processes including gene 
transcription, and any changes in the cell may also change the protein 
expression and content. Foley et al. (2010) reported that T-cell differentiation 
changes the repertoire of expressed chemokine receptors (a subgroup of 
GPCRs) and G subunits, in particular, Gi/o. PMT is involved in CD4-
positive T helper (Th) cell differentiation (Hildebrand et al., 2015) and 
inhibition of osteoblast differentiation (Lax et al., 2004). It would be 
interesting to see if PMT also affects the repertoire of expressed G 




   





In order to quantify the mRNA levels of different G subunits of Vero cells, 
specific primers for each G subunit are essential; however, although it was 
not possible to carry out quantification of different mRNA levels as intended, 
interesting information about the information of databases for the genus, 
Chlorocebus were obtained. It appeared that the sequences of C. aethiops 
in the NCBI databank and other databases were incomplete and most had 
not been annotated while the sequences of C. sabaeus were predicted. This 
initial work was carried out in collaboration with Phil Cunningham (Senior 
Bioinformatics Officer at King’s). Comparative nucleotide and amino acid 
analyses of each G subunit of H. sapiens, C. sabaeus and M. musculus 
were used to design primers for the sequencing of G subunits of Vero cells 
(Tables 4.3-A-B; Figs 4.3-A-B). The results showed that the predicted 
nucleotide and amino acid sequences of G subunits of C. sabaeus are 
highly identical to H. sapiens than M. musculus, therefore, the refseq RNA of 
both H. sapiens, and C. sabaeus were used to design primers. During the 
comparative analyses of the protein and nucleotide sequences, the 
coverage query of 80 – 94% for G12 indicated its length which appeared to 
be shorter than all G subtypes in three species. All CCDS and amino acid 
sequences of G subunits were obtained from NCBI database and aligned 
with other sequences which confirmed their length/size (Tables 4.3-A-B, and 
Figs A5 and A6 in the appendix section). Another nucleotide and protein 
sequences of G12 of Swiss 3T3 cells were found only in Uniprot database, 




   





particular G12 has 100% coverage query to G12 of Vero cells (see Figs A5 
and A6 in the appendix section). It is impossible not to speculate that the 
missing 20% in protein sequences of G12 might have a role in protein 
recognition, protein-protein interaction or other functions. A comparative 
analysis of G12 protein sequences from different species reveals that the 
mouse, cattle and many primates including humans have similar G12 
isoform (see Fig A8 in the appendix section).   
 
The varying amounts of different G-proteins between cell types may be 
linked to different response to PMT. There are two main questions that need 
to be addressed: First, does PMT recognise and deamidate the G subunits 
of Vero cells? Secondly, does the complex signalling system involving these 
differential responses indicate roles of participating molecules that regulate 













   





5  THE MODIFICATION OF G SUBUNITS IN  
    SWISS 3T3 AND VERO CELLS 
 
Activation of G-proteins by PMT involves deamidation of the conserved 
glutamine residue in the switch II of the G subunits to glutamic acid. The 
glutamine residue positions the attacking water molecule during hydrolysis of 
ATP. Deamidation of this amino acid residue renders the G-proteins in their 
constitutive active state leading to activities of the signalling pathways that 
each activated G-protein regulates. 
 
  5.1  Detection of Modified G-proteins in Swiss 3T3  
        and Vero Cells by PMT 
 
Kamitani et al. (2011), Babb et al. (2012), and Orth, et al. (2013) confirm that 
PMT modifies Gi1-3, Gq/11, and G12/13 but not Gs in different cell lines. 
  
In order to understand the differential response of Swiss 3T3 and Vero cells 
to PMT, it was essential to determine if PMT modified all G subunits in 
each cell line. An immunoprecipitation experiment using magnetic 
Dynabeads® was carried out to collect both endogenous unmodified and 
deamidated G subunits from the cell lysates of the untreated and rPMT-
treated cell lines (see section 2.13.6). The separated G subunits were 




   





reacted with antibodies specific to G subtypes or the deamidated form of 
G subunits (a rat monoclonal anti-QE). 
 
I have shown that the G subunits examined were present in different 
amounts in both cell types (Fig 4.1). The amount of each G subunit in Vero 
cells appears to be less when compared to their G subunit counterpart in 
Swiss 3T3 cells with the exception of Gi-1.  
 
The Western Blot results show that all rPMT-modified G subunits in Swiss 
3T3 and Vero cells were present up to a period of 3 days (Fig 5.1.1). As 
shown before by others (Kamitani et al., 2011 and Orth, et al., 2013), PMT 
leads to deamidation of its target G subunits starting at around 4 h. Gi-1 
deamidation is greater after 72 h, which may reflect the relatively low 
abundance of this subunit in Swiss 3T3 cells. In Vero cells, on the other 
hand, the modification of G subunits were first detected at 16 h post rPMT 
treatment with the exception of Gi-2 and G11 which appeared to be the first 
targets of rPMT. Interestingly, G12 first begins to be modified by rPMT at 
around 48 h. The modification of G13 was first detected at 16 h but this had 
increased substantially by 48 h. The unmodified G subunits, except for Gi-
1, in the untreated and rPMT-treated Swiss 3T3 cells were all present up to a 
period of 3 days. It is difficult to detect the unmodified Gi-1 in Swiss 3T3 
cells in small quantity using the polyclonal anti-Gi-1 antibody. (Fig 5.1.1, and 




   





antibody was able to detect the modified G subunits in rPMT-treated Swiss 


















   





























 Anti- G* Anti-QE
** Anti- G* Anti-QE
** 
 
                PMT 
             Time (h) 
Swiss 3T3 
-    +   +    +   +   +                 
  0    4   16   24  48  72 
Swiss 3T3 
   -   +   +    +   +   +                 
    0    4   16   24  48  72 
Vero   
   -    +   +   +   +   +                                
   0    4   16  24  48  72              
Vero  
-   +   +   +  +   +                              











      
G13 
      
Gi-1 
       
Gi-2 
       
Gi-3 
             
 
*   G subunits of Swiss 3T3 and Vero cells probed with specific G antibody 
**   G subunits of Swiss 3T3 and Vero cells probed with anti-QE antibody 
 
Fig 5.1.1  The immunoprecipitated unmodified and deamidated G subtypes in Swiss 3T3 and Vero cells. Both cell lines were either 
left untreated (-) or treated (+) with 15 ng/ml of rPMT and processed at different time points: 0, 4, 16, 24, 48, 72 h. G subunits were 
immunoprecipitated using specific G antibody and magnetic beads overnight at 4ºC in cell lysates containing a protein concentration of 500 





   





As immunoprecipitation is more difficult to quantify, total amount of modified 






Fig 5.1.2 Deamidation of G subunits by PMT occurs later in Vero cells 
compared to Swiss 3T3 cells. Both cell lines were either left untreated or treated 
with 15 ng/ml of rPMT and collected at different time points: 0, 4, 16, 24, 48, 72 h. 
Cell lysates containing a protein concentration of 1000 µg/ml (Swiss 3T3 cells) and 
1400 µg/ml (Vero cells) were analysed by SDS-PAGE and Western Blotting. Anti-
QE antibody was used to detect the total modified G subunits. 
 
The Western Blot results show that the G subunits of Swiss 3T3 cells were 
deamidated as early as 4 h while Vero cells show a low level of deamidated 
G subunits at 4 h (Fig 5.1.2). However, the amount of these modified G 
subunits in Vero cells increased at 16h reaching the maximum amount at 48 
h. These modified G subunits were all present until day 3. The level of 
modified G subunits in Swiss 3T3 cells, on the other hand, remained the 
same from 4 h until 72 h.  
 
The difference in the amount of deamidated G subunits at 4 h between the 
two cell lines raised a few more questions: 1) When did PMT start modifying 
Swiss 3T3 Vero 
                     PMT 
     0    4   16  24  48  72      Time (h) 
                     PMT    
       0   4   16  24   48  72                     Time (h) 
      
     
     
     
QE                                                                    QE 
 




   





G subunits in Swiss 3T3 and Vero cells? 2) Would there be an increase in 











Fig 5.1.3  PMT modification of G subunits is faster in Swiss 3T3 cells 
compared to Vero cells. Both cell lines were either left untreated or treated with 15 
ng/ml of rPMT and collected at different time points: 0, 1, 2, 3, 4, 5, 6 and 8 h. Cell 
lysates containing a protein concentration of 500 µg/ml were analysed by SDS-
PAGE and Western Blotting. Anti-QE antibody was used to detect the total modified 
G subunits. 
 
The Western Blot results show that the modified G subunits in Swiss 3T3 
and Vero cells can be detected from 2 h post rPMT treatment (Fig 5.1.3). 
The rPMT-treated Swiss 3T3 cells show an increment in the level of modified 
G subunits from 2 h reaching a clear thick band at 4 h. In Vero cells, on the 
other hand, a visible faint band of modified G subunits is present at 2 h 
post rPMT-treatment but there was no noticeable huge increment in the level 
of modified G subunits after 4 h compared to rPMT-treated Swiss 3T3 cells. 
Taken with the results shown in Fig 5.1.2, this shows that modification of G 
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subunits in Vero cells appears to start at the same time, but takes a much 
longer time to reach a maximum.  
 
All modified G subunits were present and their amount remained stable up 
to a period of 3 days. To determine whether these modified G subunits are 
still present for a longer period of time or undergo degradation by the 
ubiquitin proteasome degradation system and/or lysosomes, Swiss 3T3 and 
Vero cells were cultured and treated with rPMT (15 ng/ml) in DMEM without 
serum for 3 days and media were replaced with DMEM with 1% serum twice 












Fig 5.1.4  The stability of the modified G subunits in Swiss 3T3 and Vero 
cells. Both cell lines were either left untreated or treated with 15 ng/ml of rPMT and 
collected at different time points: 0, 1, 2, and 3 weeks. Cell lysates containing a 
protein concentration of 600 µg/ml (Swiss 3T3) and 1000 µg/ml (Vero cells) were 
analysed by SDS-PAGE and Western Blotting. Anti-QE antibody was used to detect 
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The rPMT-modified G subunits in Swiss 3T3 and Vero cells were present in 
different amounts for up to a period of 3 weeks (Fig 5.1.4). In Swiss 3T3 
cells, two bands of rPMT-modified G subunits were detected on week 1 
and the lower band disappeared in weeks 2 and 3. In Vero cells, only a 
single thick band was detected on week 1 which was then reduced by 
approximately half in weeks 2 and 3.  
 
In the 3 day experiment (Fig 5.1.2), only a single band of modified G 
subunits was detected from rPMT-treated Swiss 3T3 and Vero cells. Double 
bands of modified G subunits in Swiss 3T3 cells only appeared in week 1 
and then disappeared in weeks 2 and 3 (Fig 5.1.4). In rPMT-treated Vero 
cells, on the other hand, only a single band was detected in the 3-day (Fig 
5.1.2) and 3-week experiments but showed a decrease in the level of 
modified G subunits in weeks 2 and 3 (Fig 5.1.4). To determine the time 
that these double bands start to appear and/or if they disappear and 
reappear, Swiss 3T3 cells were treated with rPMT in DMEM without serum 













   











Fig 5.1.5  Detection of double bands from modified G subunits in Swiss 3T3 
cells. Swiss 3T3 cells were either left untreated or treated with 15 ng/ml of rPMT 
and collected at different time points: 0, 3, 5, and 7 days. Cell lysates containing a 
protein concentration of 600 µg/ml were analysed by SDS-PAGE and Western 
Blotting. Anti-QE antibody was used to detect the total modified G subunits. 
 
The Western Blot result shows that double or multiple bands from modified 
G subunits appeared at day 5, and were still present on day 7 (Fig 5.1.5) 
which is consistent with the long term exposure of Swiss 3T3 cells to rPMT 
(Fig 5.2.4). A single band was detected in day 3 which also confirms the 










Fig 5.1.6   Attempt to detect PMT using a goat monoclonal anti-PMT antibody.  
A) 3 µg rPMT B) Swiss 3T3 cell lysate treated with 200 ng/ml of rPMT 
after day 1. 
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Since the modified G subunits appear to be stable or have a long half-life, I 
have attempted to detect them in cell lysates but our monoclonal antibody 
could only show a clear band from 3 µg of rPMT. It is not plausible to treat 
the cells with very high amount of rPMT as this could leave drastic effects to 
the cells and possibly may not survive a few days of rPMT treatment as they 
easily detach to the matrix. A concentration of 200 ng/ml of rPMT which was 
initially used in the first few experiments already showed severe 




















   





  5.2  DISCUSSION 
 
I have confirmed that PMT modifies Gi1-3, Gq/11, and G12/13 in both rPMT-
treated Swiss 3T3 and Vero cells up to a period of 3 days. However, the 
modification of most G subunits in Vero cells was much delayed compared 
to Swiss 3T3 cells where all modified G subunits were detected as early as 
4 h. The modified Gi-2 and G11 appear to be the first target of PMT in Vero 
cells which were detected at 4 h while the modified G12 was detected at 48 
h and the rest of G subunits at 16 h.  
 
The cell lysates also confirm the observed differences in the amount of 
modified G subunits between the two cell lines (Fig 5.1.2). In particular, the 
Western Blot result shows a small amount of modified G subunits at 4 h 
which possibly were the first target of PMT, Gi-2 and G11 in Vero cells. The 
increase in the amount of modified G subunits at 16 h and 48 h coincided 
with the observed modification of the rest of G subunits. Swiss 3T3 cells, 
on the other hand, showed a similar amount of modified G subunits from 4 
h which confirms that all G subunits were modified at 4 h.  
                                                                                                                         
It was initially thought that there might be a delay in the internalisation or 
translocation of PMT via endosomes in Vero cells due to a delay in the 
modification of G subunits. To further understand this phenomenon, it is 




   





cell lines and the increase in the amount of modified G subunits in Vero 
cells. The Western Blot result shows that the G subunits in both cell lines 
were modified by PMT as early as 2 h but the increase in the amount of 
modified G subunits in Vero cells was gradual compared to Swiss 3T3 cells 
which shows a huge increment in the amount of modified G subunits within 
2 – 4 h. Lacerda et al. (1996) reported a lag period of 1 h between PMT 
treatment and phosphorylation of p125FAK and paxillin, both associated with 
focal adhesion, which indicates that PMT enters the cell and undergoes 
processing via an endosomal/lysosomal pathway. It is possible that PMT 
uses the same entry pathway in Vero cells. However, the low amount of 
modified G subunits detected at early time points in Vero cells may depend 
on the following factors: 1) the mechanism involved in trafficking, 
translocating, and activating PMT via endosomal pathway inside the cells, 2) 
recognition of G subunits by PMT (e.g. amino acid sequence of G12), or 3) 
the presence or amount of cellular proteins that might be involved in the 
translocation and activation of PMT or modification of G subunits. 
 
PMT binds to sphingophospholipid sphingomyelin or phosphatidylcholine 
with other lipid components (Brothers et al., 2011) and is then trafficked to 
late endosomes where it is proteolytically activated between pH 5 – 5.5 
(Baldwin et al., 2004; Smyth et al., 1995). The required pH (5 – 5.5) for PMT 
activation was carried out in Swiss 3T3 cells. In viral research, various 




   





dependent on the timing of pH changes in different endosomes (Holtzman, 
1976).  Rybak and Murphy (1998) reported that the mouse kidney epithelial 
cells have higher endosomal pH than the mouse fibroblast and cardiac 
muscle cells, while Murakami et al. (2012) showed that Vero cells have 
higher endosomal pH than Madin-Darby canine kidney cells. Rybak and 
Murphy (1998) also mentioned that extended culture of different cell lines 
may result in the differences in endosomal pH. During PMT transport, the 
essential recruitment and binding of small GTPase Arf6 to vacuolar ATPases 
suggests the role of these proteins in intra-endosomal acidification (Repella 
et al., 2011). Actin and microtubules are also required in trafficking PMT as 
disruption of these cytoskeletal proteins inhibits the translocation and 
cytotoxicity of PMT (Repella et al., 2011). 
 
Suzuki et al. (2009) reported that G12 and G13 have a slow rate of 
nucleotide exchange and GTP hydrolysis. In terms of their GTP-binding 
kinetics, Zhang et al. (2006) demonstrated that the fusion protein, 
thromboxane A2 receptor-G12 responded to agonists slower than the fused 
thromboxane A2 receptor-G13 in Spodoptera frugiperda (Sf9) cells. In 
contrast, purified G12 and G13 did not show any differences in their GTP-
binding property in vitro. PMT directly activates G-proteins and does not 
require GPCR. However, the PMT-mediated activation of G12 appears to be 
slower than G13 in both Swiss 3T3 and Vero cells (Fig 5.1.1), which was 




   





generated from the purified G12 and G13. Ligand-GPCR coupling and PMT 
appears to have the same coupling efficiency to G12 and G13. Such delay 
in modification may also be due to the missing 20% N-terminal amino acid 
sequence in G12 which may have a role in protein recognition, protein-
protein interaction or other functions as discussed in chapter 4.  
 
In line with the report of Wilson et al. (2000), stress fibre formation in rPMT-
treated Vero cells was less prominent than rPMT-treated Swiss 3T3 cells a 
few hours post PMT treatment (Fig 3.2.2.1). Taken together with the results 
from the comparative analysis of the amino acid sequences of G12 subunit 
(Table 4.3-B, and Table A2, Fig A5 in the appendix section), the G12 
subunit in green monkey (genus Chlorocebus) is 20% shorter than the other 
G12 isoform in human and mouse (Table A2 in the appendix section). The 
20% amino acid sequences missing in G12 subunit situated in the N-
terminus in the green monkey may have a role in protein recognition by 
PMT. It appears that humans, crab-eating macacaque (Macaca fascicularis), 
olive baboon (Papio Anubis), and domestic cow (Bos tauraus) have G12 
isoform similar to the G12 subunit of Green Monkey (Table A2 and Fig A8 in 
the appendix section). The Gq/11- and G12/13-Rho pathways regulate stress 
fibre formation in cells. The early cytoskeletal disruption in Vero cells was 
possibly due to the PMT-induced activation of Gq/11 and G13 and later on, 
actin stress fibre formation became prominent upon modification of G12. 




   





while Gq was modified at 16 h. G12, on the other hand, was modified at 48 h. 
G13, on the other hand, was modified in small quantities at 16 h. However, 
G12 appears to be required in stress fibre formation. It appears that activation 
of Gq/11 and G12/13 is required for the synergistic effect in full development of 
stress fibres. Another important event in stress fibre assembly is the 
activation of Rho kinase and MLCK which leads to phosphorylation of two 
residues of MLC and actomyosin contractility. The Gq/Ca
2+-CaM-dependent 
MLCK and G12/13-Ca
2+-independent Rho kinase systems phosphorylate MLC 
in Ser19 and Thr18 residues where the latter is essential in concert with 
Ser19 for full contractility (Totsukawa et al., 2000; Pellegrin and Mellor, 
2007; Getz et al., 2010; Katoh et al., 2011). According to Tosukawa et al. 
(2000), MCLK and Rho kinase have distinct roles in stress fibre formation. 
Rho kinase is involved in stress fibers and focal adhesions while MLCK is 
involved in microfilament assembly in the cell periphery.  
 
Post-translational modifications of proteins play a major role in cell signalling 
(as discussed in section 1.5). Palmitoylation and acylation of G12 (Cys
11), 
palmitoylation of G13 (Cys
14 or Cys18), and acylation of G13 (Cys
37) have 
been implicated to be involved in cell transformation, protein interaction, 
membrane localisation and stress fibre formation (Ponimaskin et al., 2000; 
Jones and Gutkind, 1998; Suzuki et al., 2009; Waheed and Jones, 2002). 
Jones and Gutkind (1998) reported that a nonpalmitoylated constitutively 
active mutant G12 did not form foci in NIH-3T3 cells. Myristoylation of a 




   





R6S), on the other hand, restored its transforming capability with high 
efficiency. There is no cysteine residue in the N-terminus of the G12 subunit 
in green monkey while one of the G12 isoforms (~44 kDa) in mouse 
possesses all the residues for palmitoylation and acylation (Fig A5 in the 
appendix section). The G13 subunit in both mouse and green monkey, on 
the other hand, has Cys14, Cys18, and Cys37 which are the sites for 
palmitoylation and acylation (Fig A5 in the appendix section). In the studies 
involving constitutively active Gq and Gs mutants, palmitoylation appears 
to be required for membrane anchorage in both G subunits while acylation 
or the cysteine residues in Gq are essential for effector interactions. These 
post-translational modifications appear to be essential for the G subunits to 
carry out their normal signalling functions (Wedegaertner et al., 1993; Hepler 
et al., 1996). The Gq subunit in mouse and green monkey contains two 
cysteine residues in the N-terminus, Cys9 and Cys10 (Fig A5 in the appendix 
section). The lack of cysteine residue or palmitoylation and acylation site in 
G12 subunit in Vero cells may have contributed to the loss of mitogenic 
effect of PMT. PMT-induced cell proliferation might require multiple G-
protein families (e.g. Gq and G12/13) or G12 may antagonise the proliferative 
effect of PMT-activated Gq signalling in Vero cells.  
 
The rPMT-modified G subunits were present up to 3 days. A longer time 
course experiments up to a period of 1 and 3 weeks were carried out to 




   





degradation. Results showed that the modified G subunits in both cell lines 
were present up to 3 weeks. However, multiple lower molecular weight 
bands appeared at days 5 and 7, and disappeared at weeks 2 and 3 in 
Swiss 3T3 cells. Vero cells, on the other hand, had a thick band in week 1 
indicating a high amount of modified G subunits, which then decreases in 
weeks 2 and 3. It was difficult to resolve whether this band consisted of 
double or multiple bands due to its thickness. Also, it could not be 
determined if these G subunits were stable from the time they were 
modified or PMT was still stable and actively modifying the G subunits up 
to 3 weeks. The monoclonal anti-PMT antibody could detect ~2 - 3 µg of 
PMT, a 10 - 15-fold higher than the initial concentration (200 ng/ml) used in 
this research which caused detrimental effects to both cell lines.  
                                                                                                               
Multiple lower molecular weight bands in the blot are an indicative of protein 
degradation. Protein degradation may also arise from poor handling; 
however, all samples were kept on ice while being processed at the same 
time in lysis buffer containing the same amount of protease inhibitor. This 
protein degradation most likely happened during the course of 3 weeks in 
particular 3 days post rPMT treatment in Swiss 3T3 cells. The monoclonal 
anti-QE antibody is very specific and has strong avidity to the deamidated 
form of G subunits which when used in cell lysate samples did not show 
any non-specific binding. The disappearance of multiple bands in weeks 2 
and 3 may indicate that the proteins involved in the degradation pathway 




   





indicate that the degradation pathway was inactive possibly due to the 
activation of the survival pathway. Consistent with the results in the LDH 
assay, I have shown that PMT protected Swiss 3T3 cells but not Vero cells 
from cell death, and this anti-apoptotic property was completely abolished at 
day 4. It would be interesting to determine if the anti-apoptotic property of 
PMT was activated as the multiple bands disappeared after week 1. Another 
possible reason for the disappearance of these bands could be due to 
increased efficiency in degrading proteins with quick turnover (which may 
also be the case in Vero cells after week 1) or the degradation pathway was 
shut down due to the detrimental effect of PMT in both cell lines. Wu et al. 
(2006) reported that the constitutively active Gq/11 and G12/13 inhibit the pro-
survival Akt signalling. G heterodimer is known to stimulate the PI3K/Akt 
survival signalling. However, Gq strongly inhibits this pathway with greater 
efficiency (Lee et al., 1993). In order to counteract such inhibition, G 
signalling pathways typically require 10-100 folds of its own concentration 
than the Gq. 
 
Lastly, both cell lines in the long term (3-week) experiment would have 
resulted in cell death without the replacement of media containing miminal 
serum as shown in early experiments (Figs 3.1.1, 3.1.2 and 3.2.1.1). 
Deregulation of multiple pathways leading to abberant signalling by rPMT-
modified G subunits from 3 of the 4 G-protein families would be detrimental 





   





6  THE ACTIVATION OF G-PROTEIN      
  SIGNALLING PATHWAYS BY PMT 
 
I have shown that all the G subtypes that are modified by PMT in Swiss 
3T3 and Vero cells are present in differing amounts. Furthermore, the timing 
of G-protein modification is not the same in the two cell types. The G 
subunits in Swiss 3T3 cells were modified by PMT as early as 4 hours while 
only the Gi-2 and G11 were the first target of PMT and with the G12 being 
the last. These modified G subtypes persisted up to 3 weeks.  
 
These results may have contributed to the differential response of Swiss 3T3 
and Vero cells to PMT. I have discussed in previous chapters the possible 
causes in the delay in stress fibre formation and cell proliferation. The PMT-
induced cell proliferation in Swiss 3T3 cells which ceased by day 4, which 
was also the onset of the plateau growth phase appears to be related to the 
loss of nutrients and/or growth factors. Although re-treatment with PMT was 
not carried out in this research, Wilson et al. (2000) reported that the further 
addition of PMT to PMT-treated Swiss 3T3 cells did not re-initiate the cell 
cycle.  In this chapter, I have investigated whether signalling pathways 
associated with PMT effects and activation of specific G-proteins related to 







   





  6.1  Gq/11 and Calcium Signalling  
 
Gq and G11 play a major role in PMT-induced cell proliferation in various 
cell lines such as Swiss 3T3 cells. Although Gq and G11 of Vero cells were 
also modified by PMT, no significant cell proliferation was detected.  
Activation of Gq/11 by PMT leads stimulation of calcium signalling pathways. 
Gq and G11 also activate RhoA, I therefore decided to determine if calcium 
signalling was also activated and sustained. Cells were either left untreated 
or treated with 15 ng/ml of PMT, and intracellular calcium level was 
measured over 3 days. 
 
There was an increase in the intracellular calcium level of rPMT-treated 
Swiss 3T3 cells over the 3-day period compared to the untreated cells (~3-
fold increase from day 0 compared to day 3) while there was no overall 
significant difference in intracellular calcium level in both untreated and 
rPMT-treated Vero cells (Fig 6.1).  
 
 









   










                      
 
Fig 6.1  Gq/11 and Calcium Signalling.  The PMT-induced activation of Gq/11-mediated calcium signalling is active and sustained in (A) Swiss 
3T3 (P = 0.04), but not in (B) Vero cells (P = 0.42). Cells were prepared as described in section 2.11. Red (Untreated) and Blue (rPMT-treated, 
15 ng/ml). Shown are mean ± SD of a representative calcium level carried out in triplicate.  






   





6.2  Gi1-3 and cAMP Signalling  
 
The Gi family is a negative regulator of the Gs family.  Gi proteins play a 
role in the depression of AC activity which results in a decrease of cAMP 
levels. AC is an important intracellular signalling molecule that mediates cell 
proliferation via Gs. PMT, however, does not activate Gs. Reports also shows 
that the Gi family is involved in DNA synthesis and cell proliferation (Van 
Corven et al., 1989; LaMorte et al., 1999).  
 
Since Gi1-3 was modified by PMT in both cell lines, it was important that to 
determine if Gi1-3 signalling was also activated and sustained. Cells were 
either left untreated or treated with 15 ng/ml of PMT, and the cAMP level in 
the cytosol was measured over 3 days. Since PMT does not activate Gs, 
forskolin was used to activate AC.  
 
There was a decrease in the cAMP level in both PMT-treated cell lines, with 
a greater decrease in Swiss 3T3 cells in day 1 than Vero cells (Fig 6.2). It 
appears that forskolin did not sustain activation of Gs with a small decrease 






   









           
Fig 6.2  Gi1-3   and cAMP Signalling. The PMT-induced activation of Gi1-3 and depression of AC-cAMP signalling in A) Swiss 3T3  and B) Vero 
cells. Shown above are the time courses on the effect of rPMT in forskolin stimulated cAMP level in (A) Swiss 3T3 (P = 0.28) and (B) Vero (P = 
0.41) cells, prepared as described in section 2.12. Red (Untreated) and Blue (rPMT-treated, 15 ng/ml). Shown are mean ± SD of 
a representative cAMP level carried out in triplicate.  
 
 




   





 6.3 G12/13 and the Small GTPases: RhoA, Rac1, Cdc42  
  
The 18 members of the mammalian Rho Small GTPases family have around 
~50 – 90% sequence similarity (Karnoub and Der, 2000). RhoA, Rac1 and 
Cdc42 are the most well studied and the best described Rho GTPase 
members (Karnoub and Der, 2000).   
 
The PMT-activated Gq/11 and G12/13 subunits stimulate the Rho-ROCK 
signalling pathway, which leads to cytoskeletal reorganisation in various cell 
lines (Wilson and Ho, 2011; Orth et al., 2005; Harmey et al., 2004; Wilson et 
al., 2000; Dudet et al., 1996; Lacerda et al., 1996). Many reports also 
showed that these heterotrimeric G-proteins are involved in the induction of 
apoptosis in various cell lines via RhoA-induced reduction or inhibition of Akt 
phosphorylation (Wu et al., 2006; Ueda et al, 2004; Chikumi et al, 2002; 
Ueda et al., 2001; Althoefer et al., 1997), while Rac and Cdc42 are involved 
in cell polarisation, cell-cell and cell-substratum adhesion and regulation of 
cytoskeleton.  
 
It was important to determine whether RhoA, Cdc42 and Rac1 were similarly 
activated in both PMT-treated cell lines. Cells were either left untreated or 
treated with 15 ng/ml of PMT, and the GTP-bound RhoA, Cdc42 and Rac1 




   





described in section 2.11 of chapter 2) and were analysed by SDS-PAGE 










Fig 6.3  The PMT-induced activation of RhoA, Rac1, and Cdc42 in Swiss 3T3 
and Vero cells.  Both cell lines were either left untreated or treated with 15 ng/ml of 
rPMT and collected at different time points: 0, 24, 48, and 72 h. Shown are 
representative Western blot of GTP-bound RhoA, Rac1 and Cdc42 from rPMT-
treated confluent Swiss 3T3 (left panels) and Vero (right panels) cells, prepared as 
described in section 2.11 of chapter 2. The mouse monoclonal anti-RhoA, anti-




PMT activated RhoA, Rac1, and Cdc42 in both PMT-treated cell lines, while 
the untreated cells did not show any detectable GTP-bound RhoA, Rac1 and 
Cdc42 (Fig 6.3). In terms of protein content, there was more activated RhoA 
in Swiss 3T3 cells than Vero cells. The amount of the GTP-bound RhoA also 
appeared to increase over time. The amount of GTP-bound RhoA could not 
be detected at either 24- or 72-hr PMT-treated Vero cells. Although careful 
handling and processing of the samples were carried out (e.g. keeping the 
samples on ice), it is known that GTP is quickly hydrolysed to GDP on small 
 
Time (h)      
Swiss 3T3 Vero 
     0   24  48   72 0  24  48  72 
 
RhoA           
 
Rac1 
          
cdc42 




   





GTPases. Vero cells contained more GTP-bound Cdc42 and Rac1 than 
Swiss 3T3 cells, while Swiss 3T3 cells showed more GTP-bound RhoA than 
Vero cells. The amount of both GTP-bound Rac1 and Cdc42 in Swiss 3T3 
cells increased over time, while in Vero cells, the amount of GTP-bound 
Rac1 decreased. The GTP-bound Cdc42 in Vero cells, on the other hand, 
remained almost similar over the 3-day experimental period.  
 
In general, morphological effects were the same regardless of the 
concentration of PMT (=/>1 ng/ml) used in treating the cells. However, the 
progression of these effects in particular the detachment of cells appears to 

















   





  6.4  DISCUSSION 
 
I have shown that PMT modifies Gq/11, G12/13, and Gi1-3 at different times 
in the two cell types (section 5.1 in chapter 5). Although PMT modified the 
same set of G-proteins in both cell types, no significant increase in cell 
number was detected in Vero cells. It was therefore important to examine 
whether the signalling pathways downstream of the activated G-proteins was 
activated similarly in two cell types, over a 3-day period which could explain 
the different response of the cells to PMT. 
 
The Gq-mediated calcium mobilisation in rPMT-treated Swiss 3T3 cells 
appeared to be active and sustained over a 3-day period, while no significant 
difference in intracellular calcium level was observed in Vero cells. There are 
several possible reasons why activated Gq in Vero cells fails to mobilise 
calcium. RGS2 and RGS4 are known to inhibit Gq signalling by attenuating a 
response or accelerating GTP hydrolysis to terminate the signal (Heximer et 
al., 1999). IP3 receptors (IP3R) possess the IP3 binding core, and 
suppressor domains in the N-terminus with the latter domain harbouring 
seven conserved amino acid residues in IP3R1 (Leu
30, Leu32, Val33, Asp34, 
Arg36, Arg54, and Lys127) responsible for the suppression of IP3 binding 
(Bosanac et al. 2005) while a deletion of this domain results in an enhanced 
IP3 binding (Yoshikawa et al., 1996; 1999). These conserved amino acid 
residues are all present in the 8 isoforms of IP3R1 found in human and 




   





suppressor domain is the dominant domain which could inhibit intracellular 
Ca2+ mobilisation in Vero cells.  
 
RACK1 (Receptors for Activated C-Kinase-1), a substrate of src, acts as a 
scaffold protein and binds to phosphorylated PKC and IP3R to enhance its 
binding affinity to IP3 (Patterson et al., 2004; Birikh et al., 2003). It has ~50% 
amino acid homology with G subunit and seven WD40 repeats which 
present multiple protein-binding sites. RACK1 inhibits src tyrosine kinase 
activity, cell proliferation of NIH-3T3 and anchorage-independent growth of 
v-Src transformed cells (Chang et al., 2002; Mamidipudi et al., 2004). PKC 
and src are known to be stimulated by PMT via Gq/11. It is possible that 
RACK1 also inhibits proliferation in rPMT-treated Vero cells although there is 
no evidence yet that RACK plays a role in any PMT-treated cell lines.  
 
Gq is known to either promote apoptosis or activate the PI3K/Akt survival 
signalling pathway in different cell lines (as discussed in section 1.6.1), and 
this may be relevant to the different responses elicited by PMT treatment in 
the two cell types. I have shown that PMT protected Swiss 3T3 cells from 
cell death, which was detected on day 2, but this phenomenon was not 
observed in Vero cells. It would be interesting to see if Gq signalling is still 
active and sustained in Swiss 3T3 cells after day 3, as the anti-cell death 
property of PMT was abolished by day 4. The failure to detect signalling 
downstream of Gq in rPMT-treated Vero cells, on the other hand, confirms 




   





Ca2+-CaM is important for the activation of MLCK and phosphorylation of 
Ser19 of MLC, while activation of Rho kinase leads to MLC phosphorylation 
of Thr18 (Getz et al., 2010). MLC can also be phosphorylated on Ser19 by 
Rho kinase (Amano et al., 1996). MLC phosphorylation and actomyosin 
contractility were possibly dependent on the G12/13 Rho kinase pathway 
alone in Vero cells as the cytosolic free Ca2+ was not elevated and 
modification of G12 was delayed in rPMT-treated Vero cells compared to 
Swiss 3T3 cells. This could possibly contribute to the delay in stress fibre 
formation in Vero cells.  
 
Some members of the Gi family are involved in mitogenesis e.g. Gi-2 
subunit inhibited the serum-stimulated DNA synthesis in mouse Balb/c3T3 
fibroblasts (LaMorte et al., 1999), while Gi inhibited the LPA-induced 
mitogenic activity (Van Corven et al., 1989). The forskolin-stimulated cAMP 
level decreased over time. It could not be determined if Gi was active up to 
3 days as the forskolin-stimulated cAMP level decreased and could not be 
detected in both either untreated or rPMT-treated cell lines on day 3. It is 
possible that other cellular proteins may inhibit AC activity due to the 
activation of multiple G-proteins or the G-protein-mediated deregulation of 
different signalling pathways.  
According to Taussig et al. (1994), Gs- and forskolin-stimulated AC1, but 
not CaM-stimulated AC1 is weakly inhibited or not inhibited at all by Gi1-3, 
Gz, or Go. Gi1-3 and Gz effectively inhibit AC 5 and 6 while other AC 




   





Sadana and Dessaeur, 2009).  The G heterodimer, on the other hand, can 
either stimulate or inhibit different AC isoforms (Sadana and Dessaeur, 
2009). It inhibits AC isoforms 1, 3 and 8 (Tang and Gilman, 1991; Steiner et 
al., 2006). Inhibition of AC1 by G is more potent than the inhibitory effect 
of the Gi subunit, while G negates the stimulatory effect of Gs in AC1 and 
AC8 in HEK293 cells (Nielsen et al., 1996). The Gs stimulatory effect is in 
synergy with Ca2+/CAM in AC1 only, but not in AC8. Since forskolin was 
used to directly activate AC in this research, it is possible that the G 
heterodimer upon dissociation from G subunits inhibited AC activity which 
resulted in a low cAMP level over a period of 2 days and the non-detectable 
cAMP level in serum-starved untreated or rPMT-treated Vero cells in day 3. 
G-proteins may have activated the survival pathway in the serum-starved 
untreated cells. The Gi pathway is predicted to regulate the PI3K/Akt survival 
pathway (Huang et al., 2004) and it is likely that the synergistic effect of both 
Gi and G is enough to suppress the AC activity/cAMP level.   
 
The small GTP-binding proteins: RhoA, Rac1, and Cdc42 regulate cell 
shape changes via remodelling of the cytoskeleton and the effects on cell 
adhesion (Wojciak-Stothard and Ridley, 2003). RhoA is a well-studied 
protein that PMT activates via Gq/11 and G12/13 (Orth et al., 2005). RhoA 
mediates stress fibre formation, which is one of the many effects of PMT in 
different cell lines. Swiss 3T3 cells contained more GTP-bound RhoA than 




   





rPMT-treated Swiss 3T3 cells, while in Vero cells, it was detected at day 2 
and disappeared by day 3. Extreme care was applied during experiment (as 
per manufacturer’s instruction, e.g. keeping the samples on ice); however, it 
is known that GTP is quickly hydrolysed to GDP (Cell Biolabs, 2015). It may 
be that the active RhoA was degraded and/or quickly hydrolysed by day 3 or 
the small amount of protein could not be detected by the anti-RhoA antibody. 
Members of the Rho subfamily are all involved in stress fibre formation, 
contractility and focal adhesions. However, only RhoA and RhoC are known 
to be involved in cell proliferation, while RhoB negatively regulates this effect 
(Berenjeno et al., 2007; Howe and Addison, 2012; Tseliou et al., 2016). 
Degradation of RhoA could also possibly delay stress fibre formation and 
attenuate the proliferative effect of PMT in Vero cells. The role of this protein 
and other members of the Rho subfamily e.g. RhoB needs to be explored in 
greater detail.  
 
Vero cells contained more GTP-bound Cdc42 and Rac1 than Swiss 3T3 
cells. The amount of GTP-bound Rac1 and GTP-bound Cdc42 in Swiss 3T3 
cells appeared to increase over time while in Vero cells; the amount of GTP-
bound Rac1 decreased and GTP-bound Cdc42 remained almost similar over 
the 3-day period. Activation of Rac1 and Cdc42 by PMT has not been 
investigated in detail before. Recently, PMT was shown to stimulate Rac1 
and RhoA in neonatal rat cardiac fibroblasts which led to an increased 
secretion and expression of CTGF and pathologic remodelling of the cells 




   





Cdc42 and Rac1 (Wojciak-Stothard and Ridley, 2003). I have shown that the 
assembly of stress fibres accompanied the development of stretch-induced 
orientation or elongated phenotype of both rPMT-treated cell lines. Such 
phenomenon may be dependent on the activation of Cdc42 and Rac1.  
Various reports showed that Cdc42 and Rac1 can be activated via Gq, G12/13, 
Gi and the Gi-released  complex (Tolkacheva et al., 1997; Ueda et al., 
2000; Gratacap et al., 2001; Zeng at al., 2002a-b; Gonzales et al., 2003, Niu 
et al., 2003; Sabbatini et al., 2010). 
 
I found an increased cell-cell detachment with the formation of foci or 
clumping of cells in rPMT-treated Swiss 3T3 and Vero cells, but this 
phenomenon was more prominent in the latter cell line at a very late stage of 
PMT treatment (see section 3.3.2). Cell-cell contacts are mediated by 
different adhesion molecules and their interacting partners which are 
regulated by the Rho GTPase family (Kaibuchi et al., 1999). Rho, Rac and 
Cdc42 play important roles in regulating cell-cell adhesions such as the tight 
and adherens junctions. Various studies have shown that Rho, Rac and 
Cdc42 are required in the association of -/-catenin, cadherin, and actin 
filaments in cadherin-mediated cell-cell adhesion (Kuroda et al., 1997; Braga 
et al., 1997; Takaishi et al., 1997). PMT is known to downregulate Wnt/-
catenin signalling and Notch1 level leading to inhibition of adipogenesis, but 
with a high level of -catenin (Aminova and Wilson, 2007). Assuming that all 
the important adhesion molecules are present in both cell lines, however, 




   





function (Vania et al., 1997). As discussed previously, calcium signalling was 
not observed in Vero cells, hence, prominent cell detachment was observed. 
The loss of adhesion in Swiss 3T3 cells, on the other hand, was not as 
prominent as Vero cells. This may be due to the synergistic effect of both 
Gq/11-Ca
2+ and G12/13 pathways which regulate GTPases activity. The 
prominent loss of cell adhesion in Vero cells at a later stage may have 
resulted in the decreasing level of Rac1 and Cdc42. Also, it s uknown if 
these GTPases and Gq/11-Ca
2+ signalling are sustained and active after 3 














   





7  GENERAL DISCUSSION and FUTURE WORK 
 
  7.1  GENERAL DISCUSSION 
 
PMT is a known potent mitogen in various cell lines, which causes havoc in 
cell homeostasis via deregulation of multiple signalling pathways. PMT 
targets the G subunits of 3 of the 4 families of G-proteins: Gq, G12, and Gi 
via a process called deamidation which leads to their constitutively active 
state. G-proteins are important intracellular molecular switches that convert 
messages from extracellular stimuli to intracellular signalling, leading to 
multiple biochemical responses. G-proteins are involved in the regulation of 
almost every aspect of cell metabolism and homeostasis.  
 
According to various reports, treatment of various cell lines with PMT leads 
to a plethora of downstream signalling, such as activation of protein kinase 
C, calcium signalling, activation of Rho GTPases, stimulation of -catenin 
signalling and depression of cyclic AMP levels. In many cell types such as 
Swiss 3T3 cells, stimulation of signalling by PMT leads to a mitogenic 
response and cytoskeletal rearrangements while in others such as Vero 
cells, PMT induces a cytotoxic phenotype with no evidence of mitogenicity.  
 
In this research, I have found new effects of PMT in both Swiss 3T3 and 




   





PMT treatment resulted in cytoskeletal reorganisation and cell proliferation in 
Swiss 3T3 cells while in Vero cells, cytoskeletal reorganisation was 
observed with no sign of significant change in cell number when compared 
to their untreated and PMTC1165S-treated counterpart. Most of the 
experimental condition set in proliferation assays in various research 
involved maintaining the untreated and rPMT-treated cells in media with 
serum. In this research, I determined the effects of PMT in both cell lines in 
the absence of serum. PMT (15 ng/ml) and 10% NCS stimulated cell 
proliferation in a strikingly similar fashion in Swiss 3T3 cells but no 
proliferative effect was observed in Vero cells. I observed that the loss of 
nutrients and/or serum over an extended period of time compromised the 
ability of PMT to induce its mitogenic effect in Swiss 3T3 cells. The PMT-
induced activation of Gq is known to activate different pathways such as 
ERK1/2, JNK, mTORC1, and JAK-STAT leading to mitogenesis. The 
absence of a calcium signalling, which is a secondary messenger via Gq, in 
rPMT-treated Vero cells can partly explain the non-proliferative effect of 
PMT.  
 
Regardless of the concentration (low or high) of PMT used in treating both 
cell lines, both cell types showed signs of loss of adherence, formation of 
foci or dense cell clusters and became fragile at a later stage of the 
treatment but this phenomenon was more prominent in Vero cells than in 
Swiss 3T3 cells. The loss of adherence appeared to be circumvented by a 




   





formation was not entirely avoided. The nutrients and/or serum possibly 
helped in maintaining the integrity of the cell and led to cell proliferation as 
the cells rolled up and developed foci. However, the presence of 
nutrients/serum and PMT appeared to mask the proliferative effect of the 
other in Swiss 3T3 cells.  
 
The Rho subfamily members, RhoA, Rac1, and Cdc42 were all activated by 
PMT via G12/13 and possibly Gq/11, Gi or G in both cell types (Tolkacheva et 
al., 1997; Ueda et al., 2000; Gratacap et al., 2001; Zeng at al., 2002a-b; 
Gonzalez et al., 2003, Niu et al., 2003; Sabbatini et al., 2010). The 
RhoA/Rac1/Cdc42-mediated cell adhesion is known to be regulated by two 
pathways - Gq/11 and G12/13 in both cell types. Cell adhesion in Vero cells 
possibly depended solely on G12/13 signalling pathway since this cell line is 
devoid of calcium signalling. Cadherin, which is an important cell adhesion 
molecule, requires intracellular calcium via Gq/11 in its cell adhesive function 
(Vania et al., 1997). The synergistic adhesive effect via Gq/11 and G12/13 in 
Swiss 3T3 cells, on the other hand, may have circumvented the full loss of 
adhesion as RhoA, Rac1 and Cdc42 and calcium signalling are present. A 
milder loss of cell adhesion at later stage may have resulted due to the 
decrease in the level of Rac1 and Cdc42. Also, it is unknown if the Gq/11-
Ca2+ signalling, RhoA, Rac1 and Cdc42 are present after 3 days post rPMT 
treatment since detachment was observed after this period in both cell lines.  
The amount of G-proteins in each cell line varies. It appears that Swiss 3T3 




   





appears to be at reduced level compared to other G i proteins (this work and 
Babb et al., 2012). PMT modified the different G subunits in Swiss 3T3 and 
Vero cells at different times and these modified G-proteins were present up 
to a period of 3 weeks after initial PMT exposure. However, the modification 
of most G subunits by PMT in Vero cells was much delayed compared to 
Swiss 3T3 cells. Gi-2 and G11 subunits were the first target of PMT in Vero 
cells which were detected at 4 h. The modified G12 was detected at 48 h, 
while the rest of G subunits were detected at 16 h post rPMT-treatment. 
The modified G subunits in Swiss 3T3 cells, on the other hand, were 
detected as early as 4 h. Analysis of cell lysates prepared from these cells 
confirmed the observed differences in the amount of modified G subunits 
between the two cell lines, i.e. Vero cells have lower amount of modified G 
subunits than Swiss 3T3 cells at 4 h post rPMT treatment. 
 
Both rPMT-treated Swiss 3T3 and Vero cells formed stress fibres. However, 
I have shown that Vero cells developed stress fibre at slower pace than 
Swiss 3T3 cells. The appearance of the advanced form of stress fibres 
accompanied the development of the stretch-induced orientation or 
fibroblastic feature of both rPMT-treated cell lines. Gq/11- and G12/13-Rho 
pathways regulate stress fibre formation. The two important events leading 
to stress fibre formation downstream of the Gq/11- and G12/13-Rho pathways 
are the phosphorylation of MLC and actomyosin contractility. Gq/Ca
2+-CaM-
dependent MLCK and G12/13-Ca




   





MLC phosphorylation of Ser19 and Thr18 (Totsukawa et al., 2000; Pellegrin 
and Mellor, 2007; Getz et al., 2010; Katoh et al., 2011).  The absence of 
intracellular free Ca2+ via Gq/11 in rPMT-treated Vero cells may have 
contributed to the delay in stress fibre formation as MLC phosphorylation 
was dependent solely on the G12/13 Rho kinase pathway. The delay in the 
modification of G12 in rPMT-treated Vero cells explains the slow 
development of stress fibres. Such delay appears to be linked to its protein 
sequence and possibly molecular structure. The G12 in Vero cells lacks 
20% of the N-terminus found in the G12 isoform of other species. The 
missing 20% N-terminal amino acid sequence in G12 of Vero cells may have 
a role in protein recognition, protein-protein interaction or other function. 
Amino acid analysis also revealed that the N-terminus of G12 lacks the 
cysteine residue (Cys11) that is required for acylation and palmitoylation, 
both of which are essential for cell transformation, protein interaction, 
membrane localisation or stress fibre formation (Ponimaskin et al., 2000; 
Jones and Gutkind, 1998; Suzuki et al., 2009; Waheed and Jones, 2002).  
 
I also have shown that PMT is not apoptotic to either Swiss 3T3 or Vero 
cells. PMT at concentration of 1 and 10 ng/ml exerted anti-apoptotic property 
in Swiss 3T3 cells up to day 2 while a concentration of 0.1 ng/ml partially 
protected Swiss 3T3 cells from cell death. The anti-apoptotic effect of PMT 
in Swiss 3T3 cells was abolished by day 4. This PMT-mediated anti-
apoptotic effect, on the other hand, was not observed in Vero cells. Cell 




   





appearance of multiple bands in both the 1- and 3-week experiments was a 
sign of protein degradation of G subunits in Swiss 3T3 cells on days 5 - 7 
which coincides with the loss of the anti-apoptotic property of PMT. All the 
G subunits are involved in resisting or stimulating apoptosis which appear 
to be cell-type specific and the proteins involved in the signalling pathway 
(Yanamadala et al., 2009). The G subunits that were being degraded may 
possibly be involved in the survival and mitogenic pathways in Swiss 3T3 
cells. 
 
The development of the above effects appears to be PMT dose-dependent. 
The rate of cellular response is directly proportional to concentration of PMT, 
meaning the higher the concentration of PMT used, the faster the 
appearance of the above effects. The activation of the downstream 
signalling via different G-proteins appears to be required for the synergistic 
effects of PMT in cell proliferation and immediate cytoskeletal 
reorganisation. 
 
In summary, the differences in G-protein profile and their downstream 









   





  7.2  FUTURE WORK 
 
The heterotrimeric G-proteins are important intracellular signalling 
molecules. They are targets of various bacterial toxins which lead to the 
deregulation of the host’s signalling system. The alteration in their normal 
signalling behaviour leads to various effects which affect their phenotype 
and normal function in maintaining cellular homoestasis.  
  
In this research, I explored the different effects of PMT in greater detail and 
determined the cause of differential response of Swiss 3T3 and Vero cells to 
PMT. Activation of 3 of the 4 families of G-proteins by PMT lead to cell 
proliferation, cytoskeletal reorganisation, survival, and loss of adherence. 
However, the work reported in this thesis opens up several lines of further 
investigation. 
 
The PMT-stimulated mitogenesis in Swiss 3T3 cells, delay in stress fibre 
formation and loss of adherence in Swiss 3T3 and Vero cells are possibly 
mediated by two G-protein families, Gq and G12. The calcium signalling and 
the cysteine residue (Cys11) in G12 which is essential in acylation and 
palmitoylation for its transforming activity are both absent in Vero cells but 
are present in Swiss 3T3 cells. The missing 20% N-terminal amino acid 
sequences and the absence of cysteine residue (Cys11) in G12 may 




   





and/or protein recognition and modification of the G12 subunit by PMT. To 
determine the role of the missing amino acid sequences and cysteine 
residue in cell proliferation and stress fibre formation, expression of the long 
G12 isoform (similar to the 44 kDa G12 isoform in Swiss 3T3 cells) which 
contains the important cysteine residue in Vero cells will determine whether 
this missing sequence has a role in cell proliferation and early modification 
by PMT which may lead to the early development of full stress fibres.   
 
The absence of calcium signalling may possibly have affected the cell-cell 
adhesion in Vero cells as cadherin, an adhesive protein, is dependent on 
calcium for its adhesive activity. RhoA, Rac1 and Cdc42 are required in the 
association of -/-catenin, cadherin, and actin filaments in cadherin-
mediated cell-cell adhesion. I have shown the diminishing level of RhoA and 
Rac1 in Vero cells, which may explain the prominent loss of adhesion in 
Vero cells. The low but increasing amount of RhoA, Rac1 and Cdc42 in 
Swiss 3T3 cells over a period of 3 days may have played a role in keeping 
cell-cell adhesion thereby leading to slight detachment of cells. However, it is 
unknown whether RhoA, Rac1 and Cdc42 and calcium signalling are 
present after 3 days post PMT treatment in Swiss 3T3 cells. Both cell lines 
showed detachment after this period. A further analysis of the presence of 
RhoA, Rac1 and Cdc42 in both cell lines needs to be carried out in both cell 
lines. The continuous activation of calcium signalling in Swiss 3T3 cells after 
3 days also needs to be determined. It would also be interesting to know if 




   





3T3 cells. Thapsigargin, a non-competitive inhibitor of endoplasmic reticulum 
(ER) Ca2+ ATPase, which inhibits calcium release from the ER store may be 
used to explore the effect of the absence of calcium in cell adhesion and 
stress fibre formation in Swiss 3T3 cells. Ionomycin, an ionophore, which 
stimulate calcium flux from the ER may help determine if the presence of 
intracellular calcium will inhibit or attenuate the loss of adhesion, stimulate 
stress fibres assembly via Gq-Ca
2+-dependent phosphorylation of MLC and 
cell proliferation in PMT-treated Vero cells. The source of inhibition of 
calcium signalling pathway is unknown and should be explored.  As 
discussed previously, proteins such as RGS2, RGS4, RACK1 and the 
suppressor domain in IP3 receptors are possible inhibitors of the calcium 
signalling. Inhibition of these proteins and suppressor domain of IP3 
receptors by knocking them down may shed light if they mediate 
suppression of calcium signalling.  
 
The loss of PMT-mediated anti-cell death effect, loss of adhesion and 
cessation of cell proliferation in Swiss 3T3 cells on day 4 appears to coincide 
with the degradation of G-protein observed on days 5 - 7. Although it 
appears that cessation of cell proliferation appears to be partially linked to 
the loss of nutrients and/or serum, I have not determined whether each 
specific PMT-modified G subunit and the downstream signalling  involved 
in all PMT effects are still present or active after 3 days. I have shown that 
the PMT-modified G subunits in cell lysates are present up to a period of 3 




   





subunits up to a period of 3 weeks. A monoclonal antibody with great avidity 
to PMT is needed to detect PMT molecules. Mass spectrophotometry may 
also be used as this technique can detect even the tiniest amount of specific 
molecule in the sample.  
 
Since G-protein degradation was detected on day 5, it is possible to 
determine which specific PMT-modified G subunit disappeared after day 3 
using the approach carried out in this research (immunoprecipitation). An 
anti-ubiquitin antibody can also be used to determine if the G subunits are 
targeted for degradation via the ubiquitin-proteasome degradation system. 
The PMT-induced G-protein signalling events also need to be determined if 
they are still active up to a period in which the modified G subunits are still 
present in both cell lines. It will also be interesting to see if changing of fresh 
media with nutrients and minimal amount of serum in PMT-treated cells will 
help PMT to promote cell proliferation for a longer period of time. Wilson et 
al. (2000) showed an increasing number of cells in confluent PMT-treated 
Swiss 3T3 cells maintained in fresh media with nutrients and serum up to 7 
days.   
 
Different G subunits were modified by PMT at different time in the two cell 
lines, with a delay in the modification of most G subunits in Vero cells. Due 
to this, a hyphothesis about a difference in trafficking the PMT to the cytosol 
in different cell types was proposed. As discussed in section 5.2 of chapter 




   





translocation of PMT via endosomes inside the cells. Vero cells may have 
higher endosomal pH than Swiss 3T3 cells. A precise assessment of late 
endosomal pH in both cell lines, in particular Vero cells is needed to better 
understand the mechanism of PMT translocation and the early activity of the 
toxin.  
 
Lastly, the specific role of each G-protein has not been fully explored in Vero 
cells. These G-proteins could be knocked down or inhibited to understand 
their role in stress fibre formation, adhesion, survival, cell death and cell 
proliferation in the two cell lines.  
 
The above further studies suggested in this research will further explain how 
PMT-induced G-protein activation results in specific biochemical response in 
the two cell types. They will also further our understanding of G-protein 
signalling in different systems and the mechanisms by which 












   





8  APPENDIX 
 
Fig A1 The Complete Aligned Protein Sequences of Gq/11 Family Members of H. 
sapiens, and M. musculus. Each G subtype bears the protein identifier after the name of 
species.  
 
Fig A2 The Complete Aligned Protein Sequences of G12/13 Family Members of H. 
sapiens, and M. musculus. Each G subtype bears the protein identifier after the name of 
species.  
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Gq H.sapiens P50148 MTLESIMACC ---LSEEAKE ARRINDEIER QLRRDKRDAR RELKLLLLGT GESGKSTFIK QMRIIHGSGY SDEDKRGFTK LVYQNIFTAM QAMIRAMDTL
Gq M.musculus P21279 MTLESIMACC ---LSEEAKE ARRINDEIER QLRRDKRDAR RELKLLLLGT GESGKSTFIK QMRIIHGSGY SDEDKRGFTK LVYQNIFTAM QAMIRAMDTL
G11 H.sapiens P29992 MTLESMMACC ---LSDEVKE SKRINAEIEK QLRRDKRDAR RELKLLLLGT GESGKSTFIK QMRIIHGAGY SEEDKRGFTK LVYQNIFTAM QAMIRAMETL
G11 M.musculus P21278 MTLESMMACC ---LSDEVKE SKRINAEIEK QLRRDKRDAR RELKLLLLGT GESGKSTFIK QMRIIHGAGY SEEDKRGFTK LVYQNIFTAM QAMVRAMETL
G14 H.sapiens O95837 ----MAGCCC ---LSAEEKE SQRISAEIER QLRRDKKDAR RELKLLLLGT GESGKSTFIK QMRIIHGSGY SDEDRKGFTK LVYQNIFTAM QAMIRAMDTL
G14 M.musculus P30677 ----MAGCCC ---LSAEEKE SQRISAEIER QLRRDKKDAR RELKLLLLGT GESGKSTFIK QMRIIHGSGY SDEDRKGFTK LVYQNIFTAM QAMIRAMDTL
G15 H.sapiens P30679 MARSLTWRCC PWCLTEDEKA AARVDQEINR ILLEQKKQDR GELKLLLLGP GESGKSTFIK QMRIIHGAGY SEEERKGFRP LVYQNIFVSM RAMIEAMERL
G15 M.musculus P30678 MARSLTWGCC PWCLTEEEKT AARIDQEINR ILLEQKKQER EELKLLLLGP GESGKSTFIK QMRIIHGVGY SEEDRRAFRL LIYQNIFVSM QAMIDAMDRL
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Gq H.sapiens P50148 KIPYKYEHNK AHAQLVREVD VEKVSAFENP YVDAIKSLWN DPGIQECYDR RREYQLSDST KYYLNDLDRV ADPAYLPTQQ DVLRVRVPTT GIIEYPFDLQ
Gq M.musculus P21279 KIPYKYEHNK AHAQLVREVD VEKVSAFENP YVDAIKSLWN DPGIQECYDR RREYQLSDST KYYLNDLDRV ADPSYLPTQQ DVLRVRVPTT GIIEYPFDLQ
G11 H.sapiens P29992 KILYKYEQNK ANALLIREVD VEKVTTFEHQ YVSAIKTLWE DPGIQECYDR RREYQLSDSA KYYLTDVDRI ATLGYLPTQQ DVLRVRVPTT GIIEYPFDLE
G11 M.musculus P21278 KILYKYEQNK ANALLIREVD VEKVTTFEHQ YVNAIKTLWS DPGVQECYDR RREFQLSDSA KYYLTDVDRI ATVGYLPTQQ DVLRVRVPTT GIIEYPFDLE
G14 H.sapiens O95837 RIQYVCEQNK ENAQIIREVE VDKVSMLSRE QVEAIKQLWQ DPGIQECYDR RREYQLSDSA KYYLTDIDRI ATPSFVPTQQ DVLRVRVPTT GIIEYPFDLE
G14 M.musculus P30677 RIQYMCEQNK ENAQIIREVE VDKVTALSRD QVAAIKQLWL DPGIQECYDR RREYQLSDSA KYYLTDIERI AMPSFVPTQQ DVLRVRVPTT GIIEYPFDLE
G15 H.sapiens P30679 QIPFSRPESK HHASLVMSQD PYKVTTFEKR YAAAMQWLWR DAGIRAYYER RREFHLLDSA VYYLSHLERI TEEGYVPTAQ DVLRSRMPTT GINEYCFSVQ
G15 M.musculus P30678 QIPFSRPDSK QHASLVMTQD PYKVSTFEKP YAVAMQYLWR DAGIRACYER RREFHLLDSA VYYLSHLERI SEDSYIPTAQ DVLRSRMPTT GINEYCFSVK
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq H.sapiens P50148 SVIFRMVDVG GQRSERRKWI HCFENVTSIM FLVALSEYDQ VLVESDNENR MEESKALFRT IITYPWFQNS SVILFLNKKD LLEEKIMYSH LVDYFPEYDG
Gq M.musculus P21279 SVIFRMVDVG GQRSERRKWI HCFENVTSIM FLVALSEYDQ VLVESDNENR MEESKALFRT IITYPWFQNS SVILFLNKKD LLEEKIMYSH LVDYFPEYDG
G11 H.sapiens P29992 NIIFRMVDVG GQRSERRKWI HCFENVTSIM FLVALSEYDQ VLVESDNENR MEESKALFRT IITYPWFQNS SVILFLNKKD LLEDKILYSH LVDYFPEFDG
G11 M.musculus P21278 NIIFRMVDVG GQRSERRKWI HCFENVTSIM FLVALSEYDQ VLVESDNENR MEESKALFRT IITYPWFQNS SVILFLNKKD LLEDKILHSH LVDYFPEFDG
G14 H.sapiens O95837 NIIFRMVDVG GQRSERRKWI HCFESVTSII FLVALSEYDQ VLAECDNENR MEESKALFKT IITYPWFLNS SVILFLNKKD LLEEKIMYSH LISYFPEYTG
G14 M.musculus P30677 NIIFRMVDVG GQRSERRKWI HCFESVTSII FLVALSEYDQ VLAECDNENR MEESKALFRT IITYPWFLNS SVILFLNKKD LLEEKIMYSH LISYFPEYTG
G15 H.sapiens P30679 KTNLRIVDVG GQKSERKKWI HCFENVIALI YLASLSEYDQ CLEENNQENR MKESLALFGT ILELPWFKST SVILFLNKTD ILEEKIPTSH LATYFPSFQG
G15 M.musculus P30678 KTKLRIVDVG GQRSERRKWI HCFENVIALI YLASLSEYDQ CLEENDQENR MEESLALFST ILELPWFKST SVILFLNKTD ILEDKIHTSH LATYFPSFQG
310 320 330 340 350 360 370
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....
Gq H.sapiens P50148 PQRDAQAARE FILKMFVDLN P--------- ---DSDKIIY SHFTCATDTE NIRFVFAAVK DTILQLNLKE YNLV
Gq M.musculus P21279 PQRDAQAARE FILKMFVDLN P--------- ---DSDKIIY SHFTCATDTE NIRFVFAAVK DTILQLNLKE YNLV
G11 H.sapiens P29992 PQRDAQAARE FILKMFVDLN P--------- ---DSDKIIY SHFTCATDTE NIRFVFAAVK DTILQLNLKE YNLV
G11 M.musculus P21278 PQRDAQAARE FILKMFVDLN P--------- ---DSDKIIY SHFTCATDTE NIRFVFAAVK DTILQLNLKE YNLV
G14 H.sapiens O95837 PKQDVRAARD FILKLYQDQN P--------- ---DKEKVIY SHFTCATDTD NIRFVFAAVK DTILQLNLRE FNLV
G14 M.musculus P30677 PKQDVKAARD FILKLYQDQN P--------- ---DKEKVIY SHFTCATDTE NIRFVFAAVK DTILQLNLRE FNLV
G15 H.sapiens P30679 PKQDAEAAKR FILDMYTRMY TGCVDGPEGS KKGARSRRLF SHYTCATDTQ NIRKVFKDVR DSVLARYLDE INLL
G15 M.musculus P30678 PRRDAEAAKS FILDMYARVY ASCAEPQDGG RKGSRARRFF AHFTCATDTQ SVRSVFKDVR DSVLARYLDE INLL
10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G12 H.sapiens Q03113-1 MSGVVRTLSR CLLPAEAGGA RERRAGSGAR DAEREARRRS RDIDALLARE RRAVRRLVKI LLLGAGESGK STFLKQMRII HGREFDQKAL LEFRDTIFDN
G12 H.sapiens Q03113-2 ---------- ---------- ---------- ---------- --------MK RRMFPRPCLA RMPGSRGSGS TP-------- DG----NRKC CRFEHLLIAH
G12 H.sapiens Q03113-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------MRII HGREFDQKAL LEFRDTIFDN
G12 M.musculus P27600 MSGVVRTLSR CLLPAEAG-A RERRAG-AAR DAEREARRRS RDIDALLARE RRAVRRLVKI LLLGAGESGK STFLKQMRII HGREFDQKAL LEFRDTIFDN
G13 H.sapiens Q14344-1 ---------M ADFLPSRSVL SVCFPGCLLT SGEAEQQRKS KEIDKCLSRE KTYVKRLVKI LLLGAGESGK STFLKQMRII HGQDFDQRAR EEFRPTIYSN
G13 H.sapiens Q14344-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
G13 M.musculus P27601 ---------M ADFLPSRSVL SVCFPGCVLT NGEAEQQRKS KEIDKCLSRE KTYVKRLVKI LLLGAGESGK STFLKQMRII HGQDFDQRAR EEFRPTIYSN
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G12 H.sapiens Q03113-1 -ILKGSRVLV DARDKLGIPW QYSENEKHGM FLMAFENKAG LP----VEPA TFQLYVPALS ALWRDSGIRE AFSRRSEFQL GESVKYFLDN LDRIGQLNYF
G12 H.sapiens Q03113-2 PGSRGSRVLV DARDKLGIPW QYSENEKHGM FLMAFENKAG LP----VEPA TFQLYVPALS ALWRDSGIRE AFSRRSEFQL GESVKYFLDN LDRIGQLNYF
G12 H.sapiens Q03113-3 -ILKGSRVLV DARDKLGIPW QYSENEKHGM FLMAFENKAG LP----VEPA TFQLYVPALS ALWRDSGIRE AFSRRSEFQL ---------- -------NYF
G12 M.musculus P27600 -ILKGSRVLV DARDKLGIPW QHSENEKHGM FLMAFENKAG LP----VEPA TFQLYVPALS ALWRDSGIRE AFSRRSEFQL GESVKYFLDN LDRIGQLNYF
G13 H.sapiens Q14344-1 -VIKGMRVLV DAREKLHIPW GDNSNQQHGD KMMSFDTRAP MAAQGMVETR VFLQYLPAIR ALWADSGIQN AYDRRREFQL GESVKYFLDN LDKLGEPDYI
G13 H.sapiens Q14344-2 -----MRVLV DAREKLHIPW GDNSNQQHGD KMMSFDTRAP MAAQGMVETR VFLQYLPAIR ALWADSGIQN AYDRRREFQL GESVKYFLDN LDKLGEPDYI
G13 M.musculus P27601 -VIKGMRVLV DAREKLHIPW GDNKNQLHGD KLMAFDTRAP MAAQGMVETR VFLQYLPAIR ALWEDSGIQN AYDRRREFQL GESVKYFLDN LDKLGVPDYI
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G12 H.sapiens Q03113-1 PSKQDILLAR KATKGIVEHD FVIKKIPFKM VDVGGQRSQR QKWFQCFDGI TSILFMVSSS EYDQVLMEDR RTNRLVESMN IFETIVNNKL FFNVSIILFL
G12 H.sapiens Q03113-2 PSKQDILLAR KATKGIVEHD FVIKKIPFKM VDVGGQRSQR QKWFQCFDGI TSILFMVSSS EYDQVLMEDR RTNRLVESMN IFETIVNNKL FFNVSIILFL
G12 H.sapiens Q03113-3 PSKQDILLAR KATKGIVEHD FVIKKIPFKM VDVGGQRSQR QKWFQCFDGI TSILFMVSSS EYDQVLMEDR RTNRLVESMN IFETIVNNKL FFNVSIILFL
G12 M.musculus P27600 PSKQDILLAR KATKGIVEHD FVIKKIPFKM VDVGGQRSQR QKWFQCFDGI TSILFMVSSS EYDQVLMEDR RTNRLVESMN IFETIVNNKL FFNVSIILFL
G13 H.sapiens Q14344-1 PSQQDILLAR RPTKGIHEYD FEIKNVPFKM VDVGGQRSER KRWFECFDSV TSILFLVSSS EFDQVLMEDR LTNRLTESLN IFETIVNNRV FSNVSIILFL
G13 H.sapiens Q14344-2 PSQQDILLAR RPTKGIHEYD FEIKNVPFKM VDVGGQRSER KRWFECFDSV TSILFLVSSS EFDQVLMEDR LTNRLTESLN IFETIVNNRV FSNVSIILFL
G13 M.musculus P27601 PSQQDILLAR RPTKGIHEYD FEIKNVPFKM VDVGGQRSER KRWFECFDSV TSILFLVSSS EFDQVLMEDR QTNRLTESLN IFETIVNNRV FSNVSIILFL
310 320 330 340 350 360 370 380
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|..
G12 H.sapiens Q03113-1 NKMDLLVEKV KTVSIKKHFP DFRGDPHRLE DVQRYLVQCF DRKRRNRS-K PLFHHFTTAI DTENVRFVFH AVKDTILQEN LKDIMLQ
G12 H.sapiens Q03113-2 NKMDLLVEKV KTVSIKKHFP DFRGDPHRLE DVQRYLVQCF DRKRRNRS-K PLFHHFTTAI DTENVRFVFH AVKDTILQEN LKDIMLQ
G12 H.sapiens Q03113-3 NKMDLLVEKV KTVSIKKHFP DFRGDPHRLE DVQRYLVQCF DRKRRNRS-K PLFHHFTTAI DTENVRFVFH AVKDTILQEN LKDIMLQ
G12 M.musculus P27600 NKMDLLVEKV KSVSIKKHFP DFKGDPHRLE DVQRYLVQCF DRKRRNRS-K PLFHHFTTAI DTENIRFVFH AVKDTILQEN LKDIMLQ
G13 H.sapiens Q14344-1 NKTDLLEEKV QIVSIKDYFL EFEGDPHCLR DVQKFLVECF RNKRRDQQQK PLYHHFTTAI NTENIRLVFR DVKDTILHDN LKQLMLQ
G13 H.sapiens Q14344-2 NKTDLLEEKV QIVSIKDYFL EFEGDPHCLR DVQKFLVECF RNKRRDQQQK PLYHHFTTAI NTENIRLVFR DVKDTILHDN LKQLMLQ




   









Fig A3 The Complete Aligned Protein Sequences of Gi/o Family Members of H. 





10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 H.sapiens P63096-1 MGCTLSAEDK AAVERSKMID RNLREDGEKA AREVKLLLLG AGESGKSTIV KQMKIIHEAG YSEEECKQYK AVVYSNTIQS IIAIIRAMGR LKIDFGDSAR
Gi-1 H.sapiens P63096-2 ---------- ---------- ---------- ---------- ---------- --MKIIHEAG YSEEECKQYK AVVYSNTIQS IIAIIRAMGR LKIDFGDSAR
Gi-1 M.musculus B2RSH2 MGCTLSAEDK AAVERSKMID RNLREDGEKA AREVKLLLLG AGESGKSTIV KQMKIIHEAG YSEEECKQYK AVVYSNTIQS IIAIIRAMGR LKIDFGDSAR
Gi-2 H.sapiens P04899-1 MGCTVSAEDK AAAERSKMID KNLREDGEKA AREVKLLLLG AGESGKSTIV KQMKIIHEDG YSEEECRQYR AVVYSNTIQS IMAIVKAMGN LQIDFADPSR
Gi-2 H.sapiens P04899-2 ---------- -MEYAGHLPA SSAQGTILAC TSCT-----G AGESGKSTIV KQMKIIHEDG YSEEECRQYR AVVYSNTIQS IMAIVKAMGN LQIDFADPSR
Gi-2 H.sapiens P04899-3 ---------- ---------- ---------- --MR-----G AGESGKSTIV KQMKIIHEDG YSEEECRQYR AVVYSNTIQS IMAIVKAMGN LQIDFADPSR
Gi-2 H.sapiens P04899-4 MGCTVSAEDK AAAERSKMID KNLREDGEKA AREVKLLLLG AGESGKSTIV KQMKIIHEDG YSEEECRQYR AVVYSNTIQS IMAIVKAMGN LQIDFADPSR
Gi-2 H.sapiens P04899-5 ---------- -MTEGVKTLG WTKQKGGCHW GRSE-----G AGESGKSTIV KQMKIIHEDG YSEEECRQYR AVVYSNTIQS IMAIVKAMGN LQIDFADPSR
Gi-2 H.sapiens P04899-6 ---------- ---------- ---------- ---------- ---------- --MKIIHEDG YSEEECRQYR AVVYSNTIQS IMAIVKAMGN LQIDFADPSR
Gi-3 H.sapiens P08754 MGCTLSAEDK AAVERSKMID RNLREDGEKA AKEVKLLLLG AGESGKSTIV KQMKIIHEDG YSEDECKQYK VVVYSNTIQS IIAIIRAMGR LKIDFGEAAR
Gi-3 M.musculus Q9DC51 MGCTLSAEDK AAVERSKMID RNLREDGEKA AKEVKLLLLG AGESGKSTIV KQMKIIHEDG YSEDECKQYK VVVYSNTIQS IIAIIRAMGR LKIDFGESAR
Gi-2 M.musculus P08752 MGCTVSAEDK AAAERSKMID KNLREDGEKA AREVKLLLLG AGESGKSTIV KQMKIIHEDG YSEEECRQYR AVVYSNTIQS IMAIVKAMGN LQIDFADPQR
Go H.sapiens P09471-1 MGCTLSAEER AALERSKAIE KNLKEDGISA AKDVKLLLLG AGESGKSTIV KQMKIIHEDG FSGEDVKQYK PVVYSNTIQS LAAIVRAMDT LGIEYGDKER
Go H.sapiens P09471-2 MGCTLSAEER AALERSKAIE KNLKEDGISA AKDVKLLLLG AGESGKSTIV KQMKIIHEDG FSGEDVKQYK PVVYSNTIQS LAAIVRAMDT LGIEYGDKER
Go M.musculus P18872-1 MGCTLSAEER AALERSKAIE KNLKEDGISA AKDVKLLLLG AGESGKSTIV KQMKIIHEDG FSGEDVKQYK PVVYSNTIQS LAAIVRAMDT LGVEYGDKER
Go M.musculus P18872-2 MGCTLSAEER AALERSKAIE KNLKEDGISA AKDVKLLLLG AGESGKSTIV KQMKIIHEDG FSGEDVKQYK PVVYSNTIQS LAAIVRAMDT LGVEYGDKER
Gz H.sapiens P19086 MGCRQSSEEK EAARRSRRID RHLRSESQRQ RREIKLLLLG TSNSGKSTIV KQMKIIHSGG FNLEACKEYK PLIIYNAIDS LTRIIRALAA LRIDFHNPDR
Gz M.musculus O70443 MGCRQSSEEK EAARRSRRID RHLRSESQRQ RREIKLLLLG TSNSGKSTIV KQMKIIHSGG FNLDACKEYK PLIIYNAIDS LTRIIRALAA LKIDFHNPDR
Gt-1 H.sapiens P11488 MGAGASAEEK ----HSRELE KKLKEDAEKD ARTVKLLLLG AGESGKSTIV KQMKIIHQDG YSLEECLEFI AIIYGNTLQS ILAIVRAMTT LNIQYGDSAR
Gt-2 H.sapiens P19087 MGSGASAEDK ELAKRSKELE KKLQEDADKE AKTVKLLLLG AGESGKSTIV KQMKIIHQDG YSPEECLEFK AIIYGNVLQS ILAIIRAMTT LGIDYAEPSC
Gt-3 H.sapiens A8MTJ3 MGSGISSESK ESAKRSKELE KKLQEDAERD ARTVKLLLLG AGESGKSTIV KQMKIIHKNG YSEQECMEFK AVIYSNTLQS ILAIVKAMTT LGIDYVNPRS
Gt-1 M.musculus P20612 MGAGASAEEK ----HSRELE KKLKEDAEKD ARTVKLLLLG AGESGKSTIV KQMKIIHQDG YSLEECLEFI AIIYGNTLQS ILAIVRAMTT LNIQYGDSAR
Gt-2 M.musculus P50149 MGSGISAEDK ELARRSKELE KKLQEDADKE AKTVKLLLLG AGESGKSTIV KQMKIIHQDG YSPEECLEFK SVIYGNVLQS ILAIIRAMST LGIDYAEPSC
Gt-3 M.musculus Q3V3I2 MGSGISSESK ESARRSKELE KKLQEDAERD ARTVKLLLLG AGESGKSTIV KQMKIIHKNG YSKQECMEFK AVIYSNTLQS ILAIVKAMAT LGIDYVNPRS
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 H.sapiens P63096-1 ADDARQLFVL AGAAEE-GFM TAELAGVIKR LWKDSGVQAC FNRSREYQLN DSAAYYLNDL DRIAQPNYIP TQQDVLRTRV KTTGIVETHF TFKDLHFKMF
Gi-1 H.sapiens P63096-2 ADDARQLFVL AGAAEE-GFM TAELAGVIKR LWKDSGVQAC FNRSREYQLN DSAAYYLNDL DRIAQPNYIP TQQDVLRTRV KTTGIVETHF TFKDLHFKMF
Gi-1 M.musculus B2RSH2 ADDARQLFVL AGAAEE-GFM TAELAGVIKR LWKDSGVQAC FNRSREYQLN DSAAYYLNDL DRIAQPNYIP TQQDVLRTRV KTTGIVETHF TFKDLHFKMF
Gi-2 H.sapiens P04899-1 ADDARQLFAL SCTAEEQGVL PDDLSGVIRR LWADHGVQAC FGRSREYQLN DSAAYYLNDL ERIAQSDYIP TQQDVLRTRV KTTGIVETHF TFKDLHFKMF
Gi-2 H.sapiens P04899-2 ADDARQLFAL SCTAEEQGVL PDDLSGVIRR LWADHGVQAC FGRSREYQLN DSAAYYLNDL ERIAQSDYIP TQQDVLRTRV KTTGIVETHF TFKDLHFKMF
Gi-2 H.sapiens P04899-3 ADDARQLFAL SCTAEEQGVL PDDLSGVIRR LWADHGVQAC FGRSREYQLN DSAAYYLNDL ERIAQSDYIP TQQDVLRTRV KTTGIVETHF TFKDLHFKMF
Gi-2 H.sapiens P04899-4 ADDARQLFAL SCTAEEQGVL PDDLSGVIRR LWADHGVQAC FGRSREYQLN DSAAYYLNDL ERIAQSDYIP TQQDVLRTRV KTTGIVETHF TFKDLHFKMF
Gi-2 H.sapiens P04899-5 ADDARQLFAL SCTAEEQGVL PDDLSGVIRR LWADHGVQAC FGRSREYQLN DSAAYYLNDL ERIAQSDYIP TQQDVLRTRV KTTGIVETHF TFKDLHFKMF
Gi-2 H.sapiens P04899-6 ADDARQLFAL SCTAEEQGVL PDDLSGVIRR LWADHGVQAC FGRSREYQLN DSAAYYLNDL ERIAQSDYIP TQQDVLRTRV KTTGIVETHF TFKDLHFKMF
Gi-3 H.sapiens P08754 ADDARQLFVL AGSAEE-GVM TPELAGVIKR LWRDGGVQAC FSRSREYQLN DSASYYLNDL DRISQSNYIP TQQDVLRTRV KTTGIVETHF TFKDLYFKMF
Gi-3 M.musculus Q9DC51 ADDARQLFVL AGSAEE-GVM TSELAGVIKR LWRDGGVQAC FSRSREYQLN DSASYYLNDL DRISQTNYIP TQQDVLRTRV KTTGIVETHF TFKELYFKMF
Gi-2 M.musculus P08752 ADDARQLFAL SCAAEEQGML PEDLSGVIRR LWADHGVQAC FGRSREYQLN DSAAYYLNDL ERIAQSDYIP TQQDVLRTRV KTTGIVETHF TFKDLHFKMF
Go H.sapiens P09471-1 KADAKMVCDV VSRMEDTEPF SAELLSAMMR LWGDSGIQEC FNRSREYQLN DSAKYYLDSL DRIGAADYQP TEQDILRTRV KTTGIVETHF TFKNLHFRLF
Go H.sapiens P09471-2 KADAKMVCDV VSRMEDTEPF SAELLSAMMR LWGDSGIQEC FNRSREYQLN DSAKYYLDSL DRIGAADYQP TEQDILRTRV KTTGIVETHF TFKNLHFRLF
Go M.musculus P18872-1 KTDSKMVCDV VSRMEDTEPF SAELLSAMMR LWGDSGIQEC FNRSREYQLN DSAKYYLDSL DRIGAGDYQP TEQDILRTRV KTTGIVETHF TFKNLHFRLF
Go M.musculus P18872-2 KTDSKMVCDV VSRMEDTEPF SAELLSAMMR LWGDSGIQEC FNRSREYQLN DSAKYYLDSL DRIGAGDYQP TEQDILRTRV KTTGIVETHF TFKNLHFRLF
Gz H.sapiens P19086 AYDAVQLFAL TGPAESKGEI TPELLGVMRR LWADPGAQAC FSRSSEYHLE DNAAYYLNDL ERIAAADYIP TVEDILRSRD MTTGIVENKF TFKELTFKMV
Gz M.musculus O70443 AYDAVQLFAL TGPAESKGEI TPELLGVMRR LWADPGAQAC FGRSSEYHLE DNAAYYLNDL ERIAAPDYIP TVEDILRSRD MTTGIVENKF TFKELTFKMV
Gt-1 H.sapiens P11488 QDDARKLMHM ADTIEE-GTM PKEMSDIIQR LWKDSGIQAC FERASEYQLN DSAGYYLSDL ERLVTPGYVP TEQDVLRSRV KTTGIIETQF SFKDLNFRMF
Gt-2 H.sapiens P19087 ADDGRQLNNL ADSIEE-GTM PPELVEVIRR LWKDGGVQAC FERAAEYQLN DSASYYLNQL ERITDPEYLP SEQDVLRSRV KTTGIIETKF SVKDLNFRMF
Gt-3 H.sapiens A8MTJ3 AEDQRQLYAM ANTLED-GGM TPQLAEVIKR LWRDPGIQAC FERASEYQLN DSAAYYLNDL DRITASGYVP NEQDVLHSRV KTTGIIETQF SFKDLHFRMF
Gt-1 M.musculus P20612 QDDARKLMHM ADTIEE-GTM PKEMSDIIQR LWKDSGIQAC FDRASEYQLN DSAGYYLSDL ERLVTPGYVP TEQDVLRSRV KTTGIIETQF SFKDLNFRMF
Gt-2 M.musculus P50149 ADAGRQLNNL ADSTEE-GTM PPELVDVIRK LWKDGGVQAC FDRAAEFQLN DSASYYLNQL DRITDPNYLP NEQDVLRSRV KTTGIIETKF SVKDLNFRMF
Gt-3 M.musculus Q3V3I2 REDQEQLHSM ANTLED-GDM TPQLAEIIKR LWGDPGIQAC FERASEYQLN DSAAYYLNDL DRLTAPGYVP NEQDVLHSRV KTTGIIETQF SFKDLNFRMF
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 H.sapiens P63096-1 DVGGQRSERK KWIHCFEGVT AIIFCVALSD YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN KKDLFEEKIK KSPLTICYPE YAGSNTYEEA
Gi-1 H.sapiens P63096-2 DVGGQRSERK KWIHCFEGVT AIIFCVALSD YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN KKDLFEEKIK KSPLTICYPE YAGSNTYEEA
Gi-1 M.musculus B2RSH2 DVGGQRSERK KWIHCFEGVT AIIFCVALSD YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN KKDLFEEKIK KSPLTICYPE YAGSNTYEEA
Gi-2 H.sapiens P04899-1 DVGGQRSERK KWIHCFEGVT AIIFCVALSA YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN KKDLFEEKIT HSPLTICFPE YTGANKYDEA
Gi-2 H.sapiens P04899-2 DVGGQRSERK KWIHCFEGVT AIIFCVALSA YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN KKDLFEEKIT HSPLTICFPE YTGANKYDEA
Gi-2 H.sapiens P04899-3 DVGGQRSERK KWIHCFEGVT AIIFCVALSA YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN KKDLFEEKIT HSPLTICFPE YTGANKYDEA
Gi-2 H.sapiens P04899-4 DVGGQRSERK KWIHCFEGVT AIIFCVALSA YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN KKDLFEEKIT HSPLTICFPE YTGANKYDEA
Gi-2 H.sapiens P04899-5 DVGGQRSERK KWIHCFEGVT AIIFCVALSA YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN KKDLFEEKIT HSPLTICFPE YTGANKYDEA
Gi-2 H.sapiens P04899-6 DVGGQRSERK KWIHCFEGVT AIIFCVALSA YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN KKDLFEEKIT HSPLTICFPE YTGANKYDEA
Gi-3 H.sapiens P08754 DVGGQRSERK KWIHCFEGVT AIIFCVALSD YDLVLAEDEE MNRMHESMKL FDSICNNKWF TETSIILFLN KKDLFEEKIK RSPLTICYPE YTGSNTYEEA
Gi-3 M.musculus Q9DC51 DVGGQRSERK KWIHCFEGVT AIIFCVALSD YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN KKDLFEEKIK RSPLTICYPE YTGSNTYEEA
Gi-2 M.musculus P08752 DVGGQRSERK KWIHCFEGVT AIIFCVALSA YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN KKDLFEEKIT QSSLTICFPE YTGANKYDEA
Go H.sapiens P09471-1 DVGGQRSERK KWIHCFEDVT AIIFCVALSG YDQVLHEDET TNRMHESLML FDSICNNKFF IDTSIILFLN KKDLFGEKIK KSPLTICFPE YTGPNTYEDA
Go H.sapiens P09471-2 DVGGQRSERK KWIHCFEDVT AIIFCVALSG YDQVLHEDET TNRMHESLKL FDSICNNKWF TDTSIILFLN KKDIFEEKIK KSPLTICFPE YTGPSAFTEA
Go M.musculus P18872-1 DVGGQRSERK KWIHCFEDVT AIIFCVALSG YDQVLHEDET TNRMHESLML FDSICNNKFF IDTSIILFLN KKDLFGEKIK KSPLTICFPE YPGSNTYEDA
Go M.musculus P18872-2 DVGGQRSERK KWIHCFEDVT AIIFCVALSG YDQVLHEDET TNRMHESLKL FDSICNNKWF TDTSIILFLN KKDIFEEKIK KSPLTICFPE YTGPSAFTEA
Gz H.sapiens P19086 DVGGQRSERK KWIHCFEGVT AIIFCVELSG YDLKLYEDNQ TSRMAESLRL FDSICNNNWF INTSLILFLN KKDLLAEKIR RIPLTICFPE YKGQNTYEEA
Gz M.musculus O70443 DVGGQRSERK KWIHCFEGVT AIIFCVELSG YDLKLYEDNQ TSRMAESLRL FDSICNNNWF INTSLILFLN KKDLLAEKIR RIPLSVCFPE YKGQNTYEEA
Gt-1 H.sapiens P11488 DVGGQRSERK KWIHCFEGVT CIIFIAALSA YDMVLVEDDE VNRMHESLHL FNSICNHRYF ATTSIVLFLN KKDVFFEKIK KAHLSICFPD YDGPNTYEDA
Gt-2 H.sapiens P19087 DVGGQRSERK KWIHCFEGVT CIIFCAALSA YDMVLVEDDE VNRMHESLHL FNSICNHKFF AATSIVLFLN KKDLFEEKIK KVHLSICFPE YDGNNSYDDA
Gt-3 H.sapiens A8MTJ3 DVGGQRSERK KWIHCFEGVT CIIFCAALSA YDMVLVEDEE VNRMHESLHL FNSICNHKYF STTSIVLFLN KKDIFQEKVT KVHLSICFPE YTGPNTFEDA
Gt-1 M.musculus P20612 DVGGQRSERK KWIHCFEGVT CIIFIAALSA YDMVLVEDDE VNRMHESLHL FNSICNHRYF ATTSIVLFLN KKDVFSEKIK KAHLSICFPD YDGPNTYEDA
Gt-2 M.musculus P50149 DVGGQRSERK KWIHCFEGVT CIIFCAALSA YDMVLVEDDE VNRMHESLHL FNSICNHKFF AATSIVLFLN KKDLFEEKIK KVHLSICFPE YDGNNSYEDA
Gt-3 M.musculus Q3V3I2 DVGGQRSERK KWIHCFEGVT CIIFCAALSA YDMVLVEDEE VNRMHESLHL FNSICNHKYF ATTSIVLFLN KKDLFQEKVA KVHLSICFPE YTGPNTFEDA
310 320 330 340 350 360
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|.
Gi-1 H.sapiens P63096-1 AAYIQCQFED LNKRKDTKEI YTHFTCATDT KNVQFVFDAV TDVIIKNNLK DCGLF----- ------
Gi-1 H.sapiens P63096-2 AAYIQCQFED LNKRKDTKEI YTHFTCATDT KNVQFVFDAV TDVIIKNNLK DCGLF----- ------
Gi-1 M.musculus B2RSH2 AAYIQCQFED LNKRKDTKEI YTHFTCATDT KNVQFVFDAV TDVIIKNNLK DCGLF----- ------
Gi-2 H.sapiens P04899-1 ASYIQSKFED LNKRKDTKEI YTHFTCATDT KNVQFVFDAV TDVIIKNNLK DCGLF----- ------
Gi-2 H.sapiens P04899-2 ASYIQSKFED LNKRKDTKEI YTHFTCATDT KNVQFVFDAV TDVIIKNNLK DCGLF----- ------
Gi-2 H.sapiens P04899-3 ASYIQSKFED LNKRKDTKEI YTHFTCATDT KNVQFVFDAV TDVIIKNNLK DCGLF----- ------
Gi-2 H.sapiens P04899-4 ASYIQSKFED LNKRKDTKEI YTHFTCATDT KSRKLFRETY LKLSGPDQHP HPSPAPAPPL SSDSVP
Gi-2 H.sapiens P04899-5 ASYIQSKFED LNKRKDTKEI YTHFTCATDT KNVQFVFDAV TDVIIKNNLK DCGLF----- ------
Gi-2 H.sapiens P04899-6 ASYIQSKFED LNKRKDTKEI YTHFTCATDT KNVQFVFDAV TDVIIKNNLK DCGLF----- ------
Gi-3 H.sapiens P08754 AAYIQCQFED LNRRKDTKEI YTHFTCATDT KNVQFVFDAV TDVIIKNNLK ECGLY----- ------
Gi-3 M.musculus Q9DC51 AAYIQCQFED LNRRKDTKEV YTHFTCATDT KNVQFVFDAV TDVIIKNNLK ECGLY----- ------
Gi-2 M.musculus P08752 ASYIQSKFED LNKRKDTKEI YTHFTCATDT KNVQFVFDAV TDVIIKNNLK DCGLF----- ------
Go H.sapiens P09471-1 AAYIQAQFES KN-RSPNKEI YCHMTCATDT NNIQVVFDAV TDIIIANNLR GCGLY----- ------
Go H.sapiens P09471-2 VAYIQAQYES KN-KSAHKEI YTHVTCATDT NNIQFVFDAV TDVIIAKNLR GCGLY----- ------
Go M.musculus P18872-1 AAYIQTQFES KN-RSPNKEI YCHMTCATDT NNIQVVFDAV TDIIIANNLR GCGLY----- ------
Go M.musculus P18872-2 VAHIQGQYES KN-KSAHKEV YSHVTCATDT NNIQFVFDAV TDVIIAKNLR GCGLY----- ------
Gz H.sapiens P19086 AVYIQRQFED LNRNKETKEI YSHFTCATDT SNIQFVFDAV TDVIIQNNLK YIGLC----- ------
Gz M.musculus O70443 AVYIQRQFED LNRNKETKEI YSHFTCATDT SNIQFVFDAV TDVIIQNNLK YIGLC----- ------
Gt-1 H.sapiens P11488 GNYIKVQFLE LNMRRDVKEI YSHMTCATDT QNVKFVFDAV TDIIIKENLK DCGLF----- ------
Gt-2 H.sapiens P19087 GNYIKSQFLD LNMRKDVKEI YSHMTCATDT QNVKFVFDAV TDIIIKENLK DCGLF----- ------
Gt-3 H.sapiens A8MTJ3 GNYIKNQFLD LNLKKEDKEI YSHMTCATDT QNVKFVFDAV TDIIIKENLK DCGLF----- ------
Gt-1 M.musculus P20612 GNYIKVQFLE LNMRRDVKEI YSHMTCATDT QNVKFVFDAV TDIIIKENLK DCGLF----- ------
Gt-2 M.musculus P50149 GNYIKSQFLD LNMRKDVKEI YSHMTCATDT QNVKFVFDAV TDIIIKENLK DCGLF----- ------




   








Fig A4 The Complete Aligned Protein Sequences of Gs/olf Family Members of H. 
sapiens, and M. musculus. Each G subtype bears the protein identifier after the name of 
species.  
 
10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-1 MGMFNCLHGN NMSGQHDIPP EVGEQPEQEP LEAPGAAAPG AGAGPAEEMA TEPDSEPSNN EPVPDETGSE ISGPPEDSKS DIQSPCQAFE EVRVGGDYSP
Gs M.musculus Q6R0H7-2 MGMFNCLHGN NMSGQHDIPP EVGEQPEQEP LEAPGAAAPG AGAGPAEEMA TEPDSEPSNN EPVPDETGSE ISGPPEDSKS DIQSPCQAFE EVRVGGDYSP
Gs M.musculus Q6R0H7-3 MGMFNCLHGN NMSGQHDIPP EVGEQPEQEP LEAPGAAAPG AGAGPAEEMA TEPDSEPSNN EPVPDETGSE ISGPPEDSKS DIQSPCQAFE EVRVGGDYSP
Gs M.musculus Q6R0H7-4 MGMFNCLHGN NMSGQHDIPP EVGEQPEQEP LEAPGAAAPG AGAGPAEEMA TEPDSEPSNN EPVPDETGSE ISGPPEDSKS DIQSPCQAFE EVRVGGDYSP
Gs H.sapiens Q5JWF2-1 MGVRNCLYGN NMSGQRDIPP EIGEQPEQPP LEAPGAAAPG AGPSPAEEME TEP----PHN EPIPVENDGE ACGPPEVSRP NFQVLNPAFR EAGAHGSYSP
Gs H.sapiens Q5JWF2-2 MGVRNCLYGN NMSGQRDIPP EIGEQPEQPP LEAPGAAAPG AGPSPAEEME TEP----PHN EPIPVENDGE ACGPPEVSRP NFQVLNPAFR EAGAHGSYSP
Gs H.sapiens Q5JWF2-3 MGVRNCLYGN NMSGQRDIPP EIGEQPEQPP LEAPGAAAPG AGPSPAEEME TEP----PHN EPIPVENDGE ACGPPEVSRP NFQVLNPAFR EAGAHGSYSP
Gs H.sapiens P63092-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf M.musculus Q8CGK7 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-1 PPEEAMPFET QQPSLGDFWP TLEQPG-PSG TPSGLQAFNP AILEPGTPTG ASPGLGAYTP PPEEAMPFEF NEPAQGDHSQ PPLQVPDLAP GGPE-ALVPR
Gs M.musculus Q6R0H7-2 PPEEAMPFET QQPSLGDFWP TLEQPG-PSG TPSGLQAFNP AILEPGTPTG ASPGLGAYTP PPEEAMPFEF NEPAQGDHSQ PPLQVPDLAP GGP-EALVPR
Gs M.musculus Q6R0H7-3 PPEEAMPFET QQPSLGDFWP TLEQPG-PSG TPSGLQAFNP AILEPGTPTG ASPGLGAYTP PPEEAMPFEF NEPAQGDHSQ PPLQVPDLAP GGP-EALVPR
Gs M.musculus Q6R0H7-4 PPEEAMPFET QQPSLGDFWP TLEQPGPSGT PSG-LQAFNP AILEPGTPTG ASPGLGAYTP PPEEAMPFEF NEPAQGDHSQ PPLQVPDLAP GGPEALVPR-
Gs H.sapiens Q5JWF2-1 PPEEAMPFEA EQPSLGGFWP TLEQPGFPSG VHAGLEAFGP ALMEPGAFSG ARPGLGGYSP PPEEAMPFEF DQPAQRGCSQ LLLQVPDLAP GGPGAAGVPG
Gs H.sapiens Q5JWF2-2 PPEEAMPFEA EQPSLGGFWP TLEQPGFPSG VHAGLEAFGP ALMEPGAFSG ARPGLGGYSP PPEEAMPFEF DQPAQRGCSQ LLLQVPDLAP GGPGAAGVPG
Gs H.sapiens Q5JWF2-3 PPEEAMPFEA EQPSLGGFWP TLEQPGFPSG VHAGLEAFGP ALMEPGAFSG ARPGLGGYSP PPEEAMPFEF DQPAQRGCSQ LLLQVPDLAP GGPGAAGVPG
Gs H.sapiens P63092-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf M.musculus Q8CGK7 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-1 ALPAEPGNIR FENAGFREDY SPPPEESVPF QVGGEEFGGD SPPPGLPRVI PQIGIGGEFP TVAVPSALCL APAENAPPLW VRGAIDRPFR EAVRSPPNFA
Gs M.musculus Q6R0H7-2 ALPAEPGNIR FENAGFREDY SPPPEESVPF QVGGEEFGGD SPPPGLPRVI PQIGIGGEFP TVAVPSALCL APAENAPPLW VRGAIDRPFR EAVRSPPNFA
Gs M.musculus Q6R0H7-3 ALPAEPGNIR FENAGFREDY SPPPEESVPF QVGGEEFGGD SPPPGLPRVI PQIGIGGEFP TVAVPSALCL APAENAPPLW VRGAIDRPFR EAVRSPPNFA
Gs M.musculus Q6R0H7-4 ALPAEPGNIR FENAGFREDY SPPPEESVPF QVGGEEFGGD SPPPGLPRVI PQIGIGGEFP TVAVPSALCL APAENAPPLW VRGAIDRPFR EAVRSPPNFA
Gs H.sapiens Q5JWF2-1 APPEEPQALR PAKAGSRGGY SPPPEETMPF ELDGEGFGDD SPPPGLSRVI AQVDGSSQFA AVAASSAVRL TPAANAPPLW VPGAIGSPSQ EAVRPPSNFT
Gs H.sapiens Q5JWF2-2 APPEEPQALR PAKAGSRGGY SPPPEETMPF ELDGEGFGDD SPPPGLSRVI AQVDGSSQFA AVAASSAVRL TPAANAPPLW VPGAIGSPSQ EAVRPPSNFT
Gs H.sapiens Q5JWF2-3 APPEEPQALR PAKAGSRGGY SPPPEETMPF ELDGEGFGDD SPPPGLSRVI AQVDGSSQFA AVAASSAVRL TPAANAPPLW VPGAIGSPSQ EAVRPPSNFT
Gs H.sapiens P63092-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf M.musculus Q8CGK7 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
310 320 330 340 350 360 370 380 390 400
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-1 CDSPPMEITR PLLEIGRASI GVDDDTAVNM DSPPIASDGP PIEVSGAPDK SECAERPPVE REAAEMEGSP TTATAVEGKV PSPERGDGSS TQPEAMDAKP
Gs M.musculus Q6R0H7-2 CDSPPMEITR PLLEIGRASI GVDDDTAVNM DSPPIASDGP P--------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-3 CDSPPMEITR PLLEIGRASI GVDDDTAVNM DSPPIASDGP P--------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-4 CDSPPMEITR PLLEIGRASI GVDDDTAVNM DSPPIASDGP PIEVSGAPDK SECAERPPVE REAAEMEGSP TTATAVEGKV PSPERGDGSS TQPEAMDAKP
Gs H.sapiens Q5JWF2-1 GSSPWMEISG PPFEIGSAPA GVDDTPVN-M DSPPIALDGP PIKVSGAPDK RERAERPPVE EEAAEMEG-- AADAAEGGKV PSPGYG---- ----------
Gs H.sapiens Q5JWF2-2 GSSPWMEISG PPFEIGSAPA GVDDTPVN-M DSPPIALDGP PIKVSGAPDK RERAERPPVE EEAAEMEG-- AADAAEGGKV PSPGYG---- ----------
Gs H.sapiens Q5JWF2-3 GSSPWMEISG PPFEIGSAPA GVDD-TPVNM DSPPIALDGP P--------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf M.musculus Q8CGK7 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
410 420 430 440 450 460 470 480 490 500
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-1 APAAQAVSTG SDAGAPTDSA MLTDSQSDAG EDGTAPGTPS DLQSDPEELE EAPAVRADPD GGAAPVAPAT PAESESEGSR DPAAEPASEA VPATTAESAS
Gs M.musculus Q6R0H7-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-4 APAAQAVSTG SDAGAPTDSA MLTDSQSDAG EDGTAPGTPS DLQSDPEELE EAPAVRADPD GGAAPVAPAT PAESESEGSR DPAAEPASEA VPATTAESAS
Gs H.sapiens Q5JWF2-1 ---------- ---------- ---------- ------SPAA GAASADTAAR AAPAAPADPD SGATPEDPDS GTAPADPDSG AFAADPDSGA APAAPADPDS
Gs H.sapiens Q5JWF2-2 ---------- ---------- ---------- ------SPAA GAASADTAAR AAPAAPADPD SGATPEDPDS GTAPADPDSG AFAADPDSGA APAAPADPDS
Gs H.sapiens Q5JWF2-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf M.musculus Q8CGK7 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
510 520 530 540 550 560 570 580 590 600
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-1 GAAPVTQVEP AAAAVSATLA EPAARAAPIT PKEPTTRAVP SARAHPAAGA VPGAPAMSAS ARAAAARAAY AGPLVWGARS LSATPAARAS LPARAAAAAR
Gs M.musculus Q6R0H7-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-4 GAAPVTQVEP AAAAVSATLA EPAARAAPIT PKEPTTRAVP SARAHPAAGA VPGAPAMSAS ARAAAARAAY AGPLVWGARS LSATPAARAS LPARAAAAAR
Gs H.sapiens Q5JWF2-1 GAAPDAPADP DSGAAPDAPA DPDAGAAPEA PAAPAAAETR AAHVAPAA-- ---------- ---------- ---------- ------PDAG APTAPAASAT
Gs H.sapiens Q5JWF2-2 GAAPDAPADP DSGAAPDAPA DPDAGAAPEA PAAPAAAETR AAHVAPAA-- ---------- ---------- ---------- ------PDAG APTAPAASAT
Gs H.sapiens Q5JWF2-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf M.musculus Q8CGK7 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
610 620 630 640 650 660 670 680 690 700
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-1 AASAARAVAA GRSASAAPSR AHLRPPSPEI QVADPPTPRP PPRPTAWPDK YERGRSCCRY EASSGICEIE SSSDESEEGA TGCFQWLLRR NRRPGLPRSH
Gs M.musculus Q6R0H7-2 ---------- ---------- ---------- ---------- ------IEVS GAPDKSECAE RPPVEREAAE MEGSPTTATA VEGKVPSPER GDGSSTQPEA
Gs M.musculus Q6R0H7-3 ---------- ---------- ---------- ---------- ------IEVS GAPDKSECAE RPPVEREAAE MEGSPTTATA VEGKVPSPER GDGSSTQPEA
Gs M.musculus Q6R0H7-4 AASAARAVAA GRSASAAPSR AHLRPPSPEI QVADPPTPRP PPRPTAWPDK YERGRSCCRY EASSGICEIE SSSDESEEGA TGCFQWLLRR NRRPGLPRSH
Gs H.sapiens Q5JWF2-1 RAAQVRRAAS AAPASGARRK IHLRPPSPEI QAADPPTPRP -TRASAWRGK SESSRGRRVY YDEGVASSDD DSSGDESDDG TSGCLRWFQH RRNR---RRR
Gs H.sapiens Q5JWF2-2 RAAQVRRAAS AAPASGARRK IHLRPPSPEI QAADPPTPRP -TRASAWRGK SESSRGRRVY YDEGVASSDD DSSGDESDDG TSGCLRWFQH RRNR---RRR
Gs H.sapiens Q5JWF2-3 ---------- ---------- ---------- ---------- ------IKVS GAPDKRERAE RPPVEEEAAE MEG--AADAA EGGKVPSPGY G---------
Gs H.sapiens P63092-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-1 ---------- ---------- ---------- ---------- ------MGCL GGN------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-2 ---------- ---------- ---------- ----MGLCYS -LRPLLFGGP GDDPCAASEP PVEDAQPAPA PALAPVRAAA RDTARTLLPR GGEG---SPA
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf M.musculus Q8CGK7 ---------- ---------- ---------- ---------- ------MGCL GNS------- ---------- ---------- ---------- ----------
710 720 730 740 750 760 770 780 790 800
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 ---------- -----MGCLG NSKTE----- ---------- ---------- --DQRNEEKA QREANKKIEK QLQKDKQVYR ATHRLLLLGA GESGKSTIVK
Gs M.musculus P63094-2 ---------- -----MGCLG NSKTE----- ---------- ---------- --DQRNEEKA QREANKKIEK QLQKDKQVYR ATHRLLLLGA GESGKSTIVK
Gs M.musculus P63094-3 ---------- ---------- --------MG DSVQILLVFM DK-------- ---------- ---------- ---------- --------GA GESGKSTIVK
Gs M.musculus Q6R0H7-1 TVGSNPVRNF FTRAFGSCFG LSECTRSR-S LSPGKAKDPM EERRKQMRKE AIEMREQKRA DKKRSKLIDK QLEEEKMDYM CTHRLLLLGA GESGKSTIVK
Gs M.musculus Q6R0H7-2 MDAKPAPAAQ AVSTGSDAGA PTDSAMLTDS QSDAGEDGTA PGTPSDLQSD PEELEEAPAV RADPDGGAAP VAPATPAESE SEGSRDPAAE PASEAVPATT
Gs M.musculus Q6R0H7-3 MDAKPAPAAQ AVSTGSDAGA PTDSAMLTDS QSDAGEDGTA PGTPSDLQSD PEELEEAPAV RADPDGGAAP VAPATPAESE SEGSRDPAAE PASEAVPATT
Gs M.musculus Q6R0H7-4 TVGSNPVRNF FTRAFGSCFG LSECTRSR-S LSPGKAKDPM EERRKQMRKE AIEMREQKRA DKKRSKLIDK QLEEEKMDYM CTHRLLLLGA GESGKSTIVK
Gs H.sapiens Q5JWF2-1 KPQRNLLRNF LVQAFGGCFG RSESPQPKAS RSLKVKKVPL AEKRRQMRKE ALEKRAQKRA EKKRSKLIDK QLQDEKMGYM CTHRLLLLGA GESGKSTIVK
Gs H.sapiens Q5JWF2-2 KPQRNLLRNF LVQAFGGCFG RSESPQPKAS RSLKVKKVPL AEKRRQMRKE ALEKRAQKRA EKKRSKLIDK QLQDEKMGYM CTHRLLLLGA GESGKSTIVK
Gs H.sapiens Q5JWF2-3 -----SPAAG AASADTAARA ---------- ---------- ---------- ------APAA PADPDSGATP EDPDSGTAPA DPDSGAFAAD PDSGAAPAAP
Gs H.sapiens P63092-1 ---------- -----MGCLG NSKTE----- ---------- ---------- --DQRNEEKA QREANKKIEK QLQKDKQVYR ATHRLLLLGA GESGKSTIVK
Gs H.sapiens P63092-2 ---------- -----MGCLG NSKTE----- ---------- ---------- --DQRNEEKA QREANKKIEK QLQKDKQVYR ATHRLLLLGA GESGKSTIVK
Gs H.sapiens P63092-3 ---------- -----MGCLG NSKTE----- ---------- ---------- --DQRNEEKA QREANKKIEK QLQKDKQVYR ATHRLLLLGA GESGKSTIVK
Golf H.sapiens P38405-1 ---------- --SKTTEDQG VDE------- ---------- ---------- --------KE RREANKKIEK QLQKERLAYK ATHRLLLLGA GESGKSTIVK
Golf H.sapiens P38405-2 CARPKADKPK EKRQRTEQLS AEEREAA--- ---------- ---------- --KEREAVKE ARKVSRGIDR MLRDQKRDLQ QTHRLLLLGA GESGKSTIVK
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf M.musculus Q8CGK7 ---------- --SKTAEDQG VDE------- ---------- ---------- --------KE RREANKKIEK QLQKERLAYK ATHRLLLLGA GESGKSTIVK
810 820 830 840 850 860 870 880 890 900
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 QMRILHVNGF NGEGGEEDPQ AARSNSDGEK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP NFDFPPEFYE HAKALWEDEG
Gs M.musculus P63094-2 QMRILHVNGF NGDS------ --------EK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP NFDFPPEFYE HAKALWEDEG
Gs M.musculus P63094-3 QMRILHVNGF NGEGGEEDPQ AARSNSDGEK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP NFDFPPEFYE HAKALWEDEG
Gs M.musculus Q6R0H7-1 QMRILHVNGF NGEGGEEDPQ AARSNSDGEK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP NFDFPPEFYE HAKALWEDEG
Gs M.musculus Q6R0H7-2 AESASGAAPV TQVEPAAAAV SATLAEPAAR AAPITPKEPT TRAVPSARAH PAAGAVPGAP AMSASARAAA ARAAYAGPLV WGARSLSATP AARASLPARA
Gs M.musculus Q6R0H7-3 AESASGAAPV TQVEPAAAAV SATLAEPAAR AAPITPKEPT TRAVPSARAH PAAGAVPGAP AMSASARAAA ARAAYAGPLV WGARSLSATP AARASLPARA
Gs M.musculus Q6R0H7-4 QMRILHVNGF NGDS------ --------EK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP NFDFPPEFYE HAKALWEDEG
Gs H.sapiens Q5JWF2-1 QMRILHVNGF NGEGGEEDPQ AARSNSDGEK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP DFDFPPEFYE HAKALWEDEG
Gs H.sapiens Q5JWF2-2 QMRILHVNGF NG-------- ------DSEK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP DFDFPPEFYE HAKALWEDEG
Gs H.sapiens Q5JWF2-3 ADPDSGAAPD ---------- ---------- ----APADPD SGAAPDAPAD PDAGAAPEAP AAPAAAETRA AHVAPAAPDA G-------AP TAPAASATRA
Gs H.sapiens P63092-1 QMRILHVNGF NGEGGEEDPQ AARSNSDGEK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP DFDFPPEFYE HAKALWEDEG
Gs H.sapiens P63092-2 QMRILHVNGF NGDS------ --------EK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP DFDFPPEFYE HAKALWEDEG
Gs H.sapiens P63092-3 QMRILHVNGF NGD------- --------EK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP DFDFPPEFYE HAKALWEDEG
Golf H.sapiens P38405-1 QMRILHVNGF NPE------- --------EK KQKILDIRKN VKDAIVTIVS AMSTIIPPVP LANPENQFRS DYIKSIAPIT DFEYSQEFFD HVKKLWDDEG
Golf H.sapiens P38405-2 QMRILHVNGF NPE------- --------EK KQKILDIRKN VKDAIVTIVS AMSTIIPPVP LANPENQFRS DYIKSIAPIT DFEYSQEFFD HVKKLWDDEG
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf M.musculus Q8CGK7 QMRILHVNGF NPE------- --------EK KQKILDIRKN VKDAIVTIVS AMSTIIPPVP LANPENQFRS DYIKSIAPIT DFEYSQEFFD HVKKLWDDEG
910 920 930 940 950 960 970 980 990 1000
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Gs M.musculus P63094-2 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Gs M.musculus P63094-3 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Gs M.musculus Q6R0H7-1 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Gs M.musculus Q6R0H7-2 AAAARAASAA RAVAAGRSAS AAPSRAHLRP PSPEIQVADP PTPRPPPRPT AWPDKYERGR S-CCRYEASS GICEIESSSD ESEEGATGCF QWLLRRNRRP
Gs M.musculus Q6R0H7-3 AAAARAASAA RAVAAGRSAS AAPSRAHLRP PSPEIQVADP PTPRPPPRPT AWPDKYERGR S-CCRYEASS GICEIESSSD ESEEGATGCF QWLLRRNRRP
Gs M.musculus Q6R0H7-4 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Gs H.sapiens Q5JWF2-1 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Gs H.sapiens Q5JWF2-2 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Gs H.sapiens Q5JWF2-3 AQVRRAASAA PASGARR--- ----KIHLRP PSPEIQAADP PTPR-PTRAS AWRGKSESSR GRRVYYDEGV ASSDDDSSGD ESDDGTSGCL RWFQHRRNR-
Gs H.sapiens P63092-1 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Gs H.sapiens P63092-2 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Gs H.sapiens P63092-3 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Golf H.sapiens P38405-1 VKACFERSNE --YQLIDCAQ YFLERIDSVS LVDYTPTDQD LLRCRVLTSG IFETRFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIY VAACSSYNMV
Golf H.sapiens P38405-2 VKACFERSNE --YQLIDCAQ YFLERIDSVS LVDYTPTDQD LLRCRVLTSG IFETRFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIY VAACSSYNMV
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ----MFDVGG QRDERRKWIQ CFNDVTAIIY VAACSSYNMV
Golf M.musculus Q8CGK7 VKACFERSNE --YQLIDCAQ YFLERIDSVS LVDYTPTDQD LLRCRVLTSG IFETRFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIY VAACSSYNMV
1010 1020 1030 1040 1050 1060 1070 1080 1090 1100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Gs M.musculus P63094-2 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Gs M.musculus P63094-3 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Gs M.musculus Q6R0H7-1 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Gs M.musculus Q6R0H7-2 GLPRSHTVGS NPVRNFFTRA FGSCFGLSEC TRS-RSLSPG KAKDPMEERR KQMRKEAIEM REQKRADKKR SKLIDKQLEE EKMDYMCTHR LLLLGRKVVP
Gs M.musculus Q6R0H7-3 GLPRSHTVGS NPVRNFFTRA FGSCFGLSEC TRS-RSLSPG KAKDPMEERR KQMRKEAIEM REQKRADKKR SKLIDKQLEE EKMDYMCTHR LLLLGRKVVP
Gs M.musculus Q6R0H7-4 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Gs H.sapiens Q5JWF2-1 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Gs H.sapiens Q5JWF2-2 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Gs H.sapiens Q5JWF2-3 ---RRRKPQR NLLRNFLVQA FGGCFGRSES PQPKASRSLK VKKVPLAEKR RQMRKEALEK RAQKRAEKKR SKLIDKQLQD EKMGYMCTHR LLLLGRKVVP
Gs H.sapiens P63092-1 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Gs H.sapiens P63092-2 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Gs H.sapiens P63092-3 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Golf H.sapiens P38405-1 IREDNNTNRL RESLDLFESI WNNRWLRTIS IILFLNKQDM LAEKVLAGKS K--IEDYFPE YANYTVPEDA TPDAGEDPKV TRAKFFIRDL FLRIS--TAT
Golf H.sapiens P38405-2 IREDNNTNRL RESLDLFESI WNNRWLRTIS IILFLNKQDM LAEKVLAGKS K--IEDYFPE YANYTVPEDA TPDAGEDPKV TRAKFFIRDL FLRIS--TAT
Golf H.sapiens P38405-3 IREDNNTNRL RESLDLFESI WNNRWLRTIS IILFLNKQDM LAEKVLAGKS K--IEDYFPE YANYTVPEDA TPDAGEDPKV TRAKFFIRDL FLRIS--TAT
Golf M.musculus Q8CGK7 IREDNNTNRL RESLDLFESI WNNRWLRTIS IILFLNKQDM LAEKVLAGKS K--IEDYFPE YANYTVPEDA TPDAGEDPKV TRAKFFIRDL FLRIS--TAT
1110 1120 1130 1140 1150 1160 1170 1180
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|
Gs M.musculus P63094-1 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Gs M.musculus P63094-2 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Gs M.musculus P63094-3 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Gs M.musculus Q6R0H7-1 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Gs M.musculus Q6R0H7-2 SDTEGRYRPE ASASASDRRL DRRGREVSPE LLGWALRGSP GSIVRDRGGL GPSGCAPPPR LARLLRLRQL VVGVCWCPFS VFACA
Gs M.musculus Q6R0H7-3 SDTEGRYRPE ASASASDRRL DRRGREVLES LAKAPL---- ---------- ---------- ---------- ---------- -----
Gs M.musculus Q6R0H7-4 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Gs H.sapiens Q5JWF2-1 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Gs H.sapiens Q5JWF2-2 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Gs H.sapiens Q5JWF2-3 SDTEGRFRLD RPAPATVSWT G-RGFSVSSL LIRSPN---- ---------- -------PPA FTVEKPDTQV LENLVKAPL- -----
Gs H.sapiens P63092-1 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Gs H.sapiens P63092-2 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Gs H.sapiens P63092-3 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Golf H.sapiens P38405-1 GDGKHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLKQYE LL-------- ---------- ---------- ---------- -----
Golf H.sapiens P38405-2 GDGKHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLKQYE LL-------- ---------- ---------- ---------- -----
Golf H.sapiens P38405-3 GDGKHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLKQYE LL-------- ---------- ---------- ---------- -----




   







Fig A4 (con’d) 
 
 
10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-1 MGMFNCLHGN NMSGQHDIPP EVGEQPEQEP LEAPGAAAPG AGAGPAEEMA TEPDSEPSNN EPVPDETGSE ISGPPEDSKS DIQSPCQAFE EVRVGGDYSP
Gs M.musculus Q6R0H7-2 MGMFNCLHGN NMSGQHDIPP EVGEQPEQEP LEAPGAAAPG AGAGPAEEMA TEPDSEPSNN EPVPDETGSE ISGPPEDSKS DIQSPCQAFE EVRVGGDYSP
Gs M.musculus Q6R0H7-3 MGMFNCLHGN NMSGQHDIPP EVGEQPEQEP LEAPGAAAPG AGAGPAEEMA TEPDSEPSNN EPVPDETGSE ISGPPEDSKS DIQSPCQAFE EVRVGGDYSP
Gs M.musculus Q6R0H7-4 MGMFNCLHGN NMSGQHDIPP EVGEQPEQEP LEAPGAAAPG AGAGPAEEMA TEPDSEPSNN EPVPDETGSE ISGPPEDSKS DIQSPCQAFE EVRVGGDYSP
Gs H.sapiens Q5JWF2-1 MGVRNCLYGN NMSGQRDIPP EIGEQPEQPP LEAPGAAAPG AGPSPAEEME TEP----PHN EPIPVENDGE ACGPPEVSRP NFQVLNPAFR EAGAHGSYSP
Gs H.sapiens Q5JWF2-2 MGVRNCLYGN NMSGQRDIPP EIGEQPEQPP LEAPGAAAPG AGPSPAEEME TEP----PHN EPIPVENDGE ACGPPEVSRP NFQVLNPAFR EAGAHGSYSP
Gs H.sapiens Q5JWF2-3 MGVRNCLYGN NMSGQRDIPP EIGEQPEQPP LEAPGAAAPG AGPSPAEEME TEP----PHN EPIPVENDGE ACGPPEVSRP NFQVLNPAFR EAGAHGSYSP
Gs H.sapiens P63092-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf M.musculus Q8CGK7 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-1 PPEEAMPFET QQPSLGDFWP TLEQPG-PSG TPSGLQAFNP AILEPGTPTG ASPGLGAYTP PPEEAMPFEF NEPAQGDHSQ PPLQVPDLAP GGPE-ALVPR
Gs M.musculus Q6R0H7-2 PPEEAMPFET QQPSLGDFWP TLEQPG-PSG TPSGLQAFNP AILEPGTPTG ASPGLGAYTP PPEEAMPFEF NEPAQGDHSQ PPLQVPDLAP GGP-EALVPR
Gs M.musculus Q6R0H7-3 PPEEAMPFET QQPSLGDFWP TLEQPG-PSG TPSGLQAFNP AILEPGTPTG ASPGLGAYTP PPEEAMPFEF NEPAQGDHSQ PPLQVPDLAP GGP-EALVPR
Gs M.musculus Q6R0H7-4 PPEEAMPFET QQPSLGDFWP TLEQPGPSGT PSG-LQAFNP AILEPGTPTG ASPGLGAYTP PPEEAMPFEF NEPAQGDHSQ PPLQVPDLAP GGPEALVPR-
Gs H.sapiens Q5JWF2-1 PPEEAMPFEA EQPSLGGFWP TLEQPGFPSG VHAGLEAFGP ALMEPGAFSG ARPGLGGYSP PPEEAMPFEF DQPAQRGCSQ LLLQVPDLAP GGPGAAGVPG
Gs H.sapiens Q5JWF2-2 PPEEAMPFEA EQPSLGGFWP TLEQPGFPSG VHAGLEAFGP ALMEPGAFSG ARPGLGGYSP PPEEAMPFEF DQPAQRGCSQ LLLQVPDLAP GGPGAAGVPG
Gs H.sapiens Q5JWF2-3 PPEEAMPFEA EQPSLGGFWP TLEQPGFPSG VHAGLEAFGP ALMEPGAFSG ARPGLGGYSP PPEEAMPFEF DQPAQRGCSQ LLLQVPDLAP GGPGAAGVPG
Gs H.sapiens P63092-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf M.musculus Q8CGK7 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-1 ALPAEPGNIR FENAGFREDY SPPPEESVPF QVGGEEFGGD SPPPGLPRVI PQIGIGGEFP TVAVPSALCL APAENAPPLW VRGAIDRPFR EAVRSPPNFA
Gs M.musculus Q6R0H7-2 ALPAEPGNIR FENAGFREDY SPPPEESVPF QVGGEEFGGD SPPPGLPRVI PQIGIGGEFP TVAVPSALCL APAENAPPLW VRGAIDRPFR EAVRSPPNFA
Gs M.musculus Q6R0H7-3 ALPAEPGNIR FENAGFREDY SPPPEESVPF QVGGEEFGGD SPPPGLPRVI PQIGIGGEFP TVAVPSALCL APAENAPPLW VRGAIDRPFR EAVRSPPNFA
Gs M.musculus Q6R0H7-4 ALPAEPGNIR FENAGFREDY SPPPEESVPF QVGGEEFGGD SPPPGLPRVI PQIGIGGEFP TVAVPSALCL APAENAPPLW VRGAIDRPFR EAVRSPPNFA
Gs H.sapiens Q5JWF2-1 APPEEPQALR PAKAGSRGGY SPPPEETMPF ELDGEGFGDD SPPPGLSRVI AQVDGSSQFA AVAASSAVRL TPAANAPPLW VPGAIGSPSQ EAVRPPSNFT
Gs H.sapiens Q5JWF2-2 APPEEPQALR PAKAGSRGGY SPPPEETMPF ELDGEGFGDD SPPPGLSRVI AQVDGSSQFA AVAASSAVRL TPAANAPPLW VPGAIGSPSQ EAVRPPSNFT
Gs H.sapiens Q5JWF2-3 APPEEPQALR PAKAGSRGGY SPPPEETMPF ELDGEGFGDD SPPPGLSRVI AQVDGSSQFA AVAASSAVRL TPAANAPPLW VPGAIGSPSQ EAVRPPSNFT
Gs H.sapiens P63092-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf M.musculus Q8CGK7 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
310 320 330 340 350 360 370 380 390 400
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-1 CDSPPMEITR PLLEIGRASI GVDDDTAVNM DSPPIASDGP PIEVSGAPDK SECAERPPVE REAAEMEGSP TTATAVEGKV PSPERGDGSS TQPEAMDAKP
Gs M.musculus Q6R0H7-2 CDSPPMEITR PLLEIGRASI GVDDDTAVNM DSPPIASDGP P--------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-3 CDSPPMEITR PLLEIGRASI GVDDDTAVNM DSPPIASDGP P--------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-4 CDSPPMEITR PLLEIGRASI GVDDDTAVNM DSPPIASDGP PIEVSGAPDK SECAERPPVE REAAEMEGSP TTATAVEGKV PSPERGDGSS TQPEAMDAKP
Gs H.sapiens Q5JWF2-1 GSSPWMEISG PPFEIGSAPA GVDDTPVN-M DSPPIALDGP PIKVSGAPDK RERAERPPVE EEAAEMEG-- AADAAEGGKV PSPGYG---- ----------
Gs H.sapiens Q5JWF2-2 GSSPWMEISG PPFEIGSAPA GVDDTPVN-M DSPPIALDGP PIKVSGAPDK RERAERPPVE EEAAEMEG-- AADAAEGGKV PSPGYG---- ----------
Gs H.sapiens Q5JWF2-3 GSSPWMEISG PPFEIGSAPA GVDD-TPVNM DSPPIALDGP P--------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf M.musculus Q8CGK7 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
410 420 430 440 450 460 470 480 490 500
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-1 APAAQAVSTG SDAGAPTDSA MLTDSQSDAG EDGTAPGTPS DLQSDPEELE EAPAVRADPD GGAAPVAPAT PAESESEGSR DPAAEPASEA VPATTAESAS
Gs M.musculus Q6R0H7-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-4 APAAQAVSTG SDAGAPTDSA MLTDSQSDAG EDGTAPGTPS DLQSDPEELE EAPAVRADPD GGAAPVAPAT PAESESEGSR DPAAEPASEA VPATTAESAS
Gs H.sapiens Q5JWF2-1 ---------- ---------- ---------- ------SPAA GAASADTAAR AAPAAPADPD SGATPEDPDS GTAPADPDSG AFAADPDSGA APAAPADPDS
Gs H.sapiens Q5JWF2-2 ---------- ---------- ---------- ------SPAA GAASADTAAR AAPAAPADPD SGATPEDPDS GTAPADPDSG AFAADPDSGA APAAPADPDS
Gs H.sapiens Q5JWF2-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf M.musculus Q8CGK7 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
510 520 530 540 550 560 570 580 590 600
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-1 GAAPVTQVEP AAAAVSATLA EPAARAAPIT PKEPTTRAVP SARAHPAAGA VPGAPAMSAS ARAAAARAAY AGPLVWGARS LSATPAARAS LPARAAAAAR
Gs M.musculus Q6R0H7-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-4 GAAPVTQVEP AAAAVSATLA EPAARAAPIT PKEPTTRAVP SARAHPAAGA VPGAPAMSAS ARAAAARAAY AGPLVWGARS LSATPAARAS LPARAAAAAR
Gs H.sapiens Q5JWF2-1 GAAPDAPADP DSGAAPDAPA DPDAGAAPEA PAAPAAAETR AAHVAPAA-- ---------- ---------- ---------- ------PDAG APTAPAASAT
Gs H.sapiens Q5JWF2-2 GAAPDAPADP DSGAAPDAPA DPDAGAAPEA PAAPAAAETR AAHVAPAA-- ---------- ---------- ---------- ------PDAG APTAPAASAT
Gs H.sapiens Q5JWF2-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf M.musculus Q8CGK7 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
610 620 630 640 650 660 670 680 690 700
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus P63094-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs M.musculus Q6R0H7-1 AASAARAVAA GRSASAAPSR AHLRPPSPEI QVADPPTPRP PPRPTAWPDK YERGRSCCRY EASSGICEIE SSSDESEEGA TGCFQWLLRR NRRPGLPRSH
Gs M.musculus Q6R0H7-2 ---------- ---------- ---------- ---------- ------IEVS GAPDKSECAE RPPVEREAAE MEGSPTTATA VEGKVPSPER GDGSSTQPEA
Gs M.musculus Q6R0H7-3 ---------- ---------- ---------- ---------- ------IEVS GAPDKSECAE RPPVEREAAE MEGSPTTATA VEGKVPSPER GDGSSTQPEA
Gs M.musculus Q6R0H7-4 AASAARAVAA GRSASAAPSR AHLRPPSPEI QVADPPTPRP PPRPTAWPDK YERGRSCCRY EASSGICEIE SSSDESEEGA TGCFQWLLRR NRRPGLPRSH
Gs H.sapiens Q5JWF2-1 RAAQVRRAAS AAPASGARRK IHLRPPSPEI QAADPPTPRP -TRASAWRGK SESSRGRRVY YDEGVASSDD DSSGDESDDG TSGCLRWFQH RRNR---RRR
Gs H.sapiens Q5JWF2-2 RAAQVRRAAS AAPASGARRK IHLRPPSPEI QAADPPTPRP -TRASAWRGK SESSRGRRVY YDEGVASSDD DSSGDESDDG TSGCLRWFQH RRNR---RRR
Gs H.sapiens Q5JWF2-3 ---------- ---------- ---------- ---------- ------IKVS GAPDKRERAE RPPVEEEAAE MEG--AADAA EGGKVPSPGY G---------
Gs H.sapiens P63092-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-2 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gs H.sapiens P63092-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-1 ---------- ---------- ---------- ---------- ------MGCL GGN------- ---------- ---------- ---------- ----------
Golf H.sapiens P38405-2 ---------- ---------- ---------- ----MGLCYS -LRPLLFGGP GDDPCAASEP PVEDAQPAPA PALAPVRAAA RDTARTLLPR GGEG---SPA
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf M.musculus Q8CGK7 ---------- ---------- ---------- ---------- ------MGCL GNS------- ---------- ---------- ---------- ----------
710 720 730 740 750 760 770 780 790 800
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 ---------- -----MGCLG NSKTE----- ---------- ---------- --DQRNEEKA QREANKKIEK QLQKDKQVYR ATHRLLLLGA GESGKSTIVK
Gs M.musculus P63094-2 ---------- -----MGCLG NSKTE----- ---------- ---------- --DQRNEEKA QREANKKIEK QLQKDKQVYR ATHRLLLLGA GESGKSTIVK
Gs M.musculus P63094-3 ---------- ---------- --------MG DSVQILLVFM DK-------- ---------- ---------- ---------- --------GA GESGKSTIVK
Gs M.musculus Q6R0H7-1 TVGSNPVRNF FTRAFGSCFG LSECTRSR-S LSPGKAKDPM EERRKQMRKE AIEMREQKRA DKKRSKLIDK QLEEEKMDYM CTHRLLLLGA GESGKSTIVK
Gs M.musculus Q6R0H7-2 MDAKPAPAAQ AVSTGSDAGA PTDSAMLTDS QSDAGEDGTA PGTPSDLQSD PEELEEAPAV RADPDGGAAP VAPATPAESE SEGSRDPAAE PASEAVPATT
Gs M.musculus Q6R0H7-3 MDAKPAPAAQ AVSTGSDAGA PTDSAMLTDS QSDAGEDGTA PGTPSDLQSD PEELEEAPAV RADPDGGAAP VAPATPAESE SEGSRDPAAE PASEAVPATT
Gs M.musculus Q6R0H7-4 TVGSNPVRNF FTRAFGSCFG LSECTRSR-S LSPGKAKDPM EERRKQMRKE AIEMREQKRA DKKRSKLIDK QLEEEKMDYM CTHRLLLLGA GESGKSTIVK
Gs H.sapiens Q5JWF2-1 KPQRNLLRNF LVQAFGGCFG RSESPQPKAS RSLKVKKVPL AEKRRQMRKE ALEKRAQKRA EKKRSKLIDK QLQDEKMGYM CTHRLLLLGA GESGKSTIVK
Gs H.sapiens Q5JWF2-2 KPQRNLLRNF LVQAFGGCFG RSESPQPKAS RSLKVKKVPL AEKRRQMRKE ALEKRAQKRA EKKRSKLIDK QLQDEKMGYM CTHRLLLLGA GESGKSTIVK
Gs H.sapiens Q5JWF2-3 -----SPAAG AASADTAARA ---------- ---------- ---------- ------APAA PADPDSGATP EDPDSGTAPA DPDSGAFAAD PDSGAAPAAP
Gs H.sapiens P63092-1 ---------- -----MGCLG NSKTE----- ---------- ---------- --DQRNEEKA QREANKKIEK QLQKDKQVYR ATHRLLLLGA GESGKSTIVK
Gs H.sapiens P63092-2 ---------- -----MGCLG NSKTE----- ---------- ---------- --DQRNEEKA QREANKKIEK QLQKDKQVYR ATHRLLLLGA GESGKSTIVK
Gs H.sapiens P63092-3 ---------- -----MGCLG NSKTE----- ---------- ---------- --DQRNEEKA QREANKKIEK QLQKDKQVYR ATHRLLLLGA GESGKSTIVK
Golf H.sapiens P38405-1 ---------- --SKTTEDQG VDE------- ---------- ---------- --------KE RREANKKIEK QLQKERLAYK ATHRLLLLGA GESGKSTIVK
Golf H.sapiens P38405-2 CARPKADKPK EKRQRTEQLS AEEREAA--- ---------- ---------- --KEREAVKE ARKVSRGIDR MLRDQKRDLQ QTHRLLLLGA GESGKSTIVK
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf M.musculus Q8CGK7 ---------- --SKTAEDQG VDE------- ---------- ---------- --------KE RREANKKIEK QLQKERLAYK ATHRLLLLGA GESGKSTIVK
810 820 830 840 850 860 870 880 890 900
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 QMRILHVNGF NGEGGEEDPQ AARSNSDGEK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP NFDFPPEFYE HAKALWEDEG
Gs M.musculus P63094-2 QMRILHVNGF NGDS------ --------EK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP NFDFPPEFYE HAKALWEDEG
Gs M.musculus P63094-3 QMRILHVNGF NGEGGEEDPQ AARSNSDGEK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP NFDFPPEFYE HAKALWEDEG
Gs M.musculus Q6R0H7-1 QMRILHVNGF NGEGGEEDPQ AARSNSDGEK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP NFDFPPEFYE HAKALWEDEG
Gs M.musculus Q6R0H7-2 AESASGAAPV TQVEPAAAAV SATLAEPAAR AAPITPKEPT TRAVPSARAH PAAGAVPGAP AMSASARAAA ARAAYAGPLV WGARSLSATP AARASLPARA
Gs M.musculus Q6R0H7-3 AESASGAAPV TQVEPAAAAV SATLAEPAAR AAPITPKEPT TRAVPSARAH PAAGAVPGAP AMSASARAAA ARAAYAGPLV WGARSLSATP AARASLPARA
Gs M.musculus Q6R0H7-4 QMRILHVNGF NGDS------ --------EK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP NFDFPPEFYE HAKALWEDEG
Gs H.sapiens Q5JWF2-1 QMRILHVNGF NGEGGEEDPQ AARSNSDGEK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP DFDFPPEFYE HAKALWEDEG
Gs H.sapiens Q5JWF2-2 QMRILHVNGF NG-------- ------DSEK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP DFDFPPEFYE HAKALWEDEG
Gs H.sapiens Q5JWF2-3 ADPDSGAAPD ---------- ---------- ----APADPD SGAAPDAPAD PDAGAAPEAP AAPAAAETRA AHVAPAAPDA G-------AP TAPAASATRA
Gs H.sapiens P63092-1 QMRILHVNGF NGEGGEEDPQ AARSNSDGEK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP DFDFPPEFYE HAKALWEDEG
Gs H.sapiens P63092-2 QMRILHVNGF NGDS------ --------EK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP DFDFPPEFYE HAKALWEDEG
Gs H.sapiens P63092-3 QMRILHVNGF NGD------- --------EK ATKVQDIKNN LKEAIETIVA AMSNLVPPVE LANPENQFRV DYILSVMNVP DFDFPPEFYE HAKALWEDEG
Golf H.sapiens P38405-1 QMRILHVNGF NPE------- --------EK KQKILDIRKN VKDAIVTIVS AMSTIIPPVP LANPENQFRS DYIKSIAPIT DFEYSQEFFD HVKKLWDDEG
Golf H.sapiens P38405-2 QMRILHVNGF NPE------- --------EK KQKILDIRKN VKDAIVTIVS AMSTIIPPVP LANPENQFRS DYIKSIAPIT DFEYSQEFFD HVKKLWDDEG
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Golf M.musculus Q8CGK7 QMRILHVNGF NPE------- --------EK KQKILDIRKN VKDAIVTIVS AMSTIIPPVP LANPENQFRS DYIKSIAPIT DFEYSQEFFD HVKKLWDDEG
910 920 930 940 950 960 970 980 990 1000
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Gs M.musculus P63094-2 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Gs M.musculus P63094-3 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Gs M.musculus Q6R0H7-1 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Gs M.musculus Q6R0H7-2 AAAARAASAA RAVAAGRSAS AAPSRAHLRP PSPEIQVADP PTPRPPPRPT AWPDKYERGR S-CCRYEASS GICEIESSSD ESEEGATGCF QWLLRRNRRP
Gs M.musculus Q6R0H7-3 AAAARAASAA RAVAAGRSAS AAPSRAHLRP PSPEIQVADP PTPRPPPRPT AWPDKYERGR S-CCRYEASS GICEIESSSD ESEEGATGCF QWLLRRNRRP
Gs M.musculus Q6R0H7-4 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Gs H.sapiens Q5JWF2-1 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Gs H.sapiens Q5JWF2-2 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Gs H.sapiens Q5JWF2-3 AQVRRAASAA PASGARR--- ----KIHLRP PSPEIQAADP PTPR-PTRAS AWRGKSESSR GRRVYYDEGV ASSDDDSSGD ESDDGTSGCL RWFQHRRNR-
Gs H.sapiens P63092-1 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Gs H.sapiens P63092-2 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Gs H.sapiens P63092-3 VRACYERSNE --YQLIDCAQ YFLDKIDVIK QADYVPSDQD LLRCRVLTSG IFETKFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIF VVASSSYNMV
Golf H.sapiens P38405-1 VKACFERSNE --YQLIDCAQ YFLERIDSVS LVDYTPTDQD LLRCRVLTSG IFETRFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIY VAACSSYNMV
Golf H.sapiens P38405-2 VKACFERSNE --YQLIDCAQ YFLERIDSVS LVDYTPTDQD LLRCRVLTSG IFETRFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIY VAACSSYNMV
Golf H.sapiens P38405-3 ---------- ---------- ---------- ---------- ---------- ---------- ----MFDVGG QRDERRKWIQ CFNDVTAIIY VAACSSYNMV
Golf M.musculus Q8CGK7 VKACFERSNE --YQLIDCAQ YFLERIDSVS LVDYTPTDQD LLRCRVLTSG IFETRFQVDK VNFHMFDVGG QRDERRKWIQ CFNDVTAIIY VAACSSYNMV
1010 1020 1030 1040 1050 1060 1070 1080 1090 1100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gs M.musculus P63094-1 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Gs M.musculus P63094-2 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Gs M.musculus P63094-3 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Gs M.musculus Q6R0H7-1 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Gs M.musculus Q6R0H7-2 GLPRSHTVGS NPVRNFFTRA FGSCFGLSEC TRS-RSLSPG KAKDPMEERR KQMRKEAIEM REQKRADKKR SKLIDKQLEE EKMDYMCTHR LLLLGRKVVP
Gs M.musculus Q6R0H7-3 GLPRSHTVGS NPVRNFFTRA FGSCFGLSEC TRS-RSLSPG KAKDPMEERR KQMRKEAIEM REQKRADKKR SKLIDKQLEE EKMDYMCTHR LLLLGRKVVP
Gs M.musculus Q6R0H7-4 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Gs H.sapiens Q5JWF2-1 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Gs H.sapiens Q5JWF2-2 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Gs H.sapiens Q5JWF2-3 ---RRRKPQR NLLRNFLVQA FGGCFGRSES PQPKASRSLK VKKVPLAEKR RQMRKEALEK RAQKRAEKKR SKLIDKQLQD EKMGYMCTHR LLLLGRKVVP
Gs H.sapiens P63092-1 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Gs H.sapiens P63092-2 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Gs H.sapiens P63092-3 IREDNQTNRL QEALNLFKSI WNNRWLRTIS VILFLNKQDL LAEKVLAGKS K--IEDYFPE FARYTTPEDA TPEPGEDPRV TRAKYFIRDE FLRIS--TAS
Golf H.sapiens P38405-1 IREDNNTNRL RESLDLFESI WNNRWLRTIS IILFLNKQDM LAEKVLAGKS K--IEDYFPE YANYTVPEDA TPDAGEDPKV TRAKFFIRDL FLRIS--TAT
Golf H.sapiens P38405-2 IREDNNTNRL RESLDLFESI WNNRWLRTIS IILFLNKQDM LAEKVLAGKS K--IEDYFPE YANYTVPEDA TPDAGEDPKV TRAKFFIRDL FLRIS--TAT
Golf H.sapiens P38405-3 IREDNNTNRL RESLDLFESI WNNRWLRTIS IILFLNKQDM LAEKVLAGKS K--IEDYFPE YANYTVPEDA TPDAGEDPKV TRAKFFIRDL FLRIS--TAT
Golf M.musculus Q8CGK7 IREDNNTNRL RESLDLFESI WNNRWLRTIS IILFLNKQDM LAEKVLAGKS K--IEDYFPE YANYTVPEDA TPDAGEDPKV TRAKFFIRDL FLRIS--TAT
1110 1120 1130 1140 1150 1160 1170 1180
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|
Gs M.musculus P63094-1 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Gs M.musculus P63094-2 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Gs M.musculus P63094-3 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Gs M.musculus Q6R0H7-1 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Gs M.musculus Q6R0H7-2 SDTEGRYRPE ASASASDRRL DRRGREVSPE LLGWALRGSP GSIVRDRGGL GPSGCAPPPR LARLLRLRQL VVGVCWCPFS VFACA
Gs M.musculus Q6R0H7-3 SDTEGRYRPE ASASASDRRL DRRGREVLES LAKAPL---- ---------- ---------- ---------- ---------- -----
Gs M.musculus Q6R0H7-4 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Gs H.sapiens Q5JWF2-1 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Gs H.sapiens Q5JWF2-2 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Gs H.sapiens Q5JWF2-3 SDTEGRFRLD RPAPATVSWT G-RGFSVSSL LIRSPN---- ---------- -------PPA FTVEKPDTQV LENLVKAPL- -----
Gs H.sapiens P63092-1 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Gs H.sapiens P63092-2 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Gs H.sapiens P63092-3 GDGRHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLRQYE LL-------- ---------- ---------- ---------- -----
Golf H.sapiens P38405-1 GDGKHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLKQYE LL-------- ---------- ---------- ---------- -----
Golf H.sapiens P38405-2 GDGKHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLKQYE LL-------- ---------- ---------- ---------- -----
Golf H.sapiens P38405-3 GDGKHYCYPH FTCAVDTENI RRVFNDCRDI IQRMHLKQYE LL-------- ---------- ---------- ---------- -----




   













Fig A5 The Aligned Complete Amino Acid Sequences of Different G subunits of H. 
sapiens, C. sabaeus, and M. musculus. Differences in amino acid sequence were 
highlighted with an arrow. Each G subtype bears the protein identifier after the name of 
species. The amino acid sequences of G12 of M. musculus obtained from Uniprot is 
designated with an asterisk (*).  
 
10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq H.sapiens NP002063.2 MTLESIMACC LSEEAKEARR INDEIERQLR RDKRDARREL KLLLLGTGES GKSTFIKQMR IIHGSGYSDE DKRGFTKLVY QNIFTAMQAM IRAMDTLKIP
Gq C.sabaeus XP007967740.1 MTLESIMACC LSEEAKEARR INDEIERQLR RDKRDARREL KLLLLGTGES GKSTFIKQMR IIHGSGYSDE DKRGFTKLVY QNIFTAMQAM IRAMDTLKIP
Gq M.musculus NP032165.3 MTLESIMACC LSEEAKEARR INDEIERQLR RDKRDARREL KLLLLGTGES GKSTFIKQMR IIHGSGYSDE DKRGFTKLVY QNIFTAMQAM IRAMDTLKIP
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq H.sapiens NP002063.2 YKYEHNKAHA QLVREVDVEK VSAFENPYVD AIKSLWNDPG IQECYDRRRE YQLSDSTKYY LNDLDRVADP AYLPTQQDVL RVRVPTTGII EYPFDLQSVI
Gq C.sabaeus XP007967740.1 YKYEHNKAHA QLVREVDVEK VSAFENPYVD AIKSLWNDPG IQECYDRRRE YQLSDSTKYY LNDLDRVADP AYLPTQQDVL RVRVPTTGII EYPFDLQSVI
Gq M.musculus NP032165.3 YKYEHNKAHA QLVREVDVEK VSAFENPYVD AIKSLWNDPG IQECYDRRRE YQLSDSTKYY LNDLDRVADP SYLPTQQDVL RVRVPTTGII EYPFDLQSVI
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq H.sapiens NP002063.2 FRMVDVGGQR SERRKWIHCF ENVTSIMFLV ALSEYDQVLV ESDNENRMEE SKALFRTIIT YPWFQNSSVI LFLNKKDLLE EKIMYSHLVD YFPEYDGPQR
Gq C.sabaeus XP007967740.1 FRMVDVGGQR SERRKWIHCF ENVTSIMFLV ALSEYDQVLV ESDNENRMEE SKALFRTIIT YPWFQNSSVI LFLNKKDLLE EKIMYSHLVD YFPEYDGPQR
Gq M.musculus NP032165.3 FRMVDVGGQR SERRKWIHCF ENVTSIMFLV ALSEYDQVLV ESDNENRMEE SKALFRTIIT YPWFQNSSVI LFLNKKDLLE EKIMYSHLVD YFPEYDGPQR
310 320 330 340 350
....|....| ....|....| ....|....| ....|....| ....|....| ....|....
Gq H.sapiens NP002063.2 DAQAAREFIL KMFVDLNPDS DKIIYSHFTC ATDTENIRFV FAAVKDTILQ LNLKEYNLV
Gq C.sabaeus XP007967740.1 DAQAAREFIL KMFVDLNPDS DKIIYSHFTC ATDTENIRFV FAAVKDTILQ LNLKEYNLV
Gq M.musculus NP032165.3 DAQAAREFIL KMFVDLNPDS DKIIYSHFTC ATDTENIRFV FAAVKDTILQ LNLKEYNLV
10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G11 H.sapiens NP002058.2 MTLESMMACC LSDEVKESKR INAEIEKQLR RDKRDARREL KLLLLGTGES GKSTFIKQMR IIHGAGYSEE DKRGFTKLVY QNIFTAMQAM IRAMETLKIL
G11 C.sabaeus XP007992944.1 MTLESMMACC LSDEVKESKR INAEIEKQLR RDKRDARREL KLLLLGTGES GKSTFIKQMR IIHGAGYSEE DKRSFTKLVY HNICTAIQAT IRAMETLKIL
G11 M.musculus NP034431.1 MTLESMMACC LSDEVKESKR INAEIEKQLR RDKRDARREL KLLLLGTGES GKSTFIKQMR IIHGAGYSEE DKRGFTKLVY QNIFTAMQAM VRAMETLKIL
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G11 H.sapiens NP002058.2 YKYEQNKANA LLIREVDVEK VTTFEHQYVS AIKTLWEDPG IQECYDRRRE YQLSDSAKYY LTDVDRIATL GYLPTQQDVL RVRVPTTGII EYPFDLENII
G11 C.sabaeus XP007992944.1 YKYEQNKANA LLIREVDVEK VTTFEHQYVS AIKTLWDDPG IQECYDRRRE YQLSDSAKYY LTDVDRIATS GYLPTQQDVL RVRVPTTGII EYPFDLENII
G11 M.musculus NP034431.1 YKYEQNKANA LLIREVDVEK VTTFEHQYVN AIKTLWSDPG VQECYDRRRE FQLSDSAKYY LTDVDRIATV GYLPTQQDVL RVRVPTTGII EYPFDLENII
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G11 H.sapiens NP002058.2 FRMVDVGGQR SERRKWIHCF ENVTSIMFLV ALSEYDQVLV ESDNENRMEE SKALFRTIIT YPWFQNSSVI LFLNKKDLLE DKILYSHLVD YFPEFDGPQR
G11 C.sabaeus XP007992944.1 FRMVDVGGQR SERRKWIHCF ENVTSIMFLV ALSEYDQVLV ESDNENRMEE SKALFRTIIT YPWFQNSSVI LFLNKKDLLE DKILYSHLVD YFPEFDGPQR
G11 M.musculus NP034431.1 FRMVDVGGQR SERRKWIHCF ENVTSIMFLV ALSEYDQVLV ESDNENRMEE SKALFRTIIT YPWFQNSSVI LFLNKKDLLE DKILHSHLVD YFPEFDGPQR
310 320 330 340 350
....|....| ....|....| ....|....| ....|....| ....|....| ....|....
G11 H.sapiens NP002058.2 DAQAAREFIL KMFVDLNPDS DKIIYSHFTC ATDTENIRFV FAAVKDTILQ LNLKEYNLV
G11 C.sabaeus XP007992944.1 DAQAAREFIL KMFVDLNPDS DKIIYSHFTC ATDTENIRFV FAAVKDTILQ LNLKEYNLV
G11 M.musculus NP034431.1 DAQAAREFIL KMFVDLNPDS DKIIYSHFTC ATDTENIRFV FAAVKDTILQ LNLKEYNLV
10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G12 H.sapiens NP031379.2 MSGVVRTLSR CLLPAEAGGA RERRAGSGAR DAEREARRRS RDIDALLARE RRAVRRLVKI LLLGAGESGK STFLKQMRII HGREFDQKAL LEFRDTIFDN
G12 C.sabaeus XP008017022.1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------MRII HGREFDQKAL LEFRDTIFDN
G12 M.musculus NP034432.1 MSGVVRTLSR CLLPAEAG-A RERRAG-AAR DAEREARRRS RDIDALLARE RRAVRRLVKI LLLGAGESGK STFLKQMRII HGREFDQKAL LEFRDTIFDN
G12 M. musculus* Q2NKI3-1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------MRII HGREFDQKAL LEFRDTIFDN
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G12 H.sapiens NP031379.2 ILKGSRVLVD ARDKLGIPWQ YSENEKHGMF LMAFENKAGL PVEPATFQLY VPALSALWRD SGIREAFSRR SEFQLGESVK YFLDNLDRIG QLNYFPSKQD
G12 C.sabaeus XP008017022.1 ILKGSRVLVD ARDKLGIPWQ YSENEKHGMF LMAFENKAGL PVEPATFQLY VPALSALWRD SGIREAFSRR SEFQLGESVK YFLDNLDRIG QLNYFPSKQD
G12 M.musculus NP034432.1 ILKGSRVLVD ARDKLGIPWQ HSENEKHGMF LMAFENKAGL PVEPATFQLY VPALSALWRD SGIREAFSRR SEFQLGESVK YFLDNLDRIG QLNYFPSKQD
G12 M. musculus* Q2NKI3-1 ILKGSRVLVD ARDKLGIPWQ HSENEKHGMF LMAFENKAGL PVEPATFQLY VPALSALWRD SGIREAFSRR SEFQLGESVK YFLDNLDRIG QLNYFPSKQD
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G12 H.sapiens NP031379.2 ILLARKATKG IVEHDFVIKK IPFKMVDVGG QRSQRQKWFQ CFDGITSILF MVSSSEYDQV LMEDRRTNRL VESMNIFETI VNNKLFFNVS IILFLNKMDL
G12 C.sabaeus XP008017022.1 ILLARKATKG IVEHDFVIKK IPFKMVDVGG QRSQRQKWFQ CFDGITSILF MVSSSEYDQV LMEDRRTNRL VESMNIFETI VNNKLFFNVS IILFLNKMDL
G12 M.musculus NP034432.1 ILLARKATKG IVEHDFVIKK IPFKMVDVGG QRSQRQKWFQ CFDGITSILF MVSSSEYDQV LMEDRRTNRL VESMNIFETI VNNKLFFNVS IILFLNKMDL
G12 M. musculus* Q2NKI3-1 ILLARKATKG IVEHDFVIKK IPFKMVDVGG QRSQRQKWFQ CFDGITSILF MVSSSEYDQV LMEDRRTNRL VESMNIFETI VNNKLFFNVS IILFLNKMDL
310 320 330 340 350 360 370 380
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| .
G12 H.sapiens NP031379.2 LVEKVKTVSI KKHFPDFRGD PHRLEDVQRY LVQCFDRKRR NRSKPLFHHF TTAIDTENVR FVFHAVKDTI LQENLKDIML Q
G12 C.sabaeus XP008017022.1 LVEKVKTVSI KKHFPDFRGD PHRLEDVQRY LVQCFDRKRR NRSKPLFHHF TTAIDTENVR FVFHAVKDTI LQENLKDIML Q
G12 M.musculus NP034432.1 LVEKVKSVSI KKHFPDFKGD PHRLEDVQRY LVQCFDRKRR NRSKPLFHHF TTAIDTENIR FVFHAVKDTI LQENLKDIML Q




   















10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G13 H.sapiens NP006563.2 MADFLPSRSV LSVCFPGCLL TSGEAEQQRK SKEIDKCLSR EKTYVKRLVK ILLLGAGESG KSTFLKQMRI IHGQDFDQRA REEFRPTIYS NVIKGMRVLV
G13 C.sabaeus XP008010259.1 MADFLPSRSV LSVCFPGCLL TSGEAEQQRK SKEIDKCLSR EKTYVKRLVK ILLLGAGESG KSTFLKQMRI IHGQDFDQRA REEFRPTIYS NVIKGMRVLV
G13 M.musculus NP034433.3 MADFLPSRSV LSVCFPGCVL TNGEAEQQRK SKEIDKCLSR EKTYVKRLVK ILLLGAGESG KSTFLKQMRI IHGQDFDQRA REEFRPTIYS NVIKGMRVLV
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G13 H.sapiens NP006563.2 DAREKLHIPW GDNSNQQHGD KMMSFDTRAP MAAQGMVETR VFLQYLPAIR ALWADSGIQN AYDRRREFQL GESVKYFLDN LDKLGEPDYI PSQQDILLAR
G13 C.sabaeus XP008010259.1 DAREKLHIPW GDNSNQQHGD KMMSFDTRAP MAAQGMVETR VFLQYLPAIR ALWADSGIQN AYDRRREFQL GESVKYFLDN LDKLGEPDYI PSQQDILLAR
G13 M.musculus NP034433.3 DAREKLHIPW GDNKNQLHGD KLMAFDTRAP MAAQGMVETR VFLQYLPAIR ALWEDSGIQN AYDRRREFQL GESVKYFLDN LDKLGVPDYI PSQQDILLAR
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G13 H.sapiens NP006563.2 RPTKGIHEYD FEIKNVPFKM VDVGGQRSER KRWFECFDSV TSILFLVSSS EFDQVLMEDR LTNRLTESLN IFETIVNNRV FSNVSIILFL NKTDLLEEKV
G13 C.sabaeus XP008010259.1 RPTKGIHEYD FEIKNVPFKM VDVGGQRSER KRWFECFDSV TSILFLVSSS EFDQVLMEDR LTNRLTESLN IFETIVNNRV FSNVSIILFL NKTDLLEEKV
G13 M.musculus NP034433.3 RPTKGIHEYD FEIKNVPFKM VDVGGQRSER KRWFECFDSV TSILFLVSSS EFDQVLMEDR QTNRLTESLN IFETIVNNRV FSNVSIILFL NKTDLLEEKV
310 320 330 340 350 360 370
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|..
G13 H.sapiens NP006563.2 QIVSIKDYFL EFEGDPHCLR DVQKFLVECF RNKRRDQQQK PLYHHFTTAI NTENIRLVFR DVKDTILHDN LKQLMLQ
G13 C.sabaeus XP008010259.1 QIVSIKDYFL EFEGDPHCLR DVQKFLVECF RNKRRDQQQK PLYHHFTTAI NTENIRLVFR DVKDTILHDN LKQLMLQ
G13 M.musculus NP034433.3 QVVSIKDYFL EFEGDPHCLR DVQKFLVECF RGKRRDQQQR PLYHHFTTAI NTENIRLVFR DVKDTILHDN LKQLMLQ
10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 H.sapiens NP002060.4 MGCTLSAEDK AAVERSKMID RNLREDGEKA AREVKLLLLG AGESGKSTIV KQMKIIHEAG YSEEECKQYK AVVYSNTIQS IIAIIRAMGR LKIDFGDSAR
Gi-1 C.sabaeus XP007980565.1 MGCTLSAEDK AAVERSKMID RNLREDGEKA AREVKLLLLG AGESGKSTIV KQMKIIHEAG YSEEECKQYK AVVYSNTIQS IIAIIRAMGR LKIDFGDSAR
Gi-1 M.musculus NP034435.1 MGCTLSAEDK AAVERSKMID RNLREDGEKA AREVKLLLLG AGESGKSTIV KQMKIIHEAG YSEEECKQYK AVVYSNTIQS IIAIIRAMGR LKIDFGDSAR
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 H.sapiens NP002060.4 ADDARQLFVL AGAAEEGFMT AELAGVIKRL WKDSGVQACF NRSREYQLND SAAYYLNDLD RIAQPNYIPT QQDVLRTRVK TTGIVETHFT FKDLHFKMFD
Gi-1 C.sabaeus XP007980565.1 ADDARQLFVL AGAAEEGFMT AELAGVIKRL WKDSGVQACF NRSREYQLND SAAYYLNDLD RIAQPNYIPT QQDVLRTRVK TTGIVETHFT FKDLHFKMFD
Gi-1 M.musculus NP034435.1 ADDARQLFVL AGAAEEGFMT AELAGVIKRL WKDSGVQACF NRSREYQLND SAAYYLNDLD RIAQPNYIPT QQDVLRTRVK TTGIVETHFT FKDLHFKMFD
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 H.sapiens NP002060.4 VGGQRSERKK WIHCFEGVTA IIFCVALSDY DLVLAEDEEM NRMHESMKLF DSICNNKWFT DTSIILFLNK KDLFEEKIKK SPLTICYPEY AGSNTYEEAA
Gi-1 C.sabaeus XP007980565.1 VGGQRSERKK WIHCFEGVTA IIFCVALSDY DLVLAEDEEM NRMHESMKLF DSICNNKWFT DTSIILFLNK KDLFEEKIKK SPLTICYPEY AGSNTYEEAA
Gi-1 M.musculus NP034435.1 VGGQRSERKK WIHCFEGVTA IIFCVALSDY DLVLAEDEEM NRMHESMKLF DSICNNKWFT DTSIILFLNK KDLFEEKIKK SPLTICYPEY AGSNTYEEAA
310 320 330 340 350
....|....| ....|....| ....|....| ....|....| ....|....| ....
Gi-1 H.sapiens NP002060.4 AYIQCQFEDL NKRKDTKEIY THFTCATDTK NVQFVFDAVT DVIIKNNLKD CGLF
Gi-1 C.sabaeus XP007980565.1 AYIQCQFEDL NKRKDTKEIY THFTCATDTK NVQFVFDAVT DVIIKNNLKD CGLF
Gi-1 M.musculus NP034435.1 AYIQCQFEDL NKRKDTKEIY THFTCATDTK NVQFVFDAVT DVIIKNNLKD CGLF
10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-2 H.sapiens NP002061.1 MGCTVSAEDK AAAERSKMID KNLREDGEKA AREVKLLLLG AGESGKSTIV KQMKIIHEDG YSEEECRQYR AVVYSNTIQS IMAIVKAMGN LQIDFADPSR
Gi-2 C.sabaeus XP007982488.1 MGCTVSAEDK AAAERSKMID KNLREDGEKA AREVKLLLLG AGESGKSTIV KQMKIIHEDG YSEEECRQYR AVVYSNTIQS IMAIVKAMGN LQIDFADPSR
Gi-2 M.musculus NP032164.2 MGCTVSAEDK AAAERSKMID KNLREDGEKA AREVKLLLLG AGESGKSTIV KQMKIIHEDG YSEEECRQYR AVVYSNTIQS IMAIVKAMGN LQIDFADPQR
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-2 H.sapiens NP002061.1 ADDARQLFAL SCTAEEQGVL PDDLSGVIRR LWADHGVQAC FGRSREYQLN DSAAYYLNDL ERIAQSDYIP TQQDVLRTRV KTTGIVETHF TFKDLHFKMF
Gi-2 C.sabaeus XP007982488.1 ADDARQLFAL SCTAEEQGVL PDDLSGVIRR LWADHGVQAC FGRSREYQLN DSAAYYLNDL ERIAQSDYIP TQQDVLRTRV KTTGIVETHF TFKDLHFKMF
Gi-2 M.musculus NP032164.2 ADDARQLFAL SCAAEEQGML PEDLSGVIRR LWADHGVQAC FGRSREYQLN DSAAYYLNDL ERIAQSDYIP TQQDVLRTRV KTTGIVETHF TFKDLHFKMF
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-2 H.sapiens NP002061.1 DVGGQRSERK KWIHCFEGVT AIIFCVALSA YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN KKDLFEEKIT HSPLTICFPE YTGANKYDEA
Gi-2 C.sabaeus XP007982488.1 DVGGQRSERK KWIHCFEGVT AIIFCVALSA YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN KKDLFEEKIT HSPLTICFPE YTGANKYDEA
Gi-2 M.musculus NP032164.2 DVGGQRSERK KWIHCFEGVT AIIFCVALSA YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN KKDLFEEKIT QSSLTICFPE YTGANKYDEA
310 320 330 340 350
....|....| ....|....| ....|....| ....|....| ....|....| ....|
Gi-2 H.sapiens NP002061.1 ASYIQSKFED LNKRKDTKEI YTHFTCATDT KNVQFVFDAV TDVIIKNNLK DCGLF
Gi-2 C.sabaeus XP007982488.1 ASYIQSKFED LNKRKDTKEI YTHFTCATDT KNVQFVFDAV TDVIIKNNLK DCGLF
Gi-2 M.musculus NP032164.2 ASYIQSKFED LNKRKDTKEI YTHFTCATDT KNVQFVFDAV TDVIIKNNLK DCGLF
10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 H.sapiens NP006487.1 MGCTLSAEDK AAVERSKMID RNLREDGEKA AKEVKLLLLG AGESGKSTIV KQMKIIHEDG YSEDECKQYK VVVYSNTIQS IIAIIRAMGR LKIDFGEAAR
Gi-3 C.sabaeus XP007975873.1 MGCTLSAEDK AAVERSKMID RNLREDGEKA AKEVKLLLLG AGESGKSTIV KQMKIIHEDG YSEDECKQYK VVVYSNTIQS IIAIIRAMGR LKIDFGEAAR
Gi-3 M.musculus NP034436.1 MGCTLSAEDK AAVERSKMID RNLREDGEKA AKEVKLLLLG AGESGKSTIV KQMKIIHEDG YSEDECKQYK VVVYSNTIQS IIAIIRAMGR LKIDFGESAR
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 H.sapiens NP006487.1 ADDARQLFVL AGSAEEGVMT PELAGVIKRL WRDGGVQACF SRSREYQLND SASYYLNDLD RISQSNYIPT QQDVLRTRVK TTGIVETHFT FKDLYFKMFD
Gi-3 C.sabaeus XP007975873.1 ADDARQLFVL AGSAEEGVMT TELAGVIKRL WRDGGVQACF SRSREYQLND SASYYLNDLD RISQSNYIPT QQDVLRTRVK TTGIVETHFT FKDLYFKMFD
Gi-3 M.musculus NP034436.1 ADDARQLFVL AGSAEEGVMT SELAGVIKRL WRDGGVQACF SRSREYQLND SASYYLNDLD RISQTNYIPT QQDVLRTRVK TTGIVETHFT FKELYFKMFD
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 H.sapiens NP006487.1 VGGQRSERKK WIHCFEGVTA IIFCVALSDY DLVLAEDEEM NRMHESMKLF DSICNNKWFT ETSIILFLNK KDLFEEKIKR SPLTICYPEY TGSNTYEEAA
Gi-3 C.sabaeus XP007975873.1 VGGQRSERKK WIHCFEGVTA IIFCVALSDY DLVLAEDEEM NRMHESMKLF DSICNNKWFT ETSIILFLNK KDLFEEKIKR SPLTICYPEY TGSNTYEEAA
Gi-3 M.musculus NP034436.1 VGGQRSERKK WIHCFEGVTA IIFCVALSDY DLVLAEDEEM NRMHESMKLF DSICNNKWFT DTSIILFLNK KDLFEEKIKR SPLTICYPEY TGSNTYEEAA
310 320 330 340 350
....|....| ....|....| ....|....| ....|....| ....|....| ....
Gi-3 H.sapiens NP006487.1 AYIQCQFEDL NRRKDTKEIY THFTCATDTK NVQFVFDAVT DVIIKNNLKE CGLY
Gi-3 C.sabaeus XP007975873.1 AYIQCQFEDL NRRKDTKEIY THFTCATDTK NVQFVFDAVT DVIIKNNLKE CGLY




   












Fig A6 The Aligned CCDS of Different G subunits of H. sapiens, C. sabaeus, and M. 
musculus. Each G subtype bears the protein identifier after the name of species. The 








10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq H.sapiens CCDS6658.1 ATGACTCTGG AGTCCATCAT GGCGTGCTGC CTGAGCGAGG AGGCCAAGGA AGCCCGGCGG ATCAACGACG AGATCGAGCG GCAGCTCCGC AGGGACAAGC
Gq C.sabaeus XM007969549.1 ATGACTCTGG AGTCCATCAT GGCGTGCTGC CTGAGCGAGG AGGCCAAGGA AGCCCGGCGG ATCAACGACG AGATCGAGCG GCAGCTCCGC AGGGACAAGC
Gq M.musculus CCDS29684.1 ATGACTCTGG AGTCCATCAT GGCGTGCTGC CTGAGCGAGG AGGCCAAGGA AGCCCGGAGG ATCAACGACG AGATCGAGCG GCAGCTGCGC AGGGACAAGC
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq H.sapiens CCDS6658.1 GGGACGCCCG CCGGGAGCTC AAGCTGCTGC TGCTCGGGAC AGGAGAGAGT GGCAAGAGTA CGTTTATCAA GCAGATGAGA ATCATCCATG GGTCAGGATA
Gq C.sabaeus XM007969549.1 GGGACGCCCG CCGGGAGCTC AAGCTGCTGC TGCTCGGGAC AGGAGAGAGT GGCAAGAGTA CGTTTATCAA GCAGATGAGA ATCATCCATG GGTCAGGATA
Gq M.musculus CCDS29684.1 GCGACGCCCG CCGGGAGCTC AAGCTGCTGC TGCTGGGGAC AGGGGAGAGT GGCAAGAGCA CCTTCATCAA GCAGATGAGG ATCATCCACG GGTCGGGCTA
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq H.sapiens CCDS6658.1 CTCTGATGAA GATAAAAGGG GCTTCACCAA GCTGGTGTAT CAGAACATCT TCACGGCCAT GCAGGCCATG ATCAGAGCCA TGGACACACT CAAGATCCCA
Gq C.sabaeus XM007969549.1 CTCTGATGAA GATAAAAGGG GCTTCACCAA GCTGGTGTAT CAGAACATCT TCACGGCCAT GCAGGCCATG ATCAGAGCCA TGGACACACT CAAGATCCCG
Gq M.musculus CCDS29684.1 CTCTGACGAA GACAAGCGCG GCTTCACCAA GCTGGTGTAT CAGAACATCT TCACGGCCAT GCAGGCCATG ATCAGAGCGA TGGACACGCT CAAGATCCCA
310 320 330 340 350 360 370 380 390 400
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq H.sapiens CCDS6658.1 TACAAGTATG AGCACAATAA GGCTCATGCA CAATTAGTTC GAGAAGTTGA TGTGGAGAAG GTGTCTGCTT TTGAGAATCC ATATGTAGAT GCAATAAAGA
Gq C.sabaeus XM007969549.1 TACAAGTATG AGCACAATAA GGCTCATGCA CAATTAGTTC GAGAAGTTGA TGTGGAGAAG GTGTCTGCTT TTGAGAATCC ATATGTAGAT GCAATAAAGA
Gq M.musculus CCDS29684.1 TACAAGTATG AACACAATAA GGCTCATGCA CAATTGGTTC GAGAGGTTGA TGTGGAGAAG GTGTCTGCTT TTGAGAATCC ATATGTAGAT GCAATAAAGA
410 420 430 440 450 460 470 480 490 500
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq H.sapiens CCDS6658.1 GTTTATGGAA TGATCCTGGA ATCCAGGAAT GCTATGATAG ACGACGAGAA TATCAATTAT CTGACTCTAC CAAATACTAT CTTAATGACT TGGACCGCGT
Gq C.sabaeus XM007969549.1 GTTTATGGAA TGATCCTGGA ATCCAGGAAT GCTATGATAG ACGACGAGAA TACCAATTAT CTGACTCTAC CAAATACTAT CTTAATGACT TGGACCGCGT
Gq M.musculus CCDS29684.1 GCTTGTGGAA TGATCCTGGA ATCCAGGAGT GCTACGACAG ACGACGGGAA TATCAGTTAT CTGACTCTAC CAAATACTAT CTGAATGACT TGGACCGTGT
510 520 530 540 550 560 570 580 590 600
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq H.sapiens CCDS6658.1 AGCTGACCCT GCCTACCTGC CTACGCAACA AGATGTGCTT AGAGTTCGAG TCCCCACCAC AGGGATCATC GAATACCCCT TTGACTTACA AAGTGTCATT
Gq C.sabaeus XM007969549.1 AGCTGACCCT GCCTACCTGC CTACGCAACA AGATGTGCTT AGAGTTCGAG TCCCCACCAC AGGGATCATC GAATACCCCT TTGACTTACA AAGTGTCATT
Gq M.musculus CCDS29684.1 AGCCGACCCT TCCTATCTGC CTACACAACA AGACGTGCTT AGAGTTCGAG TCCCCACTAC AGGGATCATC GAATACCCCT TTGACTTACA AAGTGTCATT
610 620 630 640 650 660 670 680 690 700
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq H.sapiens CCDS6658.1 TTCAGAATGG TCGATGTAGG GGGCCAAAGG TCAGAGAGAA GAAAATGGAT ACACTGCTTT GAAAATGTCA CCTCTATCAT GTTTCTAGTA GCGCTTAGTG
Gq C.sabaeus XM007969549.1 TTCAGAATGG TCGATGTAGG GGGCCAAAGG TCAGAGAGAA GAAAATGGAT ACACTGCTTT GAAAATGTCA CCTCTATCAT GTTTCTAGTA GCGCTTAGTG
Gq M.musculus CCDS29684.1 TTCAGAATGG TCGATGTAGG GGGCCAAAGG TCAGAGAGAA GAAAATGGAT ACACTGCTTT GAAAATGTCA CCTCCATCAT GTTTCTAGTA GCGCTTAGCG
710 720 730 740 750 760 770 780 790 800
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq H.sapiens CCDS6658.1 AATATGATCA AGTTCTCGTG GAGTCAGACA ATGAGAACCG AATGGAGGAA AGCAAGGCTC TCTTTAGAAC AATTATCACA TACCCCTGGT TCCAGAACTC
Gq C.sabaeus XM007969549.1 AATATGATCA AGTTCTCGTG GAGTCAGACA ATGAGAACCG AATGGAGGAA AGCAAGGCTC TCTTTAGAAC AATTATCACA TATCCCTGGT TCCAGAACTC
Gq M.musculus CCDS29684.1 AATATGATCA AGTTCTTGTG GAGTCAGACA ATGAGAACCG CATGGAGGAG AGCAAAGCAC TCTTTAGAAC AATTATCACC TACCCCTGGT TCCAGAACTC
810 820 830 840 850 860 870 880 890 900
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq H.sapiens CCDS6658.1 CTCGGTTATT CTGTTCTTAA ACAAGAAAGA TCTTCTAGAG GAGAAAATCA TGTATTCCCA TCTAGTCGAC TACTTCCCAG AATATGATGG ACCCCAGAGA
Gq C.sabaeus XM007969549.1 CTCGGTTATT CTGTTCTTAA ACAAGAAAGA TCTTCTAGAG GAGAAAATCA TGTATTCCCA TCTAGTTGAC TACTTCCCAG AATATGATGG ACCCCAGAGA
Gq M.musculus CCDS29684.1 CTCTGTGATT CTGTTCTTAA ACAAGAAAGA TCTTCTAGAG GAGAAAATCA TGTATTCCCA CCTAGTCGAC TACTTCCCAG AATATGATGG ACCCCAGAGA
910 920 930 940 950 960 970 980 990 1000
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq H.sapiens CCDS6658.1 GATGCCCAGG CAGCCCGAGA ATTCATTCTG AAGATGTTCG TGGACCTGAA CCCAGACAGT GACAAAATTA TCTACTCCCA CTTCACGTGC GCCACAGACA
Gq C.sabaeus XM007969549.1 GATGCCCAGG CAGCCCGAGA ATTCATTCTG AAGATGTTCG TGGACCTGAA CCCAGACAGT GACAAAATTA TCTACTCCCA CTTCACATGC GCGACAGACA
Gq M.musculus CCDS29684.1 GATGCCCAGG CAGCTCGAGA ATTCATCCTG AAAATGTTCG TGGACCTGAA CCCCGACAGT GACAAAATCA TCTACTCCCA CTTCACGTGC GCCACAGATA
1010 1020 1030 1040 1050 1060 1070 1080
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq H.sapiens CCDS6658.1 CCGAGAATAT CCGCTTTGTC TTTGCTGCCG TCAAGGACAC CATCCTCCAG TTGAACCTGA AGGAGTACAA TCTGGTCTAA
Gq C.sabaeus XM007969549.1 CCGAGAACAT CCGCTTTGTC TTTGCTGCCG TCAAGGACAC CATCCTCCAG TTGAACCTGA AGGAGTACAA TCTGGTCTAA




   


























10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G11 H.sapiens CCDS12103.1 ATGACTCTGG AGTCCATGAT GGCGTGTTGC CTGAGCGATG AGGTGAAGGA GTCCAAGCGG ATCAACGCCG AGATCGAGAA GCAGCTGCGG CGGGACAAGC
G11 C.sabaeus XM007994753.1 ATGACTCTGG AGTCCATGAT GGCGTGTTGC CTGAGCGATG AGGTGAAGGA GTCCAAGCGG ATCAACGCCG AGATCGAGAA GCAGCTGCGG CGGGACAAGC
G11 M.musculus CCDS24061.1 ATGACTCTGG AGTCCATGAT GGCGTGTTGC CTGAGCGACG AGGTGAAGGA GTCGAAGCGC ATCAACGCGG AGATCGAGAA ACAGCTGCGG CGGGACAAGC
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G11 H.sapiens CCDS12103.1 GCGACGCCCG GCGCGAGCTC AAGCTGCTGC TGCTCGGCAC GGGCGAGAGC GGGAAGAGCA CGTTCATCAA GCAGATGCGC ATCATCCACG GCGCCGGCTA
G11 C.sabaeus XM007994753.1 GCGACGCCCG GCGCGAGCTC AAGCTGCTGC TGCTCGGCAC GGGCGAGAGC GGGAAGAGCA CCTTCATCAA GCAGATGCGC ATCATCCATG GCGCTGGCTA
G11 M.musculus CCDS24061.1 GCGACGCCCG GCGCGAGCTC AAGCTGCTGC TACTTGGCAC TGGCGAGAGC GGGAAGAGTA CCTTCATCAA GCAGATGCGC ATCATCCACG GGGCCGGCTA
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G11 H.sapiens CCDS12103.1 CTCGGAGGAG GACAAGCGCG GCTTCACCAA GCTCGTCTAC CAGAACATCT TCACCGCCAT GCAGGCCATG ATCCGGGCCA TGGAGACGCT CAAGATCCTC
G11 C.sabaeus XM007994753.1 CTCGGAGGAG GACAAGCGCA GCTTCACCAA GCTCGTCTAC CACAACATCT GCACCGCCAT CCAGGCCACG ATCCGGGCCA TGGAGACGCT CAAGATCCTC
G11 M.musculus CCDS24061.1 CTCGGAGGAG GACAAGCGCG GCTTCACCAA GTTGGTGTAC CAGAACATCT TTACCGCCAT GCAGGCCATG GTGCGCGCCA TGGAGACGCT CAAGATCCTC
310 320 330 340 350 360 370 380 390 400
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G11 H.sapiens CCDS12103.1 TACAAGTACG AGCAGAACAA GGCCAATGCG CTCCTGATCC GGGAGGTGGA CGTGGAGAAG GTGACCACCT TCGAGCATCA GTACGTCAGT GCCATCAAGA
G11 C.sabaeus XM007994753.1 TACAAGTACG AGCAGAACAA GGCCAATGCG CTCCTGATCC GGGAGGTGGA CGTGGAGAAG GTGACCACCT TCGAGCATCA GTATGTCAGC GCCATCAAGA
G11 M.musculus CCDS24061.1 TACAAGTATG AGCAGAACAA GGCCAATGCA CTCCTGATCC GGGAGGTCGA TGTGGAGAAG GTCACAACTT TTGAGCACCA GTATGTGAAT GCCATCAAGA
410 420 430 440 450 460 470 480 490 500
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G11 H.sapiens CCDS12103.1 CCCTGTGGGA GGACCCGGGC ATCCAGGAAT GCTACGACCG CAGGCGCGAG TACCAGCTCT CCGACTCTGC CAAGTACTAC CTGACCGACG TTGACCGCAT
G11 C.sabaeus XM007994753.1 CCCTGTGGGA CGACCCCGGC ATCCAGGAGT GCTACGACCG CAGGCGCGAG TACCAGCTCT CCGACTCTGC CAAGTACTAC CTGACCGACG TGGACCGCAT
G11 M.musculus CCDS24061.1 CGCTGTGGAG TGACCCTGGT GTCCAGGAGT GTTACGATCG CAGGCGGGAG TTCCAGCTAT CTGACTCGGC TAAGTACTAC TTGACGGACG TGGACCGCAT
510 520 530 540 550 560 570 580 590 600
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G11 H.sapiens CCDS12103.1 CGCCACCTTG GGCTACCTGC CCACCCAGCA GGACGTGCTG CGGGTCCGCG TGCCCACCAC CGGCATCATC GAGTACCCTT TCGACCTGGA GAACATCATC
G11 C.sabaeus XM007994753.1 CGCCACCTCG GGCTACCTGC CCACCCAGCA GGACGTGCTG CGGGTCCGCG TGCCCACCAC CGGCATCATC GAGTACCCTT TCGACCTGGA GAACATCATC
G11 M.musculus CCDS24061.1 CGCCACAGTA GGCTACCTGC CCACCCAGCA GGATGTGCTG CGGGTACGCG TGCCCACCAC TGGCATCATC GAGTACCCGT TTGACCTGGA GAACATCATC
610 620 630 640 650 660 670 680 690 700
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G11 H.sapiens CCDS12103.1 TTCCGGATGG TGGATGTGGG GGGCCAGCGG TCGGAGCGGA GGAAGTGGAT CCACTGCTTT GAGAACGTGA CATCCATCAT GTTTCTCGTC GCCCTCAGCG
G11 C.sabaeus XM007994753.1 TTCAGGATGG TGGACGTGGG CGGCCAGCGG TCGGAGCGGA GGAAGTGGAT CCACTGCTTT GAGAACGTGA CATCCATCAT GTTTCTCGTG GCCCTCAGCG
G11 M.musculus CCDS24061.1 TTCAGGATGG TGGATGTGGG CGGGCAGAGG TCAGAGCGCA GGAAGTGGAT CCATTGCTTT GAGAACGTGA CTTCCATCAT GTTCTTGGTG GCACTAAGCG
710 720 730 740 750 760 770 780 790 800
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G11 H.sapiens CCDS12103.1 AATACGACCA AGTCCTGGTG GAGTCGGACA ACGAGAACCG GATGGAGGAG AGCAAAGCCC TGTTCCGGAC CATCATCACC TACCCCTGGT TCCAGAACTC
G11 C.sabaeus XM007994753.1 AGTACGACCA AGTCCTGGTG GAGTCGGACA ATGAGAACCG GATGGAGGAG AGCAAAGCCC TGTTCCGGAC CATCATCACC TACCCCTGGT TCCAGAACTC
G11 M.musculus CCDS24061.1 AGTATGACCA AGTCCTGGTG GAGTCAGACA ATGAGAACCG CATGGAGGAG AGCAAGGCCC TGTTCCGCAC AATCATCACC TACCCCTGGT TCCAGAACTC
810 820 830 840 850 860 870 880 890 900
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G11 H.sapiens CCDS12103.1 CTCCGTCATC CTCTTCCTCA ACAAGAAGGA CCTGCTGGAG GACAAGATCC TGTACTCGCA CCTGGTGGAC TACTTCCCCG AGTTCGATGG TCCCCAGCGG
G11 C.sabaeus XM007994753.1 CTCCGTCATC CTGTTCCTCA ACAAGAAGGA CCTGCTGGAG GACAAGATCC TGTACTCACA CCTGGTGGAC TACTTCCCCG AGTTCGACGG GCCCCAGCGG
G11 M.musculus CCDS24061.1 GTCTGTCATT CTCTTCCTCA ACAAGAAGGA CCTTCTAGAA GACAAGATCC TGCACTCACA CTTGGTCGAT TACTTCCCTG AGTTTGATGG GCCACAGAGG
910 920 930 940 950 960 970 980 990 1000
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G11 H.sapiens CCDS12103.1 GACGCCCAGG CGGCGCGGGA GTTCATCCTG AAGATGTTCG TGGACCTGAA CCCCGACAGC GACAAGATCA TCTACTCACA CTTCACGTGT GCCACCGACA
G11 C.sabaeus XM007994753.1 GACGCCCAGG CGGCGCGGGA GTTCATCCTG AAGATGTTCG TGGACCTGAA CCCCGACAGC GACAAGATCA TCTACTCACA CTTCACGTGT GCTACCGACA
G11 M.musculus CCDS24061.1 GATGCACAGG CCGCACGCGA GTTCATTCTG AAGATGTTTG TGGACCTGAA CCCTGACAGC GACAAAATCA TCTACTCCCA CTTCACGTGT GCCACCGACA
1010 1020 1030 1040 1050 1060 1070 1080
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G11 H.sapiens CCDS12103.1 CGGAGAACAT CCGCTTCGTG TTCGCGGCCG TGAAGGACAC CATCCTGCAG CTCAACCTCA AGGAGTACAA CCTGGTCTGA
G11 C.sabaeus XM007994753.1 CGGAGAACAT CCGCTTCGTG TTCGCGGCCG TGAAGGACAC CATCCTGCAG CTCAACCTCA AGGAGTACAA CCTGGTCTGA




   
















10 20 30 40 50 60 70 80 90 100
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
G12 H.sapiens CCDS5335.1 ATGTCCGGGGTGGTGCGGACCCTCAGCCGCTGCCTGCTGCCGGCCGAGGCCGGCGGGGCCCGCGAGCGCAGGGCGGGCAGCGGCGCGCGCGACGCGGAGC
G12 C.sabaeus XM008018831.1 ----------------------------------------------------------------------------------------------------
G12 M.musculus CCDS19825.1 ATGTCCGGGGTGGTGCGGACCCTTAGCCGCTGCTTGCTGCCGGCCGAGGCCGG---AGCCCGCGAGCGCAGGGCGGGC---GCGGCGCGCGACGCGGAGC
G12 M.musculus* BC111810.1 ----------------------------------------------------------------------------------------------------
110 120 130 140 150 160 170 180 190 200
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
G12 H.sapiens CCDS5335.1 GCGAGGCCCGGAGGCGTAGCCGCGACATCGACGCGCTGCTGGCCCGCGAGCGGCGCGCGGTCCGGCGCCTGGTGAAGATCCTGCTGCTGGGCGCGGGCGA
G12 C.sabaeus XM008018831.1 ----------------------------------------------------------------------------------------------------
G12 M.musculus CCDS19825.1 GCGAGGCCCGACGGCGCAGCCGCGACATCGACGCGCTGCTGGCCCGCGAGCGGCGCGCGGTGCGGCGGCTGGTCAAGATCCTGCTGCTGGGCGCCGGCGA
G12 M.musculus* BC111810.1 ----------------------------------------------------------------------------------------------------
210 220 230 240 250 260 270 280 290 300
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
G12 H.sapiens CCDS5335.1 GAGCGGCAAGTCCACGTTCCTCAAGCAGATGCGCATCATCCACGGCCGCGAGTTCGACCAGAAGGCGCTGCTGGAGTTCCGCGACACCATCTTCGACAAC
G12 C.sabaeus XM008018831.1 ----------------------------ATGCGCATCATCCACGGCCGCGAGTTTGACCAGAAGGCGCTGCTGGAGTTCCGCGACACCATCTTCGACAAC
G12 M.musculus CCDS19825.1 GAGCGGCAAGTCCACCTTCCTCAAGCAGATGCGCATCATCCACGGCCGGGAGTTCGACCAGAAGGCGCTGCTGGAGTTCCGCGACACCATCTTCGACAAC
G12 M.musculus* BC111810.1 ----------------------------ATGCGCATCATCCACGGCCGGGAGTTCGACCAGAAGGCGCTGCTGGAGTTCCGCGACACCATCTTCGACAAC
310 320 330 340 350 360 370 380 390 400
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
G12 H.sapiens CCDS5335.1 ATCCTCAAGGGCTCAAGGGTTCTTGTTGATGCACGAGATAAGCTTGGCATTCCTTGGCAGTATTCTGAAAATGAGAAGCATGGGATGTTCCTGATGGCCT
G12 C.sabaeus XM008018831.1 ATCCTCAAGGGCTCAAGGGTTCTTGTTGATGCACGAGATAAGCTTGGCATTCCCTGGCAGTATTCTGAAAATGAGAAGCATGGGATGTTCCTGATGGCCT
G12 M.musculus CCDS19825.1 ATCCTTAAGGGTTCGAGGGTTCTTGTGGACGCTCGAGACAAGCTCGGCATTCCCTGGCAGCACTCTGAGAACGAGAAGCACGGGATGTTTCTGATGGCCT
G12 M.musculus* BC111810.1 ATCCTTAAGGGTTCGAGGGTTCTTGTGGACGCTCGAGACAAGCTCGGCATTCCCTGGCAGCACTCTGAGAACGAGAAGCACGGGATGTTTCTGATGGCCT
410 420 430 440 450 460 470 480 490 500
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
G12 H.sapiens CCDS5335.1 TCGAGAACAAGGCGGGGCTGCCTGTGGAGCCGGCCACCTTCCAGCTGTACGTCCCGGCCCTGAGCGCACTCTGGAGGGATTCTGGCATCAGGGAGGCTTT
G12 C.sabaeus XM008018831.1 TCGAGAACAAGGCGGGGCTGCCTGTGGAGCCCGCCACCTTCCAGCTGTACGTCCCGGCCTTGAGCGCACTCTGGAGGGATTCCGGCATCAGGGAGGCTTT
G12 M.musculus CCDS19825.1 TCGAGAACAAGGCAGGGCTGCCTGTGGAGCCTGCCACCTTCCAGCTCTACGTGCCAGCCCTGAGTGCCCTCTGGAGAGACTCGGGGATCAGGGAAGCCTT
G12 M.musculus* BC111810.1 TCGAGAACAAGGCAGGGCTGCCTGTGGAGCCTGCCACCTTCCAGCTCTACGTGCCAGCCCTGAGTGCCCTCTGGAGAGACTCGGGGATCAGGGAAGCCTT
510 520 530 540 550 560 570 580 590 600
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
G12 H.sapiens CCDS5335.1 CAGCCGGAGAAGCGAGTTTCAGCTGGGGGAGTCGGTGAAGTACTTCCTGGACAACTTGGACCGGATCGGCCAGCTGAATTACTTTCCTAGTAAGCAAGAT
G12 C.sabaeus XM008018831.1 CAGCCGGAGGAGCGAGTTCCAGCTGGGGGAATCAGTGAAGTACTTCCTGGACAACTTGGACCGGATCGGCCAGCTGAATTACTTTCCTAGTAAGCAAGAC
G12 M.musculus CCDS19825.1 CAGCCGCAGAAGCGAGTTCCAGCTGGGTGAATCAGTGAAGTACTTCCTGGATAACTTGGACCGGATTGGCCAGCTGAACTACTTCCCCAGTAAGCAAGAC
G12 M.musculus* BC111810.1 CAGCCGCAGAAGCGAGTTCCAGCTGGGTGAATCAGTGAAGTACTTCCTGGATAACTTGGACCGGATTGGCCAGCTGAACTACTTCCCCAGTAAGCAAGAC
610 620 630 640 650 660 670 680 690 700
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
G12 H.sapiens CCDS5335.1 ATCCTGCTGGCTAGGAAAGCCACCAAGGGAATTGTGGAGCATGACTTCGTTATTAAGAAGATCCCCTTTAAGATGGTGGATGTGGGCGGCCAGCGGTCCC
G12 C.sabaeus XM008018831.1 ATTCTGCTGGCGAGGAAGGCCACCAAGGGAATTGTGGAGCATGACTTCGTTATTAAGAAGATCCCATTTAAGATGGTGGATGTGGGCGGCCAGCGGTCCC
G12 M.musculus CCDS19825.1 ATCCTGCTGGCTAGAAAGGCCACCAAGGGAATCGTGGAACATGACTTCGTTATAAAGAAAATCCCATTTAAGATGGTGGATGTGGGCGGCCAGAGGTCAC
G12 M.musculus* BC111810.1 ATCCTGCTGGCTAGAAAGGCCACCAAGGGAATCGTGGAACATGACTTCGTTATAAAGAAAATCCCATTTAAGATGGTGGATGTGGGCGGCCAGAGGTCAC
710 720 730 740 750 760 770 780 790 800
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
G12 H.sapiens CCDS5335.1 AGCGCCAGAAGTGGTTCCAGTGCTTCGACGGGATCACGTCCATCCTGTTCATGGTCTCCTCCAGCGAGTACGACCAGGTCCTCATGGAGGACAGGCGCAC
G12 C.sabaeus XM008018831.1 AGCGCCAGAAGTGGTTCCAGTGCTTCGACGGGATCACGTCCATCCTGTTCATGGTCTCCTCCAGCGAGTACGACCAGGTCCTCATGGAGGACAGGCGCAC
G12 M.musculus CCDS19825.1 AGCGCCAGAAGTGGTTCCAGTGCTTCGACGGCATCACATCTATCCTGTTCATGGTGTCCTCGAGCGAGTATGACCAGGTCCTCATGGAGGACAGGCGCAC
G12 M.musculus* BC111810.1 AGCGCCAGAAGTGGTTCCAGTGCTTCGACGGCATCACATCTATCCTGTTCATGGTGTCCTCGAGCGAGTATGACCAGGTCCTCATGGAGGACAGGCGCAC
810 820 830 840 850 860 870 880 890 900
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
G12 H.sapiens CCDS5335.1 CAACCGGCTGGTGGAGTCCATGAACATCTTCGAGACCATCGTCAACAACAAGCTCTTCTTCAACGTCTCCATCATTCTCTTCCTCAACAAGATGGACCTC
G12 C.sabaeus XM008018831.1 CAACCGGCTGGTGGAGTCCATGAACATCTTCGAGACCATCGTCAACAACAAGCTCTTCTTCAACGTCTCCATCATTCTCTTCCTCAACAAGATGGACCTC
G12 M.musculus CCDS19825.1 CAACCGGCTGGTGGAGTCCATGAACATCTTCGAGACCATCGTCAACAACAAGCTCTTCTTCAACGTCTCCATCATCCTCTTCCTCAACAAGATGGACCTC
G12 M.musculus* BC111810.1 CAACCGGCTGGTGGAGTCCATGAACATCTTCGAGACCATCGTCAACAACAAGCTCTTCTTCAACGTCTCCATCATCCTCTTCCTCAACAAGATGGACCTC
910 920 930 940 950 960 970 980 990 1000
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
G12 H.sapiens CCDS5335.1 CTGGTGGAGAAGGTGAAGACCGTGAGCATCAAGAAGCACTTCCCGGACTTCAGGGGCGACCCGCACAGGCTGGAGGACGTCCAGCGCTACCTGGTCCAGT
G12 C.sabaeus XM008018831.1 CTGGTGGAGAAGGTGAAGACCGTGAGCATCAAGAAGCACTTCCCGGACTTCAGGGGCGACCCGCACAGGCTAGAGGACGTCCAGCGCTACCTGGTCCAGT
G12 M.musculus CCDS19825.1 CTGGTGGAGAAGGTGAAGTCTGTGAGCATTAAGAAGCACTTCCCAGATTTCAAGGGCGACCCGCACCGGCTGGAGGACGTCCAGCGCTACCTGGTGCAGT
G12 M.musculus* BC111810.1 CTGGTGGAGAAGGTGAAGTCTGTGAGCATTAAGAAGCACTTCCCAGATTTCAAGGGCGACCCGCACCGGCTGGAGGACGTCCAGCGCTACCTGGTGCAGT
1010 1020 1030 1040 1050 1060 1070 1080 1090 1100
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
G12 H.sapiens CCDS5335.1 GCTTCGACAGGAAGAGACGGAACCGCAGCAAGCCACTCTTCCACCACTTCACCACCGCCATCGACACCGAGAACGTCCGCTTCGTGTTCCATGCTGTGAA
G12 C.sabaeus XM008018831.1 GCTTCGACCGGAAGAGACGGAACCGCAGCAAGCCGCTGTTCCACCACTTCACCACCGCCATCGACACCGAGAACGTCCGCTTTGTGTTCCACGCGGTGAA
G12 M.musculus CCDS19825.1 GCTTCGACAGGAAGCGCAGGAACCGCAGCAAGCCCCTGTTCCACCACTTCACCACCGCCATAGACACCGAGAACATCCGCTTCGTGTTTCATGCTGTGAA
G12 M.musculus* BC111810.1 GCTTCGACAGGAAGCGCAGGAACCGCAGCAAGCCCCTGTTCCACCACTTCACCACCGCCATAGACACCGAGAACATCCGCTTCGTGTTTCATGCTGTGAA
1110 1120 1130 1140
....|....|....|....|....|....|....|....|....|.
G12 H.sapiens CCDS5335.1 AGACACCATCCTGCAGGAGAACCTGAAGGACATCATGCTGCAGTGA
G12 C.sabaeus XM008018831.1 AGACACCATCCTGCAGGAGAACCTGAAGGACATCATGCTGCAGTGA
G12 M.musculus CCDS19825.1 GGACACGATCCTGCAGGAGAACCTGAAAGACATCATGCTGCAGTGA




   
























10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G13 H.sapiens CCDS11661.1 ATGGCGGACT TCCTGCCGTC GCGGTCCGTG CTGTCCGTGT GCTTCCCCGG CTGCCTGCTG ACGAGTGGCG AGGCCGAGCA GCAACGCAAG TCCAAGGAGA
G13 C.sabaeus XM_008012068.1 ATGGCGGACT TCCTGCCGTC GCGGTCCGTG CTGTCCGTGT GCTTCCCCGG CTGCTTGCTG ACGAGCGGCG AGGCCGAGCA GCAACGCAAG TCCAAGGAGA
G13 M.musculus CCDS25577.1 ATGGCGGACT TCCTGCCGTC GCGCTCCGTG CTGTCCGTGT GCTTCCCGGG CTGCGTGCTG ACGAACGGCG AGGCCGAGCA GCAGCGCAAG TCCAAGGAGA
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G13 H.sapiens CCDS11661.1 TCGACAAATG CCTGTCTCGG GAAAAGACCT ATGTGAAGCG GCTGGTGAAG ATCCTGCTGC TGGGCGCGGG CGAGAGCGGC AAGTCCACCT TCCTGAAGCA
G13 C.sabaeus XM_008012068.1 TCGACAAATG CCTGTCTCGG GAAAAGACTT ACGTGAAGCG GCTGGTGAAG ATCCTGCTGC TGGGCGCAGG CGAGAGCGGC AAGTCCACCT TCCTAAAGCA
G13 M.musculus CCDS25577.1 TCGACAAATG CCTGTCGCGG GAGAAGACCT ACGTGAAGCG GCTGGTGAAG ATCCTGCTGC TGGGCGCGGG CGAGAGCGGC AAGTCCACCT TCCTGAAGCA
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G13 H.sapiens CCDS11661.1 GATGCGGATC ATCCACGGGC AGGACTTCGA CCAGCGCGCG CGCGAGGAGT TCCGCCCCAC CATCTACAGC AACGTGATCA AAGGTATGAG GGTGCTGGTT
G13 C.sabaeus XM_008012068.1 GATGCGGATC ATCCACGGGC AGGATTTCGA CCAGCGCGCG CGCGAGGAGT TCCGCCCCAC CATCTACAGC AACGTGATCA AAGGTATGAG GGTGCTGGTT
G13 M.musculus CCDS25577.1 GATGCGGATC ATCCACGGCC AGGACTTCGA CCAGCGCGCG CGCGAGGAGT TCCGCCCCAC CATCTACAGC AACGTGATCA AAGGTATGAG GGTGCTGGTA
310 320 330 340 350 360 370 380 390 400
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G13 H.sapiens CCDS11661.1 GATGCTCGAG AGAAGCTTCA TATTCCCTGG GGAGACAACT CAAACCAACA ACATGGAGAT AAGATGATGT CGTTTGATAC CCGGGCCCCC ATGGCAGCCC
G13 C.sabaeus XM_008012068.1 GATGCTCGAG AGAAGCTTCA TATTCCCTGG GGAGATAATT CAAACCAACA ACATGGAGAT AAGATGATGT CGTTTGATAC CCGGGCCCCC ATGGCAGCCC
G13 M.musculus CCDS25577.1 GATGCCCGAG AGAAGCTTCA TATTCCCTGG GGAGATAACA AAAACCAGCT CCATGGAGAC AAGTTGATGG CATTTGATAC CCGCGCCCCC ATGGCTGCCC
410 420 430 440 450 460 470 480 490 500
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G13 H.sapiens CCDS11661.1 AAGGAATGGT GGAAACAAGG GTTTTCTTAC AATATCTTCC TGCTATAAGA GCATTATGGG CAGACAGCGG CATACAGAAT GCCTATGACC GGCGTCGAGA
G13 C.sabaeus XM_008012068.1 AAGGAATGGT GGAAACAAGG GTTTTCTTAC AATATCTTCC TGCTATAAGA GCATTATGGG CAGACAGCGG CATACAGAAT GCCTATGACC GGCGTCGAGA
G13 M.musculus CCDS25577.1 AGGGGATGGT GGAGACTCGA GTGTTCCTGC AGTATCTTCC TGCTATCAGA GCCTTATGGG AGGACAGTGG TATACAGAAT GCCTACGATC GGCGCCGGGA
510 520 530 540 550 560 570 580 590 600
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G13 H.sapiens CCDS11661.1 ATTTCAACTG GGTGAATCTG TAAAATATTT CCTGGATAAC TTGGATAAAC TTGGAGAACC AGATTATATT CCATCACAAC AAGATATTCT GCTTGCCAGA
G13 C.sabaeus XM_008012068.1 ATTTCAGCTG GGTGAATCTG TAAAATATTT CCTGGATAAC TTGGATAAAC TTGGAGAACC AGATTATATT CCATCACAAC AAGATATTCT GCTTGCCAGA
G13 M.musculus CCDS25577.1 ATTCCAGCTG GGTGAGTCTG TAAAGTATTT CTTGGATAAC TTGGATAAAC TTGGAGTACC GGATTACATT CCATCACAGC AAGATATCCT GCTTGCCAGA
610 620 630 640 650 660 670 680 690 700
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G13 H.sapiens CCDS11661.1 AGACCCACCA AAGGCATCCA TGAATACGAC TTTGAAATAA AAAATGTTCC TTTCAAAATG GTTGATGTAG GTGGTCAGAG ATCAGAAAGG AAACGTTGGT
G13 C.sabaeus XM_008012068.1 AGACCCACCA AAGGCATTCA TGAATATGAC TTTGAAATTA AAAATGTTCC TTTCAAAATG GTTGATGTAG GTGGTCAGAG ATCAGAAAGG AAACGTTGGT
G13 M.musculus CCDS25577.1 AGGCCCACCA AAGGCATCCA TGAGTACGAC TTTGAAATTA AAAATGTTCC TTTCAAAATG GTTGATGTAG GTGGCCAGAG ATCAGAACGG AAACGCTGGT
710 720 730 740 750 760 770 780 790 800
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G13 H.sapiens CCDS11661.1 TTGAATGTTT CGACAGTGTG ACATCAATAC TTTTCCTTGT TTCCTCAAGT GAATTTGACC AGGTGCTTAT GGAAGATCGA CTGACCAATC GCCTTACAGA
G13 C.sabaeus XM_008012068.1 TTGAGTGTTT CGACAGTGTC ACATCAATAC TTTTCCTTGT TTCCTCAAGT GAATTTGACC AGGTGCTTAT GGAAGATCGA CTGACCAATC GCCTTACAGA
G13 M.musculus CCDS25577.1 TTGAATGCTT TGACAGTGTG ACGTCGATAC TTTTCCTTGT CTCTTCAAGT GAATTTGACC AGGTGCTTAT GGAGGACCGC CAGACCAATC GCCTTACAGA
810 820 830 840 850 860 870 880 890 900
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G13 H.sapiens CCDS11661.1 GTCTCTGAAC ATTTTTGAAA CAATCGTCAA TAACCGGGTT TTCAGCAATG TCTCCATAAT TCTGTTCTTA AACAAGACAG ACTTGCTTGA GGAGAAGGTG
G13 C.sabaeus XM_008012068.1 GTCTCTGAAC ATTTTTGAAA CAATCGTCAA TAACCGGGTT TTCAGCAATG TCTCCATAAT TCTGTTCTTA AACAAAACAG ACTTGCTTGA GGAGAAGGTG
G13 M.musculus CCDS25577.1 ATCTCTGAAC ATTTTTGAAA CAATTGTCAA CAATCGGGTT TTCAGCAACG TCTCCATAAT CCTCTTCTTA AACAAGACAG ACTTGCTCGA GGAGAAAGTG
910 920 930 940 950 960 970 980 990 1000
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G13 H.sapiens CCDS11661.1 CAAATTGTGA GCATCAAAGA CTATTTCCTA GAATTTGAAG GGGATCCCCA CTGCTTAAGA GACGTCCAAA AATTCCTGGT GGAATGTTTC CGGAACAAAC
G13 C.sabaeus XM_008012068.1 CAAATTGTGA GCATCAAAGA CTATTTCCTA GAATTTGAAG GGGATCCCCA CTGCTTAAGA GACGTCCAAA AATTCCTGGT GGAATGTTTC CGGAACAAAC
G13 M.musculus CCDS25577.1 CAAGTTGTTA GCATCAAAGA CTATTTCCTA GAATTTGAAG GGGACCCCCA CTGCTTAAGA GACGTCCAAA AGTTTCTGGT GGAATGCTTC CGGGGGAAAC
1010 1020 1030 1040 1050 1060 1070 1080 1090 1100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G13 H.sapiens CCDS11661.1 GCCGGGACCA GCAACAGAAG CCCTTATACC ACCACTTCAC CACTGCTATC AACACGGAGA ACATCCGCCT TGTTTTCCGT GACGTGAAGG ATACTATTCT
G13 C.sabaeus XM_008012068.1 GCCGGGACCA GCAGCAGAAG CCCTTATACC ACCACTTCAC CACTGCTATC AATACGGAGA ACATCCGCCT TGTTTTCCGT GATGTGAAGG ATACTATTCT
G13 M.musculus CCDS25577.1 GCCGGGACCA GCAGCAGAGG CCGTTGTACC ACCACTTCAC CACCGCGATC AACACAGAGA ACATCCGCCT CGTGTTCCGG GACGTGAAGG ACACGATCCT
1110 1120 1130
....|....| ....|....| ....|....| ....
G13 H.sapiens CCDS11661.1 GCATGACAAC CTCAAGCAGC TTATGCTACA GTGA
G13 C.sabaeus XM_008012068.1 GCATGACAAC CTCAAGCAGC TTATGCTACA GTGA




   


























10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 H.sapiens CCDS5595.1 ATGGGCTGCA CGCTGAGCGC CGAGGACAAG GCGGCGGTGG AGCGGAGTAA GATGATCGAC CGCAACCTCC GTGAGGACGG CGAGAAGGCG GCGCGCGAGG
Gi-1 C.sabaeus XM007982374.1 ATGGGCTGCA CGCTGAGCGC CGAGGACAAG GCGGCGGTGG AGCGGAGTAA GATGATCGAC CGCAACCTCC GCGAGGACGG CGAGAAGGCG GCGCGCGAGG
Gi-1 M.musculus CCDS39018.1 ATGGGCTGCA CATTGAGCGC TGAGGACAAG GCGGCCGTGG AGCGCAGCAA GATGATCGAC CGCAACCTCC GGGAGGACGG CGAGAAGGCG GCGCGGGAGG
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 H.sapiens CCDS5595.1 TCAAGCTGCT GCTGCTCGGT GCTGGTGAAT CTGGTAAAAG TACAATTGTG AAGCAGATGA AAATTATCCA TGAAGCTGGT TATTCAGAAG AGGAGTGTAA
Gi-1 C.sabaeus XM007982374.1 TCAAGCTGCT GCTGCTTGGT GCTGGTGAAT CTGGTAAAAG TACAATTGTG AAGCAGATGA AAATTATCCA TGAAGCTGGT TATTCAGAAG AGGAGTGTAA
Gi-1 M.musculus CCDS39018.1 TCAAGCTGCT GCTGCTGGGT GCTGGGGAAT CTGGAAAGAG TACCATTGTG AAGCAGATGA AGATTATCCA CGAAGCCGGC TACTCGGAAG AGGAGTGTAA
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 H.sapiens CCDS5595.1 ACAATACAAA GCAGTGGTCT ACAGTAACAC CATCCAGTCA ATTATTGCTA TCATTAGGGC TATGGGGAGG TTGAAGATAG ACTTTGGTGA CTCAGCCCGG
Gi-1 C.sabaeus XM007982374.1 ACAGTACAAA GCAGTCGTCT ACAGTAACAC CATCCAGTCG ATTATTGCTA TCATTAGGGC CATGGGGAGG TTGAAGATAG ACTTTGGTGA CTCAGCCCGG
Gi-1 M.musculus CCDS39018.1 GCAGTACAAG GCAGTGGTCT ACAGCAACAC TATCCAGTCC ATCATTGCCA TCATTAGAGC CATGGGGAGG TTGAAAATCG ACTTCGGAGA CTCTGCTCGG
310 320 330 340 350 360 370 380 390 400
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 H.sapiens CCDS5595.1 GCGGATGATG CACGCCAACT CTTTGTGCTA GCTGGAGCTG CTGAAGAAGG CTTTATGACT GCAGAACTTG CTGGAGTTAT AAAGAGATTG TGGAAAGATA
Gi-1 C.sabaeus XM007982374.1 GCGGATGATG CACGCCAACT CTTTGTGCTA GCTGGAGCTG CTGAAGAAGG CTTTATGACT GCAGAACTTG CTGGAGTTAT AAAGAGATTG TGGAAAGATA
Gi-1 M.musculus CCDS39018.1 GCGGATGATG CTCGCCAACT TTTCGTGCTT GCTGGGGCTG CAGAAGAAGG CTTTATGACT GCAGAGCTCG CCGGTGTCAT AAAGAGACTG TGGAAAGACA
410 420 430 440 450 460 470 480 490 500
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 H.sapiens CCDS5595.1 GTGGTGTACA AGCCTGTTTC AACAGATCCC GAGAGTACCA GCTTAATGAT TCTGCAGCAT ACTATTTGAA TGACTTGGAC AGAATAGCTC AACCAAATTA
Gi-1 C.sabaeus XM007982374.1 GTGGTGTACA AGCCTGTTTC AACAGATCCC GAGAGTACCA GCTTAATGAT TCTGCAGCAT ACTATTTGAA TGACTTGGAC AGAATAGCTC AGCCAAATTA
Gi-1 M.musculus CCDS39018.1 GTGGTGTGCA AGCCTGCTTC AACAGATCCC GGGAGTACCA GCTGAACGAT TCGGCAGCGT ACTATCTGAA TGACTTGGAC AGAATAGCAC AGCCAAATTA
510 520 530 540 550 560 570 580 590 600
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 H.sapiens CCDS5595.1 CATCCCGACT CAACAAGATG TTCTCAGAAC TAGAGTGAAA ACTACAGGAA TTGTTGAAAC CCATTTTACT TTCAAAGATC TTCATTTTAA AATGTTTGAT
Gi-1 C.sabaeus XM007982374.1 CATCCCGACT CAACAAGATG TCCTCAGAAC TAGAGTGAAA ACTACAGGAA TTGTTGAAAC CCATTTTACT TTCAAAGATC TTCATTTTAA AATGTTTGAT
Gi-1 M.musculus CCDS39018.1 CATCCCAACT CAGCAGGATG TCCTCAGAAC CAGAGTGAAG ACCACAGGGA TTGTGGAAAC CCACTTTACC TTCAAAGATC TTCATTTTAA AATGTTTGAC
610 620 630 640 650 660 670 680 690 700
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 H.sapiens CCDS5595.1 GTGGGAGGTC AGAGATCTGA GCGGAAGAAG TGGATTCATT GCTTCGAAGG AGTGACGGCG ATCATCTTCT GTGTAGCACT GAGTGACTAC GACCTGGTTC
Gi-1 C.sabaeus XM007982374.1 GTGGGAGGTC AGAGATCTGA GCGGAAGAAG TGGATTCATT GCTTCGAAGG AGTGACGGCA ATCATCTTCT GTGTAGCACT GAGTGACTAC GACCTGGTTC
Gi-1 M.musculus CCDS39018.1 GTGGGAGGTC AGAGGTCAGA GCGGAAGAAG TGGATCCACT GCTTTGAAGG GGTGACCGCC ATCATCTTCT GTGTGGCCCT GAGTGACTAT GACCTGGTTC
710 720 730 740 750 760 770 780 790 800
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 H.sapiens CCDS5595.1 TAGCTGAAGA TGAAGAAATG AACCGAATGC ATGAAAGCAT GAAATTGTTT GACAGCATAT GTAACAACAA GTGGTTTACA GATACATCCA TTATACTTTT
Gi-1 C.sabaeus XM007982374.1 TAGCTGAAGA TGAAGAAATG AATCGAATGC ATGAAAGCAT GAAGTTGTTT GACAGCATAT GTAACAACAA GTGGTTTACA GATACATCCA TTATACTTTT
Gi-1 M.musculus CCDS39018.1 TTGCTGAAGA TGAAGAAATG AACCGTATGC ACGAGAGCAT GAAGCTGTTC GATAGCATCT GTAACAACAA GTGGTTTACA GACACGTCCA TCATCCTTTT
810 820 830 840 850 860 870 880 890 900
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 H.sapiens CCDS5595.1 TCTAAACAAG AAGGATCTCT TTGAAGAAAA AATCAAAAAG AGCCCTCTCA CTATATGCTA TCCAGAATAT GCAGGATCAA ACACATATGA AGAGGCAGCT
Gi-1 C.sabaeus XM007982374.1 TCTAAACAAG AAGGATCTCT TTGAAGAAAA AATCAAGAAG AGCCCTCTCA CTATATGCTA TCCAGAATAT GCAGGATCAA ACACATATGA AGAGGCAGCT
Gi-1 M.musculus CCDS39018.1 CCTCAACAAG AAGGACCTCT TCGAAGAAAA AATAAAAAAG AGCCCCCTCA CGATATGCTA CCCAGAATAT GCAGGCTCAA ACACATATGA AGAAGCGGCC
910 920 930 940 950 960 970 980 990 1000
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 H.sapiens CCDS5595.1 GCATATATTC AATGTCAGTT TGAAGACCTC AATAAAAGAA AGGACACAAA GGAAATATAC ACCCACTTCA CATGTGCCAC AGATACTAAG AATGTGCAGT
Gi-1 C.sabaeus XM007982374.1 GCATATATTC AGTGTCAGTT TGAAGACCTC AATAAAAGAA AGGACACAAA GGAAATATAC ACCCACTTCA CATGTGCCAC AGATACTAAG AATGTGCAGT
Gi-1 M.musculus CCDS39018.1 GCGTATATTC AGTGTCAGTT TGAAGACCTC AATAAAAGGA AGGACACAAA GGAAATTTAC ACCCACTTCA CGTGCGCCAC AGATACGAAG AACGTGCAGT
1010 1020 1030 1040 1050 1060
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|
Gi-1 H.sapiens CCDS5595.1 TTGTTTTTGA TGCTGTAACA GATGTCATCA TAAAAAATAA TCTAAAAGAT TGTGGTCTCT TTTAA
Gi-1 C.sabaeus XM007982374.1 TTGTTTTTGA TGCTGTAACA GATGTCATCA TAAAAAATAA TCTAAAAGAT TGTGGTCTCT TCTAA




   


























10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-2 H.sapiens CCDS2813.1 ATGGGCTGCA CCGTGAGCGC CGAGGACAAG GCGGCGGCCG AGCGCTCTAA GATGATCGAC AAGAACCTGC GGGAGGACGG AGAGAAGGCG GCGCGGGAGG
Gi-2 C.sabaeus XM007984297.1 ATGGGCTGCA CCGTGAGCGC CGAGGACAAG GCGGCGGCCG AGCGCTCTAA GATGATCGAC AAGAACCTGC GGGAGGACGG AGAGAAGGCG GCGCGGGAGG
Gi-2 M.musculus CCDS23502.1 ATGGGCTGCA CCGTGAGCGC CGAGGACAAG GCGGCAGCCG AGCGCTCTAA AATGATCGAC AAGAACCTGC GGGAGGACGG CGAGAAGGCG GCGCGGGAGG
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-2 H.sapiens CCDS2813.1 TGAAGTTGCT GCTGTTGGGT GCTGGGGAGT CAGGGAAGAG CACCATCGTC AAGCAGATGA AGATCATCCA CGAGGATGGC TACTCCGAGG AGGAATGCCG
Gi-2 C.sabaeus XM007984297.1 TGAAGTTGCT GCTGTTGGGT GCTGGGGAGT CAGGGAAGAG CACCATCGTC AAGCAGATGA AGATCATCCA CGAGGATGGC TACTCCGAGG AGGAATGCCG
Gi-2 M.musculus CCDS23502.1 TGAAGTTGCT TCTGTTAGGT GCTGGAGAGT CAGGGAAGAG CACCATCGTC AAGCAGATGA AGATCATCCA TGAAGATGGC TACTCAGAAG AGGAGTGCCG
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-2 H.sapiens CCDS2813.1 GCAGTACCGG GCGGTTGTCT ACAGCAACAC CATCCAGTCC ATCATGGCCA TTGTCAAAGC CATGGGCAAC CTGCAGATCG ACTTTGCCGA CCCCTCCAGA
Gi-2 C.sabaeus XM007984297.1 GCAGTACCGG GCGGTTGTTT ACAGCAACAC CATCCAGTCC ATCATGGCCA TTGTCAAAGC CATGGGCAAC CTGCAGATCG ACTTTGCCGA CCCCTCCAGA
Gi-2 M.musculus CCDS23502.1 GCAGTACCGT GCCGTGGTCT ACAGCAACAC CATCCAGTCT ATCATGGCCA TCGTGAAGGC CATGGGCAAC CTGCAGATCG ACTTTGCTGA TCCCCAGCGT
310 320 330 340 350 360 370 380 390 400
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-2 H.sapiens CCDS2813.1 GCGGACGACG CCAGGCAGCT ATTTGCACTG TCCTGCACCG CCGAGGAGCA AGGCGTGCTC CCTGATGACC TGTCCGGCGT CATCCGGAGG CTCTGGGCTG
Gi-2 C.sabaeus XM007984297.1 GCGGACGACG CCAGGCAGCT ATTTGCACTG TCCTGCACCG CCGAGGAGCA AGGCGTGCTC CCCGATGACC TGTCCGGCGT CATCCGGAGG CTCTGGGCTG
Gi-2 M.musculus CCDS23502.1 GCGGATGATG CCAGGCAGCT GTTCGCCCTG TCCTGTGCTG CAGAGGAACA AGGGATGCTT CCTGAAGACC TGTCCGGTGT CATCCGGAGG CTCTGGGCTG
410 420 430 440 450 460 470 480 490 500
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-2 H.sapiens CCDS2813.1 ACCATGGTGT GCAGGCCTGC TTTGGCCGCT CAAGGGAATA CCAGCTCAAC GACTCAGCTG CCTACTACCT GAACGACCTG GAGCGTATTG CACAGAGTGA
Gi-2 C.sabaeus XM007984297.1 ACCATGGTGT GCAGGCCTGC TTTGGCCGCT CAAGGGAATA CCAGCTCAAC GACTCAGCCG CCTACTACCT GAACGACCTG GAGCGCATTG CACAGAGTGA
Gi-2 M.musculus CCDS23502.1 ACCACGGTGT GCAAGCCTGC TTTGGCCGCT CACGAGAATA CCAGCTCAAT GACTCAGCCG CTTACTACCT GAATGATCTG GAGCGCATTG CACAGAGTGA
510 520 530 540 550 560 570 580 590 600
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-2 H.sapiens CCDS2813.1 CTACATCCCC ACACAGCAAG ATGTGCTACG GACCCGCGTA AAGACCACGG GGATCGTGGA GACACACTTC ACCTTCAAGG ACCTACACTT CAAGATGTTT
Gi-2 C.sabaeus XM007984297.1 CTACATCCCC ACGCAGCAAG ATGTGTTACG GACCCGCGTA AAGACCACGG GGATCGTGGA GACACACTTC ACCTTCAAGG ACCTACACTT CAAGATGTTT
Gi-2 M.musculus CCDS23502.1 CTACATCCCT ACACAGCAGG ATGTGCTGCG GACCCGTGTG AAGACCACGG GCATCGTGGA AACACACTTC ACCTTCAAGG ACTTACACTT CAAGATGTTT
610 620 630 640 650 660 670 680 690 700
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-2 H.sapiens CCDS2813.1 GATGTGGGTG GTCAGCGGTC TGAGCGGAAG AAGTGGATCC ACTGCTTTGA GGGCGTCACA GCCATCATCT TCTGCGTAGC CTTGAGCGCC TATGACTTGG
Gi-2 C.sabaeus XM007984297.1 GATGTGGGTG GTCAGCGGTC TGAGCGAAAG AAGTGGATCC ACTGCTTTGA GGGCGTCACA GCCATCATCT TCTGCGTAGC CTTGAGCGCC TACGACTTGG
Gi-2 M.musculus CCDS23502.1 GATGTGGGTG GTCAGCGGTC TGAGCGCAAG AAGTGGATCC ACTGCTTTGA GGGCGTCACG GCCATCATCT TCTGTGTCGC CTTGAGCGCT TATGACTTGG
710 720 730 740 750 760 770 780 790 800
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-2 H.sapiens CCDS2813.1 TGCTAGCTGA GGACGAGGAG ATGAACCGCA TGCATGAGAG CATGAAGCTA TTCGATAGCA TCTGCAACAA CAAGTGGTTC ACAGACACGT CCATCATCCT
Gi-2 C.sabaeus XM007984297.1 TGCTAGCTGA GGACGAGGAG ATGAACCGCA TGCATGAGAG CATGAAGCTA TTCGACAGCA TCTGCAACAA CAAGTGGTTC ACAGACACGT CCATCATCCT
Gi-2 M.musculus CCDS23502.1 TGCTGGCTGA GGATGAGGAG ATGAACCGCA TGCATGAGAG CATGAAGCTG TTTGACAGCA TCTGCAACAA CAAGTGGTTC ACAGACACCT CCATCATCCT
810 820 830 840 850 860 870 880 890 900
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-2 H.sapiens CCDS2813.1 CTTCCTCAAC AAGAAGGACC TGTTTGAGGA GAAGATCACA CACAGTCCCC TGACCATCTG CTTCCCTGAG TACACAGGGG CCAACAAATA TGATGAGGCA
Gi-2 C.sabaeus XM007984297.1 CTTCCTCAAC AAGAAGGACC TGTTTGAGGA GAAGATCACA CACAGTCCCC TGACCATCTG CTTCCCTGAG TACACAGGGG CCAACAAGTA TGATGAGGCA
Gi-2 M.musculus CCDS23502.1 CTTCCTCAAC AAGAAGGACC TGTTTGAAGA AAAGATCACA CAGAGCTCCC TGACCATCTG TTTCCCTGAG TACACGGGGG CCAACAAGTA CGACGAGGCA
910 920 930 940 950 960 970 980 990 1000
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-2 H.sapiens CCDS2813.1 GCCAGCTACA TCCAGAGTAA GTTTGAGGAC CTGAATAAGC GCAAAGACAC CAAGGAGATC TACACGCACT TCACGTGCGC CACCGACACC AAGAACGTGC
Gi-2 C.sabaeus XM007984297.1 GCCAGCTACA TCCAGAGTAA GTTTGAGGAC CTGAATAAGC GCAAAGACAC CAAGGAGATC TACACGCACT TCACGTGCGC CACCGACACC AAGAACGTGC
Gi-2 M.musculus CCDS23502.1 GCCAGCTACA TCCAGAGCAA GTTTGAGGAT CTAAATAAGC GCAAAGACAC CAAGGAGATC TACACGCACT TCACGTGCGC CACCGACACC AAGAACGTGC
1010 1020 1030 1040 1050 1060
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|...
Gi-2 H.sapiens CCDS2813.1 AGTTCGTGTT TGACGCCGTC ACCGATGTCA TCATCAAGAA CAACCTGAAG GACTGCGGCC TCTTCTGA
Gi-2 C.sabaeus XM007984297.1 AGTTCGTGTT TGACGCCGTC ACCGACGTCA TCATCAAGAA CAACCTGAAG GACTGCGGCC TCTTCTGA




   


























10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 H.sapiens CCDS802.1 ATGGGCTGCA CGTTGAGCGC CGAAGACAAG GCGGCAGTGG AGCGAAGCAA GATGATCGAC CGCAACTTAC GGGAGGACGG GGAAAAAGCG GCCAAAGAAG
Gi-3 C.sabaeus XM007977682.1 ATGGGCTGCA CGTTGAGCGC CGAAGACAAG GCGGCAGTGG AGCGAAGCAA GATGATCGAC CGCAACTTAC GGGAGGACGG GGAAAAAGCG GCCAAAGAAG
Gi-3 M.musculus CCDS17751.1 ATGGGCTGCA CGTTGAGCGC CGAGGACAAG GCGGCGGTGG AGCGGAGCAA GATGATCGAC CGCAACTTGC GGGAGGACGG GGAGAAAGCG GCCAAAGAAG
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 H.sapiens CCDS802.1 TGAAGCTGCT GCTACTCGGT GCTGGAGAAT CTGGTAAAAG CACCATTGTG AAACAGATGA AAATCATTCA TGAGGATGGC TATTCAGAGG ATGAATGTAA
Gi-3 C.sabaeus XM007977682.1 TGAAGCTGCT GCTACTCGGT GCTGGAGAAT CTGGTAAAAG CACCATTGTG AAACAGATGA AAATCATTCA TGAGGATGGC TATTCAGAGG ATGAATGTAA
Gi-3 M.musculus CCDS17751.1 TGAAGCTGCT GCTGCTCGGC GCTGGAGAAT CTGGTAAAAG TACCATCGTG AAACAGATGA AAATCATTCA TGAGGACGGC TATTCAGAGG ACGAATGTAA
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 H.sapiens CCDS802.1 ACAATATAAA GTAGTTGTCT ACAGCAATAC TATACAGTCC ATCATTGCAA TCATAAGAGC CATGGGACGG CTAAAGATTG ACTTTGGGGA AGCTGCCAGG
Gi-3 C.sabaeus XM007977682.1 ACAATATAAA GTAGTTGTCT ACAGCAATAC TATACAGTCC ATCATTGCAA TCATAAGAGC CATGGGACGG CTAAAGATTG ACTTTGGGGA AGCTGCCAGG
Gi-3 M.musculus CCDS17751.1 ACAGTATAAA GTAGTTGTCT ACAGCAATAC TATTCAGTCC ATCATTGCAA TCATACGAGC CATGGGACGG TTGAAGATTG ATTTTGGGGA ATCTGCCAGA
310 320 330 340 350 360 370 380 390 400
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 H.sapiens CCDS802.1 GCAGATGATG CCCGGCAATT ATTTGTTTTA GCTGGCAGTG CTGAAGAAGG AGTCATGACT CCAGAACTAG CAGGAGTGAT TAAACGGTTA TGGCGAGATG
Gi-3 C.sabaeus XM007977682.1 GCAGATGATG CCCGACAATT ATTTGTTTTA GCTGGCAGTG CTGAAGAAGG AGTCATGACT ACAGAACTAG CAGGAGTGAT TAAACGGTTA TGGCGAGATG
Gi-3 M.musculus CCDS17751.1 GCAGATGATG CCCGACAGTT ATTTGTTTTA GCTGGGAGTG CTGAAGAAGG AGTCATGACT TCAGAACTAG CAGGCGTGAT TAAACGTTTA TGGCGAGATG
410 420 430 440 450 460 470 480 490 500
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 H.sapiens CCDS802.1 GTGGGGTACA AGCTTGCTTC AGCAGATCCA GGGAATATCA GCTCAATGAT TCTGCTTCAT ATTATCTAAA TGATCTGGAT AGAATATCCC AGTCTAACTA
Gi-3 C.sabaeus XM007977682.1 GTGGGGTACA AGCTTGCTTC AGCAGATCCA GGGAATATCA GCTCAATGAT TCTGCTTCAT ATTATCTAAA TGATCTGGAT AGAATATCCC AGTCTAACTA
Gi-3 M.musculus CCDS17751.1 GCGGGGTACA GGCATGCTTT AGCAGGTCCA GGGAATATCA GCTCAATGAT TCTGCTTCAT ACTACCTAAA TGATTTGGAT AGAATATCCC AGACCAACTA
510 520 530 540 550 560 570 580 590 600
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 H.sapiens CCDS802.1 CATTCCAACT CAGCAAGATG TTCTTCGGAC GAGAGTGAAG ACCACAGGCA TTGTAGAAAC ACATTTCACC TTCAAAGACC TATACTTCAA GATGTTTGAT
Gi-3 C.sabaeus XM007977682.1 CATTCCAACT CAGCAAGATG TTCTTCGGAC GAGAGTGAAG ACCACAGGCA TTGTAGAAAC GCATTTCACC TTCAAAGACC TATACTTCAA GATGTTTGAT
Gi-3 M.musculus CCDS17751.1 CATTCCAACT CAGCAAGATG TTCTTCGGAC AAGAGTGAAG ACTACAGGCA TTGTGGAGAC CCACTTCACC TTCAAGGAAC TCTACTTCAA AATGTTTGAT
610 620 630 640 650 660 670 680 690 700
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 H.sapiens CCDS802.1 GTAGGTGGCC AAAGATCAGA ACGAAAAAAG TGGATTCACT GTTTTGAGGG AGTGACAGCA ATTATCTTCT GTGTGGCCCT CAGTGATTAT GACCTTGTTC
Gi-3 C.sabaeus XM007977682.1 GTAGGTGGCC AAAGATCAGA ACGAAAAAAG TGGATTCACT GTTTTGAGGG AGTGACAGCA ATTATTTTCT GTGTGGCCCT CAGTGATTAT GACCTTGTTC
Gi-3 M.musculus CCDS17751.1 GTAGGTGGCC AAAGATCCGA ACGAAAAAAG TGGATTCACT GTTTTGAGGG AGTGACAGCA ATTATCTTTT GTGTGGCTCT CAGTGATTAC GACCTTGTTC
710 720 730 740 750 760 770 780 790 800
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 H.sapiens CCDS802.1 TGGCTGAGGA CGAGGAGATG AACCGAATGC ATGAAAGCAT GAAACTGTTT GACAGCATTT GTAATAACAA ATGGTTTACA GAAACTTCAA TCATTCTCTT
Gi-3 C.sabaeus XM007977682.1 TGGCTGAGGA CGAGGAGATG AACCGAATGC ATGAAAGCAT GAAACTGTTT GACAGCATTT GTAATAACAA ATGGTTTACA GAAACTTCAA TCATTCTCTT
Gi-3 M.musculus CCDS17751.1 TGGCTGAGGA TGAGGAAATG AACCGAATGC ATGAAAGCAT GAAATTGTTT GACAGCATTT GTAACAACAA ATGGTTTACA GACACTTCAA TCATTCTCTT
810 820 830 840 850 860 870 880 890 900
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 H.sapiens CCDS802.1 CCTTAACAAG AAAGACCTTT TTGAGGAAAA AATAAAGAGG AGTCCGTTAA CTATCTGTTA TCCAGAATAC ACAGGTTCCA ATACATATGA AGAGGCAGCT
Gi-3 C.sabaeus XM007977682.1 TCTTAACAAG AAAGACCTGT TTGAGGAAAA AATAAAGAGG AGTCCGTTAA CTATCTGTTA TCCAGAATAC ACAGGTTCCA ATACATATGA AGAGGCAGCT
Gi-3 M.musculus CCDS17751.1 TCTTAATAAG AAAGACCTTT TTGAGGAAAA AATAAAGAGG AGTCCATTAA CAATCTGTTA TCCAGAATAC ACAGGTTCCA ATACATACGA AGAGGCAGCT
910 920 930 940 950 960 970 980 990 1000
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 H.sapiens CCDS802.1 GCCTATATTC AATGCCAGTT TGAAGATCTG AACAGAAGAA AAGATACCAA GGAGATCTAT ACTCACTTCA CCTGTGCCAC AGACACGAAG AATGTGCAGT
Gi-3 C.sabaeus XM007977682.1 GCCTATATTC AATGCCAGTT TGAAGATCTG AACAGAAGAA AAGATACCAA GGAGATCTAC ACTCACTTCA CCTGTGCCAC AGACACGAAG AATGTGCAGT
Gi-3 M.musculus CCDS17751.1 GCTTACATTC AGTGCCAGTT TGAAGATCTG AACCGAAGAA AAGATACCAA GGAGGTCTAC ACTCACTTCA CCTGTGCCAC AGACACCAAA AATGTGCAGT
1010 1020 1030 1040 1050 1060
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|
Gi-3 H.sapiens CCDS802.1 TTGTTTTTGA TGCTGTTACA GATGTCATCA TTAAAAACAA CTTAAAGGAA TGTGGACTTT ATTGA
Gi-3 C.sabaeus XM007977682.1 TTGTTTTTGA TGCTGTTACA GATGTCATCA TTAAAAACAA CTTAAAGGAA TGTGGACTTT ATTGA




   











Fig A7  The Aligned Nucleotide Sequences of G subunits of H. sapiens, C. sabaeus, 
M. musculus and the Sample. A long segment of sequences with the fewest ambiguities 







10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq Sample --AGCGGCCG CACTAAGACT GAACAATCCT CTATACAGGT AAATGGGGAC ATTCTTCCAA AGTGCATACA GAGCCTAGGT GGCA--TTCG ACCCCCTGGC
Gq H.sapiens CCDS6658.1 ATGACTCTGG AGTCCATCAT GGCGTGCTGC CTGAGCGAGG AGGCCAAGGA AGCCCGGCGG ATCAACGAC- GAGATCGAGC GGCAGCTCCG CAGGGACAAG
Gq C.sabaeus XM007969549.1 ATGACTCTGG AGTCCATCAT GGCGTGCTGC CTGAGCGAGG AGGCCAAGGA AGCCCGGCGG ATCAACGAC- GAGATCGAGC GGCAGCTCCG CAGGGACAAG
Gq M.musculus CCDS29684.1 ATGACTCTGG AGTCCATCAT GGCGTGCTGC CTGAGCGAGG AGGCCAAGGA AGCCCGGAGG ATCAACGAC- GAGATCGAGC GGCAGCTGCG CAGGGACAAG
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq Sample TTAAGCACCG GCATTGGTCA CATGATACTC CTTCATGCTA AAGGGGT--- --GCCAGAGT -CCTTGAC-- GGCAGCTAAG ACGGTGCGGA TGTTCTCGGT
Gq H.sapiens CCDS6658.1 CGGGACGCCC GCCGGGAGCT CAAGCTGCTG CTGCTCGGGA CAGGAGAGAG TGGCAAGAGT ACGTTTATCA AGCAGATGAG A-ATCATCCA TGGGTCAGGA
Gq C.sabaeus XM007969549.1 CGGGACGCCC GCCGGGAGCT CAAGCTGCTG CTGCTCGGGA CAGGAGAGAG TGGCAAGAGT ACGTTTATCA AGCAGATGAG A-ATCATCCA TGGGTCAGGA
Gq M.musculus CCDS29684.1 CGCGACGCCC GCCGGGAGCT CAAGCTGCTG CTGCTGGGGA CAGGGGAGAG TGGCAAGAGC ACCTTCATCA AGCAGATGAG G-ATCATCCA CGGGTCGGGC
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq Sample GTCTGTCGCG CATGTGAAGT GGGAGTAGAT AATTT--TGT CACTGTCTGG CTTCAGGTCC ACGAACATCT TCAGAATGAA TTCTCGGGCT GCCTGGGCAT
Gq H.sapiens CCDS6658.1 TACTCTGATG AAGATAAAAG GGGCTTCACC AAGCTGGTGT ATCAGAACAT CTTCACGGCC ATGCAGGCCA TGATCA-GAG CCATGGACAC ACTCAAGATC
Gq C.sabaeus XM007969549.1 TACTCTGATG AAGATAAAAG GGGCTTCACC AAGCTGGTGT ATCAGAACAT CTTCACGGCC ATGCAGGCCA TGATCA-GAG CCATGGACAC ACTCAAGATC
Gq M.musculus CCDS29684.1 TACTCTGACG AAGACAAGCG CGGCTTCACC AAGCTGGTGT ATCAGAACAT CTTCACGGCC ATGCAGGCCA TGATCA-GAG CGATGGACAC GCTCAAGATC
310 320 330 340 350 360 370 380 390 400
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq Sample CTCTCTGGGG ACCATCATAA TCTGGGAAGT AGTCAACTAG AT--GGGAAT ACATG----- --ATTTTCTC CTCTAGAAGA TCTTTCTT-- -GTTTAAGAA
Gq H.sapiens CCDS6658.1 CCATACAAGT ATGAGCACAA TAAGGCTCAT GCACAATTAG TTCGAGAAGT TGATGTGGAG AAGGTGTCTG CTTTTGAGAA TCCATATGTA GATGCAATAA
Gq C.sabaeus XM007969549.1 CCGTACAAGT ATGAGCACAA TAAGGCTCAT GCACAATTAG TTCGAGAAGT TGATGTGGAG AAGGTGTCTG CTTTTGAGAA TCCATATGTA GATGCAATAA
Gq M.musculus CCDS29684.1 CCATACAAGT ATGAACACAA TAAGGCTCAT GCACAATTGG TTCGAGAGGT TGATGTGGAG AAGGTGTCTG CTTTTGAGAA TCCATATGTA GATGCAATAA
410 420 430 440 450 460 470 480 490 500
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq Sample CAGAATAACC GAGGAGTTCT GGAACCAGGG ATATGTGATA ATTGTTCTAA AGAGAGCC-- TTGCTTTCCT CCATTCGGTT CTCATTGTCT GACTCCA--C
Gq H.sapiens CCDS6658.1 AGAGTTTATG GAATGATCCT GGAATCCAGG A-ATGCTATG ATAGACGACG AGAATATCAA TTATCTGACT CTACCAAATA CTATCTTAAT GACTTGGACC
Gq C.sabaeus XM007969549.1 AGAGTTTATG GAATGATCCT GGAATCCAGG A-ATGCTATG ATAGACGACG AGAATACCAA TTATCTGACT CTACCAAATA CTATCTTAAT GACTTGGACC
Gq M.musculus CCDS29684.1 AGAGCTTGTG GAATGATCCT GGAATCCAGG A-GTGCTACG ACAGACGACG GGAATATCAG TTATCTGACT CTACCAAATA CTATCTGAAT GACTTGGACC
510 520 530 540 550 560 570 580 590 600
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq Sample GAGAACTTGA TCATATTCAC TAAGCGCTAC TAGAA-ACAT GAT-AGAGGT GACATTTTCA AAGCAGTGTA TCCATTTTCT TCTCTCTGAC CTTTGGCCCC
Gq H.sapiens CCDS6658.1 GCGTAGCTGA CCCTGCCTAC CTGCCTACGC AACAAGATGT GCTTAGAGTT CGAGTCCCCA CCACAGGG-A TCATCGAATA CCCCTTTGAC TTACAAAGTG
Gq C.sabaeus XM007969549.1 GCGTAGCTGA CCCTGCCTAC CTGCCTACGC AACAAGATGT GCTTAGAGTT CGAGTCCCCA CCACAGGG-A TCATCGAATA CCCCTTTGAC TTACAAAGTG
Gq M.musculus CCDS29684.1 GTGTAGCCGA CCCTTCCTAT CTGCCTACAC AACAAGACGT GCTTAGAGTT CGAGTCCCCA CTACAGGG-A TCATCGAATA CCCCTTTGAC TTACAAAGTG
610 620 630 640 650 660 670 680 690 700
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq Sample CTACATCGAC CATTCTGAAA ATGACACTTT GTAAGTCAAA GGGGTATTCG ATGAT-CCCT GTGGTGGGGA CTCGAACTCT AAAGCACATC TTGTTGCGTA
Gq H.sapiens CCDS6658.1 TCATTTTCAG AATGGTCGAT GTAGGGGGCC AAAGGTCAGA GAGAAGAAAA TGGATACACT GCTTTGAAAA TGTCACCTCT ATCATGTTTC TAGTAGCGCT
Gq C.sabaeus XM007969549.1 TCATTTTCAG AATGGTCGAT GTAGGGGGCC AAAGGTCAGA GAGAAGAAAA TGGATACACT GCTTTGAAAA TGTCACCTCT ATCATGTTTC TAGTAGCGCT
Gq M.musculus CCDS29684.1 TCATTTTCAG AATGGTCGAT GTAGGGGGCC AAAGGTCAGA GAGAAGAAAA TGGATACACT GCTTTGAAAA TGTCACCTCC ATCATGTTTC TAGTAGCGCT
710 720 730 740 750 760 770 780 790 800
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq Sample GGCGGTAGGC AGGGTCAGCT ACGCGGTCCA AGTCATTAAG ATAGTATTTG GTAGAGTCAG ATAATTGGTA TTCTCGTCGT CTATCATAGC -TATCCTGGA
Gq H.sapiens CCDS6658.1 --TAGTGAAT ATGATCAAGT TCTCG--TGG AGTCAGACAA TGAGAACCGA ATGGAGGAAA GCAA--GGCT CTCTTTAGAA CAATTATCAC ATACCCCTGG
Gq C.sabaeus XM007969549.1 --TAGTGAAT ATGATCAAGT TCTCG--TGG AGTCAGACAA TGAGAACCGA ATGGAGGAAA GCAA--GGCT CTCTTTAGAA CAATTATCAC ATATCCCTGG
Gq M.musculus CCDS29684.1 --TAGCGAAT ATGATCAAGT TCTTG--TGG AGTCAGACAA TGAGAACCGC ATGGAGGAGA GCAA--AGCA CTCTTTAGAA CAATTATCAC CTACCCCTGG
810 820 830 840 850 860 870 880 890 900
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq Sample TTCCAGGATC ATTCCATTAA TCTCT--TTA TTGCATCTAC ATATGGGATT CTCAGAAAGC AGACACCTTC TCCACATCAA CTTCTCGAAC TAATGTGCAT
Gq H.sapiens CCDS6658.1 TTCCAGAACT CCTCGGTTAT TCTGTTCTTA AACAAGAAAG ATCTTCTAGA GGAGAAAATC ATGTATTCCC ATCTAGTCGA CTACTTCCCA GAATATG-AT
Gq C.sabaeus XM007969549.1 TTCCAGAACT CCTCGGTTAT TCTGTTCTTA AACAAGAAAG ATCTTCTAGA GGAGAAAATC ATGTATTCCC ATCTAGTTGA CTACTTCCCA GAATATG-AT
Gq M.musculus CCDS29684.1 TTCCAGAACT CCTCTGTGAT TCTGTTCTTA AACAAGAAAG ATCTTCTAGA GGAGAAAATC ATGTATTCCC ACCTAGTCGA CTACTTCCCA GAATATG-AT
910 920 930 940 950 960 970 980 990 1000
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq Sample GAGCCTTATT G---TGCTCA TAC---TTGT ACGGGCATCT TGAGTGTGTC CATGGCTCTG ATCATCGGCT GCATGGACGT GAAGATGTTC CTGATACATC
Gq H.sapiens CCDS6658.1 GGACCCCAGA GAGATGCCCA GGCAGCCCGA GAATTCATTC TGAAGATGTT CGTGGACCTG AACCCAGACA GTGACAAAAT TATC-TACTC CCACTTCACG
Gq C.sabaeus XM007969549.1 GGACCCCAGA GAGATGCCCA GGCAGCCCGA GAATTCATTC TGAAGATGTT CGTGGACCTG AACCCAGACA GTGACAAAAT TATC-TACTC CCACTTCACA
Gq M.musculus CCDS29684.1 GGACCCCAGA GAGATGCCCA GGCAGCTCGA GAATTCATCC TGAAAATGTT CGTGGACCTG AACCCCGACA GTGACAAAAT CATC-TACTC CCACTTCACG
1010 1020 1030 1040 1050 1060 1070 1080 1090
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ...
Gq Sample AGCTCGATGA GCCCCGA--- --TTTATCTT TCAATCAGCG AATTCCTGGA TGCAG----- ---------- ---------- ---------- ---
Gq H.sapiens CCDS6658.1 TGCGCCACAG ACACCGAGAA TATCCGCTTT GTCTTTGCTG CCGTCAAGGA CACCATCCTC CAGTTGAACC TGAAGGAGTA CAATCTGGTC TAA
Gq C.sabaeus XM007969549.1 TGCGCGACAG ACACCGAGAA CATCCGCTTT GTCTTTGCTG CCGTCAAGGA CACCATCCTC CAGTTGAACC TGAAGGAGTA CAATCTGGTC TAA




   














10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G12 Sample ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
G12 H.sapiens CCDS5335.1 ATGTCCGGGG TGGTGCGGAC CCTCAGCCGC TGCCTGCTGC CGGCCGAGGC CGGCGGGGCC CGCGAGCGCA GGGCGGGCAG CGGCGCGCGC GACGCGGAGC
G12 M.musculus CCDS19825.1 ATGTCCGGGG TGGTGCGGAC CCTTAGCCGC TGCTTGCTGC CGGCCGAGGC CGG---AGCC CGCGAGCGCA GGGCGGGC-G CGGCGCGCG- -ACGCGGAGC
G12 C.sabaeus XM008018831.1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G12 Sample ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
G12 H.sapiens CCDS5335.1 GCGAGGCCCG GAGGCGTAGC CGCGACATCG ACGCGCTGCT GGCCCGCGAG CGGCGCGCGG TCCGGCGCCT GGTGAAGATC CTGCTGCTGG GCGCGGGCGA
G12 M.musculus CCDS19825.1 GCGAGGCCCG ACGGCGCAGC CGCGACATCG ACGCGCTGCT GGCCCGCGAG CGGCGCGCGG TGCGGCGGCT GGTCAAGATC CTGCTGCTGG GCGCCGGCGA
G12 C.sabaeus XM008018831.1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G12 Sample ---------- ---------- ---------- --------TC TGCGGGGTGG AGCATGGACC GTGTCGGTCT GGTAAACGTT ACAGGACTCA TCCTACTTGT
G12 H.sapiens CCDS5335.1 GAGCGGCAAG TCCACGTTCC TCAAGCAGAT GCGCATCATC CACGGCCGCG AGT-TCGACC AGAAGGCGCT GCTGGA-GTT CCGCGAC--A CCATCTTCGA
G12 M.musculus CCDS19825.1 GAGCGGCAAG TCCACCTTCC TCAAGCAGAT GCGCATCATC CACGGCCGGG AGT-TCGACC AGAAGGCGCT GCTGGA-GTT CCGCGAC--A CCATCTTCGA
G12 C.sabaeus XM008018831.1 ---------- ---------- --------AT GCGCATCATC CACGGCCGCG AGT-TTGACC AGAAGGCGCT GCTGGA-GTT CCGCGAC--A CCATCTTCGA
310 320 330 340 350 360 370 380 390 400
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G12 Sample TAACGAATCC TGGAGTC--- AGGCTTCCGT TCATGAGGCA GTTATGCTTG GCATTCCTCG TCAGATTTCT GAAAATTAGA AGGATGGAAT GTTCCTGATG
G12 H.sapiens CCDS5335.1 CAACATCCTC AAGGGCTCAA GGGTTCTTGT TGATGCACGA GATAAGCTTG GCATTCCTTG GCAGTATTCT GAAAATGAGA AGCATGGGAT GTTCCTGATG
G12 M.musculus CCDS19825.1 CAACATCCTT AAGGGTTCGA GGGTTCTTGT GGACGCTCGA GACAAGCTCG GCATTCCCTG GCAGCACTCT GAGAACGAGA AGCACGGGAT GTTTCTGATG
G12 C.sabaeus XM008018831.1 CAACATCCTC AAGGGCTCAA GGGTTCTTGT TGATGCACGA GATAAGCTTG GCATTCCCTG GCAGTATTCT GAAAATGAGA AGCATGGGAT GTTCCTGATG
410 420 430 440 450 460 470 480 490 500
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G12 Sample GCCTTCGAGA ACAAGGCGGG GCTGCCTGTG GAGCCCGCTA AATTCCAGCT GTACGTCCCG GCCTTGAGCG CACTCTGGAG GGATTCCGAG GTCATGTTGG
G12 H.sapiens CCDS5335.1 GCCTTCGAGA ACAAGGCGGG GCTGCCTGTG GAGCCGGCCA CCTTCCAGCT GTACGTCCCG GCCCTGAGCG CACTCTGGAG GGATTCTGGC ATCAGGGAGG
G12 M.musculus CCDS19825.1 GCCTTCGAGA ACAAGGCAGG GCTGCCTGTG GAGCCTGCCA CCTTCCAGCT CTACGTGCCA GCCCTGAGTG CCCTCTGGAG AGACTCGGGG ATCAGGGAAG
G12 C.sabaeus XM008018831.1 GCCTTCGAGA ACAAGGCGGG GCTGCCTGTG GAGCCCGCCA CCTTCCAGCT GTACGTCCCG GCCTTGAGCG CACTCTGGAG GGATTCCGGC ATCAGGGAGG
510 520 530 540 550 560 570 580 590 600
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G12 Sample CTTTCAGC-G GAGGAGTGAG TTCGAGCTGG GAGAATAAGT TATGGATTTC CTGGACAACT TGGACCGGAT TGGCCTGCTG CATTAGTTTC CTAGTAATCG
G12 H.sapiens CCDS5335.1 CTTTCAGCCG GAGAAGCGAG TTTCAGCTGG GGGAGTCGGT GAAGTACTTC CTGGACAACT TGGACCGGAT CGGCCAGCTG AATTACTTTC CTAGTAAGCA
G12 M.musculus CCDS19825.1 CCTTCAGCCG CAGAAGCGAG TTCCAGCTGG GTGAATCAGT GAAGTACTTC CTGGATAACT TGGACCGGAT TGGCCAGCTG AACTACTTCC CCAGTAAGCA
G12 C.sabaeus XM008018831.1 CTTTCAGCCG GAGGAGCGAG TTCCAGCTGG GGGAATCAGT GAAGTACTTC CTGGACAACT TGGACCGGAT CGGCCAGCTG AATTACTTTC CTAGTAAGCA
610 620 630 640 650 660 670 680 690 700
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G12 Sample AGACATTCTG CTGCCGAGCA AGGTCACCAA GGGAATTGTG GAGCATGACT TCGTTATTAA GAAGATCCCA TTTAAGATGG TTGATGTGGG CGGCCAGGGG
G12 H.sapiens CCDS5335.1 AGATATCCTG CTGGCTAGGA AAGCCACCAA GGGAATTGTG GAGCATGACT TCGTTATTAA GAAGATCCCC TTTAAGATGG TGGATGTGGG CGGCCAGCGG
G12 M.musculus CCDS19825.1 AGACATCCTG CTGGCTAGAA AGGCCACCAA GGGAATCGTG GAACATGACT TCGTTATAAA GAAAATCCCA TTTAAGATGG TGGATGTGGG CGGCCAGAGG
G12 C.sabaeus XM008018831.1 AGACATTCTG CTGGCGAGGA AGGCCACCAA GGGAATTGTG GAGCATGACT TCGTTATTAA GAAGATCCCA TTTAAGATGG TGGATGTGGG CGGCCAGCGG
710 720 730 740 750 760 770 780 790 800
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G12 Sample CCCCAGCGCC AGAAGTGGTT TCCAGTGCTT CTGACTCTTA TCTCGTCCAT CCTGTTCATG GTCTTCCCCC AGCGAGCACG ACCAGGTACC TCATTGGAGT
G12 H.sapiens CCDS5335.1 TCCCAGCGCC AGAAGTGGTT -CCAGTGCTT C-GACGGG-A TCACGTCCAT CCTGTTCATG GTCT-CCTCC AGCGAGTACG ACCAGGT-CC TCAT-GGAGG
G12 M.musculus CCDS19825.1 TCACAGCGCC AGAAGTGGTT -CCAGTGCTT C-GACGGC-A TCACATCTAT CCTGTTCATG GTGT-CCTCG AGCGAGTATG ACCAGGT-CC TCAT-GGAGG
G12 C.sabaeus XM008018831.1 TCCCAGCGCC AGAAGTGGTT -CCAGTGCTT C-GACGGG-A TCACGTCCAT CCTGTTCATG GTCT-CCTCC AGCGAGTACG ACCAGGT-CC TCAT-GGAGG
810 820 830 840 850 860 870 880 890 900
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G12 Sample ATAGTTACAC CAACCGGCTG GCGGAGGCCA TGAACATTCT TCGAGACCAT CGTCAACAAA CTAAGCTCTT CTTCAAAGGT CTCCATCATT CTCTTCGTCA
G12 H.sapiens CCDS5335.1 ACAGGCGCAC CAACCGGCTG GTGGAGTCCA TGAACAT-CT TCGAGACCAT CGTCAACAA- -CAAGCTCTT CTTCAACG-T CTCCATCATT CTCTTCCTCA
G12 M.musculus CCDS19825.1 ACAGGCGCAC CAACCGGCTG GTGGAGTCCA TGAACAT-CT TCGAGACCAT CGTCAACAA- -CAAGCTCTT CTTCAACG-T CTCCATCATC CTCTTCCTCA
G12 C.sabaeus XM008018831.1 ACAGGCGCAC CAACCGGCTG GTGGAGTCCA TGAACAT-CT TCGAGACCAT CGTCAACAA- -CAAGCTCTT CTTCAACG-T CTCCATCATT CTCTTCCTCA
910 920 930 940 950 960 970 980 990 1000
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G12 Sample AAAAAGATGG ACCTCCTGGG GGAGAAGTCG AAAGACCCTC TGCATCAAGA AAGCACTTCC CCGGACTTCA GGGGGCGATC CGCACAGGCT AGAGCACTTG
G12 H.sapiens CCDS5335.1 ACAA-GATGG ACCTCCTGGT GGAGAAGGTG AA-GACCGTG AGCATCAAGA A-GCACTTCC C-GGACTTCA GGGG-CGACC CGCACAGGCT GGAGGACGT-
G12 M.musculus CCDS19825.1 ACAA-GATGG ACCTCCTGGT GGAGAAGGTG AA-GTCTGTG AGCATTAAGA A-GCACTTCC C-AGATTTCA AGGG-CGACC CGCACCGGCT GGAGGACGT-
G12 C.sabaeus XM008018831.1 ACAA-GATGG ACCTCCTGGT GGAGAAGGTG AA-GACCGTG AGCATCAAGA A-GCACTTCC C-GGACTTCA GGGG-CGACC CGCACAGGCT AGAGGACGT-
1010 1020 1030 1040 1050 1060 1070 1080 1090 1100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G12 Sample CCAGCGATAC CTAGTCCAGT TGCTTCGACG GTAAGTAATA TTGCAGCAGC TAGCTAAGAC GGTATATCCA CCCACTTTCA CCACCGGACA TTACGAAGAC
G12 H.sapiens CCDS5335.1 CCAGCGCTAC CTGGTCCAGT -GCTTCGACA GGAAGAGACG GAACCGCAGC AAGCCAC--- ----TCTTCC ACCACTT-CA CCACCG---- CCATCGACAC
G12 M.musculus CCDS19825.1 CCAGCGCTAC CTGGTGCAGT -GCTTCGACA GGAAGCGCAG GAACCGCAGC AAGCCCC--- ----TGTTCC ACCACTT-CA CCACCG---- CCATAGACAC
G12 C.sabaeus XM008018831.1 CCAGCGCTAC CTGGTCCAGT -GCTTCGACC GGAAGAGACG GAACCGCAGC AAGCCGC--- ----TGTTCC ACCACTT-CA CCACCG---- CCATCGACAC
1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
G12 Sample AGACGATCGG ACCGCTTTTG GTGTTTC-TA CTCCGGAGAA AAGTACTACC CATGCATTGC TAGGAGGCAG CTCTTACGTG CATCAATGCC TCTGCAGGTC
G12 H.sapiens CCDS5335.1 CGAGAAC--G TCCGCTTC-- GTGTTCCATG CTGTGAAAGA CACCATCCTG CAGGAGAACC TGAAGGACA- -TCATGC-TG CAGTGA---- ----------
G12 M.musculus CCDS19825.1 CGAGAAC--A TCCGCTTC-- GTGTTTCATG CTGTGAAGGA CACGATCCTG CAGGAGAACC TGAAAGACA- -TCATGC-TG CAGTGA---- ----------
G12 C.sabaeus XM008018831.1 CGAGAAC--G TCCGCTTT-- GTGTTCCACG CGGTGAAAGA CACCATCCTG CAGGAGAACC TGAAGGACA- -TCATGC-TG CAGTGA---- ----------
1210 1220 1230 1240
....|....| ....|....| ....|....| ....|....| ...
G12 Sample GTAGTCAGAG TTAGTGTCCT GCGGCGTCTT TTGTTGACGT TAT
G12 H.sapiens CCDS5335.1 ---------- ---------- ---------- ---------- ---
G12 M.musculus CCDS19825.1 ---------- ---------- ---------- ---------- ---




   
















10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 Sample GCCTCTACAT AATCTCGTGA TAGTGAGGCT GTCAGAGAGG GGCATTCATG CCCAGCGGGT ACGAGGGACC GCA-GCTGAG AG--AGCAAG CAGCCGGAAG
Gi-1 H.sapiens CCDS5595.1 ---------- ---------- ---------- ---------- ---------- ---------- ---ATGGGCT GCACGCTGAG CGCCGAGGAC AAGGCGGCGG
Gi-1 C.sabaeus XM007982374.1 ---------- ---------- ---------- ---------- ---------- ---------- ---ATGGGCT GCACGCTGAG CGCCGAGGAC AAGGCGGCGG
Gi-1 M.musculus CCDS39018.1 ---------- ---------- ---------- ---------- ---------- ---------- ---ATGGGCT GCACATTGAG CGCTGAGGAC AAGGCGGCCG
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 Sample CAGTACCCAG CTGCACCAAC CCACTCAGCG ACTGCAGGTC CTGGAGTCAG AGGGACCCAT AGCATGAACT G-TGGAACTG AGAAGAGACC GCAATCTGTT
Gi-1 H.sapiens CCDS5595.1 TGGAGCGGAG TAAGATGATC GACCGCAACC TCCGTGAGGA CGGCGAGAAG GCGGCGCGCG AGGTCAAGCT GCTGCTGCTC GGTGCTGG-- TGAATCTGGT
Gi-1 C.sabaeus XM007982374.1 TGGAGCGGAG TAAGATGATC GACCGCAACC TCCGCGAGGA CGGCGAGAAG GCGGCGCGCG AGGTCAAGCT GCTGCTGCTT GGTGCTGG-- TGAATCTGGT
Gi-1 M.musculus CCDS39018.1 TGGAGCGCAG CAAGATGATC GACCGCAACC TCCGGGAGGA CGGCGAGAAG GCGGCGCGGG AGGTCAAGCT GCTGCTGCTG GGTGCTGG-- GGAATCTGGA
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 Sample AGATTATTTT TTATGATGGC TGCTGTTACT GCATCAAAAA CAAACTGCAC --ATTCTTAG TATCTGTGGC ACAGGGGAGG CGGGTACA-T ATTTCCTTTG
Gi-1 H.sapiens CCDS5595.1 AAAAGTACAA TTGTGAAGCA GATGAAAATT ATCCATGAAG CTGGTTATTC AGAAGAGGAG TGTAAACAAT ACAAAGCAGT GGTCTACAGT AACACCATCC
Gi-1 C.sabaeus XM007982374.1 AAAAGTACAA TTGTGAAGCA GATGAAAATT ATCCATGAAG CTGGTTATTC AGAAGAGGAG TGTAAACAGT ACAAAGCAGT CGTCTACAGT AACACCATCC
Gi-1 M.musculus CCDS39018.1 AAGAGTACCA TTGTGAAGCA GATGAAGATT ATCCACGAAG CCGGCTACTC GGAAGAGGAG TGTAAGCAGT ACAAGGCAGT GGTCTACAGC AACACTATCC
310 320 330 340 350 360 370 380 390 400
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 Sample AGTCCTTTCT TTTATTGAGG ACTTCCAAGT GGAACTTAAA AAATGCCGCT GCCTCTTCAG ACGGGGTTGA TGCTGCATAT TCTGTCTATG TTATAGTGGG
Gi-1 H.sapiens CCDS5595.1 AGTCAATTAT TGCTATCATT AGGGCTATGG GGAGGTTGAA GATAGACTTT GGTGACTCAG CCCGGGCGGA TGATGCACGC CAACTCTTTG TGCTAGCTGG
Gi-1 C.sabaeus XM007982374.1 AGTCGATTAT TGCTATCATT AGGGCCATGG GGAGGTTGAA GATAGACTTT GGTGACTCAG CCCGGGCGGA TGATGCACGC CAACTCTTTG TGCTAGCTGG
Gi-1 M.musculus CCDS39018.1 AGTCCATCAT TGCCATCATT AGAGCCATGG GGAGGTTGAA AATCGACTTC GGAGACTCTG CTCGGGCGGA TGATGCTCGC CAACTTTTCG TGCTTGCTGG
410 420 430 440 450 460 470 480 490 500
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 Sample AGGT-CTCTT CTTGGTTTTT TCTTCAAAGA GATTCTTCGT GTTTAGAAAA AGTATGAGGG ATGTTTCTGT AAACCAGCTG GTGTTAAATA TGCTGGCAAA
Gi-1 H.sapiens CCDS5595.1 AGCTGCTGAA GAAGGCTTTA TGACTGCAGA ACTTGCTGGA GTTATAAAGA GATTGTGGAA AGATAGTGGT GTACAAGCCT GTTTCAACAG ATCCCGAGAG
Gi-1 C.sabaeus XM007982374.1 AGCTGCTGAA GAAGGCTTTA TGACTGCAGA ACTTGCTGGA GTTATAAAGA GATTGTGGAA AGATAGTGGT GTACAAGCCT GTTTCAACAG ATCCCGAGAG
Gi-1 M.musculus CCDS39018.1 GGCTGCAGAA GAAGGCTTTA TGACTGCAGA GCTCGCCGGT GTCATAAAGA GACTGTGGAA AGACAGTGGT GTGCAAGCCT GCTTCAACAG ATCCCGGGAG
510 520 530 540 550 560 570 580 590 600
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 Sample CACCTTCTTG CTGTCTCTGC AGCATATCAT TTCTATATCT TCGGCTGGAA AGCGGACGCA GATTATCTCC CCTATCAACA AGATGTTTTC CGACCCTCAG
Gi-1 H.sapiens CCDS5595.1 TACCAGCTTA ATGATTCTGC AGCATACTAT TTGAATGACT TGGACAGAAT AGCTCAACCA AATTACATCC CGACTCAACA AGATGTTCTC AGAACTAGAG
Gi-1 C.sabaeus XM007982374.1 TACCAGCTTA ATGATTCTGC AGCATACTAT TTGAATGACT TGGACAGAAT AGCTCAGCCA AATTACATCC CGACTCAACA AGATGTCCTC AGAACTAGAG
Gi-1 M.musculus CCDS39018.1 TACCAGCTGA ACGATTCGGC AGCGTACTAT CTGAATGACT TGGACAGAAT AGCACAGCCA AATTACATCC CAACTCAGCA GGATGTCCTC AGAACCAGAG
610 620 630 640 650 660 670 680 690 700
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 Sample TCGAAGCTAA AGAAATTCTT CATCCCCTCA TTACTTT-GA CCTCCCACAT TTAAATATGA TAAAGGAGAT CTGTCAAAGA ACTATGGGTT TCAAGTGGTC
Gi-1 H.sapiens CCDS5595.1 TGAAAACTAC AGGAATTGTT GAAACCCATT TTACTTTCAA AGATCTTCAT TTTAAAATGT TTGATGTGGG AGGTCAGAGA TCTGAGCGGA AGAAGTGGAT
Gi-1 C.sabaeus XM007982374.1 TGAAAACTAC AGGAATTGTT GAAACCCATT TTACTTTCAA AGATCTTCAT TTTAAAATGT TTGATGTGGG AGGTCAGAGA TCTGAGCGGA AGAAGTGGAT
Gi-1 M.musculus CCDS39018.1 TGAAGACCAC AGGGATTGTG GAAACCCACT TTACCTTCAA AGATCTTCAT TTTAAAATGT TTGACGTGGG AGGTCAGAGG TCAGAGCGGA AGAAGTGGAT
710 720 730 740 750 760 770 780 790 800
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 Sample TCGTTGCTTT CGACGGTGGG TCTGAGAGCA TCTTGTGTAG ACGCACTTGT ATATTGCCAG CGGTATTCTA GCTCAAGTTA GTACAAAATA GAATCGCAGG
Gi-1 H.sapiens CCDS5595.1 TCATTGCTTC -GAAGGAGTG ACGGCGATCA TCTTCTGTGT A-GCACTGAG TGACTACGAC CTG-GTTCTA GCTGAAGATG A---AGAAAT GAACCGAATG
Gi-1 C.sabaeus XM007982374.1 TCATTGCTTC -GAAGGAGTG ACGGCAATCA TCTTCTGTGT A-GCACTGAG TGACTACGAC CTG-GTTCTA GCTGAAGATG A---AGAAAT GAATCGAATG
Gi-1 M.musculus CCDS39018.1 CCACTGCTTT -GAAGGGGTG ACCGCCATCA TCTTCTGTGT G-GCCCTGAG TGACTATGAC CTG-GTTCTT GCTGAAGATG A---AGAAAT GAACCGTATG
810 820 830 840 850 860 870 880 890 900
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 Sample CAAGTCATCA TGCAGGTACT TCTACGAGCA CTATGTGAAA CAAGTTGTTT TACAACTACC TTCTCCTACT ACTTCTTTCT TACTACGAGC AGCTCTGTGG
Gi-1 H.sapiens CCDS5595.1 CATGAAAGCA TGAAATTG-T TTGAC-AGCA -TATGTAACA ACAAGTGGTT TACAGATACA TCCATTA--T ACTTTTTCTA AACAAGAAGG ATCTCT-TTG
Gi-1 C.sabaeus XM007982374.1 CATGAAAGCA TGAAGTTG-T TTGAC-AGCA -TATGTAACA ACAAGTGGTT TACAGATACA TCCATTA--T ACTTTTTCTA AACAAGAAGG ATCTCT-TTG
Gi-1 M.musculus CCDS39018.1 CACGAGAGCA TGAAGCTG-T TCGAT-AGCA -TCTGTAACA ACAAGTGGTT TACAGACACG TCCATCA--T CCTTTTCCTC AACAAGAAGG ACCTCT-TCG
910 920 930 940 950 960 970 980 990 1000
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 Sample AAGATAAAAG TCATGCATGC AGCAGCTTCA CTAGG-ACTA TGCAGGTAGT ATGGCAGTCA TCCAGCCCGG ACGGAGGAGA CGCATGCCTA TCTTCAGCGT
Gi-1 H.sapiens CCDS5595.1 AAGA-AAAAA TCAAAAAG-- AGCCCTCTCA CTATATGCTA TCCAG--AAT ATG-CAGGA- TCAAACACAT ATGAAGAGGC AGC-TGCATA TATTCAATGT
Gi-1 C.sabaeus XM007982374.1 AAGA-AAAAA TCAAGAAG-- AGCCCTCTCA CTATATGCTA TCCAG--AAT ATG-CAGGA- TCAAACACAT ATGAAGAGGC AGC-TGCATA TATTCAGTGT
Gi-1 M.musculus CCDS39018.1 AAGA-AAAAA TAAAAAAG-- AGCCCCCTCA CGATATGCTA CCCAG--AAT ATG-CAGGC- TCAAACACAT ATGAAGAAGC GGC-CGCGTA TATTCAGTGT
1010 1020 1030 1040 1050 1060 1070 1080 1090 1100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 Sample CCGAATGAGC ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gi-1 H.sapiens CCDS5595.1 CAGTTTGAAG ACCTCAATAA AAGAAAGGAC ACAAAGGAAA TATACACCCA CTTCACATGT GCCACAGATA CTAAGAATGT GCAGTTTGTT TTTGATGCTG
Gi-1 C.sabaeus XM007982374.1 CAGTTTGAAG ACCTCAATAA AAGAAAGGAC ACAAAGGAAA TATACACCCA CTTCACATGT GCCACAGATA CTAAGAATGT GCAGTTTGTT TTTGATGCTG
Gi-1 M.musculus CCDS39018.1 CAGTTTGAAG ACCTCAATAA AAGGAAGGAC ACAAAGGAAA TTTACACCCA CTTCACGTGC GCCACAGATA CGAAGAACGT GCAGTTCGTG TTCGATGCTG
1110 1120 1130 1140 1150
....|....| ....|....| ....|....| ....|....| ....|....|
Gi-1 Sample ---------- ---------- ---------- ---------- ----------
Gi-1 H.sapiens CCDS5595.1 TAACAGATGT CATCATAAAA AATAATCTAA AAGATTGTGG TCTCTTTTAA
Gi-1 C.sabaeus XM007982374.1 TAACAGATGT CATCATAAAA AATAATCTAA AAGATTGTGG TCTCTTCTAA




   

















10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 Sample ---------- -----GGCTC CACCACGGGA TTTCTCCTGG AAGCACATGA AGAAGTCGGC AGCCAATGTT GTGAAGAAGC TTGTAATCCT GCTCGTGGAG
Gi-3 H.sapiens CCDS802.1 ATGGGCTGCA CGTTGAGCGC CGAAGACAAG GCGGCAGTGG AGCGAAGCAA GATGATCGAC CGCAACTTAC GGGAGGACGG GGAAAAAGCG GCCAAAGAAG
Gi-3 C.sabaeus XM007977682.1 ATGGGCTGCA CGTTGAGCGC CGAAGACAAG GCGGCAGTGG AGCGAAGCAA GATGATCGAC CGCAACTTAC GGGAGGACGG GGAAAAAGCG GCCAAAGAAG
Gi-3 M.musculus CCDS17751.1 ATGGGCTGCA CGTTGAGCGC CGAGGACAAG GCGGCGGTGG AGCGGAGCAA GATGATCGAC CGCAACTTGC GGGAGGACGG GGAGAAAGCG GCCAAAGAAG
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 Sample AGGAAGT--- -CTACAGGGG GTTGAAGG-- -TGGGTAGAG C-TCGTGCTT GAATAATTGT GTGG-GCGGG CAAGGAGTGA AAATCAGAAA TATGGAATAT
Gi-3 H.sapiens CCDS802.1 TGAAGCTGCT GCTACTCGGT GCTGGAGAAT CTGGTAAAAG CACCATTGTG AAACAGATGA AAATCATTCA TGAGGATGGC TATTCAGAGG -ATGAATGTA
Gi-3 C.sabaeus XM007977682.1 TGAAGCTGCT GCTACTCGGT GCTGGAGAAT CTGGTAAAAG CACCATTGTG AAACAGATGA AAATCATTCA TGAGGATGGC TATTCAGAGG -ATGAATGTA
Gi-3 M.musculus CCDS17751.1 TGAAGCTGCT GCTGCTCGGC GCTGGAGAAT CTGGTAAAAG TACCATCGTG AAACAGATGA AAATCATTCA TGAGGACGGC TATTCAGAGG -ACGAATGTA
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 Sample GGGGGGATTG TCCGGTAGGT GAGGGCTAGT ATATTTAAGA CATTATTGCT ATTGTTTGCA ATCCTGGATG --TTAAGATT GA--TGAGTG GAATGGCTAT
Gi-3 H.sapiens CCDS802.1 AACAATATAA AGTAGTTGTC TACAGCAATA CTATACAGTC CATCATTGCA ATCATAAGAG CCATGGGACG GCTAAAGATT GACTTTGGGG AAGCTGCCAG
Gi-3 C.sabaeus XM007977682.1 AACAATATAA AGTAGTTGTC TACAGCAATA CTATACAGTC CATCATTGCA ATCATAAGAG CCATGGGACG GCTAAAGATT GACTTTGGGG AAGCTGCCAG
Gi-3 M.musculus CCDS17751.1 AACAGTATAA AGTAGTTGTC TACAGCAATA CTATTCAGTC CATCATTGCA ATCATACGAG CCATGGGACG GTTGAAGATT GATTTTGGGG AATCTGCCAG
310 320 330 340 350 360 370 380 390 400
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 Sample AGT-GATGTT TTCTTAC--T TTATTAGTTT GGCTGGCAGT GATTTAGAAC TGGTT-TGAC TTCAGAATTT AAGGGAG-GG TTCAGCGGG- ATAGC-AGAG
Gi-3 H.sapiens CCDS802.1 GGCAGATGAT GCCCGGCAAT TATTTGTTTT AGCTGGCAGT GCTGAAGAAG GAGTCATGAC TCCAGAACTA GCAGGAGTGA TTAAACGGTT ATGGCGAGAT
Gi-3 C.sabaeus XM007977682.1 GGCAGATGAT GCCCGACAAT TATTTGTTTT AGCTGGCAGT GCTGAAGAAG GAGTCATGAC TACAGAACTA GCAGGAGTGA TTAAACGGTT ATGGCGAGAT
Gi-3 M.musculus CCDS17751.1 AGCAGATGAT GCCCGACAGT TATTTGTTTT AGCTGGGAGT GCTGAAGAAG GAGTCATGAC TTCAGAACTA GCAGGCGTGA TTAAACGTTT ATGGCGAGAT
410 420 430 440 450 460 470 480 490 500
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 Sample GTTGGGGTTC AAGCTTGCTT CTGCAGATCC CGGGAATATC AGCTCAGTGA TTCTGCTTCC TATTATCTAA ATGATCTGGG TAGAATATGC TAGTCTAGCT
Gi-3 H.sapiens CCDS802.1 GGTGGGGTAC AAGCTTGCTT CAGCAGATCC AGGGAATATC AGCTCAATGA TTCTGCTTCA TATTATCTAA ATGATCTGGA TAGAATATCC CAGTCTAACT
Gi-3 C.sabaeus XM007977682.1 GGTGGGGTAC AAGCTTGCTT CAGCAGATCC AGGGAATATC AGCTCAATGA TTCTGCTTCA TATTATCTAA ATGATCTGGA TAGAATATCC CAGTCTAACT
Gi-3 M.musculus CCDS17751.1 GGCGGGGTAC AGGCATGCTT TAGCAGGTCC AGGGAATATC AGCTCAATGA TTCTGCTTCA TACTACCTAA ATGATTTGGA TAGAATATCC CAGACCAACT
510 520 530 540 550 560 570 580 590 600
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 Sample ACCTTCGAAC TCAGCAAGGT GTTCTTCGGA CGAGAGTGAT GACTTCAGGC AAACCAA--- ---------- ---------- ---------- ----------
Gi-3 H.sapiens CCDS802.1 ACATTCCAAC TCAGCAAGAT GTTCTTCGGA CGAGAGTGAA GACCACAGGC ATTGTAGAAA CACATTTCAC CTTCAAAGAC CTATACTTCA AGATGTTTGA
Gi-3 C.sabaeus XM007977682.1 ACATTCCAAC TCAGCAAGAT GTTCTTCGGA CGAGAGTGAA GACCACAGGC ATTGTAGAAA CGCATTTCAC CTTCAAAGAC CTATACTTCA AGATGTTTGA
Gi-3 M.musculus CCDS17751.1 ACATTCCAAC TCAGCAAGAT GTTCTTCGGA CAAGAGTGAA GACTACAGGC ATTGTGGAGA CCCACTTCAC CTTCAAGGAA CTCTACTTCA AAATGTTTGA
610 620 630 640 650 660 670 680 690 700
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 Sample ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gi-3 H.sapiens CCDS802.1 TGTAGGTGGC CAAAGATCAG AACGAAAAAA GTGGATTCAC TGTTTTGAGG GAGTGACAGC AATTATCTTC TGTGTGGCCC TCAGTGATTA TGACCTTGTT
Gi-3 C.sabaeus XM007977682.1 TGTAGGTGGC CAAAGATCAG AACGAAAAAA GTGGATTCAC TGTTTTGAGG GAGTGACAGC AATTATTTTC TGTGTGGCCC TCAGTGATTA TGACCTTGTT
Gi-3 M.musculus CCDS17751.1 TGTAGGTGGC CAAAGATCCG AACGAAAAAA GTGGATTCAC TGTTTTGAGG GAGTGACAGC AATTATCTTT TGTGTGGCTC TCAGTGATTA CGACCTTGTT
710 720 730 740 750 760 770 780 790 800
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 Sample ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gi-3 H.sapiens CCDS802.1 CTGGCTGAGG ACGAGGAGAT GAACCGAATG CATGAAAGCA TGAAACTGTT TGACAGCATT TGTAATAACA AATGGTTTAC AGAAACTTCA ATCATTCTCT
Gi-3 C.sabaeus XM007977682.1 CTGGCTGAGG ACGAGGAGAT GAACCGAATG CATGAAAGCA TGAAACTGTT TGACAGCATT TGTAATAACA AATGGTTTAC AGAAACTTCA ATCATTCTCT
Gi-3 M.musculus CCDS17751.1 CTGGCTGAGG ATGAGGAAAT GAACCGAATG CATGAAAGCA TGAAATTGTT TGACAGCATT TGTAACAACA AATGGTTTAC AGACACTTCA ATCATTCTCT
810 820 830 840 850 860 870 880 890 900
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 Sample ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gi-3 H.sapiens CCDS802.1 TCCTTAACAA GAAAGACCTT TTTGAGGAAA AAATAAAGAG GAGTCCGTTA ACTATCTGTT ATCCAGAATA CACAGGTTCC AATACATATG AAGAGGCAGC
Gi-3 C.sabaeus XM007977682.1 TTCTTAACAA GAAAGACCTG TTTGAGGAAA AAATAAAGAG GAGTCCGTTA ACTATCTGTT ATCCAGAATA CACAGGTTCC AATACATATG AAGAGGCAGC
Gi-3 M.musculus CCDS17751.1 TTCTTAATAA GAAAGACCTT TTTGAGGAAA AAATAAAGAG GAGTCCATTA ACAATCTGTT ATCCAGAATA CACAGGTTCC AATACATACG AAGAGGCAGC
910 920 930 940 950 960 970 980 990 1000
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gi-3 Sample ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gi-3 H.sapiens CCDS802.1 TGCCTATATT CAATGCCAGT TTGAAGATCT GAACAGAAGA AAAGATACCA AGGAGATCTA TACTCACTTC ACCTGTGCCA CAGACACGAA GAATGTGCAG
Gi-3 C.sabaeus XM007977682.1 TGCCTATATT CAATGCCAGT TTGAAGATCT GAACAGAAGA AAAGATACCA AGGAGATCTA CACTCACTTC ACCTGTGCCA CAGACACGAA GAATGTGCAG
Gi-3 M.musculus CCDS17751.1 TGCTTACATT CAGTGCCAGT TTGAAGATCT GAACCGAAGA AAAGATACCA AGGAGGTCTA CACTCACTTC ACCTGTGCCA CAGACACCAA AAATGTGCAG
1010 1020 1030 1040 1050 1060
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|.
Gi-3 Sample ---------- ---------- ---------- ---------- ---------- ---------- ------
Gi-3 H.sapiens CCDS802.1 TTTGTTTTTG ATGCTGTTAC AGATGTCATC ATTAAAAACA ACTTAAAGGA ATGTGGACTT TATTGA
Gi-3 C.sabaeus XM007977682.1 TTTGTTTTTG ATGCTGTTAC AGATGTCATC ATTAAAAACA ACTTAAAGGA ATGTGGACTT TATTGA




   









Fig A8  The Aligned Amino Acid Sequences of G12 subunit of different species. Each 
species bear the G12 protein identifier after the name of species. H. sapiens has three G12 





10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Homo sapiens Q03113-1 MSGVVRTLSR CLLPAEAGGA RERRAGSGAR DA----EREA RRRSRDIDAL LARERRAVRR LVKILLLGAG ESGKSTFLKQ MRIIHGREFD QKALLEFRDT
Homo sapiens Q03113-2 ---------- ---------- ---------- ----MKRRMF PRPCLAR--- ---MPGSRGS G--------- -----STPDG NRKCCRFEHL LIAHPGSR--
Homo sapiens Q03113-3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- MRIIHGREFD QKALLEFRDT
Pan troglodytes H2QU42 MSGVVRTLSR CLLPAEAGGA RERRAGSGAR DA----EREA RRRSRDIDAL LARERRAVRR LVKILLLGAG ESGKSTFLKQ MRIIHGREFD QKALLEFRDT
Chlorocebus sabaeus A0A0D9RYG1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- MRIIHGREFD QKALLEFRDT
Callithrix jacchus F7HML1 MSGVVRTLSR CLLPAEAGGA RERRAG-GAR DA----EREA RRRSRDIDAL LARERRAVRR LVKILLLGAG ESGKSTFLKQ MRIIHGREFD QKALLEFRDT
Macaca fascicularis I7GI11 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- MRIIHGREFD QKALLEFRDT
Papio anubis A0A096N266 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- MRIIHGREFD QKALLEFRDT
Gorilla gorilla G3R227 MSGVVRTLSR CLLPAEAGGA RERRAGGGAR DA----EREA RRRSRDIDAL LARERRAVRR LVKILLLGAG ESGKSTFLKQ MRIIHGREFD QKALLEFRDT
Bos taurus E1BIL1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- MRIIHGREFD QKALLEFRDT
Ovis aries W5P2U6 MG---WPSSR HPAPAPSFTQ NLLQRFQQLP ESLAPEKPEF PTPAETEPQL FVSISNARNP NRKQREVPPS PAPTISAPNP SPRPNPSGVA RLCVPGEREP
Mus musculus Q2NKI3 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- MRIIHGREFD QKALLEFRDT
Mus musculus P27600 MSGVVRTLSR CLLPAEAG-A RERRAG-AAR DA----EREA RRRSRDIDAL LARERRAVRR LVKILLLGAG ESGKSTFLKQ MRIIHGREFD QKALLEFRDT
Rattus norvegicus Q63210 MSGVVRTLSR CLLPAEAG-A RERRAG-AAR DA----EREA RRRSRDIDAL LARERRAVRR LVKILLLGAG ESGKSTFLKQ MRIIHGREFD QKALLEFRDT
Danio rerio Q5YKG4 MAGVVRTLSR CLLPAEAAHD DRSTGKDRTR ERDVNREREA KRRSREIDSM LKRERRSIRR LVKILLLGAG ESGKSTFLKQ MRIIHGKEFD QKALLDFRDT
Oryzias latipes H2LYK0 MSGVVRTLSR CLLPAEASRD TGGS-KEGTR ERNAAQEREA KRRSREIDAM LARERRAVRR LVKILLLGAG ESGKSTFLKQ MRIINGQEFD QKALLDFRDT
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Homo sapiens Q03113-1 IFDN-ILKGS RVLVDARDKL GIPWQYSENE KHGMFLMAFE NKAGLP-VEP ATFQLYVPAL SALWRDSGIR EAFSRRSEFQ LGESVKYFLD NLDRIGQLNY
Homo sapiens Q03113-2 --------GS RVLVDARDKL GIPWQYSENE KHGMFLMAFE NKAGLP-VEP ATFQLYVPAL SALWRDSGIR EAFSRRSEFQ LGESVKYFLD NLDRIGQLNY
Homo sapiens Q03113-3 IFDN-ILKGS RVLVDARDKL GIPWQYSENE KHGMFLMAFE NKAGLP-VEP ATFQLYVPAL SALWRDSGIR EAFSRRSEFQ L--------- --------NY
Pan troglodytes H2QU42 IFDN-ILKGS RVLVDARDKL GIPWQYSENE KHGMFLMAFE NKAGLP-VEP ATFQLYVPAL SALWRDSGIR EAFSRRSEFQ LGESVKYFLD NLDRIGQLNY
Chlorocebus sabaeus A0A0D9RYG1 IFDN-ILKGS RVLVDARDKL GIPWQYSENE KHGMFLMAFE NKAGLP-VEP ATFQLYVPAL SALWRDSGIR EAFSRRSEFQ LGESVKYFLD NLDRIGQLNY
Callithrix jacchus F7HML1 IFDN-ILKGS RVLVDARDKL GIPWQYSENE KHGMFLMAFE NKAGLP-VEP ATFQLYVPAL SALWRDSGIR EAFSRRSEFQ LGESVKYFLD NLDRIGQLNY
Macaca fascicularis I7GI11 IFDN-ILKGS RVLVDARDKL GIPWQYSENE KHGMFLMAFE NKAGLP-VEP ATFQLYVPAL SALWRDSGIR EAFSRRSEFQ LGESVKYFLD NLDRIGQLNY
Papio anubis A0A096N266 IFDN-ILKGS RVLVDARDKL GIPWQYSENE KHGMFLMAFE NKAGLP-VEP ATFQLYVPAL SALWRDSGIR EAFSRRSEFQ LGESVKYFLD NLDRIGQLNY
Gorilla gorilla G3R227 IFDN-ILKGS RVLVDARDKL GIPWQYSENE KHGMFLMAFE NKAGLP-VEP ATFQLYVPAL SALWRDSGIR EAFSRRSEFQ LGESVKYFLD NLDRIGQLNY
Bos taurus E1BIL1 IFDN-ILKGS RVLVDARDKL GIPWQYSENE KHGMFLMAFE NKAGLP-VDP ATFQLYVPAL SALWGDSGIR EAFSRRSEFQ LGESVKYFLD NLDRIGQLNY
Ovis aries W5P2U6 RKNPIILKGS RVLVDARDKL GIPWQHSENE KHGMFLMAFE NKAGLP-VDP ATFQLYVPAL SALWGDSGIR EAFSRRSEFQ LGESVKYFLD NLDRIGQLNY
Mus musculus Q2NKI3 IFDN-ILKGS RVLVDARDKL GIPWQHSENE KHGMFLMAFE NKAGLP-VEP ATFQLYVPAL SALWRDSGIR EAFSRRSEFQ LGESVKYFLD NLDRIGQLNY
Mus musculus P27600 IFDN-ILKGS RVLVDARDKL GIPWQHSENE KHGMFLMAFE NKAGLP-VEP ATFQLYVPAL SALWRDSGIR EAFSRRSEFQ LGESVKYFLD NLDRIGQLNY
Rattus norvegicus Q63210 IFDN-ILKGS RVLVDARDKL GIPWQHSENE KHGMFLMAFE NKAGLP-VEP ATFQLYVPAL SALWRDSGIR EAFSRRSEFQ LGESVKYFLD NLDRIGQLNY
Danio rerio Q5YKG4 IFEN-VIKGM RVLVDARDKL GISWQNSENE KHGMFVMSFE NKAGMA-VEP CTFQLYVPAL QALWNDSGIQ EAYGRRSEFQ LSESVKYFLD NLDRIGQLSY
Oryzias latipes H2LYK0 IYEN-ILKGM RVLVDARDKL GITWQSCENE KQGMLVMSWE GRVGASGVEP SEFQLYVMAL SSLWADAGIQ QAYARRSEFQ LSESVKYFLD NLDRIGQLNY
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Homo sapiens Q03113-1 FPSKQDILLA RKATKGIVEH DFVIKKIPFK MVDVGGQRSQ RQKWFQCFDG ITSILFMVSS SEYDQVLMED RRTNRLVESM NIFETIVNNK LFFNVSIILF
Homo sapiens Q03113-2 FPSKQDILLA RKATKGIVEH DFVIKKIPFK MVDVGGQRSQ RQKWFQCFDG ITSILFMVSS SEYDQVLMED RRTNRLVESM NIFETIVNNK LFFNVSIILF
Homo sapiens Q03113-3 FPSKQDILLA RKATKGIVEH DFVIKKIPFK MVDVGGQRSQ RQKWFQCFDG ITSILFMVSS SEYDQVLMED RRTNRLVESM NIFETIVNNK LFFNVSIILF
Pan troglodytes H2QU42 FPSKQDILLA RKATKGIVEH DFVIKKIPFK MVDVGGQRSQ RQKWFQCFDG ITSILFMVSS SEYDQVLMED RRTNRLVESM NIFETIVNNK LFFNVSIILF
Chlorocebus sabaeus A0A0D9RYG1 FPSKQDILLA RKATKGIVEH DFVIKKIPFK MVDVGGQRSQ RQKWFQCFDG ITSILFMVSS SEYDQVLMED RRTNRLVESM NIFETIVNNK LFFNVSIILF
Callithrix jacchus F7HML1 FPSKQDILLA RKATKGIVEH DFVIKKIPFK MVDVGGQRSQ RQKWFQCFDG ITSILFMVSS SEYDQVLMED RRTNRLVESM NIFETIVNNK LFFNVSIILF
Macaca fascicularis I7GI11 FPSKQDILLA RKATKGIVEH DFVIKKIPFK MVDVGGQRSQ RQKWFQCFDG ITSILFMVSS SEYDQVLMED RRTNRLVESM NIFETIVNNK LFFNVSIILF
Papio anubis A0A096N266 FPSKQDILLA RKATKGIVEH DFVIKKIPFK MVDVGGQRSQ RQKWFQCFDG ITSILFMVSS SEYDQVLMED RRTNRLVESM NIFETIVNNK LFFNVSIILF
Gorilla gorilla G3R227 FPSKQDILLA RKATKGIVEH DFVIKKIPFK MVDVGGQRSQ RQKWFQCFDG ITSILFMVSS SEYDQVLMED RRTNRLVESM NIFETIVNNK LFFNVSIILF
Bos taurus E1BIL1 FPSKQDILLA RKATKGIVEH DFVIKKIPFK MVDVGGQRSQ RQKWFQCFDG ITSILFMVSS SEYDQVLMED RHTNRLVESM NIFETIVNNK LFFNVSIILF
Ovis aries W5P2U6 FPSKQDILLA RKATKGIVEH DFVIKKIPFK MVDVGGQRSQ RQKWFQCFDG ITSILFMVSS SEYDQVLMED RRTNRLVESM NIFETIVNNK LFFNVSIILF
Mus musculus Q2NKI3 FPSKQDILLA RKATKGIVEH DFVIKKIPFK MVDVGGQRSQ RQKWFQCFDG ITSILFMVSS SEYDQVLMED RRTNRLVESM NIFETIVNNK LFFNVSIILF
Mus musculus P27600 FPSKQDILLA RKATKGIVEH DFVIKKIPFK MVDVGGQRSQ RQKWFQCFDG ITSILFMVSS SEYDQVLMED RRTNRLVESM NIFETIVNNK LFFNVSIILF
Rattus norvegicus Q63210 FPSKQDILLA RKATKGIVEH DFVIKKIPFK MVDVGGQRSQ RQKWFQCFDG ITSILFMVSS SEYDQVLMED RRTNRLVESM NIFETIVNNK LFFNVSIILF
Danio rerio Q5YKG4 VPSRQDILLA RKATKGIVEH DFVIKKIPFK MVDVGGQRSQ RQKWFQCFDG ITSILFMVSS SEYDQVLMED RRTNRLVESM NIFETIVNNK LFSNVSIILF
Oryzias latipes H2LYK0 IPSRQDILFA RKATKGIVEH DFVIKKIPFK MVDVGGQRSQ RQKWFQCFDG ITSILFMVSS SEYDQVLMED RRTNRLVESM NIFETIVNNK LFLNVSIILF
310 320 330 340 350 360 370 380
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|..
Homo sapiens Q03113-1 LNKMDLLVEK VKTVSIKKHF PDFRGDPHRL EDVQRYLVQC FDRKRRNRSK PLFHHFTTAI DTENVRFVFH AVKDTILQEN LKDIMLQ
Homo sapiens Q03113-2 LNKMDLLVEK VKTVSIKKHF PDFRGDPHRL EDVQRYLVQC FDRKRRNRSK PLFHHFTTAI DTENVRFVFH AVKDTILQEN LKDIMLQ
Homo sapiens Q03113-3 LNKMDLLVEK VKTVSIKKHF PDFRGDPHRL EDVQRYLVQC FDRKRRNRSK PLFHHFTTAI DTENVRFVFH AVKDTILQEN LKDIMLQ
Pan troglodytes H2QU42 LNKMDLLVEK VKTVSIKKHF PDFRGDPHRL EDVQRYLVQC FDRKRRNRSK PLFHHFTTAI DTENVRFVFH AVKDTILQEN LKDIMLQ
Chlorocebus sabaeus A0A0D9RYG1 LNKMDLLVEK VKTVSIKKHF PDFRGDPHRL EDVQRYLVQC FDRKRRNRSK PLFHHFTTAI DTENVRFVFH AVKDTILQEN LKDIMLQ
Callithrix jacchus F7HML1 LNKMDLLVEK VKTVSIKKHF PDFRGDPHRL EDVQRYLVQC FDRKRRNRSK PLFHHFTTAI DTENVRFVFH AVKDTILQEN LKDIMLQ
Macaca fascicularis I7GI11 LNKMDLLVEK VKTVSIKKHF PDFRGDPHRL EDVQRYLVQC FDRKRRNRSK PLFHHFTTAI DTENVRFVFH AVKDTILQEN LKDIMLQ
Papio anubis A0A096N266 LNKMDLLVEK VKTVSIKKHF PDFRGDPHRL EDVQRYLVQC FDRKRRNRSK PLFHHFTTAI DTENVRFVFH AVKDTILQEN LKDIMLQ
Gorilla gorilla G3R227 LNKMDLLVEK VKTVSIKKHF PDFRGDPHRL EDVQRYLVQC FDRKRRNRSK PLFHHFTTAI DTENVRFVFH AVKDTILQEN LKDIMLQ
Bos taurus E1BIL1 LNKMDLLVEK VKTVSIKKHF PDFKGDPHRL EDVQRFLVQC FDRKRRNRSK PLFHHFTTAI DTENIRFVFH AVKDTILQEN LKDIMLQ
Ovis aries W5P2U6 LNKTDLLVEK VKTVSIKKHF PDFRGDPHRL EDVQRFLVQC FDRKRRNRSK PLFHHFTTAI DTENIRFVFH AVKDTILQEN LKDIMLQ
Mus musculus Q2NKI3 LNKMDLLVEK VKSVSIKKHF PDFKGDPHRL EDVQRYLVQC FDRKRRNRSK PLFHHFTTAI DTENIRFVFH AVKDTILQEN LKDIMLQ
Mus musculus P27600 LNKMDLLVEK VKSVSIKKHF PDFKGDPHRL EDVQRYLVQC FDRKRRNRSK PLFHHFTTAI DTENIRFVFH AVKDTILQEN LKDIMLQ
Rattus norvegicus Q63210 LNKMDLLVEK VKSVSIKKHF PDFKGDPHRL EDVQRYLVQC FDRKRRNRGK PLFHHFTTAI DTENIRFVFH AVKDTILQEN LKDIMLQ
Danio rerio Q5YKG4 LNKMDLLVEK VRKVSICKHF SDFRGDPHRL VDVQAYLVQC FNRKRRNRIK PLFHHFTTAI DTENIRFVFH AVKDTILQEN LKDIMLQ




   














Fig A9 The Aligned Amino Acid Sequences of IP3R1 of different species: human, 









10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Q14643-1|ITPR1_HUMAN Inositol MSDKMSSFLH IGDICSLYAE GSTNGFISTL GLVDDRCVVQ PETGDLNNPP KKFRDCLFKL CPMNRYSAQK QFWKAAKPGA NSTTDAVLLN KLHHAADLEK
Q14643-2|ITPR1_HUMAN Isoform 2 MSDKMSSFLH IGDICSLYAE GSTNGFISTL GLVDDRCVVQ PETGDLNNPP KKFRDCLFKL CPMNRYSAQK QFWKAAKPGA NSTTDAVLLN KLHHAADLEK
Q14643-3|ITPR1_HUMAN Isoform 3 MSDKMSSFLH IGDICSLYAE GSTNGFISTL GLVDDRCVVQ PETGDLNNPP KKFRDCLFKL CPMNRYSAQK QFWKAAKPGA NSTTDAVLLN KLHHAADLEK
Q14643-4|ITPR1_HUMAN Isoform 4 MSDKMSSFLH IGDICSLYAE GSTNGFISTL GLVDDRCVVQ PETGDLNNPP KKFRDCLFKL CPMNRYSAQK QFWKAAKPGA NSTTDAVLLN KLHHAADLEK
Q14643-5|ITPR1_HUMAN Isoform 5 MSDKMSSFLH IGDICSLYAE GSTNGFISTL GLVDDRCVVQ PETGDLNNPP KKFRDCLFKL CPMNRYSAQK QFWKAAKPGA NSTTDAVLLN KLHHAADLEK
Q14643-6|ITPR1_HUMAN Isoform 6 MSDKMSSFLH IGDICSLYAE GSTNGFISTL GLVDDRCVVQ PETGDLNNPP KKFRDCLFKL CPMNRYSAQK QFWKAAKPGA NSTTDAVLLN KLHHAADLEK
Q14643-7|ITPR1_HUMAN Isoform 7 MSDKMSSFLH IGDICSLYAE GSTNGFISTL GLVDDRCVVQ PETGDLNNPP KKFRDCLFKL CPMNRYSAQK QFWKAAKPGA NSTTDAVLLN KLHHAADLEK
Q14643-8|ITPR1_HUMAN Isoform 8 MSDKMSSFLH IGDICSLYAE GSTNGFISTL GLVDDRCVVQ PETGDLNNPP KKFRDCLFKL CPMNRYSAQK QFWKAAKPGA NSTTDAVLLN KLHHAADLEK
P11881-1|ITPR1_MOUSE Inositol MSDKMSSFLH IGDICSLYAE GSTNGFISTL GLVDDRCVVQ PEAGDLNNPP KKFRDCLFKL CPMNRYSAQK QFWKAAKPGA NSTTDAVLLN KLHHAADLEK
P11881-2|ITPR1_MOUSE Isoform 2 MSDKMSSFLH IGDICSLYAE GSTNGFISTL GLVDDRCVVQ PEAGDLNNPP KKFRDCLFKL CPMNRYSAQK QFWKAAKPGA NSTTDAVLLN KLHHAADLEK
P11881-3|ITPR1_MOUSE Isoform 3 MSDKMSSFLH IGDICSLYAE GSTNGFISTL GLVDDRCVVQ PEAGDLNNPP KKFRDCLFKL CPMNRYSAQK QFWKAAKPGA NSTTDAVLLN KLHHAADLEK
P11881-4|ITPR1_MOUSE Isoform 4 MSDKMSSFLH IGDICSLYAE GSTNGFISTL GLVDDRCVVQ PEAGDLNNPP KKFRDCLFKL CPMNRYSAQK QFWKAAKPGA NSTTDAVLLN KLHHAADLEK
P11881-5|ITPR1_MOUSE Isoform 5 MSDKMSSFLH IGDICSLYAE GSTNGFISTL GLVDDRCVVQ PEAGDLNNPP KKFRDCLFKL CPMNRYSAQK QFWKAAKPGA NSTTDAVLLN KLHHAADLEK
P11881-6|ITPR1_MOUSE Isoform 6 MSDKMSSFLH IGDICSLYAE GSTNGFISTL GLVDDRCVVQ PEAGDLNNPP KKFRDCLFKL CPMNRYSAQK QFWKAAKPGA NSTTDAVLLN KLHHAADLEK
P11881-7|ITPR1_MOUSE Isoform 7 MSDKMSSFLH IGDICSLYAE GSTNGFISTL GLVDDRCVVQ PEAGDLNNPP KKFRDCLFKL CPMNRYSAQK QFWKAAKPGA NSTTDAVLLN KLHHAADLEK
P11881-8|ITPR1_MOUSE Isoform 8 MSDKMSSFLH IGDICSLYAE GSTNGFISTL GLVDDRCVVQ PEAGDLNNPP KKFRDCLFKL CPMNRYSAQK QFWKAAKPGA NSTTDAVLLN KLHHAADLEK
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Q14643-1|ITPR1_HUMAN Inositol KQNETENRKL LGTVIQYGNV IQLLHLKSNK YLTVNKRLPA LLEKNAMRVT LDEAGNEGSW FYIQPFYKLR SIGDSVVIGD KVVLNPVNAG QPLHASSHQL
Q14643-2|ITPR1_HUMAN Isoform 2 KQNETENRKL LGTVIQYGNV IQLLHLKSNK YLTVNKRLPA LLEKNAMRVT LDEAGNEGSW FYIQPFYKLR SIGDSVVIGD KVVLNPVNAG QPLHASSHQL
Q14643-3|ITPR1_HUMAN Isoform 3 KQNETENRKL LGTVIQYGNV IQLLHLKSNK YLTVNKRLPA LLEKNAMRVT LDEAGNEGSW FYIQPFYKLR SIGDSVVIGD KVVLNPVNAG QPLHASSHQL
Q14643-4|ITPR1_HUMAN Isoform 4 KQNETENRKL LGTVIQYGNV IQLLHLKSNK YLTVNKRLPA LLEKNAMRVT LDEAGNEGSW FYIQPFYKLR SIGDSVVIGD KVVLNPVNAG QPLHASSHQL
Q14643-5|ITPR1_HUMAN Isoform 5 KQNETENRKL LGTVIQYGNV IQLLHLKSNK YLTVNKRLPA LLEKNAMRVT LDEAGNEGSW FYIQPFYKLR SIGDSVVIGD KVVLNPVNAG QPLHASSHQL
Q14643-6|ITPR1_HUMAN Isoform 6 KQNETENRKL LGTVIQYGNV IQLLHLKSNK YLTVNKRLPA LLEKNAMRVT LDEAGNEGSW FYIQPFYKLR SIGDSVVIGD KVVLNPVNAG QPLHASSHQL
Q14643-7|ITPR1_HUMAN Isoform 7 KQNETENRKL LGTVIQYGNV IQLLHLKSNK YLTVNKRLPA LLEKNAMRVT LDEAGNEGSW FYIQPFYKLR SIGDSVVIGD KVVLNPVNAG QPLHASSHQL
Q14643-8|ITPR1_HUMAN Isoform 8 KQNETENRKL LGTVIQYGNV IQLLHLKSNK YLTVNKRLPA LLEKNAMRVT LDEAGNEGSW FYIQPFYKLR SIGDSVVIGD KVVLNPVNAG QPLHASSHQL
P11881-1|ITPR1_MOUSE Inositol KQNETENRKL LGTVIQYGNV IQLLHLKSNK YLTVNKRLPA LLEKNAMRVT LDEAGNEGSW FYIQPFYKLR SIGDSVVIGD KVVLNPVNAG QPLHASSHQL
P11881-2|ITPR1_MOUSE Isoform 2 KQNETENRKL LGTVIQYGNV IQLLHLKSNK YLTVNKRLPA LLEKNAMRVT LDEAGNEGSW FYIQPFYKLR SIGDSVVIGD KVVLNPVNAG QPLHASSHQL
P11881-3|ITPR1_MOUSE Isoform 3 KQNETENRKL LGTVIQYGNV IQLLHLKSNK YLTVNKRLPA LLEKNAMRVT LDEAGNEGSW FYIQPFYKLR SIGDSVVIGD KVVLNPVNAG QPLHASSHQL
P11881-4|ITPR1_MOUSE Isoform 4 KQNETENRKL LGTVIQYGNV IQLLHLKSNK YLTVNKRLPA LLEKNAMRVT LDEAGNEGSW FYIQPFYKLR SIGDSVVIGD KVVLNPVNAG QPLHASSHQL
P11881-5|ITPR1_MOUSE Isoform 5 KQNETENRKL LGTVIQYGNV IQLLHLKSNK YLTVNKRLPA LLEKNAMRVT LDEAGNEGSW FYIQPFYKLR SIGDSVVIGD KVVLNPVNAG QPLHASSHQL
P11881-6|ITPR1_MOUSE Isoform 6 KQNETENRKL LGTVIQYGNV IQLLHLKSNK YLTVNKRLPA LLEKNAMRVT LDEAGNEGSW FYIQPFYKLR SIGDSVVIGD KVVLNPVNAG QPLHASSHQL
P11881-7|ITPR1_MOUSE Isoform 7 KQNETENRKL LGTVIQYGNV IQLLHLKSNK YLTVNKRLPA LLEKNAMRVT LDEAGNEGSW FYIQPFYKLR SIGDSVVIGD KVVLNPVNAG QPLHASSHQL
P11881-8|ITPR1_MOUSE Isoform 8 KQNETENRKL LGTVIQYGNV IQLLHLKSNK YLTVNKRLPA LLEKNAMRVT LDEAGNEGSW FYIQPFYKLR SIGDSVVIGD KVVLNPVNAG QPLHASSHQL
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Q14643-1|ITPR1_HUMAN Inositol VDNPGCNEVN SVNCNTSWKI VLFMKWSDNK DDILKGGDVV RLFHAEQEKF LTCDEHRKKQ HVFLRTTGRQ SATSATSSKA LWEVEVVQHD PCRGGAGYWN
Q14643-2|ITPR1_HUMAN Isoform 2 VDNPGCNEVN SVNCNTSWKI VLFMKWSDNK DDILKGGDVV RLFHAEQEKF LTCDEHRKKQ HVFLRTTGRQ SATSATSSKA LWEVEVVQHD PCRGGAGYWN
Q14643-3|ITPR1_HUMAN Isoform 3 VDNPGCNEVN SVNCNTSWKI VLFMKWSDNK DDILKGGDVV RLFHAEQEKF LTCDEHRKKQ HVFLRTTGRQ SATSATSSKA LWEVEVVQHD PCRGGAGYWN
Q14643-4|ITPR1_HUMAN Isoform 4 VDNPGCNEVN SVNCNTSWKI VLFMKWSDNK DDILKGGDVV RLFHAEQEKF LTCDEHRKKQ HVFLRTTGRQ SATSATSSKA LWEVEVVQHD PCRGGAGYWN
Q14643-5|ITPR1_HUMAN Isoform 5 VDNPGCNEVN SVNCNTSWKI VLFMKWSDNK DDILKGGDVV RLFHAEQEKF LTCDEHRKKQ HVFLRTTGRQ SATSATSSKA LWEVEVVQHD PCRGGAGYWN
Q14643-6|ITPR1_HUMAN Isoform 6 VDNPGCNEVN SVNCNTSWKI VLFMKWSDNK DDILKGGDVV RLFHAEQEKF LTCDEHRKKQ HVFLRTTGRQ SATSATSSKA LWEVEVVQHD PCRGGAGYWN
Q14643-7|ITPR1_HUMAN Isoform 7 VDNPGCNEVN SVNCNTSWKI VLFMKWSDNK DDILKGGDVV RLFHAEQEKF LTCDEHRKKQ HVFLRTTGRQ SATSATSSKA LWEVEVVQHD PCRGGAGYWN
Q14643-8|ITPR1_HUMAN Isoform 8 VDNPGCNEVN SVNCNTSWKI VLFMKWSDNK DDILKGGDVV RLFHAEQEKF LTCDEHRKKQ HVFLRTTGRQ SATSATSSKA LWEVEVVQHD PCRGGAGYWN
P11881-1|ITPR1_MOUSE Inositol VDNPGCNEVN SVNCNTSWKI VLFMKWSDNK DDILKGGDVV RLFHAEQEKF LTCDEHRKKQ HVFLRTTGRQ SATSATSSKA LWEVEVVQHD PCRGGAGYWN
P11881-2|ITPR1_MOUSE Isoform 2 VDNPGCNEVN SVNCNTSWKI VLFMKWSDNK DDILKGGDVV RLFHAEQEKF LTCDEHRKKQ HVFLRTTGRQ SATSATSSKA LWEVEVVQHD PCRGGAGYWN
P11881-3|ITPR1_MOUSE Isoform 3 VDNPGCNEVN SVNCNTSWKI VLFMKWSDNK DDILKGGDVV RLFHAEQEKF LTCDEHRKKQ HVFLRTTGRQ SATSATSSKA LWEVEVVQHD PCRGGAGYWN
P11881-4|ITPR1_MOUSE Isoform 4 VDNPGCNEVN SVNCNTSWKI VLFMKWSDNK DDILKGGDVV RLFHAEQEKF LTCDEHRKKQ HVFLRTTGRQ SATSATSSKA LWEVEVVQHD PCRGGAGYWN
P11881-5|ITPR1_MOUSE Isoform 5 VDNPGCNEVN SVNCNTSWKI VLFMKWSDNK DDILKGGDVV RLFHAEQEKF LTCDEHRKKQ HVFLRTTGRQ SATSATSSKA LWEVEVVQHD PCRGGAGYWN
P11881-6|ITPR1_MOUSE Isoform 6 VDNPGCNEVN SVNCNTSWKI VLFMKWSDNK DDILKGGDVV RLFHAEQEKF LTCDEHRKKQ HVFLRTTGRQ SATSATSSKA LWEVEVVQHD PCRGGAGYWN
P11881-7|ITPR1_MOUSE Isoform 7 VDNPGCNEVN SVNCNTSWKI VLFMKWSDNK DDILKGGDVV RLFHAEQEKF LTCDEHRKKQ HVFLRTTGRQ SATSATSSKA LWEVEVVQHD PCRGGAGYWN
P11881-8|ITPR1_MOUSE Isoform 8 VDNPGCNEVN SVNCNTSWKI VLFMKWSDNK DDILKGGDVV RLFHAEQEKF LTCDEHRKKQ HVFLRTTGRQ SATSATSSKA LWEVEVVQHD PCRGGAGYWN
310 320 330 340 350 360 370 380 390 400
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Q14643-1|ITPR1_HUMAN Inositol SLFRFKHLAT GHYLAAEVDP DFEEECLEFQ PSVDPDQDAS RSRLRNAQEK MVYSLVSVPE GNDISSIFEL DPTTLRGGDS LVPRNSYVRL RHLCTNTWVH
Q14643-2|ITPR1_HUMAN Isoform 2 SLFRFKHLAT GHYLAAEVD- ---------- ----PDQDAS RSRLRNAQEK MVYSLVSVPE GNDISSIFEL DPTTLRGGDS LVPRNSYVRL RHLCTNTWVH
Q14643-3|ITPR1_HUMAN Isoform 3 SLFRFKHLAT GHYLAAEVDP DFEEECLEFQ PSVDPDQDAS RSRLRNAQEK MVYSLVSVPE GNDISSIFEL DPTTLRGGDS LVPRNSYVRL RHLCTNTWVH
Q14643-4|ITPR1_HUMAN Isoform 4 SLFRFKHLAT GHYLAAEVD- ---------- ----PDQDAS RSRLRNAQEK MVYSLVSVPE GNDISSIFEL DPTTLRGGDS LVPRNSYVRL RHLCTNTWVH
Q14643-5|ITPR1_HUMAN Isoform 5 SLFRFKHLAT GHYLAAEVD- ---------- ----PDQDAS RSRLRNAQEK MVYSLVSVPE GNDISSIFEL DPTTLRGGDS LVPRNSYVRL RHLCTNTWVH
Q14643-6|ITPR1_HUMAN Isoform 6 SLFRFKHLAT GHYLAAEVDP DFEEECLEFQ PSVDPDQDAS RSRLRNAQEK MVYSLVSVPE GNDISSIFEL DPTTLRGGDS LVPRNSYVRL RHLCTNTWVH
Q14643-7|ITPR1_HUMAN Isoform 7 SLFRFKHLAT GHYLAAEVD- ---------- ----PDQDAS RSRLRNAQEK MVYSLVSVPE GNDISSIFEL DPTTLRGGDS LVPRNSYVRL RHLCTNTWVH
Q14643-8|ITPR1_HUMAN Isoform 8 SLFRFKHLAT GHYLAAEVD- ---------- ----PDQDAS RSRLRNAQEK MVYSLVSVPE GNDISSIFEL DPTTLRGGDS LVPRNSYVRL RHLCTNTWVH




   











Fig A10  The Complete Amino Acid Sequences of Different G subunits of H. sapiens, 
C. sabaeus, and M. musculus. A segment of the conserved sequences containing the 
target amino acid of PMT, glutamine (Q) is highlighted with an arrow inside a black box. 




10 20 30 40 50 60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq H.sapiens NP002063.2 ---------- --------MT LESIMACCLS EEAKEARRIN DEIERQLRRD KRDARRELKL LLLGTGESGK STFIKQMRII HGSGYSDEDK RGFTKLVYQN
Gq C.sabeus XP007967740.1 ---------- --------MT LESIMACCLS EEAKEARRIN DEIERQLRRD KRDARRELKL LLLGTGESGK STFIKQMRII HGSGYSDEDK RGFTKLVYQN
Gq M.musculus NP032165.3 ---------- --------MT LESIMACCLS EEAKEARRIN DEIERQLRRD KRDARRELKL LLLGTGESGK STFIKQMRII HGSGYSDEDK RGFTKLVYQN
G11 H.sapiens NP002058.2 ---------- --------MT LESMMACCLS DEVKESKRIN AEIEKQLRRD KRDARRELKL LLLGTGESGK STFIKQMRII HGAGYSEEDK RGFTKLVYQN
G11 C.sabeus XP007992944.1 ---------- --------MT LESMMACCLS DEVKESKRIN AEIEKQLRRD KRDARRELKL LLLGTGESGK STFIKQMRII HGAGYSEEDK RSFTKLVYHN
G11 M.musculus NP034431.1 ---------- --------MT LESMMACCLS DEVKESKRIN AEIEKQLRRD KRDARRELKL LLLGTGESGK STFIKQMRII HGAGYSEEDK RGFTKLVYQN
G12 H.sapiens NP031379.2 MSGVVRTLSR CLLPAEAGGA RERRAGSGAR DAEREARRRS RDIDALLARE RRAVRRLVKI LLLGAGESGK STFLKQMRII HGREFDQKAL LEFRDTIFDN
G12 C.sabeus XP008017022.1 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------MRII HGREFDQKAL LEFRDTIFDN
G12 M.musculus NP034432.1 MSGVVRTLSR CLLPAEAG-A RERRAG-AAR DAEREARRRS RDIDALLARE RRAVRRLVKI LLLGAGESGK STFLKQMRII HGREFDQKAL LEFRDTIFDN
G13 H.sapiens NP006563.2 MADFLP--SR SVLS------ -VCFPGCLLT SGEAEQQRKS KEIDKCLSRE KTYVKRLVKI LLLGAGESGK STFLKQMRII HGQDFDQRAR EEFRPTIYSN
G13 C.sabeus XP008010259.1 MADFLP--SR SVLS------ -VCFPGCLLT SGEAEQQRKS KEIDKCLSRE KTYVKRLVKI LLLGAGESGK STFLKQMRII HGQDFDQRAR EEFRPTIYSN
G13 M.musculus NP034433.3 MADFLP--SR SVLS------ -VCFPGCVLT NGEAEQQRKS KEIDKCLSRE KTYVKRLVKI LLLGAGESGK STFLKQMRII HGQDFDQRAR EEFRPTIYSN
Gi-1 H.sapiens NP002060.4 ---------- ---------- ----MGCTLS AEDKAAVERS KMIDRNLRED GEKAAREVKL LLLGAGESGK STIVKQMKII HEAGYSEEEC KQYKAVVYSN
Gi-1 C.sabeus XP007980565.1 ---------- ---------- ----MGCTLS AEDKAAVERS KMIDRNLRED GEKAAREVKL LLLGAGESGK STIVKQMKII HEAGYSEEEC KQYKAVVYSN
Gi-1 M.musculus NP034435.1 ---------- ---------- ----MGCTLS AEDKAAVERS KMIDRNLRED GEKAAREVKL LLLGAGESGK STIVKQMKII HEAGYSEEEC KQYKAVVYSN
Gi-2 H.sapiens NP002061.1 ---------- ---------- ----MGCTVS AEDKAAAERS KMIDKNLRED GEKAAREVKL LLLGAGESGK STIVKQMKII HEDGYSEEEC RQYRAVVYSN
Gi-2 C.sabeus XP007982488.1 ---------- ---------- ----MGCTVS AEDKAAAERS KMIDKNLRED GEKAAREVKL LLLGAGESGK STIVKQMKII HEDGYSEEEC RQYRAVVYSN
Gi-2 M.musculus NP032164.2 ---------- ---------- ----MGCTVS AEDKAAAERS KMIDKNLRED GEKAAREVKL LLLGAGESGK STIVKQMKII HEDGYSEEEC RQYRAVVYSN
Gi-3 H.sapiens NP006487.1 ---------- ---------- ----MGCTLS AEDKAAVERS KMIDRNLRED GEKAAKEVKL LLLGAGESGK STIVKQMKII HEDGYSEDEC KQYKVVVYSN
Gi-3 C.sabeus XP007975873.1 ---------- ---------- ----MGCTLS AEDKAAVERS KMIDRNLRED GEKAAKEVKL LLLGAGESGK STIVKQMKII HEDGYSEDEC KQYKVVVYSN
Gi-3 M.musculus NP034436.1 ---------- ---------- ----MGCTLS AEDKAAVERS KMIDRNLRED GEKAAKEVKL LLLGAGESGK STIVKQMKII HEDGYSEDEC KQYKVVVYSN
110 120 130 140 150 160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq H.sapiens NP002063.2 IFTAMQAMIR AMDTLKIPYK YEH--NKAHA QLVREVDVEK V------SAF ENPYVDAIKS LWNDPGIQEC YDRRREYQLS DSTKYYLNDL DRVADPAYLP
Gq C.sabeus XP007967740.1 IFTAMQAMIR AMDTLKIPYK YEH--NKAHA QLVREVDVEK V------SAF ENPYVDAIKS LWNDPGIQEC YDRRREYQLS DSTKYYLNDL DRVADPAYLP
Gq M.musculus NP032165.3 IFTAMQAMIR AMDTLKIPYK YEH--NKAHA QLVREVDVEK V------SAF ENPYVDAIKS LWNDPGIQEC YDRRREYQLS DSTKYYLNDL DRVADPSYLP
G11 H.sapiens NP002058.2 IFTAMQAMIR AMETLKILYK YEQ--NKANA LLIREVDVEK V------TTF EHQYVSAIKT LWEDPGIQEC YDRRREYQLS DSAKYYLTDV DRIATLGYLP
G11 C.sabeus XP007992944.1 ICTAIQATIR AMETLKILYK YEQ--NKANA LLIREVDVEK V------TTF EHQYVSAIKT LWDDPGIQEC YDRRREYQLS DSAKYYLTDV DRIATSGYLP
G11 M.musculus NP034431.1 IFTAMQAMVR AMETLKILYK YEQ--NKANA LLIREVDVEK V------TTF EHQYVNAIKT LWSDPGVQEC YDRRREFQLS DSAKYYLTDV DRIATVGYLP
G12 H.sapiens NP031379.2 ILKGSRVLVD ARDKLGIPWQ YSENEKHGMF LMAFENKAGL P----VEPAT FQLYVPALSA LWRDSGIREA FSRRSEFQLG ESVKYFLDNL DRIGQLNYFP
G12 C.sabeus XP008017022.1 ILKGSRVLVD ARDKLGIPWQ YSENEKHGMF LMAFENKAGL P----VEPAT FQLYVPALSA LWRDSGIREA FSRRSEFQLG ESVKYFLDNL DRIGQLNYFP
G12 M.musculus NP034432.1 ILKGSRVLVD ARDKLGIPWQ HSENEKHGMF LMAFENKAGL P----VEPAT FQLYVPALSA LWRDSGIREA FSRRSEFQLG ESVKYFLDNL DRIGQLNYFP
G13 H.sapiens NP006563.2 VIKGMRVLVD AREKLHIPWG DNSNQQHGDK MMSFDTRAPM AAQGMVETRV FLQYLPAIRA LWADSGIQNA YDRRREFQLG ESVKYFLDNL DKLGEPDYIP
G13 C.sabeus XP008010259.1 VIKGMRVLVD AREKLHIPWG DNSNQQHGDK MMSFDTRAPM AAQGMVETRV FLQYLPAIRA LWADSGIQNA YDRRREFQLG ESVKYFLDNL DKLGEPDYIP
G13 M.musculus NP034433.3 VIKGMRVLVD AREKLHIPWG DNKNQLHGDK LMAFDTRAPM AAQGMVETRV FLQYLPAIRA LWEDSGIQNA YDRRREFQLG ESVKYFLDNL DKLGVPDYIP
Gi-1 H.sapiens NP002060.4 TIQSIIAIIR AMGRLKIDFG DSARADDARQ LFVLAGAAEE -------GFM TAELAGVIKR LWKDSGVQAC FNRSREYQLN DSAAYYLNDL DRIAQPNYIP
Gi-1 C.sabeus XP007980565.1 TIQSIIAIIR AMGRLKIDFG DSARADDARQ LFVLAGAAEE -------GFM TAELAGVIKR LWKDSGVQAC FNRSREYQLN DSAAYYLNDL DRIAQPNYIP
Gi-1 M.musculus NP034435.1 TIQSIIAIIR AMGRLKIDFG DSARADDARQ LFVLAGAAEE -------GFM TAELAGVIKR LWKDSGVQAC FNRSREYQLN DSAAYYLNDL DRIAQPNYIP
Gi-2 H.sapiens NP002061.1 TIQSIMAIVK AMGNLQIDFA DPSRADDARQ LFALSCTAEE Q------GVL PDDLSGVIRR LWADHGVQAC FGRSREYQLN DSAAYYLNDL ERIAQSDYIP
Gi-2 C.sabeus XP007982488.1 TIQSIMAIVK AMGNLQIDFA DPSRADDARQ LFALSCTAEE Q------GVL PDDLSGVIRR LWADHGVQAC FGRSREYQLN DSAAYYLNDL ERIAQSDYIP
Gi-2 M.musculus NP032164.2 TIQSIMAIVK AMGNLQIDFA DPQRADDARQ LFALSCAAEE Q------GML PEDLSGVIRR LWADHGVQAC FGRSREYQLN DSAAYYLNDL ERIAQSDYIP
Gi-3 H.sapiens NP006487.1 TIQSIIAIIR AMGRLKIDFG EAARADDARQ LFVLAGSAEE -------GVM TPELAGVIKR LWRDGGVQAC FSRSREYQLN DSASYYLNDL DRISQSNYIP
Gi-3 C.sabeus XP007975873.1 TIQSIIAIIR AMGRLKIDFG EAARADDARQ LFVLAGSAEE -------GVM TTELAGVIKR LWRDGGVQAC FSRSREYQLN DSASYYLNDL DRISQSNYIP
Gi-3 M.musculus NP034436.1 TIQSIIAIIR AMGRLKIDFG ESARADDARQ LFVLAGSAEE -------GVM TSELAGVIKR LWRDGGVQAC FSRSREYQLN DSASYYLNDL DRISQTNYIP
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....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Gq H.sapiens NP002063.2 TQQDVLRVRV PTTGIIEYPF DLQSVIFRMV DVGGQRSERR KWIHCFENVT SIMFLVALSE YDQVLVESDN ENRMEESKAL FRTIITYPWF QNSSVILFLN
Gq C.sabeus XP007967740.1 TQQDVLRVRV PTTGIIEYPF DLQSVIFRMV DVGGQRSERR KWIHCFENVT SIMFLVALSE YDQVLVESDN ENRMEESKAL FRTIITYPWF QNSSVILFLN
Gq M.musculus NP032165.3 TQQDVLRVRV PTTGIIEYPF DLQSVIFRMV DVGGQRSERR KWIHCFENVT SIMFLVALSE YDQVLVESDN ENRMEESKAL FRTIITYPWF QNSSVILFLN
G11 H.sapiens NP002058.2 TQQDVLRVRV PTTGIIEYPF DLENIIFRMV DVGGQRSERR KWIHCFENVT SIMFLVALSE YDQVLVESDN ENRMEESKAL FRTIITYPWF QNSSVILFLN
G11 C.sabeus XP007992944.1 TQQDVLRVRV PTTGIIEYPF DLENIIFRMV DVGGQRSERR KWIHCFENVT SIMFLVALSE YDQVLVESDN ENRMEESKAL FRTIITYPWF QNSSVILFLN
G11 M.musculus NP034431.1 TQQDVLRVRV PTTGIIEYPF DLENIIFRMV DVGGQRSERR KWIHCFENVT SIMFLVALSE YDQVLVESDN ENRMEESKAL FRTIITYPWF QNSSVILFLN
G12 H.sapiens NP031379.2 SKQDILLARK ATKGIVEHDF VIKKIPFKMV DVGGQRSQRQ KWFQCFDGIT SILFMVSSSE YDQVLMEDRR TNRLVESMNI FETIVNNKLF FNVSIILFLN
G12 C.sabeus XP008017022.1 SKQDILLARK ATKGIVEHDF VIKKIPFKMV DVGGQRSQRQ KWFQCFDGIT SILFMVSSSE YDQVLMEDRR TNRLVESMNI FETIVNNKLF FNVSIILFLN
G12 M.musculus NP034432.1 SKQDILLARK ATKGIVEHDF VIKKIPFKMV DVGGQRSQRQ KWFQCFDGIT SILFMVSSSE YDQVLMEDRR TNRLVESMNI FETIVNNKLF FNVSIILFLN
G13 H.sapiens NP006563.2 SQQDILLARR PTKGIHEYDF EIKNVPFKMV DVGGQRSERK RWFECFDSVT SILFLVSSSE FDQVLMEDRL TNRLTESLNI FETIVNNRVF SNVSIILFLN
G13 C.sabeus XP008010259.1 SQQDILLARR PTKGIHEYDF EIKNVPFKMV DVGGQRSERK RWFECFDSVT SILFLVSSSE FDQVLMEDRL TNRLTESLNI FETIVNNRVF SNVSIILFLN
G13 M.musculus NP034433.3 SQQDILLARR PTKGIHEYDF EIKNVPFKMV DVGGQRSERK RWFECFDSVT SILFLVSSSE FDQVLMEDRQ TNRLTESLNI FETIVNNRVF SNVSIILFLN
Gi-1 H.sapiens NP002060.4 TQQDVLRTRV KTTGIVETHF TFKDLHFKMF DVGGQRSERK KWIHCFEGVT AIIFCVALSD YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN
Gi-1 C.sabeus XP007980565.1 TQQDVLRTRV KTTGIVETHF TFKDLHFKMF DVGGQRSERK KWIHCFEGVT AIIFCVALSD YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN
Gi-1 M.musculus NP034435.1 TQQDVLRTRV KTTGIVETHF TFKDLHFKMF DVGGQRSERK KWIHCFEGVT AIIFCVALSD YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN
Gi-2 H.sapiens NP002061.1 TQQDVLRTRV KTTGIVETHF TFKDLHFKMF DVGGQRSERK KWIHCFEGVT AIIFCVALSA YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN
Gi-2 C.sabeus XP007982488.1 TQQDVLRTRV KTTGIVETHF TFKDLHFKMF DVGGQRSERK KWIHCFEGVT AIIFCVALSA YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN
Gi-2 M.musculus NP032164.2 TQQDVLRTRV KTTGIVETHF TFKDLHFKMF DVGGQRSERK KWIHCFEGVT AIIFCVALSA YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN
Gi-3 H.sapiens NP006487.1 TQQDVLRTRV KTTGIVETHF TFKDLYFKMF DVGGQRSERK KWIHCFEGVT AIIFCVALSD YDLVLAEDEE MNRMHESMKL FDSICNNKWF TETSIILFLN
Gi-3 C.sabeus XP007975873.1 TQQDVLRTRV KTTGIVETHF TFKDLYFKMF DVGGQRSERK KWIHCFEGVT AIIFCVALSD YDLVLAEDEE MNRMHESMKL FDSICNNKWF TETSIILFLN
Gi-3 M.musculus NP034436.1 TQQDVLRTRV KTTGIVETHF TFKELYFKMF DVGGQRSERK KWIHCFEGVT AIIFCVALSD YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN
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....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|.
Gq H.sapiens NP002063.2 KKDLLEEKIM YSHLVDYFPE YDGPQRDAQA AREFILKMFV DLNPDSD-KI IYSHFTCATD TENIRFVFAA VKDTILQLNL KEYNLV
Gq C.sabeus XP007967740.1 KKDLLEEKIM YSHLVDYFPE YDGPQRDAQA AREFILKMFV DLNPDSD-KI IYSHFTCATD TENIRFVFAA VKDTILQLNL KEYNLV
Gq M.musculus NP032165.3 KKDLLEEKIM YSHLVDYFPE YDGPQRDAQA AREFILKMFV DLNPDSD-KI IYSHFTCATD TENIRFVFAA VKDTILQLNL KEYNLV
G11 H.sapiens NP002058.2 KKDLLEDKIL YSHLVDYFPE FDGPQRDAQA AREFILKMFV DLNPDSD-KI IYSHFTCATD TENIRFVFAA VKDTILQLNL KEYNLV
G11 C.sabeus XP007992944.1 KKDLLEDKIL YSHLVDYFPE FDGPQRDAQA AREFILKMFV DLNPDSD-KI IYSHFTCATD TENIRFVFAA VKDTILQLNL KEYNLV
G11 M.musculus NP034431.1 KKDLLEDKIL HSHLVDYFPE FDGPQRDAQA AREFILKMFV DLNPDSD-KI IYSHFTCATD TENIRFVFAA VKDTILQLNL KEYNLV
G12 H.sapiens NP031379.2 KMDLLVEKVK TVSIKKHFPD FRGDPHRLED VQRYLVQCFD RKRRNRS-KP LFHHFTTAID TENVRFVFHA VKDTILQENL KDIMLQ
G12 C.sabeus XP008017022.1 KMDLLVEKVK TVSIKKHFPD FRGDPHRLED VQRYLVQCFD RKRRNRS-KP LFHHFTTAID TENVRFVFHA VKDTILQENL KDIMLQ
G12 M.musculus NP034432.1 KMDLLVEKVK SVSIKKHFPD FKGDPHRLED VQRYLVQCFD RKRRNRS-KP LFHHFTTAID TENIRFVFHA VKDTILQENL KDIMLQ
G13 H.sapiens NP006563.2 KTDLLEEKVQ IVSIKDYFLE FEGDPHCLRD VQKFLVECFR NKRRDQQQKP LYHHFTTAIN TENIRLVFRD VKDTILHDNL KQLMLQ
G13 C.sabeus XP008010259.1 KTDLLEEKVQ IVSIKDYFLE FEGDPHCLRD VQKFLVECFR NKRRDQQQKP LYHHFTTAIN TENIRLVFRD VKDTILHDNL KQLMLQ
G13 M.musculus NP034433.3 KTDLLEEKVQ VVSIKDYFLE FEGDPHCLRD VQKFLVECFR GKRRDQQQRP LYHHFTTAIN TENIRLVFRD VKDTILHDNL KQLMLQ
Gi-1 H.sapiens NP002060.4 KKDLFEEKIK KSPLTICYPE YAGSNTYEEA A-AYIQCQFE DLNKRKDTKE IYTHFTCATD TKNVQFVFDA VTDVIIKNNL KDCGLF
Gi-1 C.sabeus XP007980565.1 KKDLFEEKIK KSPLTICYPE YAGSNTYEEA A-AYIQCQFE DLNKRKDTKE IYTHFTCATD TKNVQFVFDA VTDVIIKNNL KDCGLF
Gi-1 M.musculus NP034435.1 KKDLFEEKIK KSPLTICYPE YAGSNTYEEA A-AYIQCQFE DLNKRKDTKE IYTHFTCATD TKNVQFVFDA VTDVIIKNNL KDCGLF
Gi-2 H.sapiens NP002061.1 KKDLFEEKIT HSPLTICFPE YTGANKYDEA A-SYIQSKFE DLNKRKDTKE IYTHFTCATD TKNVQFVFDA VTDVIIKNNL KDCGLF
Gi-2 C.sabeus XP007982488.1 KKDLFEEKIT HSPLTICFPE YTGANKYDEA A-SYIQSKFE DLNKRKDTKE IYTHFTCATD TKNVQFVFDA VTDVIIKNNL KDCGLF
Gi-2 M.musculus NP032164.2 KKDLFEEKIT QSSLTICFPE YTGANKYDEA A-SYIQSKFE DLNKRKDTKE IYTHFTCATD TKNVQFVFDA VTDVIIKNNL KDCGLF
Gi-3 H.sapiens NP006487.1 KKDLFEEKIK RSPLTICYPE YTGSNTYEEA A-AYIQCQFE DLNRRKDTKE IYTHFTCATD TKNVQFVFDA VTDVIIKNNL KECGLY
Gi-3 C.sabeus XP007975873.1 KKDLFEEKIK RSPLTICYPE YTGSNTYEEA A-AYIQCQFE DLNRRKDTKE IYTHFTCATD TKNVQFVFDA VTDVIIKNNL KECGLY





   





Table A1.  The Position of Glutamine (Q), the Target Amino Acid of PMT, in 
Different G Subunits of H. sapiens, C. sabaeus, and M. musculus. 
 
 
Table A2.  The Size of CCDS and Protein of Different G subunits of H. 
sapiens, C. sabaeus, and M. musculus 
 
* G subtypes with their unique CCDS and protein sequence identifier were obtained from 















































































































































































































































   





Table A3.  The Molecular Weight of Different G Subtypes of H. sapiens,  
C. sabeus, and M. musculus 
 
Note: G proteins with their unique identifier were obtained from Uniprot with the exception   




















          H. Sapiens C. sabeus M. musculus 
G Identifier Protein Mol. 
Weight 
Identifier Protein Mol. 
Weight 
Identifier Protein Mol. 
Weight 
  AA Da  AA Da  AA Da 
Gq P50148-1 359 42,142 A0A0D9R5U9-1 301 35,422 P21279-1 359 42,158 
    XP007967740.1 359 42,011    
G11 P29992-1 359 42,123 A0A0D9RFQ6-1 394 45,922 P21278-1 359 42,024 
G12 Q03113-1 381 44,279 A0A0D9RYG1-1 305 35,952 P27600-1 379 44,095 
 Q03113-2 322 37,601    Q2NKI3-1 305 35,898 
 Q03113-3 288 34,002       
G13 Q14344-1 377 44,050 A0A0D9QVL0-1 377 44.050 P27601-1 377 44,055 
 Q14344-2 282 33,287       
Gi-1 P63096-1 354 40,361 A0A0D9RHH6-1 354 40,361 B2RSH2-1 354 40,361 
 P63096-2 302 34,775       
Gi-2 P04899-1 355 40,451 A0A0D9RPC3-1 355 40,451 P08752-1 355 40,489 
 P04899-2 339 38,473       
 P04899-3 318 36,465       
 P04899-4 366 41,548       
 P04899-5 339 38,737       
 P04899-6 303 34,935       
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